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Abstract 
Tetraazamacrocyclic frameworks of 1,4,7,10-tetraazacylcododecane (cyclen) and 
1,4,8,11-tetraazacyclotetradecane (cyclam) with functional pendent arms and 
porphyrins with solubilising polyethylene glycol (PEG) chains have been 
synthesised. The pendent arms possess different properties which tailor the metal 
complex towards a particular role. 
Both transition metal and lanthanide complexes of cyclam and cyclen metal 
complexes have been prepared with phenolate and thiophenolate pendent arms. The 
phenolate and thiophenolate pendent arms have tert-butyl groups in the ortho and 
para positions to stabilise radical formation. Cyclic voltammograms show that the 
phenoxyl and thiyl radical species can be generated by one electron oxidation 
processes at values around +0.5 to 0.7 V and +0.6 to 1.0 V respectively. Formation 
of the phenoxyl radical is reversible whereas formation of the thiyl radical is 
irreversible. The cyclic voltammogram of the europium(III) complex of cyclen 
bearing a thiophenolate and three acetate pendent arms ([Eu56]
−
)
 
is temperature 
dependent as the thiyl radical is 0.31 V easier to oxidise at −40°C than at room 
temperature (RT). The formation of the phenoxyl radical was also observed using 
UV-visible spectroscopy after the one electron oxidation by ferricyanide. 
Fluorescence spectra of the europium(III) and terbium(III) complexes of cyclen 
bearing a phenolate and three acetate pendent arms ([Eu52]
−
 and [Tb52]
−
) possess 
two and four emission peaks respectively. Europium(III) and terbium(III) complexes 
of the corresponding thiophenolate ligand ([Eu56]
−
 and [Tb56]
−
) also possess two 
and four emission peaks respectively. T1 weighted images of [Gd52]
−
 and [Gd56]
−
 
show enhanced image brightness relative to water. 
A cyclen ligand with a single aspartic acid derived pendent arm (27) and three 
acetate arms has been synthesised. This was used to attach a further cyclam 
macrocyclic component towards dual-imaging probe synthetics. 
Transition metal and p-block metal complexes of porphyrins have been produced 
with chains on the periphery which can enhance water solubility (either hydroxyl or 
PEG chains). Cyclic voltammetry of the tetra(3,5-dihydroxyphenyl)porphyrin (62) 
leads to the formation of a poly-porphyrin species. This was deposited on to the 
ii 
surface of carbon paper electrochemically and was visualised using scanning 
electron microscopy (SEM). PEGylated tetra(pentafluorophenyl)porphyrins have 
also been synthesised. The PEG chains aid water solubility and also have an effect 
on the light induced cytotoxicity of the compound. Zinc(II), nickel(II) and 
gallium(III) complexes have also been produced. Zinc(II) and nickel(II) complexes 
are not light induced toxic whereas the gallium(III) complexes are. Furthermore, the 
anion in the gallium(III) complexes can also dictate the light induced cytotoxicity of 
the complex.  
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 v 
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1.1. Macrocyclic ligands 
Macrocyclic ligands are polydentate ligands which contain donor atoms either 
incorporated in or attached to a cyclic backbone. Usually macrocyclic ligands 
possess at least three donor atoms and the macrocyclic ring consists of no less than 
nine atoms.
1
 The number of atoms in the polydentate chain is the main factor that 
determines the cavity size, but this is also affected by the rigidity in the backbone 
and by the hybridisation and nature of the donor atom. Bonds between atoms in the 
cyclic chain can be saturated or unsaturated, although extensive unsaturation results 
in loss of flexibility, therefore decreasing the propensity for metal chelation. These 
factors can be used advantageously to develop macrocyclic derivatives that can be 
tailored towards binding certain types of metal ions e.g. transition or lanthanide 
metal ions. 
The donor atoms of the macrocyclic ligand are arranged so that it can form five, six 
and seven-membered chelate rings with a metal centre. Thus ring sizes for a 
macrocycle containing three donor atoms possess usually between nine to thirteen 
atoms in the macrocyclic ring. For four donors, between twelve and seventeen atoms 
are required. Therefore macrocyclic ring sizes tend to possess between 3x and 4x+1 
(where x= the number of donor atoms) atoms in its chain. 
Enhanced kinetic and thermodynamic stabilities of the respective metal complexes 
offer distinct advantages over acyclic systems. This is because the propensity for 
decomplexation to occur is significantly lower and therefore, this does not affect the 
desired function of the metal complex. Such a property is highly desirable in 
biological systems. 
1.1.1. The chelate and macrocyclic effect 
The chelate effect is the gain of free energy when a bidentate or polydentate ligand is 
bonded to a metal ion instead of the corresponding number of unidentate ligands. 
The chelate effect is driven by a favourable entropic factor.
2
 
The macrocyclic effect is an extension of the chelate effect. This term was first 
coined by Cabbiness and Margerum in the late 1960‟s after studying the copper(II) 
 3 
 
complexes of the reduced Curtis macrocycle and an open chain tetramine analogue, 
„2.3.2-tet‟.3,4  
 
Figure 1: Chemical Structure of 2.3.3-tet. 
A macrocycle has the donor atoms arranged so that it is preorganised to accept an 
incoming metal centre.
5
 This means that there is less of an entropic effect in the 
binding energy of the resultant metal complex when compared with bidentate or 
polydentate ligands of the same donor type and number. The enthalpy of the reaction 
is governed by the following equation 
M2+(aq) + L aq  ⇌ ML2+(aq) 
which can be determined calorimetrically for both the macrocyclic and open-chain 
systems. The difference between the respective enthalpy values gives the 
macrocyclic enthalpy for the following equation 
MLoc(aq)+Lmac  aq  ⇌ MLmac  aq + Loc (aq) 
where L
mac
 is the macrocycle and L
oc
 is the open chain analogue. The entropy for 
such a reaction is always favourable; whereas the enthalpy term can be either 
favourable or unfavourable. Table 1
6
 shows the thermodynamic parameters for a 
series of macrocyclic ligands relative to their open chain analogues for high spin 
nickel(II) complexes. Clearly, the enthalpy and entropy terms contribute differently 
to each complex in the series.  
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L
oc
 L
mac
 -ΔG 
(kJ mol
-1
) 
ΔH 
(kJ mol
-1
) 
TΔS 
(kJ mol
-1
) 
 
 
2.43 5.1 7.4 
  
21.05 5.3 26.4 
  
15.69 3.5 19.2 
 
 
33.67 -20.5 13.2 
Table 1: Thermodynamic parameters for a series of open chain nickel(II) 
complexes relative to their macrocyclic counterparts. 
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1.1.2. Macrocyclic systems incorporating pendent arms 
Macrocyclic ligands are involved in a number of fundamental biological processes 
e.g. photosynthetic pathways and mammalian oxygen transport. Synthetic 
macrocyclic complexes have been prepared to mimic these systems. In addition, 
macrocyclic complexes have also been synthesised towards therapeutic and 
diagnostic applications. These compounds can be used as positron emission 
tomography (PET) imaging radiopharmaceuticals, magnetic resonance imaging 
(MRI) contrast agents, anti-cancer therapeutics and chemokine receptor antagonists. 
Pendent arms are frequently attached to the macrocyclic backbone for a number of 
reasons. Firstly, they can provide additional donor atoms to coordinate to the metal 
centre. Secondly, the pendent arms can be used as a linker group, providing 
additional functionality which can be used to attach further moieties to the complex. 
This is especially important in the synthesis of bioconjugate assemblies. Thirdly, the 
pendent arm can be responsive to a certain set of conditions which alters or 
attenuates the coordination sphere around the metal centre. This effect can then be 
monitored by analytical techniques. Pendent arms are therefore an important aspect 
in macrocycle design. A review on the topic of macrocyclic complexes bearing 
pendent arms as models for biological molecules was published in 2000.
7
 
The aim of this introduction is to highlight selected examples in four key areas in 
which macrocyclic complexes are exploited. These are enzyme mimicry, therapeutic 
and diagnostic applications and optical probes. These four areas include several key 
topics of current interest, including anti-human immunodeficiency virus (HIV) drugs 
and magnetic resonance contrast agents. The examples discussed within this 
introduction offer a cross-section of the literature available but are not 
comprehensive due to the large volume of research in this area. The selected 
examples discussed focus on aza-macrocyles and mixed donor systems and their 
complexes. A recent review on the medical applications of macrocyclic polyamines 
has been published by Liang et al., which provides further information.
8
 The 
introduction is divided in to sections based on the number of nitrogen atoms 
incorporated in the macrocyclic framework.  
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1.2. Tri-aza macrocyclic ligands and their analogues 
Tri-aza macrocyclic ligands are currently being investigated for a number of 
diagnostic applications, which includes PET and MRI. They are also used in enzyme 
mimicry, such as in the production of photosystem II models. A further application 
for tri-aza macrocycles is for hydrolytic ribonucleic acid (RNA) and 
deoxyribonucleic acid (DNA) cleavage catalysts. The rest of this section will focus 
upon these areas and selected examples are discussed. 
1.2.1. Enzyme mimics 
1.2.1.1. Hydrolytic cleavage catalysts 
A number of triazacyclononane (TACN) complexes have been produced in order to 
investigate their properties as hydrolytic cleavage catalysts. For example, zinc(II) 
complexes have been produced in order to study the mechanism of P-O bond 
cleavage occurring in the phosphate moiety of RNA model systems.
9
 A dinuclear 
zinc(II) complex of L
1
 (see Figure 3) with a bridging methoxide ion has been used to 
investigate the progressive change in mechanism from rate-limiting P-O bond 
cleavage to substrate binding.
10
 The two zinc(II) centres were shown to be 
coordinated via a bridging methoxide. At pH 9.8, the catalyst is maximally active, 
catalysing the cyclisation of a range of phosphate esters with an acceleration of 1 - 4 
x 10
12
 relative to the background reaction at the same pH.  
A copper(II) methoxide bridged complex of L
1
 has also been reported as a hydrolytic 
cleavage catalyst.
11
 In this case, each TACN compartment holds a copper(II) ion, 
and it also exhibits efficient catalytic cleavage of phosphate esters. The catalyst 
exhibits Michaelis-Menten kinetics with a kcat/KM value of 30 M
-1
s
-1
 which is 3.8 x 
10
7
 fold greater than the methoxide promotion of the phosphate ester methyl p-
nitrophenyl phosphate (MNPP). The transition state is stabilised by −24 kcal mol-1 
relative to that of methoxide promoted reactions. 
Further hydrolytic catalysts have been produced to cleave the more stable phosphate 
bonds in DNA. Zinc(II) and copper(II) bis-TACN complexes have been synthesised 
with bridging p-methyl phenol groups towards this aim.
12
 The two metal centres are 
held in an almost perfect square based pyramidal geometry (η values of 0.02 and 
 7 
 
0.07 for dinuclear copper(II) (crystal structure shown in Figure 2) and zinc(II) 
complexes respectively). η is a geometric parameter applicable to five coordinate 
structures to determine whether a metal ion adopts either a square-based pyramidal 
or trigonal bipyramidal geometry.
13,14
 η is defined as (β-α)/60, where β and α are the 
bond angles involving the trans donor atoms in the basal plane. Both complexes 
effectively cleave DNA in the presence of either mercaptoethanol (kcat = 1.61 hr
-1
, 
Km =1.35 x 10
-5
 M, where M = copper(II)) or hydrogen peroxide (kcat = 2.48 hr
-1
, Km 
= 5.5 x 10
-5
 M, where M = zinc(II)). 
 
Figure 2: Ball and stick representation of the X-ray crystal structure of a bis-
TACN bridged dinuclear copper(II) complex. H-atoms and perchlorate anions 
omitted for clarity (Qian et al.).
12
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Figure 3: Chemical structures of L
1
-L
5
. 
Further examples of dinuclear zinc(II) hydrolytic DNA cleavage catalysts have been 
synthesised.
15
 The zinc(II) ions are held in each TACN cleft of L
2
. Binding affinity 
 9 
 
for this dinuclear complex for calf thymus DNA was found to be higher than the 
mononuclear TACN complex (3.57 x 10
6
 M
-1
 and 1.43 x 10
5
 M
-1
 respectively). 
Kinetic data for the dinuclear complex showed a 10
7
-fold acceleration of DNA 
cleavage (kobs = 0.136 h
-1
) over uncatalysed supercoiled DNA. A hydrolytic process 
was suggested as the mechanism for cleavage. 
1.2.1.2. Photosystem II and superoxide dismutase mimics 
Tri-aza complexes have been used in enzyme mimicry. Two illustrative enzymes 
investigated using this type of complex are photosystem II and superoxide dismutase 
(SOD). Tetra- to nonanuclear transition metal complexes incorporating manganese 
ions, oxidisable phenolates and tris(2,2‟-bipyridyl)ruthenium(II)-type units have 
been synthesised as a model for photosystem II.
16
 The manganese centres were 
shown to exist in several oxidation states (II, III and IV) which are capable of 
undergoing one-electron transfer steps. Electrochemically, very slow heterogeneous 
electron-transfer was observed in several cases. This transfer was found to be 
dependent on the length of spacer between the manganese ion and the tris(2,2‟-
bipyridyl)ruthenium(II) unit. A long spacer unit enabled the observation of 
particularly slow electron-exchange kinetics by thin-layer electrochemical methods. 
Other systems have been developed as SOD mimics. Oliveria and co-workers used 
several low molecular weight mixed oxygen and nitrogen donor macrocycles to 
complex copper(II) in order to investigate possible applications as superoxide 
scavenging agents.
17
 All the complexes except 1,4-diaza-6-oxo-nonane showed 
reasonably high stability constants. Two different endpoints were used to evaluate 
the ability of the complexes to scavenge the superoxide anions generated by the 
xanthine-xanthine oxidase system; the nitro blue tetrazolium (NBT) reduction assay 
and the dihydroethidium (DHE) oxidation assay. Low micromolar IC50 (the molar 
concentration of antagonist which produces 50% of the maximum inhibitory 
response for that antagonist) values were found for most of the compounds tested 
(circa 13-31 μM). 
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1.2.2. Diagnostic agents 
Triaza-macrocyclic complexes have been prepared for use as radiopharmaceuticals 
and as magnetic resonance imaging contrast agents. The following two sections 
discuss relevant examples for each area. 
1.2.2.1. Radiopharmaceuticals 
Diagnostic agents for use in PET have been prepared using TACN derived 
macrocycles with either transition or p-block metal ions. For example, Brechbiel and 
co-workers synthesised 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA) 
based octadentate ligands as potential yttrium chelators.
18
 A pendent 
bis(carboxymethyl)-amino donor group is linked to the macrocyclic ring by either an 
ethyl or propyl chain (L
3a
 and L
3b
). The length of this alkyl chain was important with 
regard to the serum stability. The ethyl linker had 100% stability over 14 days 
whereas the propyl linker only 75%. In vivo distribution was shown to mirror that of 
the 
86
Y complex of 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA).  
Copper isotopes are also of interest as complexes of PET imaging agents. 
62
Cu, 
64
Cu 
and 
67
Cu have been or are in current use as labels of compounds such as 
62
Cu-
pyruvaldehyde-bis(N
4
-methylthiosemicarbazone) (
62
Cu-PTSM) and monoclonal 
antibodies.
19
 Brechbiel and co-workers have produced 
64
Cu radiopharmaceuticals by 
modification of L
3a
 and L
3b
. Replacing the pendent bis(carboxymethyl)-amino donor 
in L
3a
 and L
3b
 with a hydroxypropyl or hydroxyethyl (L
4a
 and L
4b
) has been shown 
to lead to in vivo instability, with 59% and 29% of copper radioisotope dissociating 
from each macrocycle respectively.
20
 The hydroxypropyl can form a six-membered 
chelate ring with the copper which gives rise to increased stability over the 
hydroxyethyl derivative. Aminocarboxylate groups were found to efficiently hold the 
64
Cu in place, with no measurable loss of radioactivity over a 48 hr period. 
Further examples of TACN based radiopharmaceuticals have been produced by 
Brechbiel‟s group. The ligands produced have both macrocyclic and acyclic clefts.21 
Two chelators were synthesised; both comprising of a modified p-isothiocyanate 
phenylalanine pendent arm which possessed either a secondary (C-NE3TA-NCS) or 
tertiary amino group (C-NETA-NCS). Both chelators were radiolabelled with 
177
Lu, 
90
Y, 
203
Pb, 
205/6
Bi and 
153
Gd; and the in vitro stability of the complexes assessed in 
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human serum. All complexes were stable for up to 11 days in serum apart from the 
lead(II) complexes of both chelators which displayed significant dissociation of the 
metal from the complex. Relaxivity data indicated that Gd-C-NETA (4.77 mM
-1
s
-1
) 
and Gd-C-NE3TA (5.89 mM
-1
s
-1
) possess enhanced relaxivity compared to Gd(C-
DOTA) (3.96 mM
-1
s
-1
). The varying number of coordination donors of NETA (8 
donors) and NE3TA (7 donors) provided to the metal centre was believed to be 
responsible for the difference in relaxivities between the two complexes. 
177
Lu and 
90
Y labelled C-NETA and C-NE3TA exhibited rapid blood clearance from arythmic 
mice and also displayed relatively low radioactivity levels in normal organs as well 
as a favourable distribution profile. NE3TA and NETA have also been assessed for 
use in iron depletion tumour therapy.
22
 Enhanced cytotoxicities were displayed in 
both HeLa and HT29 cells by NE3TA compared with desferoxamine (DFO). 
Radio-labelled peptide-conjugates have been produced. NODAGATOC, a chelator-
coupled somatostatin analogue with 
67/68
Ga and 
111
In has been designed for 
application in single photon emission computed tomography (SPECT), PET and 
targeted therapeutic applications of somatostatin receptors (hsst2).
23
 
67
Ga and 
111
In 
are both γ emitters, whilst 68Ga is β+ emitter with a half-life of 68 min.24 The two 
former radioisotopes are therefore suited for SPECT imaging and the latter for PET. 
The chelator produced uses a di-protected glutamic derived amino acid linker 
synthesised previously.
25
 The 
111
In radiolabelled complexes displayed notably higher 
binding affinity to both sstr2 and sstr5 (factor of 2 and 4 times higher respectively 
when compared with 
67
Ga-NODAGATOC). The receptor binding affinities for the 
radiolabelled conjugates are shown in Table 2. 
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Peptide/ conjugate hsst 1 hsst 2 hsst 3 hsst 4 hsst 5 
Somatostatin-28 4.1 ± 0.3 (15) 2.6 ± 0.2 
(16) 
5.4 ± 0.6 
(13) 
4.1 ± 0.3 
(16) 
3.9 ± 0.4 
(17) 
DOTA-Tyr
3
-octreotide 
(DOTATOC) 
>10000 (7) 13. 9 ± 
2.8 (6) 
13. 9 ± 
2.8 (6) 
>1000 (5) 393 ± 85 
(6) 
Y-DOTA-Tyr
3
-octreotide >10000 (6) 11.4 ± 
1.7 (6) 
11.4 ± 
1.7 (6) 
>100000 
(6) 
204 ± 92 
(6) 
Ga-DOTA-Tyr
3
-octreotide >10000 (6) 2.5 ± 0.5 
(7) 
2.5 ± 0.5 
(7) 
>1000 (2) 106 ± 37 
(7) 
NODAGA-Tyr
3
-octreotide 
(NODAGATOC) 
>10000 (2) 3.2 ± 1.0 
(2) 
3.2 ± 1.0 
(2) 
>1000 (2) 305 ± 85 
(2) 
Ga-NODA-Tyr
3
-octreotide >1000 (2) 3.5 ± 1.6 
(2) 
3.5 ±1.6 
(2) 
>1000 (2) 185 ± 35 
(20 
In-NODA-Tyr
3
-octreotide >1000 (3) 1.7 ± 0.2 
(3) 
1.7 ± 0.2 
(3) 
320 ± 17 
(3) 
44 ± 8 
(3) 
Table 2: Affinity profiles (IC50 (nM ± SE)) for Human sst1-sst5 receptors for a 
series of somatostatin anologues. Number of independent studies is given in 
brackets. 
A related peptide-conjugate has been synthesised for targeted uptake. The synthesis 
of a TACN derivative with two pyridyl methyl pendent arms and one single 
carboxylic arm provided a point of attachment for a bombesin (BN) stabilised 
derivative (βAla-βAla-[Cha13, Nle14]BN(7-14)).26 The resulting 64Cu complex was 
highly stable both in the presence of cyclam as a competing ligand and copper-
seeking superoxide dismutase (SOD). Biodistribution studies showed a high uptake 
for the kidneys, which was believed to be due to the high affinity that BN displays 
for the gastrin-releasing peptide receptor (GRPR) which is present in high levels 
within the organ. As GRPR is over expressed in a large number of breast and 
prostrate carcinomas, this would point to a possible application as a cancer 
diagnostic agent.  
Development of synthetic chemistry to produce macrocyclic ligands for use in 
radiopharmaceuticals has been reported. An example of such a ligand was produced 
by a Mannich aminomethylation of kojic acid at the ortho position in the presence of 
formaldehyde and TACN (L
5
).
27
 Complexation to copper(II), gallium(III) and 
iron(III) produced solid structures where the metal either adopted a distorted square-
pyramidal coordination (copper) or distorted octahedral (gallium and iron). Cyclic 
voltammetry highlighted that the ligand stabilised both the iron(III) and copper(II) 
 13 
 
oxidation states, therefore suggesting the complexes would be stable enough for 
radiolabelling and use as a target-specific radiotracer. 
1.2.2.2. Magnetic resonance imaging contrast agents 
An example of a gadolinium contrast agent has already been discussed in section 
1.2.2.1. TACN iron complexes also have potential application in MRI, because the 
iron centre can possesses un-paired electrons, resulting in the complex being 
paramagnetic. TACN iron complexes have been investigated by Hasserodt and co-
workers.
28
 Using two previously literature prepared compounds, 
[Fe
II
(tptacn)](ClO4)2
29,30
 and [Fe
II
(dptacn)(Cl)](PF6)
31
, the magnetic properties of 
both complexes were probed. This data showed that the former was diamagnetic 
(low spin iron(II)) whereas the latter was paramagnetic (high spin iron(II)) in both 
the solid and liquid phase. Relaxivity measurements of [Fe
II
(dptacn)(Cl)](PF6) gave 
an observed value of r1 of 1.29 mM
-1
s
-1
 which compares to gadolinium(III) DOTA 
(2.44 mM
-1
s
-1
). 
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1.3. Tetraazamacrocycles and their analogues 
This section on tetraazamacrocycles will mainly focus on ligands derived from 
cyclam and cyclen and their complexes. The suitability of complexes of cyclen and 
cyclam for medical applications with regard to their thermodynamic stability 
constants and structural data has been reported.
32
 Because of the volume of literature 
published on these two ligand systems, a section is dedicated to each. In each section 
selected examples are discussed to highlight current applications. 
1.3.1. Cyclam derivatives 
Cyclam complexes are pursued for a variety of reasons. The role of cyclam 
complexes and their applications in medicine has been highlighted in a review by 
Sadler and Liang.
33
 In addition topologically constrained ligands are of interest 
because the ligand can then dictate coordination chemistry of a chelated metal centre 
and offer enhanced complex stability.
34
 Cyclam type complexes can be used as PET 
imaging agents and as CXCR4 antagonists. Pendent arms attached to the 
macrocyclic framework can increase the stability of these complexes. Selected 
examples of ligand systems and their complexes of this type are discussed below. 
1.3.1.1. Diagnostic agents 
1.3.1.1.1. Copper-64 radiopharmaceuticals 
1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) (Figure 4) has 
been extensively used as a bi-functional chelator (BFC) for copper radionuclides in 
clinical imaging and therapy studies involving both antibodies and peptides.
35
 
64
Cu is 
often used as the radionuclide because it can be used in both PET imaging and 
targeted radiotherapy due to its half life (t½=12.7 hr), decay characteristics (β
+
 
(19%); β- (39%)) and the ability for large-scale production with high specific activity 
on a biomedical cyclotron.
36
 
Cyclam ligands complexed to 
64
Cu have been investigated by numerous groups as 
radiopharmaceuticals. Weisman, Wong and co-workers have developed a cyclam 
based macrocycle to act as a copper-64 radionuclide carrier.
37
 Three amide 
derivatives of CB-TE2A (see Figure 4 for structure) were produced, all of which had 
carboxylic and amide pendent arms. CB-TE2A is a configurationally restricted 
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macrocycle. Compared with TETA, these compounds had better in vivo clearance, 
with liver and bone marrow uptake at 24 hr being less than 10% of the uptake at 30 
min. In comparison, 
64
Cu-TETA displayed greater than 60% of 30 min uptake in the 
same tissues at 24 hr. Kinetic stability data for these compounds could not be 
obtained due to hydrolysis of the amide bond in 5M HCl. 
 
Figure 4: Chemical structures of TETA, CB-TE2A, HSBTE1A and L
6
. 
The influence of pendent arms on the in vitro and in vivo behaviour of copper cross-
bridged copper complexes has been investigated.
38
 N-carboxymethyl pendant arms 
gave the resulting copper cyclam cross bridged complex considerably better kinetic 
inertness and resistance to reduction than its N-carboxyethyl (crystal structure shown 
in Figure 5) analogue and cyclen cross bridged derivatives. The crystal structure of 
the N-carboxyethyl copper(II) complex shows that both of the carbonyl arms are 
coordinated to the copper(II) ion. The five coordinate copper(II) species was also 
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isolated in which one of the carbonyl arms is not coordinated to the copper centre. 
The copper ion adopts a square pyramidal geometry, with one of the nitrogens from 
the ring system providing the axial coordination site. The N-carboxymethyl cross-
bridged cyclam and cyclen copper complexes had better clearance than both N-
carboxyethyl complexes. As the N-carboxyethyl cross bridged cyclam complex was 
less resistant to reduction by 400 mV than the N-carboxymethyl analogue, it was 
presumed that this was important for optimal in vivo clearance. 
 
Figure 5: Ball and stick representation of the X-ray crystal structure of a 
copper(II) cross-bridged cyclam complex with two ethyl acetate arms. Sodium 
and perchlorate ions omitted for clarity (Sprague et al.).
38
 
Other examples in the literature of side- and cross-bridged configurationally 
restricted complexes have been synthesised. For example, a cross-bridged cyclam 
derivative bearing carboxylic acid and amide pendant arms has been synthesised.
39
 
The cross-bridged cyclam compound with two carboxylic arms cleared quickly from 
all tissues whereas cross-bridged cyclams with amide arms cleared far slower, being 
taken up by the liver and kidney over a period of 24 hr. The rapid clearance of the 
copper-64 complex of the cross-bridged cyclam with two pendant arms suggests that 
it is highly stable in vivo. The in vivo stability of cross-bridged complexes has been 
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studied further. Data shows that the cross-bridged compounds have enhanced in vivo 
stability by reduction of metal loss to protein in both cyclam and cyclen cross-
bridged 
64
Cu complexes.
35
 Lower levels of protein associated 
64
Cu were observed for 
64
Cu-CB-TE2A than 
64
Cu-TETA (13 ± 6% vs 75 ± 9% at 4 hr). Anderson and co-
workers have also observed dissociation in bioconjugates such as 
64
Cu-TETA-OC.
40
 
Archibald and co-workers
41
 have focused on the design and characterisation of 
copper(II) complexes of H4TETA and HSBTE1A, which are both side-bridged 
cyclam compounds. Two different crystal structures were obtained for Cu(H2TETA) 
displaying Jahn-Teller distortion through either the macrocyclic plane or through the 
axially coordinated carboxylate pendent arms. A side bridged cyclam copper(II) 
complex with one carboxylic pendent arm was also isolated with the copper ion 
adopting a square based pyramidal structure. 
64
Cu radiopharmaceuticals of monooxo tetraazamacrocycles have also been 
synthesised.
42
 Copper(II) complexes were synthesised which had comparable in vivo 
properties. The copper(II) complex of the 14-membered ring with the oxo at the 5 
position (L
6
) had the best biodistribution, although this was still not as good as 
traditional BFCs based on DOTA and TETA. 
1.3.1.1.2. Bioconjugate radiopharmaceuticals 
Radio-labelled complexes with targeting vectors are crucial for selective imaging of 
particular tumour/tissue types. Vectors include peptides and antibodies. A 
comprehensive review on labelling macrocyclic radiometal complexes with 
monoclonal antibodies has been published.
43
 Radio-labelled complexes enable the 
diagnostic imaging of a particular tissue or organ type. Octreotate, for example, has 
received considerable interest from research groups as it can be used to selectively 
target somatostatin receptor subtype 2 (SSTr2)-positive tissues.
44-47
 A cross-bridged 
cyclam bearing an attached octreotate vector has been synthesised (L
7
).
44
 Compared 
with copper-64 TETA and TETA-conjugates, the copper-64 complex of L
7
 displayed 
improved in vivo stability as well as a reduction of in vivo transchelation. In addition, 
the additional stability was thought to be responsible for the broader specificity in 
that SSTr1, SSTr3 and SSTr5 as well SSTr2 were targeted as evidenced from the 
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significant difference in the Bmax (binding maximum) values (
64
Cu-TETA-octreotate 
192 fmol/g; 
64
Cu-cross bridged TETA-octreotate 1551 fmol/g). 
Further peptides have been incorporated into structurally reinforced peptide 
conjugates. Recently, Brechbiel and co-workers have developed a cross-bridged 
cyclam cyclic RGD peptide conjugate radiolabelled with 
64
Cu,
48
 which utilised a 
bromide-functionalised glutamic acid derivative.
25
 Structurally, the conjugate is a 
derivative of CB-TE2A. In vitro studies conducted demonstrated that the complex 
remained intact over a 48 hr period as no transchelation was observed. 
 
Figure 6: Chemical structure of L
7
. 
1.3.1.2. Therapeutic agents 
1.3.1.2.1. CXCR4 antagonists 
One of the main areas in which cyclam complexes have been investigated as 
therapeutics is in the treatment of acquired immunodeficiency syndrome (AIDS). In 
particular, cyclam complexes are widely investigated as potential CXCR4 
antagonists. AMD3100 (Figure 7), a configurationally unrestricted bi-cyclam was, 
until recently, in clinical trials against HIV. Sadler and co-workers investigated the 
bi-metallic complexes of AMD3100 which had been evaluated for their anti-HIV 
activity. Zinc(II) perchlorate complexes were produced towards this aim.
49
 NMR 
studies showed that the complexes have two major conformers; trans-I (nitrogen 
chirality R, S, R, S) and trans-III (S, S, R, R). The six conformations of cyclam are 
shown in Figure 8. Addition of acetate to the perchlorate salts induced major 
structural change to the cis-V (R, R, R, R) configuration which was evidenced from 
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X-ray crystallography data. In solution phase, the trans-I conformer is also present. 
The mixed conformations present in the acetate complexes enable binding to 
CXCR4 (via a cis-V site) whilst the second cyclam adopts a trans-I conformation to 
bind to Asp
171
. 
 
Figure 7: Chemical structures of AMD3100 and L
8
. 
The configurational activity of cyclam and its effect on the docking of the antagonist 
with the receptor has been further modelled. The configurational equilibria of 
nickel(II)-cyclam derivatives have been investigated.
50
 [Ni(cyclam)(OAc)2].H2O and 
[Ni(benzylcyclam)(NO3)2] were found to adopt a trans-III configuration with either 
axial acetate or nitrate ligands, whereas [Ni(benzylcyclam)(OAc)](OAc)]. 2H2O 
adopted a cis-V configuration. X-ray diffraction studies showed that crystals of 
lysozyme soaked in either nickel(II) cyclam or nickel(II)2-xylbicyclam contain two 
major binding sites. One involves the coordination of nickel(II) to Asp
101
 and 
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hydrophobic interactions between the cyclam ring and Trp
62
 and Trp
63
, and the 
second is hydrophobic interactions with Trp
123
. For nickel(II) cyclam bound to the 
Asp
101
 residue, the cis-V configuration was found to dominate. 
 
Figure 8: The six configurations of cyclam.
51
 
Development of configurationally restricted AMD3100 derivatives to produce more 
potent compounds has been carried out. For example, mono- and bis-macrocyclic 
copper(II) complexes have been synthesised and their anti-HIV efficacy measured.
52
 
The restricted di-copper(II) complex of L
8
 is more active (average EC50 (the molar 
concentration of an agonist, which produces 50% of the maximum possible response 
for that agonist) =0.026 μM against HIV-1) than the corresponding di-copper(II) 
AMD3100 complex (average EC50=0.047 μM against HIV-1). Interestingly the di-
zinc(II) restricted macrocyclic complex has an EC50 in the nanomolar range (average 
EC50=8 nM against HIV-1).
53
 
Furthermore, fluorescent CXCR4 chemokine receptor antagonists have been 
evaluated with regard to metal activated binding.
54
 Antibody competition studies 
show binding of the fluorescent conjugate to CXCR4 in Jurkat cells. However, both 
a CXCR4 negative control and Jurkat gave positive fluorescent response by flow 
cytometry. To investigate the uptake of the conjugates, cell surface blocking studies 
were carried out, highlighting that an active transport mechanism is used. A ball and 
stick representation of the crystal structure of the copper(II) benzyl side-bridged 
cyclam complex is shown in Figure 9. In the crystal structure, the ring system has 
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adopted a trans-II configuration with the copper(II) ion having distorted square-
based pyramidal geometry. 
 
Figure 9: Ball and stick representation of the X-ray crystal structure of the 
copper(II) complex formed with the benzyl derivative of the piperzine tetra-aza 
macrocycle. H-atoms and [CuCl2]
-
 counter ion have been removed for clarity 
(Khan et al.).
54
 
1.3.1.2.2. Anti-cancer therapeutics 
Cyclam complexes are also used as anti-cancer drugs. Lipophilic derivatives of 
cyclam which show inhibition of tumour cell growth have been synthesised.
55
 The 
use of isopropyl and isobutyl appendages was found to increase lipophilicity without 
diminishing overall water solubility. Against the cell line L1210, effective inhibition 
was achieved with IC50 values of 6.2 and 8.7 μM for the isopropyl and isobutyl 
derivatives respectively. Cyclam was found to be an ineffective inhibitor even at the 
highest concentration studied (25 μM).  
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1.3.2. Cyclen derivatives 
Cyclen ligands and their analogues have found applications in a variety of different 
areas of biomedical chemistry. Complexation occurs to lanthanide ions as well as 
transition metal ions. Pendent arm selection is important to generate the high 
coordination numbers required by the lanthanide ion which sits above the ring 
cavity. 
1.3.2.1. Enzyme mimics 
1.3.2.1.1. Hydrolytic catalysts 
Cyclen derivatives have been developed as enzyme mimics. A lot of research effort 
has been focused on the production of hydrolytic catalysts. For example, RNA 
hydrolytic catalysts have been produced with either transition metal or lanthanide 
ions at the catalytic centre. Europium(III) cyclen complexes with pendent arms have 
been synthesised by Morrow et al. These were designed to promote cleavage of, and 
bind to, models for the 5‟-cap of mRNA.56 By modifying the coordination sphere 
around the europium(III) centre, different rates of cleavage of GpppG were achieved. 
With all four pendent arms present as hydroxyethyls a pseudo first order rate 
constant of 5.3x10
-5
 s
-1
 was reported.
57
 Replacing one hydroxyethyl for an amide 
reduces the rate constant to 2.6x10
-5
 s
-1. Both europium(III) complexes cleave the 5‟ 
cap of mRNA by attack of an ethyl alcohol pendent group on the phosphoric 
anhydride linkage. Replacing all four pendent arms for 2-hydroxypropyl groups 
causes the complex to bind to the 5‟ cap of mRNA but does not promote cleavage. 
This was attributed to the difference in nucleophilicity of 2-hydroxypropyl compared 
with hydroxyl ethyl which results in a diminished promotion of transesterification. 
A transition metal complex has also been prepared as a hydrolytic RNA cleavage 
catalyst. Two 1-oxa-4,7-10-triazacyclodecane macrocycles, a cyclen analogue where 
one nitrogen has been replaced by an oxygen, with either a single methyl or acridine 
pendent arm (L
9
) have been synthesised.
58
 The zinc(II) complexes of both ligands 
were tested for catalytic activity in the presence of 2-hydroxypropyl-4-nitrophenyl 
phosphate (HpPNP), a simple RNA analogue. Transesterification of the HpPNP by 
zinc(II) complexes was followed by monitoring the increasing absorbance of 4-
nitrophenolate at 400 nm. Cleavage of HpPNP produces a single phosphate 
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containing product as identified from 
31
P nuclear magnetic resonance (NMR). 
Pseudo first rate constants of 6.3x10
-6
 s
-1
 and 2.2x10
-6
 s
-1
 were obtained for 
L
9
(R=Me) and L
9
(R=Acr) respectively (see below). pH profiling of both zinc 
complexes identified that basic conditions gave better rates of cleavage of HpPNP. 
This was attributed to the catalyst-substrate complex being converted to its active 
form by loss of a proton. 
 
Figure 10: Chemical structures of the derivatives of L
9
. 
Carboxy-ester hydrolysis is also of interest. Tren-(tris(2-aminoethyl)amine)-based 
tris-macrocycles have been synthesised and characterised with the aim of 
investigating both their catalytic carboxy- and phosphate-ester hydrolysis.
59
 The tris-
zinc(II) complex was synthesised (see Figure 11 for crystal structure). In the crystal 
structure the zinc(II) ions are five coordinate and adopt a distorted square pyramidal 
geometry. The tris-zinc(II) complexes displayed elevated hydrolysis rates compared 
with the mononuclear zinc(II) [12]aneN4 complex. Bis(p-nitrophenyl) phosphate 
cleavage occurs through a bridging interaction with at least two metals with 
simultaneous nucelophilic attack at phosphorous by a Zn-OH function. In p-
nitrophenyl acetate hydrolysis, the three zinc(II) ions are not involved in substrate 
activation. 
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Figure 11: Ball and stick representation of the X-ray crystal structure of tri-
zinc(II) chloride complex of a tren-based tris-[12]aneN4 ligand. H-atoms are 
omitted for clarity (Bazzicalupi et al.).
59
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1.3.2.2. Diagnostic agents 
1.3.2.2.1. Radiopharmaceuticals 
Another main area in which cyclen macrocycles are used is in the production of 
radiopharmaceuticals. Radiopharmaceuticals have been synthesised for either whole 
organism or site specific imaging. Selected examples for both areas are now 
discussed. 
1.3.2.2.1.1. 64Cu Radiopharmaceuticals 
Radiopharmaceuticals using 
64
Cu have been studied extensively, as has been 
discussed for cyclam compounds in section 1.3.1.1.1. The in vivo behaviour of 
copper(II) cyclen complexes bearing tert-butyl benzyl and acetate arms has been 
investigated by Welch and co-workers.
60
 Partition coefficient measurements showed 
an increase in hydrophobic tendencies for copper(II) complexes bearing tert-butyl 
benzyl arms. Conversely, acetate groups caused the complexes to display hydrophilic 
tendencies. However, the biodistribution of both types of compounds was found to 
be reliant on the overall charge of the complex. These charged complexes studied 
were found to have high blood retention times over an initial 15 min period 
compared with neutral complexes. 
The copper(II) complex of the ligand H2Me2DO2A has also been investigated as a 
potential positron emission tomography imaging agent.
61
 Protonation studies of the 
copper(II) complex showed that protonation occurs at the two methyl-substituted 
amines before protonation of the carboxylate arms, suggesting good stability for the 
complex in vivo. The crystal structure of this complex is shown in Figure 12. In the 
crystal structure, the copper(II) ion lies in a distorted octahedral geometry with two 
nitrogens from the ring capping the octahedron. Further evidence for stability at 
physiological pH was gained from cyclic voltammetry, which displayed only one 
irreversible peak at -0.81 V, assigned as the reduction of copper(II) to copper(I) with 
concomitant decomplexation. Biodistribution studies highlighted that the compound 
was able to cross the blood brain barrier. 
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Figure 12: Ball and stick representation of the X-ray crystal structure of the 
Cu(II) complex of Me2DO2A. H-atoms have been omitted for clarity (Sun et 
al.).
61
 
1.3.2.2.1.2. Bone-seeking radiopharmaceuticals 
Another area of radiopharmaceutical design in which cyclen ligands are currently 
being used is in the development of bone-seeking agents. These ligands typically 
possess phosphate groups to enable favourable distribution to the bone. Cyclen 
derivatives with two, three or four methanephosphate pendant arms have been 
synthesised.
62
 All complexes displayed high accumulation in the bone, possibly due 
to the binding of the methanephosphonate groups to hydroxyapatite. Of the three 
complexes studied 1,4,7,10-tetraazacyclodecane-1,7-di(methanephosphonic acid) 
was the most suitable candidate for bone imaging as it was highly stable in rat serum 
over a period of 24 hr and also showed the best clearance through the blood and 
liver. A further ligand synthesised with methanephosphate arms attached is shown in 
Figure 13 (L
10
). The lanthanum(III), samarium(III) and holmium(III)
 
complexes of 
the ligand were prepared.
63
 These ligands formed highly stable complexes, which 
 27 
 
possessed higher thermodynamic stability constants than their acetate counterparts. 
Biological distribution studies showed that for the 
166
Ho 13-membered 
tetraphosphanote complex a pronounced level of uptake occurred in the bone after 30 
min (~6.5%). Because of this, bone/blood and bone/muscle ratios were quite 
favourable (0.4 and 3.1% ID (injection dose) respectively). 
153
Sm labelled compound 
had less favourable ratios due to a faster decrease of radioactivity, and excretion 
from main organs being slower. 
Another cyclen ligand with phosphate arms attached which was developed for bone 
palliation is L
11 
(Figure 13).
64
 The bis(phosponate) arm does not coordinate to the 
metal centre and is protonated at physiological pH. Radioimaging studies using 
177
Lu 
were conducted using a large excess of ligand to negate the high affinity of the 
lutetium(III) ion for bone. The complexes showed high affinity for newly formed 
bone thus making them suitable candidates as diagnostic agents for bone tumours. 
Although a single water molecule is still present in the first coordination sphere of 
the gadolinium complex, the poor clearance from the skeleton probably makes these 
compounds unsuitable as contrast agents for MRI. 
 
Figure 13: Chemical structures of L
10
 and L
11
. 
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1.3.2.2.1.3. Bioconjugate radiopharmaceuticals 
Cyclen ligands can have peptide targeting vectors tethered to them. This enables 
selective diagnostic imaging of particular cells or tissues. A review on the synthesis 
and chelation chemistry of DOTA-peptide conjugates has been published recently,
65
 
as well as a review on the rational design of protein-conjugated MRI contrast 
agents.
66
 
A number of examples of cyclen derived protein- and antibody-conjugates have been 
produced. Examples of biomolecules used in the formation of protein-conjugates 
include RGD, octreotate, estradiol and naltrindole. A DOTA-conjugated 
111
In-
labeled RGD-dendrimer has been synthesised.
67
 These dendrimers display enhanced 
uptake in αvβ3 integrin expressing tumours in vivo. Monomeric, dimeric and 
tetrameric cyclo(Arg-Gly-Asp-D-Phe-Lys) dendrimers were produced using click 
chemistry, all consisting of a single gadolinium(III) chelate. In vivo studies showed 
that the tetrameric RGD-dendrimer had better tumour targeting properties than its 
dimeric and monomeric congeners. 
DOTA derived macrocycles were also used to synthesise octreotate conjugates. The 
synthesis of DOTA-D-Tyr
1
-Octreotate enabled both labelling with both 
radiohalogens and radiometals.
45
 The 
125
I labelled conjugate showed high residual 
concentration in the tumour 4 hr post injection, suggesting retention of the 
radioisotope within the tumour mass. The 
64
Cu conjugate displayed better selectivity 
for the tumour compared with the 
125
I conjugate (1.515 ± 0.154 % ID/g and 0.814 ± 
0.058% ID/g respectively). 
The choice of metal ion chelated to DOTA-D-Tyr
1
-Octreotate is of structural 
significance as it can induce conformation change upon the D-Phe
1
 linker.
47
 The 
peptidic part of the conjugate exists in a dynamic equilibrium between a helical and 
sheetlike structure. NMR data obtained from both yttrium(III) and gallium(III) 
complexes
46
 are comparable for the peptidic moiety meaning that the differences 
reported in bioavailability
68
 must be due to differences found in the D-Phe
1
 linker. In 
the yttrium conjugate, the D-Phe
1
 linker is involved in the metal coordination sphere 
whereas in the gallium conjugate the linker assumes an extended conformation. As 
the D-Phe
1
 residue is important in the binding of the peptide to the somatostatin 
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receptor, the differences in the coordination sphere of the metal ions leads to the 
enhanced specificity as observed for the gallium conjugate. The crystal structure of 
the gallium(III) complex of the ligand is shown in Figure 14.
23
 It is worth noting that 
in the crystal structure one of the acetate arms on the cyclen ring is not coordinated 
to the metal centre. The gallium ion adopts a cis-pseudo-octahedral geometry with a 
folded macrocyclic unit (2424 conformation). The benzyl amine on the pendent arm 
provides a convenient point for biomolecule attachment. 
 
Figure 14: Ball and stick representation of the X-ray crystal structure of 
gallium(III)-DOTA-D-PheNH2. H-atoms are omitted for clarity (Eisenwiener et 
al.).
23
 
Further cancer selective radiopharmaceuticals have been synthesised. Estradiol-
conjugates have been reported for use as a radiotherapeutic agent in targeting breast 
carcinomas. p-NCS-benzyl-DOTA conjugated to estradiol with a radioactive 
177
Lu 
centre was tested for its binding affinity to MCF-7 cells.
69
 A binding of 13.2 ± 0.8% 
was observed with 5x10
4
 MCF-7 cells for 1 μg of the conjugate. Studies carried out 
using the radiolabelled bifunctional chelator showed no retention of activity in the 
cell pellet, thus ruling out carrier mediated uptake. Furthermore, antibody 
competition binding studies confirmed that there was no change in binding 
properties after incorporation of the BFC.  
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Radiopharmaceuticals which can pass the blood brain barrier have been synthesised. 
These are of interest as they can be used to image brain signalling pathways, for 
example. Naltrindole (NTI) is currently used in in vivo studies for imaging of δ 
opioid receptors. Radioligands incorporating this moiety have been synthesised for 
use in PET. These ligands are lipophilic to enable passage across the blood brain 
barrier, but there is an emerging need for hydrophilic radioligands to be synthesised 
to enable peripheral δ opioid receptors to be imaged. This is because δ opioid 
receptors are present in normal heart cells and in primary tumours of the lung and 
breast. Lever and co-workers have synthesised 
111
In DOTA and DO3A NTI 
bioconjugates for exactly this purpose.
70
 Both metal complexes displayed high 
binding affinities (0.1 - 0.2 nM) and excellent selectivities for binding to δ receptors 
in vivo. An alkyl chain ((CH2)n, where n=3 or 6) was used to attach the NTI to the 
macrocycle and this also acts as a pharmacokinetic modifier with the log D7.4 values 
ranging from -2.74 (n=3) to -1.79 (n=6). A high level of specific binding (75 - 94%) 
to δ opioid receptors was observed in mouse gut, heart, spleen and pancreas. 
Sugar moieties have also been used to prepare radiopharmaceutical conjugates. For 
example, lanthanide(III) complexes of DOTA-glycoconjugates have been prepared 
as a potential new class of lectin-mediated medical imaging agents.
71
 Samarium(III), 
europium(III) and gadolinium(III) mono, di and tetra mono-amide linked 
glycoconjugates (glucose, lactose and galactose) complexes were prepared. 
Biodistribution studies of 
153
Sm- labelled glycoconjugates of different valancies and 
sugar type indicated a specific hepatic uptake of the galactose and lactose 
glycoconjugates through the ASGPR (asialoglycoprotein receptor). 
An example of an antibody conjugate has been published by Jurisson and co-
workers, who were investigating B72.3 (a bombesin antibody) conjugates of DOTA 
derivatives.
72
 Three analogues were evaluated by Jurisson and co-workers; “NHS-
DOTA”, “Arm-DOTA” and “Back-DOTA” (chemical structures shown in Figure 
15). B72.3 was conjugated to these macrocyclic ligands and complexed with 
111
In, 
177
Lu and 
90
Y. Overall, the 
90
Y labelled conjugates were the least stable based on 
bone uptake (2 - 20% ID/g compared with 2 - 8% ID/g for 
111
In and 
177
Lu). In fact 
for the 
90
Y Arm-DOTA conjugate, significant instability of the complex was 
observed, suggesting possible leaching of the metal from the chelate rather than 
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metabolism of the radiolabelled conjugate to smaller molecule weight fragments. 
Further conjugates towards bombesin receptor-positive tumours have been 
synthesised using the 15-amino-4,7,10,13-tetraoxopentadecanoic acid (PEG4) 
spacer.
73
 IC50 values of the lutetium(III) and gadolinium(III) complexes were found 
to be 6.1 ± 3.0 and 6.6 ± 0.1 nmol/l respectively. Binding studies showed good 
binding to neuromedin B receptors (NMB-R) and GRPR but no affinity to BB3-R (a 
bombesin receptor). Rapid blood clearance was observed for both conjugates (0.1-
0.47 % ID/g at 4 hr post injection) and, in addition, were quickly washed from 
GRPR negative tissues except the kidneys. 
 
Figure 15: Chemical structures of “NHS-DOTA”, “Arm-DOTA” and “Back-
DOTA”. 
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1.3.2.2.2. Magnetic resonance imaging contrast agents 
Magnetic Resonance Imaging (MRI) is another major area in which cyclen 
derivatives are used for diagnostic purposes. Gadolinium(III) complexes have been 
widely investigated as MRI contrast agents.
74
 The small cavity size of cyclen and the 
ability to attach pendent arms through the nitrogen atoms enables gadolinium(III) 
complexes to be formed which are highly stable. Gadolinium(III) is used in MRI 
extensively as is paramagnetic. Interaction of the magnetic field with protons in the 
near vicinity enables an enhanced image to be produced. For image enhancement to 
occur, water must ideally be able to enter the inner coordination sphere of the metal 
ion. It is therefore fitting that considerable research effort has been dedicated to the 
manipulation of the inner coordination sphere through biological and chemical 
intervention. 
An example of how the inner coordination surrounding the gadolinium ion can be 
altered via a biological process has been reported. Meade and co-workers 
synthesised a gadolinium(III) 1,4,7,10-tetraazacyclodecane-1,4,7-triacetic acid 
(DO3A) complex bearing a pendent β-glucuronic acid moiety.75 This complex is 
enzymatically processed by bovine liver β-glucuronidase, generating 2-aminoethyl 
gadolinium(III)DO3A (Scheme 1). The relaxivity differential between glucose-
DO3A and non-glucose DO3A was found to be approximately 27% brighter in 
human serum. This difference is suggested by the authors to be sufficient for in vivo 
imaging. Meade and co-workers have produced another bioactivated MR contrast 
agent. In this compound a galactopyranose sugar is tethered to a DO3A chelated 
gadolinium(III) to modulate the hydration state of the metal.
76
 A propyl linker was 
used in between the sugar and macrocyclic scaffold, which possessed a 
sterochemical centre, enabling the R and S compounds to be isolated as either the α 
or β form. The β form was found to have a bidentate carbonate anion to 
coordinatively saturate the complex (relaxivity measurements showed a dependence 
on carbonate concentration). Upon cleavage of the sugar, a newly formed hydroxyl 
group displaces the carbonate enabling water to enter the inner sphere. The α form is 
entirely different, as the stereochemistry means that the galactopyranose is likely to 
be positioned directly over the open coordination of the gadolinium(III) and as such 
prevents water entering the inner sphere (relaxivity measurements showed a 
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carbonate concentration independence). However, just like the β form, upon 
cleavage, water is able to enter the coordination sphere. 
 
Scheme 1: Hydrolysis of the β-glucuronic acid moiety by β-glucuronidase 
leading to a change in the hydration state of the gadolinium(III) ion. 
The choice of pendent arm attached to the cyclen framework can effect the number 
of water molecules able to access the inner coordination sphere. For example, 
heptadentate gadolinium(III) complexes with functionalised propyl or polyethylene 
glycol (PEG) chains attached show different effects upon interaction with human 
serum albumin (HSA).
77
 The complexes with propyl functionalised pendent arms 
enable two water molecules to enter the inner coordination sphere whereas 
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complexes with PEG chains only allow access for one water molecule. However, the 
expected relaxation enhancement upon binding to HSA was not observed; this was 
attributed to the displacement of coordinated water molecules by the protein. 
 
Figure 16: Chemical structure of L
12
. 
Chemical modification of the coordination sphere has also been investigated. This 
can be achieved by, for example, the inclusion of a pH responsive group. This can 
allow the modulation of the hydration state, enabling the relaxivity of the complex to 
be “tuned”. This has been explored by Sherry and co-workers, by using a p-
nitrophenol pendent arm which dissociates at low pH.
78
 Two gadolinium(III) 
chelates were formed based on L
12 
(Figure 16), consisting of a nitrophenolic arm 
plus either three acetates or three amide pendent arms. The crystal structure of the 
europium(III) complex of L
12
 (R = NH2) is shown in Figure 17. The formal charge 
of the complex was found to be 2+, implying that the phenol is deprotonated. The 
europium(III) ion sits in a distorted monocapped square antiprismatic geometry with 
the cyclen ring adopting a [3333] conformation. The relaxivity of the gadolinium(III) 
complexes were found to differ over a range of pH. At pH 9 the acetate complex has 
a relaxivity of 4.1 mM
-1
s
-1
 whereas the amide complex has a relaxivity of ~2.75  
mM
-1
s
-1
. At pH 5, these values increase to 7 and 3.4 mM
-1
s
-1
 respectively. For the 
acetate complex, the change is ascribed to the phenol becoming protonated and 
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dissociating from the complex, which results in an increase in the hydration state of 
the metal from 1 to 2. The increase in relaxivity for the amide complex was believed 
to be due to an increase in prototropic exchange of bound water and/or phenolic 
protons. Dissociation does not occur due to the reduced electron-donating capacity of 
the amide-ligating groups rendering the gadolinium(III) ion too electron deficient to 
enable release of the phenol. 
 
Figure 17: Ball and stick representation of the X-ray crystal structure of the 
Europium complex of L
12
 (R = NH2). H-atoms and triflate counter ions have 
been omitted for clarity (Woods et al.).
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Sherry and co-workers have also investigated the effect of electronic substituents on 
the modulation of water exchange.
79
 Cyclen was tri-alkylated with ethyl-N-
bromoacetylglycinate, with the remaining secondary amine being alkylated with 
various p-substituted bromoacetyl aniline derivatives (where X=CO2
t
Bu, CN, F, H, 
OMe, Me and NO2/NH2). Residence lifetimes for electron-withdrawing groups were 
longer than electron-donating groups, with the opposite being observed for groups 
considered inductive (see Table 3). The p-nitro derivative was chemically reduced to 
the p-amino derivative which showed a difference in intensity of ~30% from 
chemical exchange saturation transfer (CEST) images. 
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X substituent effect τM(μs) Δω (ppm) 1-(Ms/M0) 
  Mesomeric   
CO2
t
Bu -M 352±17 47.69 0.415 
CN -M 324±33 47.61 0.477 
H 0 269±32 46.72 0.611 
OMe +M 198±19 47.25 0.194 
  Inductive   
F -I 144±8 44.98 0.347 
H 0 269±32 46.72 0.611 
Me +1 310±55 46.89 0.113 
 Table 3: Effects of the X substituent on residence lifetimes in the europium(III) 
complexes prepared by Sherry and co-workers.
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Modification of the ligand framework can be used to allow site specific imaging. 
This can be approached in a number of ways, including the formation of liposomes. 
A bimodal fluorescent and paramagnetic liposome has been described by Miller and 
co-workers.
80
 Long alkyl chains were tethered to a DO3A chelator through the use of 
di-amide small linker. Liposomal formulations of gadolinium(III) complexes were 
then evaluated by fluorescence microspcopy and MRI. Uptake of the Gd-liposomes 
into cells (HeLa) showed a marked reduction in their MRI T1 relaxation times. 
Formulations were shown to have minimal cytotoxicity and also have a capacity for 
plasmid DNA transfection. A second neutral bimodal gadolinium(III)-liposome is 
described for labelling tumours in vivo. From MRI images obtained, the imaging 
agent was clearly localised in the tumour mass and this was verified using 
fluorescence microscopy. 
A tetra-nuclear gadolinium contrast agent which is fibrin-specific has been designed 
and synthesised for detection of thrombus.
81
 The gadolinium(III) ion is bound to a 
DO3A derived macrocycle with two such entities capping each end of a polypeptide 
through both C and N termini. Two binding assays were used to assess the viability 
of these agents for thrombin detection. Plasma clot and dried fibrin assays yielded 
comparable results in both the number of binding sites (1.9 ± 0.1 and 1.7 ± 0.1 
respectively) and the dissociation constant, Kd (0.9 ± 0.3 and 1.6 ± 0.2 respectively). 
High binding specificity to fibrin was observed in the presence and absence of 
plasma proteins, indicative of good selectivity. Binding of the polypeptide conjugate 
to fibrin increases relaxivity to 25 times that of Gd(DOTA) suggesting that this may 
be a good candidate for detecting blood clots in vivo. 
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Contrast agents which are sensitive towards metal ions are desirable because they 
can highlight areas of high concentration of certain metallic ions. This is highlighted 
by either an increase or decrease in image brightness in these areas. Calcium 
sensitive contrast agents have been produced. One such agent has been reported by 
Logothetis,
82
 which shows ~100% relaxivity enhancement upon addition of 
calcium(II). This agent is also selective for calcium(II) in the presence of 
magnesium(II) and zinc(II). Relaxivity enhancement occurs by a water molecule 
entering the inner sphere of the gadolinium(III) centre upon binding to calcium(II). 
The hydration numbers obtained are 0.17 in the absence of calcium(II) and 0.88 in 
the presence of calcium(II). 
The development of new synthetic protocols with which to synthesise contrast agents 
are being developed. For example, click chemistry has been used by Meade and co-
workers to produce multimeric MR contrast agents with high relaxivities.
83
 Agents 
synthesised had either three, six, or seven gadolinium(III) centres, with the latter 
producing a relaxivity of 85.4 ± 3.74 mM
-1
s
-1
. Examination of the three agents 
showed that they were mono-disperse and had good biocompatibility. 
Further investigations into using DO3A derived complexes for molecular imaging 
have focused on using α-amino acids as linkers.25,84 This enables the tethering of a 
biomolecule to achieve selectivity for tissue type and also a further acetate group 
with which to coordinate to the lanthanide metal to give a coordination number of 
eight. 
New imaging techniques based on magnetic resonance are currently in development. 
Two such examples are Magnetic Resonance Spectrosopy (MRS) of biological 
systems and paramagnetic chemical exchange saturation transfer (PARACEST). 
MRS enables the analysis of the chemical content of living tissue to take place in 
vivo. A variety of heptadentate ligands complexed with lanthanide metals have been 
prepared to act as shift and relaxation agents in MRS.
85
 
1
H NMR studies for the 
detection of lactate highlighted that the later lanthanides (terbium(III), 
dysprosium(III), thulium(III), ytterbium(III)) may exhibit an optimal Δδ/Δv½ ratio. 
However, the high Lewis acidity of these ions prevents fast exchange conditions 
from being met. Early lanthanide ions possess opposite characteristics in that they 
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have a reduced Lewis acidity but spectral analysis is made difficult by line 
broadening and small spectral range. 
Di-peptide PARACEST MRI agents have been developed by Hudson and co-
workers.
86
 The methodology that they utilised enabled the preparation of 
tetraalkylated cyclen-oligopeptide conjugates to be produced in yields greater than 
90%. Complexation of these oligopeptide conjugates to dysprosium(III), 
europium(III), neodymium(III), terbium(III), thulium(III) and ytterbium(III) is 
strongly dependent on the oligopeptide sequence with yields ranging from 42 - 98%. 
Europium(III) DOTAM complexes displayed the most strongly bound water signal 
in the CEST spectrum, especially the complex possessing the Gly-Phe-OH 
oligopeptide sequence (CEST effect ~45% at physiological pH and temperature). 
Conversely, changing the oligopeptide sequence to Asp-Phe-OH showed only a 
small CEST effect. 
1.3.2.3. Therapeutic agents 
Cyclen derived macrocycles have also been investigated with regard to possible 
therapeutic benefit. For example, macrocyclic ligands formed from the condensation 
of ethylene diamine or 1,3-dibromopropane with malonic or succinic acid have been 
synthesised with a view to examining their anti-inflammatory, anti-fertility and anti–
microbial properties.
87
 Sperm motility and fertilizing capacity of spermatozoa 
displayed a severe decrease in the presence of manganese(II) complexes. Protein 
content in the testes, epididymis, ventral prostrate and seminal prostrate decreased by 
as much as 50% when compared with the control. This decrease in protein content 
was attributed to androgen deficiency, which was reinforced by data showing a 
decrease in sialic acid content in rats treated with the manganese complexes. Anti-
inflammatory action was shown to increase with the increasing size of the 
macrocyclic ring, but all compounds tested displayed lower anti-inflammatory 
activity than phenylbutazone, a known anti-inflammatory. 
A further therapeutic use of cyclen macrocycles is in the development of urea-
checkpoint kinase inhibitors.
88
 Macrocyclic ureas formed using a Grubbs metathesis 
macrocyclisation were investigated. Amino or ether analogues at the 4-position of a 
component benzene ring were developed, with IC50 values being obtained in the 1 to 
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10000 nM range. A number of compounds were identified as ideal Chk1 inhibitors, 
as they exhibited little or no antiproliferative activity alone but significantly 
potentiated the cytotoxities of DNA-damaging agents. 
1.3.2.4. Optical probes 
The use of cyclen ligands in the preparation of optical probes for use in a range of 
different techniques is well documented. A perspective article on emissive 
europium(III) and terbium(III) complexes discussing their applications for molecular 
imaging and sensing has been published.
89
 Optical probes utilise the luminescence 
properties of lanthanides. This requires the lanthanide centre to be excited using light 
of an appropriate wavelength. Excited state lifetimes of the lanthanide(III) ions range 
from microseconds to milliseconds. This is advantageous as they allow time-
resolved spectroscopy and microscopy to be used, in which light scattering and auto-
fluorescence can be gated out prior to detection of luminescence from the lanthanide 
ions. However, excitation of the lanthanide(III) ion is very inefficient, leading to low 
values of ε (≤1 M-1cm-1) as the relevant f-f transitions are Laporte forbidden. 
Lanthanide complexes have therefore been developed which incorporate into the 
ligand structure a sensitising chromophore, capable of transferring its excited state 
energy to the encapsulated lanthanide(III) ion.  
Chromophores are typically conjugated systems which transfer energy during 
excitation directly to the metal centre. This increases the quantum yield of 
luminescence. The evaluation of europium(III) complexes bearing either 
azaxanthone or azathiaxanthone chromophores has been reported by Parker et al.
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These complexes were assessed as responsive probes for the intracellular 
environment. The most notable of these were the complexes of L
13
 which upon 
addition of HSA led to a very large decrease in europium(III) emission intensity with 
concomitant emission lifetime increase from 0.26 ms to 0.35 ms. More interesting 
was the addition of NaHCO3 causing the hypersensitive and electric-dipole allowed 
ΔJ=2 emission band to become more pronounced. The complexes of both derivatives 
were found to be non-cytotoxic, and they were found to localise in the mitochondria. 
Bi-nuclear optical probes are also of considerable interest. Faulkner and Pope have 
investigated bis-lanthanide systems using two DO3A chelators to chelate the ions. 
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These were joined together via the free secondary amine using linker groups (L
14
). 
By using a phenol derivative as the linker group, the authors were able to create two 
environments for which the lanthanide ion could be held.
91
 Luminescence studies 
showed that there were two distinct lanthanide environments co-existing on the 
luminescence timescale. Luminescence lifetimes measured in D2O and H2O fitted to 
two exponential decay components were obtained, which gave rise to two inner 
sphere hydration numbers of 0.3 and 1. Given that the two metal centres have 
coordination numbers of 7 and 8, the low inner sphere hydration numbers were 
attributed to the lipophilicity of the linking phenolate preventing water molecules 
approaching the metal centres. The authors have also used xylene as the linker group 
(L
15
).
92
 This allowed the inner sphere hydration of different metal ions to be probed. 
The inner sphere solvation (q) of the lanthanide(III) ions under study decreased 
along the group; for lanthanum(III) q=2, terbium(III) q=1.4 and ytterbium(III) q=0.4. 
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Figure 18: Chemical structures of LnL
13
, Yb2L
14
 and L
15
. 
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Tri-nuclear optical probes have also been produced. An example of such a probe has 
been synthesised by Pope and Faulkner.
93
 DTPA was used as the linker between two 
terbium DO3A complexes each with a pendent aminobenzyl arm, before introducing 
ytterbium(III) into the cleft of the DTPA. The close proximity of the metal ions 
enabled near-infrared (NIR) emission sensitized by the terbium(III) ions, evidenced 
by a peak at 980 nm in the ytterbium(III) sensitized emission. 
A further area in which optical probes are currently being developed is in the 
synthesis of metal ion sensitive probes. DOTA complexes and their analogues have 
been prepared as zinc(II) sensitive probes for biological systems.
94
 
 
Figure 19: Modulation of the coordination sphere surrounding the 
europium(III) ion due to coordination of a zinc ion by the bis-picolyl group. 
An example of a zinc(II) probe is shown in Figure 19. This example was prepared by 
Pope and Laye in which the structure incorporates a bis-picolyl unit into a europium 
DO3A complex (L
16
). Upon binding of zinc(II), the intensity of ligand fluorescence 
increased as did the inner sphere hydration of the europium(III) ion (q=0 to q=2).
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The aqueous environment was designed to replicate physiological conditions; pH 7.4 
using 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and an ionic 
buffer solution (140 mM NaCl, 4 mM KCl, 1.16 mM MgCl2, 2.3 mM CaCl2). The 
crystal structure of the sodium(I) complex of L
18
 is shown in Figure 20. The sodium 
is eight coordinate; three ester carbonyl groups, four macrocyclic nitrogens and the 
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nitrogen of the bridging 2,6-pyridyl moiety all coordinate to it. The bis-picoyl 
nitrogens remain uncoordinated. 
 
Figure 20: Ball and stick representation of the X-ray crystal structure of the 
sodium complex of L
16
. H-atoms and two water molecules of crystallisation 
omitted for clarity (Pope and Laye).
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A further zinc(II) sensitive optical probe has been prepared. Aoki and co-workers 
have recently reported a compound which undergoes hydrolytic uncaging upon 
complexation with zinc(II).
96
 H2L
17
 possesses negligible fluorescence emission at 
pH 7.4, but upon the addition of zinc(II) significant fluorescence emission is 
observed at 512 nm (see Figure 21). The increase in fluorescence is attributed to the 
hydrolysis of a sulfonamide which is promoted by zinc(II) bound hydroxide. 
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Figure 21: Figure showing conditions for the formation of the zinc(II) complex 
of L
17
 which occurs at neutral pH. 
A further example of fluorescent metal sensitive probes has been published, which 
can be used in the detection of zinc(II) and cadmium(II) ions.
97
 The probe consists of 
an 8-hydroxy-5-N,N-dimethylamidosulfonylquinolin-2-ylmethyl pendent arm 
tethered to a cyclen ring. The cyclen ring quenches the fluorescence emission of the 
quinolinol moiety. However, when complexed to either zinc(II) or cadmium(II), 
emission at 512 nm was increased by factor of seventeen and forty-three 
respectively. 
A number of techniques such as luminescence resonant energy-transfer (LRET) and 
time-resolved long-lived luminescence microscopy (TRLLM ) are being developed 
which use luminescent optical probes. For example, LRET experiments using 
europium(III) complexes have shown these to be viable potential probes for 
bioanalysis.
98
 The europium(III) centre is held in the cleft of a DOTA derived 
macrocycle, with a non-coordinated carboxylic acid function as a potential linker to 
biomolecules (L
18
). LRET was observed when Cy5 dye was added to a solution of 
the europium(III) complex. 
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Figure 22: Chemical structure of L
18
. 
TRLLM can also be used to visualise biomolecules within living biological samples. 
This technique enables nano-second resolution enabling the interactions of proteins, 
for example, to be imaged. Nagono and co-workers have developed a new TRLLM 
system using conventional fluorescence microscopy coupled with an image 
intensifier and a xenon flash lamp in order to use luminescent europium(III) DOTA 
derived complexes (L
19
).
99
 The newly developed europium(III) complexes were used 
to obtain fluorescence images from cells in conjunction with the TRLLM system, 
with short-lived fluorescence being excluded. 
 
Figure 23: Chemical structure of L
19
. 
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1.4. Penta-, hexa- and octa-aza macrocycles and their 
analogues 
Penta-, hexa- and octa-aza macrocyles have been synthesised towards enzyme 
mimicry and therapeutic and diagnostic applications. The larger ring size of the 
macrocycle can be tailored towards the design of cage complexes. A recent review 
has been published in 2007 on cage complexes of transition metals in biochemistry 
and medicine.
100
 Selected examples for enzyme mimicry and therapeutic and 
diagnostic applications are now discussed. 
1.4.1. Enzyme Mimics 
Hydrolytic phosphate-ester cleavage catalysts have been produced using lanthanide 
and transition metal ions. An example of a lanthanide hydrolytic catalyst has been 
prepared, with the specific aim of cleaving RNA.
101
 A europium(III) ion was 
complexed to the ligand 1,7-diaza-4,10,13-trioxacyclopentadecane-N,N’-diacetic 
acid which exists as a monomer below pH 7. Upon increasing the pH above 7, a 
dimeric complex is formed, in which the europium(III) centres are bridged by one 
hydroxide initially, and upon further increase in pH (>10), by two hydroxides. k’obsd 
plots for both the monomer and dimeric species in the presence of HpPNP show that 
the dimeric complex is the better catalyst. The monomeric and dimeric transition 
states involved in the cleavage of HpPNP are stabilised to a similar extent (-7.1 and -
7.6 kcal mol
-1
), suggesting that the europium(III) ion in both complexes only weakly 
interacts with the substrate. 
A further example of a hydrolytic catalyst has been prepared using transition metal 
ions at the catalytic centre. The di-nuclear copper(II) complexes of the hexaaza 
macrocycle 2,5,8,17,20,23-hexaaza[9.9]paracyclophane (PEA) has been prepared.
102
 
The complex catalyses hydrolysis of the phosphotriester 2,4,-dinitrophenyl diethyl 
phosphate (DNPDEP), where [Cu2(PEA)(OH)2]
2+
 and [Cu2(PEA)(OH)]
3+
 were 
identified as the active species. Low activity was observed below pH 7 but 
substantial rate increases above pH 7 are consistent with the active species being a 
hydroxo species. Two mechanisms for hydrolytic cleavage are suggested; one in 
which the same copper ion is used for coordination of the substrate and hydrolytic 
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cleavage, and one where both copper ions are actively involved in coordination and 
hydrolysis.  
Hexaaza copper(II) macrocyles have been synthesised to investigate their interaction 
with calf thymus DNA.
103
 Copper(II) complexes of both cyclam and the di-propyl 
hexaaza ring were produced. The crystal structure of the former (Figure 24) shows 
that the copper(II) ion adopts a square planar geometry. Both complexes bind to 
DNA through electrostatic interactions, whereas the di-benzyl hexaaza ringed 
complex (crystal structure shown in Figure 24) intercalates with DNA through the 
two aromatic rings. As such, the side chain plays a key role in determining the mode 
of binding of the copper complex to DNA. The copper complexes were shown to 
exhibit nuclease activities, in that circular plasmid DNA was converted to nicked 
DNA. 
 
Figure 24: Ball and stick representation of the X-ray crystal structure of the 
copper(II) dibenzyl hexa-aza ringed complex. H atoms have been omitted for 
clarity (Liu et al.).
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1.4.2. Diagnostic agents 
MRI contrast agents and radiopharmaceuticals using penta-, hexa- or octa-
macrocycles have also been investigated. For example, a macrocyclic ligand formed 
by the condensation of 2,6-pyridinedimethaneamine (PDA) with diethylenetriamine 
pentaacetate (DTPA) has been reported by Li et al. for the purpose of cell labelling 
and magnetic resonance imaging applications.
104
 Two long alkyl chains rendered the 
complexes lipophilic with the gadolinium(III) complexes being able to label 
mammalian cells non-invasively at concentrations in the micromolar range. Cultured 
cells took up the gadolinium(III) complexes rapidly leading to the production of T1-
weighted MR images of increased intensity. From diffusion enhanced fluorescence 
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resonance energy transfer (DEFRET) studies it was possible for the authors to 
hypothesise that the complexes labelled the cells by insertion of the two hydrophobic 
chains into the cell membrane with the hydrophilic binding site facing the 
extracellular medium.  
 
Figure 25: Chemical structures of L
20
 and L
21
. 
Further compounds for diagnostic purposes have been prepared. SarAr, a hexa-aza 
cage, has recently been used to coordinate 
64
Cu as a PET emitter.
105
 An antibody, 
B72.3, was tethered to SarAr via a aminobenzyl linker, which meant that the 
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conjugate would interact with a tumour-associated glycoprotein, TAG-72. Tumour 
localisation of the bioconjugate to the target site reached 38% ± 5% ID/g within 48 
hr. Stability of the 
64
Cu complex was maintained in vivo. 
1.4.3. Therapeutic agents 
Therapeutic agents have been prepared utilising penta-, hexa- or octa-macrocyclic 
frameworks. One such example uses a templated synthesis to produce octaaza 
macrocyles and reports their biological screening.
106
 The cadmium(II) bromide 
complex had desirable anti-microbial properties, with minimum inhibitory 
concentrations (MICs) of between 2-4 μg ml-1 against S. aureus, S. epidermidis, S. 
typhi and P. aeruginosa. These values showed that this compound was more potent 
than Cefaclor and Linezolid, two standard antibiotics. 
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1.5. Porphyrin and phthalocyanine based macrocycles 
Porphyrins and phthalocyanines are currently being developed as photo-dynamic 
therapeutic agents. Photodynamic therapy (PDT) is an emerging technique which is 
used to treat cancer. Porphyrin and phthalocyanine (Pc) compounds and complexes 
when irradiated with light of an appropriate wave-length produce singlet oxygen, a 
cytotoxic species. The highly reactive nature of singlet oxygen damages cancerous 
cells leading to cell death. Both types of compound are currently being developed to 
increase the quantum yields of singlet oxygen and to also mitigate the innate 
hydrophobicity of the porphyrins so that they can be used intravenously. Other uses 
of phthalocyanines and porphyrins include enzyme mimicry and catalytic therapy.  
1.5.1. Porphyrin photodynamic therapy agents 
The main area in which porphyrins are used is as PDT sensitisers. A variety of 
different approaches to obtain this goal have been taken. For example, tetra(4-
pyridyl)porphyrin (L
22
) organometallic ruthenium(II) arene complexes have been 
produced by Therrien and co-workers.
107
 The ruthenium(II) ions coordinate to the 
nitrogens around the periphery, creating tetra-nuclear species. These compounds also 
possess chemotherapeutic activity whilst still retaining photodynamic therapeutic 
properties. Cellular uptake and localization microscopy studies revealed that the 
compounds accumulated in the melanoma cell cytoplasm in granular structures 
different from lysosomes. Upon irradiation at 652 nm (5 Jcm
-2
) cell survival in the 
presence of the ruthenium(II) compounds ranged from approximately 20 - 45%. 
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Figure 26: The chemical structure of L
22
. 
Site selective PDT is also a major goal of current research. A meta-
tetra(hydroxyphenyl)chlorin-like photosensitiser conjugated to folic acid has been 
developed to increase the delivery of the agent to tumour sites.
108
 A polyethylene 
glycol chain is used as a spacer between the chlorin and folic acid. The folic acid 
conjugate and the unconjugated chlorin were incubated with FR-α-positve KB cells 
or HT-29 cells lacking FR-α. The folic acid conjugate was shown by optical fiber 
fluorimetry to have enhanced accumulation in KB cells and displayed remarkable 
selectivity for tumour-to-normal tissue (5:1 ratio) after 4 hr postinjection. The 
unconjugated chlorin was shown to be taken up by KB and HT-29 cells. 
Further research has focused on the delivery of the photosensitiser and its 
photoactivity. The photodynamic effect of 5-(4-carboxyphenyl)-10,15,20-tris(4-
methylphenyl) porphyrin has been compared in homogenous medium and in reverse 
micelles of n-heptane/sodium bis(2-ethylhexyl)sulfo-succinate (AOT)/water bearing 
urease as a biological substrate model.
109
 In AOT micelles, the high amphiphilic 
capability of the sensitisers binds the porphyrins to the interfacial region of the 
reverse micelles. The singlet oxygen generated in these systems was thought not to 
be distributed evenly across the microheterogenous system as the enzyme activity 
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was much higher than in homogeneous solution. In addition, the presence of azide 
led to the photo-protection of the enzyme in both systems. Therefore, the authors 
concluded that singlet oxygen was responsible for the inactivity of the urease.  
1.5.2. Phthalocyanine photodynamic therapy agents 
Phthalocyanines are also used as sensitisers for PDT. A route to the production of 
metal-free phthalocyanines for this purpose has been reported. The cyclisation of 
1,2,:5,6-di-O-isopropylidine-α-D-glucofuranose or 1,2:3,4-di-O-isopropylidine-α-D-
galactopyranose analogues using cerium(III) chloride affords the metal-free 
phthalocycanines in moderate yield (47% and 58% respectively).
110
 Mono-
glycosylated Pcs exhibit significantly higher phototoxicity compared with the tetra-
α-glycosated analogues. IC50 values for the former were reported down to 0.9 μM. 
The lower phototoxicities of the tetra-α-glycosated Pcs was explained in terms of 
lower cellular uptake and/or higher aggregation tendency. 
Functionalisation of the phthalocyanine periphery can aid water solubility, whilst 
still retaining light induced phototoxicity. Vicente and co-workers utilised this 
approach in preparing PEGylated cationic zinc(II) phthalocyanine complexes.
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Despite high water solubility, the complexes were not present as monomers in 
solution but as aggregates. Exchange of the zinc(II) ion for silicon incorporating 
axial substituents was efficient in preventing aggregation. These amphiphilic silicon 
complexes were highly phototoxic (IC50 = 2.2 μM at 1 J cm
-2
 light dose) and also 
localised in the lysosomes despite their octa-cationic nature. 
The preparation of peptide-pthalocyanine conjugate can enable the site selective light 
induced cytotoxicity. Two zinc(II) phthalocyanine complexes bearing a bifunctional 
peptide have been reported.
112
 The peptide contains sequences for both the bipartite 
nuclear localisation signals (NLS) of nucleoplasmin and the human 
immunodeficiency virus I transcriptional activator (HIV-1 Tat). The peptide 
increases water solubility and these conjugates fluoresce in aqueous solutions 
(highest quantum yields observed at pH 5.0). Both conjugates were found to have 
low dark cytotoxicity towards human HEp2 cells (IC50 > 77 μM) but were highly 
phototoxic (IC50 < 2 μM at 1 J cm
-2
). The conjugate utilising a long PEG chain as a 
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linker accumulated considerably more effectively than the conjugate with a short 
PEG chain. 
1.5.3. Catalytic therapy agents 
CT (catalytic therapy) is a cancer treatment modality based on the generation of ROS 
(reactive oxygen species). Unlike PDT, light of an appropriate wavelength is not 
required to generate ROS. ROS is instead generated through a catalyst/substrate pair. 
This technique enables the treatment of cancers which are not accessible by light. 
The most frequently used substrate and catalyst pair is ascorbate/Co phthalocycanine 
(PcCo). However, porphyrins are now being explored as a possible alternative to 
phthalocycanines as they have fewer side effects and are considered to be just as 
potent.
113
 Breast cancer tumour cells were reduced by 20-40% after a single in vitro 
treatment, using Co(III) hemaotoporphyrin chloride/ascorbate. Apoptosis was 
stimulated in the cancer cells and the cell cycle disrupted. The number of cells 
accumulating in the sub G0/G1 stage of the cell cycle increased from 3- to 10-fold, 
providing evidence for possible DNA induced damage in the tumour cells. 
1.5.4. Enzyme mimics 
Porphyrins have been synthesised to mimic SOD. A multitude of approaches have 
been taken to modify porphyrin analogues to obtain the catalytic efficiency shown by 
the enzyme. One such approach has been reported by Batinić-Haberle and co-
workers.
114
 Their work led them to synthesise porphyrins with positively charged 
pendent arms at the meso positions. Their findings show that for porphyrins of the 
same overall cationic charge, the charge placement and distribution within the aryl 
rings influence dramatically the redox modulation potency of the manganese(III) 
complexes. Placement of charge closer to the metal centre results in better in vitro 
and in vivo activity.  
A further example is where tri(ethyleneglycol)-derivatised manganese(III) 
porphyrins have been synthesised.
115
 Use of ortho pyridyl or di-ortho imidazolyl 
electron withdrawing groups enabled the metal centre to attain highly positive redox 
potentials (+250 mV for the tetra PEGylated pyridyl complex and +412 mV for the 
octa PEGylated imidazolyl complex). The PEG chains aid the water solubility of the 
complex. SOD-like activity was observed; log kcat of 8.11 (tetra PEGylated pyridyl 
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complex) and 8.55 (octa PEGylated imidazolyl complex). The former is only a few-
fold less potent in disproportionating O2
●−
 than the SOD enzyme itself. 
1.5.5. Therapeutic agents 
One aspect of therapeutic research using porphyrins and phthalocyanines has focused 
on their ability to intercalate with DNA. Tabata and co-workers have reported the 
use of lead(II), mercury(II) and cadmium(II) porphyrins towards this aim.
116
 These 
complexes were more effective than their free base analogues. The binding mode of 
the metal complexes relies on the strong intercalation of the ligand to DNA which 
results in the release of the metal ions. The released metal ions possess strong 
affinity for the DNA bases or phosphate groups of the DNA. Because of these two 
factors, the metal complexes were found to be toxic towards protozoan parasites that 
cause African sleeping sickness in man and livestock. 
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1.6. Summary 
This introduction contains a discussion of selected examples of aza-macrocycles 
used in enzyme mimicry, diagnostic and therapeutic applications and in the 
production of optical probes. The different cavity sizes of the macrocycles discussed 
enable the production of complexes using metal ions from the transition series, 
lanthanide series and p-block. The tailoring of the cavity can be used to 
accommodate ions of varying size. The metal ion used to form the complex is chosen 
based on the properties it possesses. For example, gadolinium(III) ions are used as 
MRI contrast agents because they are highly paramagnetic and can therefore enhance 
relaxivity of water protons in the immediate vicinity. Another example is the use of 
64
Cu in radiopharmaceuticals because it has favourable characteristics for both PET 
imaging and targeted radiotherapy. The structure of the ligand is designed to 
maximise the effectiveness of the metallic ion in its role (for example in enabling 
water molecules to access the coordination sphere of a gadolinium(III) ion in a 
contrast agent). In addition, the ligand is designed to meet the coordination 
requirements of the metal centre. This often requires the use of pendent arms which 
possess additional donor atoms. The macrocycle can be designed to increase the 
stability of the metal complex. This is an important consideration as decomplexation 
of the metal centre can lead to in vivo toxicity and loss of activity of the complex. 
The following chapters of this thesis discuss the design and synthesis of novel aza-
macrocyclic complexes bearing pendent arms. In Chapter 2 the design and synthesis 
of the pendent arms are discussed. In Chapters 3, 4 and 5 the attachment of the 
pendent arms to form new macrocyclic chelators and their complexes is reported. 
The properties of these complexes have been investigated with respect to biological 
applications. These applications include MRI and PDT. In Chapter 6 a summation of 
the research conducted is given and areas for further work discussed. 
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2. Design and synthesis of 
pendent arms 
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2.1. Introduction 
Pendent arms are used in ligand systems for a variety of structural or chemical 
reasons. The use of pendent arms expands the set of available donors and provides 
access to a variety of relatively preorganized ligands possessing ligating 
functionalities that cannot be incorporated into a macrocycle. This is often exploited 
in the production of complexes with attached biomolecules. The pendent arms 
themselves can be of chemical importance, possessing for example redox active 
centres or other desirable properties (such as acting as a photosensitiser).
1
 
Two types of pendent arm exist; coordinating pendent arm and non-coordinating 
pendent arms. Both types are considered, and examples of each type given. 
2.1.1. Coordinating pendent arms 
Coordinating pendent arms need to possess a donor atom in order to form an 
interaction with the metal centre. Such groups include ROH, RCONH2 and RCOOH 
for example. One of the most used pendent arms is the carboxylic group, mainly 
because it can be deprotonated and thus form an ionic bond with the metal centre. 
However, many pendent arms can induce metal-ion coordination even though the 
pendent arm incorporates weaker donors. This is because the donors are held near to 
the metal, favouring such interactions to occur. 
 
Figure 27: Ligands used in the formation of M(II) complexes in order to study 
their formation constants. 
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Table 4 shows the formation constants at 298.2 K for the complexation of cobalt(II), 
copper(II), zinc(II), cadmium(II) and lead(II) to the ligands as shown in Figure 27.
117
 
The data shows that the formation constant becomes lower as the number of donor 
atoms of the ligand increases.  
Ligand Co(II) Cu(II) Zn(II) Cd(II) Pb(II) 
mhpc12 10.5(1) 17.3(1) 13.7(1) 13.0(1) 14.7(1) 
1,4-dhpc12 9.7(1) 16.6(1) 12.3(1) 11.8(1) 13.5(1) 
Cyclen 13.8 23.3 16.2 14.3 15.9 
Table 4: Formation constants at 298.2 K for metal complexes of the ligands 
displayed in Figure 27. 
Parker and co-workers have used a sensitising azaxanthone group in a series of 
terbium(III) and europium(III) complexes.
118
 The azaxanthone group coordinates to 
the metal centre as well as acting as a sensitiser for the metal centre. It coordinates to 
the metal centre through a nitrogen atom, see Figure 28. 
 
Figure 28: An example of a lanthanide complex with a coordinating sensitiser. 
2.1.2. Non-coordinating pendent arms 
Non-coordinating pendent arms do not possess donor atoms capable of coordinating 
to a metal centre. They can instead be used to modify the properties of a ligand. For 
example, a hydrocarbon chain can be appended to a macrocycle in order to render it 
lipophilic. Sibert and Cory have used this principle to produce lipophilic cyclam 
derivatives.
55
 Isopropyl and isobutyl chains were N-appended to render the 
compounds lipophilic but without completely compromising water solubility. Botta 
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and co-workers utilised polyethylene glycol (PEG) chains to accomplish exactly the 
opposite.
77
 They wanted to increase the water solubility of their complexes in water. 
In addition the increased molecular weight also served to enhance the inner sphere 
relaxivity of the resulting MRI contrast agent.  
Non-coordinating pendent arms can also be used to append further moieties to the 
ligand. This route has been explored by Archibald and co-workers who prepared a 
side-bridged cyclam bearing an aminobenzyl pendent arm.
54
 This was used to form 
an isothiocyanate bond to rhodamine, a fluorescent dye. The structure of the side-
bridged ligand is shown in Figure 29. 
 
Figure 29: Chemical structure of a side-bridged cyclam bearing an aminobenzyl 
pendent arm. 
The rest of this chapter is concerned with highlighting three different classes of 
pendent arm and to discuss their design and synthesis, with particular focus on the 
properties they possess. 
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2.1.3. Redox active pendent arms 
Stabilised di-tert-butyl phenyl-X pendent arms (where X = O, NH or S) have been 
the subject of much focus in the literature. The production of the phenoxyl radical is 
highly stabilised by the tert-butyl groups in the ortho and para positions and has 
been reported to be stable for days.
119,120
 The same properties were also noted for the 
anilino radical analogue.
121
 The reason for this stability is because the radical can be 
delocalised throughout the ring system. Density functional theory calculations have 
shown that the phenoxyl radical possess quinoide character in that the C-O bond 
length is of apparent double bond character and hence a localised radical.
122
 The 
same is true of the anilino radical,
122
 but in the case of the thiyl radical, the C-S bond 
length would suggest only single bond character.
123
 Table 5 gives the bond lengths 
for X-C6H5 radical species, where X = O, NH or S. 
 X=O X=NH X=S 
C1X 1.26 1.34 1.75 
C1C2 1.45 1.44 1.39 
C2C3 1.38 1.38 1.38 
C3C4 1.41 1.41 1.39 
Table 5: Bond-lengths (Å) of X-C6H5 radicals, where X=O, NH or S. 
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Figure 30: Ball and stick representations of the X-ray crystal structures of two 
copper complexes prepared by Garner and co-workers.
124
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Only a few examples of the phenoxyl radical have been found in the solid state. 
Figure 30 shows two crystal structures of copper complexes chelated to two 2-[2‟-
(4‟,6‟-di-tert-butylhydroxyphenyl)]-4,5-diphenylimidazole ligands.124 Figure 30 
shows the ball and stick representations of the copper(II) complexes obtained by 
reaction of two equivalents of ligand with Cu(BF4)2.H2O. The crystal at the top of 
Figure 30 was grown from a dichloromethane (DCM)-dimethylformamide (DMF) 
mix. The bottom crystal structure was obtained after oxidation with Ag[BF4] 
followed by recrystallisation from DCM-hexane. For the top complex the C-O length 
is 1.316(2) Å for both ligand units. For the bottom complex, the ligand units are 
structurally inequivalent- C-O bond lengths were found to be 1.264(5) and 1.322(5) 
Å. The latter length is in good agreement for one unit existing as a phenolate, but the 
former suggests that the C-O bond possesses double-bond character as seen in the 
contraction of the bond length. Therefore the bottom complex consists of both 
phenolate and phenoxyl radical species. 
Phenoxyl radicals are commonplace in nature, being implicated in a number of 
enzyme active sites where the radical is generated on a tyrosine residue. These are 
often copper enzymes
125
 such as photosystem II
126
, ribonucleotide reductase, 
prostaglandin H synthase and DNA photolyase. Covalent crosslinking of the phenol 
moiety on the tyrosine residue to another amino acid side chain has also been 
observed, which leads to the perturbation of its pKa or redox potential. This is found 
within galactose oxidase (cysteine side chain)
127
 and cytochrome c oxidase (histidine 
side chain). Galactose oxidase is interesting as it oxidises primary alcohols to 
aldehydes without the need of a redox cofactor present.
128
 Oxidation of alcohols 
occurs through a free radical mechanism, in which the tyrosyl radical, which is 
directly coordinated to the copper centre, is reduced and oxidised during the catalytic 
cycle.
129
 Formation of the tyrosine-cysteine covalent bond causes a stabilisation of 
the phenoxyl radical by nearly 0.5 V over the corresponding unsubstituted phenol.
128
 
The thioether also makes the phenol easier to oxidise, lowering the energy required 
to generate this species during the catalytic cycle. 
Thiyl radicals have also been found in biological systems. They have been found at 
the active site of all three classes of ribonucleotide reductases (RNR). A cysteine 
residue located at the active site is converted to the thiyl radical, which is believed to 
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initiate substrate turnover by abstracting a hydrogen atom from the ribose ring of the 
substrate.
130
 A cysteine radical is also used to mediate the catalytic cycle of pyruvate 
formate-lyase (PFL), and is believed to be required for homolytic substrate cleavage. 
Crystal structures of the enzyme reported by Becker and Kabsch provide evidence 
for how the enzyme uses the thiyl radical for pyruvate cleavage.
131
 The crystal 
structure was obtained of PFL with its two substrates docked (see Figure 31). This 
scenario is presumed to be the moment prior to pyruvate cleavage. This structure 
shows that the pyruvate is aligned for radical attack, in conjunction with confining 
radical migration. 
 
Figure 31: Stereoview of the PFL dimer in complex with pyruvate and CoA. 
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2.2. Synthesis of di-tert-butyl phenol pendent arms  
Development of phenolate pendent arms was desirable with respect to the 
investigation of redox behaviour in conjunction with either transition series or p-
block metal ions which are chelated by a macrocycle. They were specifically 
designed to have a methyl bromide ortho to the hydroxyl on the ring system as this 
could be used to react with an amine and when complexed, a 6-coordinate ring could 
effectively be formed. In addition, tert-butyl groups were used in the other ortho 
position as well as the para position to stabilise the radical species once generated. 
Because of the phenol being acidic, it was decided to produce a range of di-tert-
butyl-2-hydroxy-benzyl bromide pendent arms of which the phenol was either 
protected or free. This would enable a suitable coupling strategy to the macrocyclic 
framework by an SN2 reaction to be explored whilst also providing several routes to 
an effective de-protection strategy to be investigated. 
 
Scheme 2: Synthesis of 2. Conditions; i) paraformaldehyde, LiOH, MeOH, 
reflux, 24 hr (50%); ii) PBr3, CHCl3, RT, 2 hr (95%). 
The first route investigated was the production of the 3,5-di-tert-butyl-2-hydroxy 
benzyl bromide, 2. The synthesis of the pendent arm (2) as shown in Scheme 2 has 
been published by Wieghardt and co-workers.
132
 This route to the un-protected 
phenol would be advantageous in the latter stages of ligand preparation because there 
is no need for a further deprotection step. 1 was synthesised from 2,4-di-tert-butyl 
phenol by reacting with paraformaldehyde and LiOH in MeOH for 16 hr at reflux. 1 
was isolated from the crude mixture by placing a concentrated hexane solution in a 
fridge for 3 days after which the crystalline material formed was collected by 
filtration. 1 was then reacted with PBr3 in CHCl3 at RT to form the viscous oil form 
of 2, which solidified when left in a freezer overnight. 
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Scheme 3: Synthesis of 5. Conditions; i) MeI, K2CO3 acetone, RT, 15 hr (83%); 
ii) NaBH4, ethanol, 2.5 hr (100%); iii) PBr3, CHCl3, 0°C, 1.5 hr (85%). 
Analogues of 2 were now investigated with respect to the introduction of a 
protecting group for the phenol. This was thought necessary because the phenol is 
acidic and as such the pendent arm may participate in acid-base reactions as well as 
nucleophilic substitutions. It was envisaged that a protection-deprotection strategy 
would be employed, where deprotection would occur once the pendent arm had been 
appended to the macrocyclic framework. A methyl group was used to produce the 
first protected phenol pendent arm. The methyl group was introduced on to 2,4-di-
tert-butyl-2-hydroxy-benzaldehyde using MeI and potassium carbonate. This is 
shown in Scheme 3. The aldehyde functional group of the molecule is used to form a 
suitable alkyl halide which can participate in SN2 reactions involving the 
macrocycle. This was achieved by firstly reducing the aldehyde using NaBH4 to 
form the alcohol. The alcohol was then brominated using PBr3 in CHCl3 to give 
pendent arm 5. 
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Scheme 4: Synthesis of 8. Conditions; i) benzyl bromide, K2CO3, DMF, 75°C, 24 
hr (90%); ii) NaBH4, MeOH, 1 hr, RT (99%); iii) PBr3, CHCl3, 0°C, 1 hr (96%). 
Having synthesised the methyl protected phenol pendent arm, 5, further protecting 
groups for the phenol group were explored. This is because there are limited 
procedures available for cleaving methyl ethers.
133
 In the literature, benzyl protecting 
groups are used extensively for successful protection-deprotection strategies. There 
are a large number of ways for deprotecting such groups making them highly 
versatile. It was because of these reasons that the benzyl group was chosen as a 
suitable protecting group. Synthetically, the benzyl group was introduced by reaction 
with 2,4-di-tert-butyl-2-hydroxy benzaldehyde in the presence of potassium 
carbonate using DMF as the solvent. A similar type of reaction had been reported by 
Counsell and co-workers in the synthesis of di-substituted 1-phenol-2-propanones,
134
 
and by Belmar and Jiménez for preparing hindered polyanionic chelating ligands.
135
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The desired product was found to precipitate readily when the cooled reaction 
mixture was poured in to an ice-water mixture, allowing the desired product 6, to be 
isolated via filtration. Crystals of 6 were grown from hexane by evaporation; the 
structure elucidated is shown in Figure 32. 
 
Figure 32: Ball and stick representation of the X-ray crystal structure of 6 with 
all non-H atoms labelled. 
The asymmetric unit of 6 consists of two molecules, rotated through by 180° relative 
to each other. The benzene rings in each molecule are rotated perpendicular to one 
another. This is extended to the asymmetric unit where benzene rings opposite each 
other are again found to be in a perpendicular arrangement. 
A similar procedure to the formation of 5 was then used to reduce the aldehyde to 
form the alcohol which was then brominated using PBr3 to give 7. 
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Scheme 5: Synthesis of 11. Conditions; i) MeI, K2CO3, acetone, 50°C, 24 hr 
(100%); ii) NaBH4, isopropan-2-ol, RT, 4 hr (84%); iii) PBr3, CHCl3, 0°C, 1 hr 
(96%). 
The benzyl protecting group can be chemically modified to make deprotection more 
facile. By introducing a p-OMe group, the para position becomes activated towards 
electrophilic attack. The conditions needed to cleave the protecting group therefore 
become less harsh than the corresponding benzyl group. This protecting group was 
synthesised according to Scheme 5. 
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Scheme 6: Synthesis of 14. Conditions; i) 11, K2CO3, DMF, 55°C, 24 hr (70%); 
ii) NaBH4, ethanol, RT, 3 hr (81%); iii) CBr4, PPh3, DCM, RT, 18 hr (68%). 
The synthesis of 14 was analogous to the synthesis of 8 apart from the ultimate step 
where the alcohol is brominated to form the bromide. Considering the literature 
precedence for p-methoxybenzyl cleavage in acidic conditions, bromination using 
PBr3 was avoided in this case. This is because during bromination using PBr3 small 
amounts of HBr are formed as a by-product to the reaction. An alternative 
brominating agent was therefore required. Carbon tetrabromide in conjunction with 
PPh3 provided such an alternative, producing the desired bromide in 68% yield after 
column chromatography. 
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Scheme 7: Synthesis of 15. Conditions; i) paraformaldehyde, LiOH, MeOH, 
reflux, 24 hr (50%); ii) PBr3, CHCl3, RT, 2 hr (95%); iii) acetic anhydride, 
H2SO4 (cat.), RT, 12 hr (100%). 
So far, the phenol has been protected using an ether linkage. To extend the library of 
protected phenol ligands, esters were investigated as a means for protection. Scheme 
7 shows the formation of the acetyl protected phenol, 15. Initial attempts at the 
formation of an ester to protect the phenol utilised a dimethylamino-pyridine 
(DMAP) coupling between 2,4,-di-tert-butyl-2-hydroxy benzaldehyde and Boc2O.
136
 
The reaction was judged complete after 3 hr by TLC (Rf of 0.32 in 5% 
EtOAc/hexane compared with 0.59 for the starting material). Although this 
compound was isolated, the reduction of the aldehyde using NaBH4 accomplished 
the desired reduction but unfortunately also reduced the ester, reforming the phenol. 
An alternative reaction pathway to the desired acetyl protected di-tert-butyl 
compound was therefore sought. Wieghardt and co-workers have performed a 
similar form of protection in protecting 6-tert-butyl-o-cresol as the acetyl ester using 
acetic anhydride and H2SO4 as a catalyst.
137
 Using the conditions these authors 
reported, compound 2 was reacted with acetic anhydride in the presence of H2SO4 as 
a catalyst at RT. This proved to be a highly efficient way of protecting the phenol, as 
 71 
 
after an aqueous work-up 15 was obtained in >95% yield. Crystals of 15 suitable for 
X-ray crystallography were grown by evaporation of a toluene solution. The 
structure of 15 is shown in Figure 33. 
 
Figure 33: Ball and stick representation of the X-ray crystal structure of 15 
with all non-H atoms labelled. 
Having established a small library of protected phenolic pendent arms, attention 
turned to other protecting groups which may be of interest. Extension of the library 
focused on producing further protecting groups which either utilised one of the 
existing linkages (ether or ester) or using a previously unexplored one. Despite 
laborious attempts at synthesis and work-up, none of these groups could be 
successfully introduced at the phenolic position. These groups will now be discussed 
and reasons as to why they were not appropriate to be used to protect the phenol 
highlighted. 
Three further ether protecting groups were explored; 3,4-di-hydro-2H-pyrane (THP), 
bromoacetonitrile and methoxymethyl chloride. THP is well documented in the 
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literature as being a versatile protecting group for both alcohols and phenols. 
Because of its lack of selectivity, the reaction between THP and the phenol was only 
attempted with di-tert-butyl-2-hydroxy-benzaldehye and 2. This ether formation was 
first investigated using pyridinium p-toluenesulfonate (PPTS) as a weak acid to 
catalyse the reaction.
138
 PPTS was freshly prepared by reacting p-toluenesulfonic 
acid monohydrate with pyridine for 20 min at RT. Reaction of THP with 2 using 
PPTS as a catalyst led to formation of a complex mixture (four spots noticeable on a 
TLC plate using 5% EtOAc/hexane as an eluent). Reaction of THP with di-tert-
butyl-2-hydroxy-benzaldehyde resulted in no appreciable product formation. Using 
copper sulphate pentahydrate, another reported catalyst for 
tetrahydropyranylation,
139
 again no reaction was observed. From both attempts it 
became apparent that the hydrogen bonding existing between the phenol and the 
aldehyde at the ortho position renders the phenol unavailable for reaction when using 
an acidic catalyst. 
Bromoacetonitrile has been reported as being a robust protecting group as it is 
reported to be cleaved using a platinum oxide catalyst in a hydrogen atmosphere.
140
 
Methoxymethyl chloride (MOMCl), was also a suitable candidate, given the ease 
with which it can be cleaved.
133
 Both of these reagents were used in an attempt to 
form the phenolic ether; they were used in the presence of potassium carbonate and 
the experiment conducted in either acetone or neat (as in the case for MOMCl). 
However from the TLC and NMR data collected from these experiments it was 
apparent that the desired reactions had not occurred. 
The sulfonate ester was selected as an alternative protection group which was worthy 
of study. Two attempts were made at forming the sulfonate ester using either 1 or di-
tert-butyl-2-hydroxy-benzaldehyde. The reaction of 1 with one equivalent of tosyl 
chloride resulted in the formation of a mixture. This mixture could not be separated 
successfully to obtain the desired sulfonate ester. Because of the difficulty in 
separation, di-tert-butyl-2-hydroxy-benzaldehyde presented itself as a better 
candidate as it only has one hydroxyl group available for reaction. Monitoring this 
reaction over the course of a week by TLC gave no evidence for the formation of the 
sulfonate ester. This would seem to suggest that the because of the size of the 
tosylate group, steric considerations around the phenolic site prevent the formation 
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of the sulfonate ester. To add further weight to this hypothesis, mesyl was also used 
in an attempt to protect the phenol. Under similar conditions, TLC again gave no 
evidence for the formation of the ester. Given the difference in hydrocarbon 
substituent of the sulfonyl chloride (either toluene or methyl), both sets of 
experiments would suggest that the steric hindrance originates in the sulfonyl group.  
The syntheses of di-tert-butyl phenols either masked or unmasked with a methyl 
bromide in the ortho position were attempted. A series of protecting groups have 
been investigated for their suitability to mask the phenol. Four groups were found to 
be suited to this role; methyl, benzyl, p-methoxybenzyl and acetyl. These four 
protected species as well as the unmasked phenol analogue can be used to construct 
macrocyclic species bearing pendent arms. This is reported in Chapters 3 and 4. In 
these chapters, the redox chemistry of the metal complexes is explored. 
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2.3. Thiophenol pendent arm synthesis 
Production of sulphur analogues of the phenolic systems was also of interest. The 
reason for this was two fold; firstly that the 2,4,6-tri-tert-butyl thiylphenyl radical is 
not stable when compared with the corresponding phenoxyl radical (half-life of 2.5 
min in benzene at 30°C), and also has the propensity to form di-sulphide bonds.
141
 
This contrasts nicely with the robust nature of the phenoxyl radical. Secondly, 
sulphur is soft in nature whereas oxygen is hard, therefore providing a means by 
which analogous complexes can be compared with regard to their coordination 
preferences. 
 
Scheme 8: Synthesis of 18. Conditions; i) K2CO3, DMF, 80°C, 24 hr (89%); ii) 
NaBH4, propan-2-ol, RT, 1 hr (88%); iii) PBr3, CHCl3, −5°C, 1 hr (68%). 
The synthesis of 18 has been reported in the literature to produce triazacyclononane 
(TACN) metal complexes to study their redox properties.
142
 Electrophilic attack by 
the thiol on the aromatic ring displaces the nitro group as nitrite, leading to the 
formation of 16. Crystals isolated from this reaction were suitable for X-ray 
crystallography. Figure 34 shows the structure of 16 obtained after refinement. 
Figure 35 shows the packing of 16 within the unit cell. 
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Figure 34: Ball and stick representation of the X-ray crystal structure of 16 
with all non-H atoms labelled. 
 
Figure 35: Ball stick representation of the X-ray crystallographic unit cell 
contents of 16 with H atoms omitted. 
17 was synthesised from 16 by reducing the aldehyde with NaBH4 in iso-propanol. 
Crystals were obtained by evaporation of a toluene solution from which the structure 
could be elucidated by X-ray analysis. The structure of 17 is shown in Figure 36. 
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Figure 36: Ball and stick representation of the X-ray crystal structure of 17 
with all non-H atoms labelled.  
The unit cell of 17 (Figure 37) shows that the molecules are aligned in a co-linear 
fashion. The distance between phenyl rings is however too large for π-π stacking 
interactions. However, H-bonding does exist between neighbouring alcohol groups. 
This is shown in Figure 38. The hydrogen bonding is arranged in a zig-zag fashion 
between adjacent repeating units. Table 6 shows the hydrogen bond parameters 
between donor and acceptor atoms in 17.  
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Figure 37: Ball and stick representation of the X-ray crystallographic unit cell 
contents of 17 with H atoms omitted. 
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Figure 38: Ball and stick representation of the X-ray crystal structure of 17 
showing H-bonding existing between equivalent molecules. A symmetry 
transformation of -x, y-½, -z+½ was used to generate equivalent atoms. 
 
D-H...A D(D-H) (Å) D(H…A) (Å) d(D…A) (Å) <(DHA) (°) 
O(1)-H(1)…O(1)#1 0.89(2) 1.88(2) 2.7657(10) 174(2) 
Table 6: Hydrogen bond parameters for compound 17. 
The final step in the preparation of the pendent arm 18, involved the bromination of 
the alcohol. The reported procedure for this step was followed, but the product 
obtained wasn‟t pure as analysed by NMR. It was believed that the protecting group 
is slightly acid sensitive and therefore a complex mixture of 18 and the products 
obtained from cleavage of the thio ether was obtained. The susceptibility of the thio 
ether to cleavage is not discussed in the original paper and so no purification method 
was given. After many attempts at recrystallisation, the best method for purification 
was found to be layering hexane over the oil and allowing it to stand in a freezer 
overnight. Methanol was then added, and the mixture sonicated at which point a 
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white solid precipitated. The white precipitate formed by this process was isolated by 
filtration, and was shown by NMR to be the desired product, 18. 
 
Scheme 9: Synthesis of 24. Conditions; i) trimethylphosphate, Br2, 65 - 70°C, 40 
hr (65%); ii) NBS, CCl4, reflux, 1 hr (65%); iii) hexamethylenetetramine, 
CHCl3, acetic acid, 75°C for 24 hr and then 102°C for 24 hr (30%); iv) NaBH4, 
propan-2-ol, RT, 2 hr (86%); v) BuLi, thiosulfonic acid S-(4-methoxybenzyl) 
ester, Et2O, −75°C to −30°C, 5 hr (47%); vi) PBr3, CHCl3,−0°C 1.5 hr (64%). 
Focus was then directed to the synthesis of a thiophenolate pendent arm which 
possessed tert-butyl groups for stabilisation of the thiyl radical. Wieghardt and co-
workers have reported the synthesis of a thiophenolate which has tert-butyl groups in 
both meta positions
143
 or in just one
144
, but it was thought prudent to produce 
pendent arms with the tert-butyl groups in the ortho and para positions which would 
then be isostructural with the phenol analogues once deprotected. In having a tert-
butyl group in the para position, the propensity of the thiyl radical to form disulfide 
bonds would also be lowered. This is because the steric bulk surrounding the thiol 
would inhibit thio radicals reacting with each other to form a disulfide bond. The 
synthesis of such a compound is shown in Scheme 9, where 24 is the sulphur 
analogue of 14. The first step in the preparation of 24 involved the bromination of 
the aromatic ring, which Wieghardt and co workers reported as being effected using 
bromine and an iron support in carbon tetrachloride.
142
 This step proved difficult to 
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reproduce despite using very pure bromine (99.999%). A literature search revealed 
that another route existed for this bromination using the same starting material (2,4-
di-tert-butyl toluene). Voβ and Edler reported that by using trimethylphosphate and 
bromine, 19 was isolated after distillation in 65% yield.
145
 By using these conditions, 
19 was successfully obtained with a yield in direct agreement with the literature. 
Furthermore, the oil obtained crystallises at RT if left for a week. These crystals 
were suitable for X-ray diffraction and from the refinement of the X-ray data the 
structure of 19 was obtained as shown in Figure 39.  
 
Figure 39: Ball and stick representation of the X-ray crystal structure of 19 
with all non-H atoms labelled. 
In the next step, the methyl group was brominated using N-bromo succinimide 
(NBS) in CCl4. This allowed a Duff type reaction to be used to form the aldehyde. 
After purification using silica gel chromatography, compound 21 was isolated in 
30% yield. Reduction of the aldehyde in the presence of NaBH4 was then carried out, 
enabling the formation of the lithium salt of 22 by reaction with n-BuLi. The 
introduction of the sulphur containing moiety via reaction of the lithium salt with 
toluene-4-thiosulfonic acid S-(4-methoxybenzyl)
146,147
 was then performed. This was 
followed by purification via silica gel chromatography enabling the thio ether, 23, to 
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be isolated. From the purification process, the unreacted toluene-4-thiosulfonic acid 
S-(4-methoxybenzyl) was isolated. Crystals of this material were grown using a 
hexane/toluene mix. Transparent crystals formed after allowing the mixture to 
evaporate for 3 days at RT. These crystals were suitable for X-ray analysis, enabling 
the crystal structure to be obtained. This is shown in Figure 40. 
 
Figure 40: Ball and stick representation of the X-ray crystal structure of 
toluene-4-thiosulfonic acid S-(4-methoxybenzyl) with all non-H atoms labelled.  
The S-(4-methoxybenzyl)ester could have been introduced to compound 19, the 
methyl group thereby offering a potential site for further functionalisation,
148
 such as 
brominating the methyl group in the same way as 20.
142
 However, with 23 in hand, 
this was reacted with PBr3 to give the desired alkyl bromide, which was purified by 
silica gel column chromatography. The literature stated that this purification was 
only performed for analytical measurements, although in following this method, 
purification was found to be required as a substantial amount of by-product was 
formed. The by-product was believed to be due to the acid cleavage of the thioether, 
in exactly the same manner as was observed for 18. Clearly the use of a brominating 
agent which forms a strong acid is not suitable when preparing these thioether 
compounds. 
The two protected thiol compounds, 24 and 18, were appended to tetraaza-
macrocyclic compounds which are discussed in Chapters 3 and 4. They were then 
used in a comparative study alongside the phenol analogues already discussed. 
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2.4. Amino acid derived pendent arm synthesis 
Pendent arms which incorporate a reactive group for tethering to the macrocyclic 
ring as well as providing additional functional groups for coordination to the metal 
centre and as a point of attachment for further moieties to be chemically joined to the 
framework are very desirable. Essentially these pendent arms fulfil the role of a 
pendent arm and linker group. Amino acids have been investigated for this role, as 
the wide range of side chains affords versatility. The aim of this research was to 
construct an amino acid capable of providing three functional groups; one for 
attaching the amino acid derivative to the macrocyclic, a second for acting as a donor 
group and a third for the attachment of further molecules to the metal complex.
 
Scheme 10: Synthesis of 25-28. Conditions; i) NaBr, 1 N HBr, NaNO2, H2O, 0°C, 
2 hr (25 = 50%, 26 = 86%); ii) TBTA, BF3.OEt2, cyclohexane, DMA, RT, 5 d (27 
= 77%, 28 = 41%). 
Aspartic acid and 4-nitro-L-phenylalanine were selected as potential amino acids 
which could then be manipulated to form pendent arms capable of coordinating to a 
metal centre and also possessing a functional group which can be used as a chemical 
linker. The amino group of the parent amino acid can be converted to the 
corresponding secondary bromide by formation of a diazonium salt in the presence 
of a bromide source. This secondary bromide could then act as the point at which it 
can be appended to the macrocyclic backbone. A route in which the glutamic and 
aspartic amino acids have been manipulated in a similar fashion has been 
published.
149
 The respective γ and β benzyl esters of glutamic and aspartic acid can 
be purchased (Sigma), meaning that the other carboxylic acid can be protected with a 
different protecting group. The protection of molecules utilising two different 
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chemical protecting groups which are labile under different conditions are highly 
desirable, enabling each prospective site to be reacted individually. Another route 
which utilises an amino acid with two chemically different protecting groups has 
been reported by Yoo and Pagel.
84
 Two routes are presented in this paper to the 
preparation of α-brominated glycine templates attached to a DO3A backbone. The 
attachment of the α-brominated glycine templates to DO3A was accomplished in 
high yield (90% or greater). 
The route used in this work to produce such a di-protected amino acid is outlined in 
Scheme 10. The primary amine was firstly converted to the bromide via an SN2 
reaction of the diazonium salt in the presence of a bromide ion. After column 
chromatography, both 25 and 26 were isolated in moderate yield. The second step 
involved the protection of the free carboxylic acid. Use of a tert-butyl protecting 
group, which is acid sensitive, provided a means by which either the benzyl or the 
tert-butyl ester could be selectively deprotected in the latter stages of synthesis when 
the pendent arm is appended to the macrocycle. Introduction of this tert-butyl 
protecting group was performed under mild conditions using boron trifluoride 
etherate as a catalyst.
150
 Isolation of 27 and 28 was achieved after aqueous extraction 
to remove any dimethylacetamide (DMA) that remained. Crystals suitable for X-ray 
crystallography were produced from which the structure of 28 was obtained as 
shown in Figure 41. 
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Figure 41: Ball and stick representation of the X-ray crystal structure of 28 
with all non-H atoms labelled. 
The unit cell of 28 consists of both the R and S forms. This is because two possible 
reaction mechanisms exist for the SN2 reaction which occurs at the chiral carbon. A 
bromide could displace the diazonium ion, which would leave as dinitrogen. This 
reaction mechanism would cause a Walden inversion at the chiral centre leading to 
the formation of the R product. The second possible reaction mechanism incurs via 
internal nucleophilic attack by the carboxylic group, leading to the formation of an 
epoxide. Again this would lead to the R form being obtained. However, the epoxide 
ring can then undergo nucleophilic attack by a bromide ion, leading to the epoxide 
ring breaking. This would result in the S product being formed (as two Walden 
inversions have occurred at the chiral centre). The presence of both R and S forms in 
the crystal structure would suggest that both reaction mechanisms are equally as 
likely. In the unit cell these stereo-isomers are orientated so that π-π stacking is 
observed. This π-π stacking occurs in a face-to-face arrangement with a ring centre-
ring centre distance of around 3.79 Å. This is shown in Figure 42. Data obtained 
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from optimised structures for the related benzene dimer are in good agreement, 
reporting this interplane separation distance as 3.8 Å.
151
 
 
Figure 42: Ball and stick representation of the X-ray crystallographic unit cell 
contents of 28 with H atoms omitted for clarity. A C2 axis is present which runs 
through the centre of the cell. 
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2.5. Polyethylene glycol pendent arm synthesis 
Water solubilising pendent arms are useful for macrocyclic systems which are 
designed towards a biological application but possess hydrophobic properties. 
Polyethylene glycol (PEG) chains are used for this purpose by increasing water 
solubility and as such, development of pendent arms of this nature was highly 
desirable. The synthesis of mono-methoxy capped PEGs was of interest as this gave 
the possibility of functionalising the remaining hydroxyl group selectively. The 
length of the PEG chain affects the level of solubilisation and so multiple chain 
lengths were investigated. These PEG chains were to be used to solubilise porphyrin 
macrocyclic systems, which are very hydrophobic in nature. Therefore, it was 
decided to investigate two methoxy capped PEG chains with average molecular 
weights of 550 and 750 each and triethylene monomethoxy alcohol. The latter could 
be characterised fully and therefore provided the bench mark for the synthesis and 
analysis of the two other PEG chains. The synthesis of these PEG chains is outlined 
in Scheme 11. 
 
Scheme 11: Synthesis of 29-31. Conditions; i) PBr3, DCM, 0°C, 1.5 hr (40-76%); 
ii) SOCl2, pyridine, reflux, 3 hr (89%). 
The synthesis of these PEG chains was convenient given the fact that the mono-
methoxy derivatives could be purchased from Sigma. The alcohol could then be 
functionalised selectively given the robust nature of the methoxy group (with little 
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concern for cleaving the methyl ether). PEG chains 29 and 30 were synthesised by 
reaction with PBr3 followed by an extensive extraction of the aqueous layer to enable 
full recovery of the product. However, this procedure was not compatible for 
brominating the alcohol of the triethylene monomethoxy analogue. Because of this, a 
literature search was performed to investigate other potential routes to producing the 
alkyl halide. The alcohol was converted to the chloride using thionyl chloride to 
prepare 31.
152
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2.6. Conclusion 
This chapter has discussed the design and synthesis of primary and secondary alkyl 
halides which were used as pendent arms in macrocyclic systems. Three different 
types of pendent arm have been synthesised; redox active pendent arms, amino acid 
pendent arms and PEG arms. Phenol and thiophenol pendent arms have been 
synthesised in which the phenol or thiophenol is protected. Phenol pendent arms 
have been synthesised either as the unmasked phenol or as the methyl, benzyl and p-
methoxybenzyl ethers or as the acetyl ester. A wide range of deprotection methods 
can therefore be trialled when coupled to a macrocyclic system. The thiophenol 
pendent arms were all synthesised as the p-methoxybenzyl thioethers. Thiophenol 
and phenol pendent arms were synthesised with tert-butyl groups in the ortho and 
para positions. This is to stabilise the radical species once formed by preventing 
radical coupling.  
The amino acid pendent arms were synthesised from 4-nitro-L-phenylalanine and β-
benzyl-aspartic acid. Conversion of the amine group to the corresponding secondary 
bromide formed the tethering point. Both amino acids were synthesised with two 
other functional groups which can be selectively deprotected to enable a further 
moiety to be introduced. The remaining donor can be used to coordinate to the metal 
centre. 
The PEG chains were synthesised as either the bromide or chloride derivatives. The 
triethylene glycol chain, 31, was synthesised to act as a model for the other two PEG 
chains which have average molecular weights of 550 (29) and 750 (30) prior to 
bromination. These chains possess water solubilising properties which were 
investigated and are reported in Chapter 5. 
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3. Synthesis of cyclam derivatives 
with N-appended phenolates or 
thiophenolates 
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3.1. Introduction 
This chapter reports the synthesis and characterisation of side-bridged cyclam 
(Figure 43) macrocyclic frameworks with pendent thiophenolate and phenolate arms. 
Side-bridged cyclam is a laterally reinforced macrocycle, in which two amines are 
linked by an ethyl chain. This gives rise to a piperazine ring, which can adopt four 
different conformations (similar to cyclohexane). Of the four conformations (chair, 
half-boat, boat and twist), the chair is the most stable.
51
 Pendent arms can be 
appended to the macrocyclic ring through the nitrogen atoms. Previous work on side-
bridged cyclam derivatives is limited, with only eleven such compounds found 
within the literature. Of these eleven compounds, only three possess functional 
groups in the pendent arm. Carboxylic, nitro and amine groups all provide the 
additional functionality, and all three have been reported by Archibald and co-
workers.
41,54
 
3.1.1. Side-bridged cyclam compounds 
Yamamoto and Maruoka have reported the formation of the side-bridged cyclam 
directly from the glyoxal condensate of cyclam.
153
 This was achieved through the 
use of diisobutyl aluminium hydride (DIBAL). An adapted procedure has also been 
reported by Fabbrizzi et al.
154
 This compound has two secondary amines which can 
then be further reacted. However, this does mean that selective mono-alkylation is 
difficult as both sites are, theoretically, equally reactive. A synthetic protocol that 
circumvents this problem was published by Koliński in 1995.155 This paper reported 
the mono alkylation of a bisaminal species, formed by reaction of glyoxal with 
cyclam. Cross-bridged cyclam derivatives synthesised using this methodology had 
been published prior to this by Weisman and Wong.
156
 The mono-alkylated 
bisaminal species can then be reduced to give the side-bridged species. Methyl and 
benzyl arms were both reported as pendent arms in this asymmetric approach.  
Archibald and co-workers have synthesised the copper(II) complexes of side-bridged 
cyclams bearing either a tert-butyl acetate or an acetic acid (HSBTE1A, see Figure 
43) pendent arm. The copper(II) ion is five coordinate bound in a distorted square-
based pyramidal geometry with considerable distortion towards trigonal bipyramidal 
(η parameter of 0.37).41 
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Figure 43: Structures of side-bridged cyclam and HSBTE1A. 
Plutnar et al. have probed the reaction of mono-alkylated side-bridged cyclams with 
respect to further alkylation reactions.
157
 The compound that they chose to study was 
one which had been synthesised previously by Archibald and co-workers.
54
 Their 
results, which include X-ray structural data (Figure 44), show that the addition of a 
carboxylic acid occurs at one of the nitrogens on the piperazine ring and not at the 
secondary amine. 
 
Figure 44: Ball and stick representation of the X-ray crystal structure of a side-
bridged cyclam with a p-nitrobenzyl arm and an acetate arm. Non H-atoms and 
a bromide counter ion have been omitted for clarity (Plutnar et al.).
157
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3.1.2. Side-bridged cyclen compounds 
Similar side-bridged macrocyclic species have been synthesised using cyclen, the 
[12]aneN4 macrocycle. For this type of configurationally restricted macrocycle there 
are only three published examples. The synthesis of the side-bridged species first 
published by Wainwright and co-workers in 1982 was carried out using 1,2-
dibromo-ethane.
158
 The main product isolated from this process is the mono-side 
bridged cyclen although the di-bridged species is also formed in small quantities. 
Further examples have been published by Handel and co-workers.
159
 Two side-
bridged cyclens are attached together by a xylene ring, with the macrocycle units 
being tethered through either the 1,2, 1,3 or 1,4 positions. Another derivative, 
whereby the central linker is exchanged for a pyridyl group is also detailed in the 
same paper by Handel. The macrocyclic units are attached to this central unit in the 
ortho positions.  
3.1.3. Examples of known phenolate complexes 
Kimura and co-workers have published the crystal structure of a phenol containing 
cyclam ligand as well as its copper complex. The ligand was synthesised from 
coumarin and the corresponding tetraamine via Michael addition followed by 
intramolecular lactamization in a yield of 20% after a period of two weeks.
160
 It was 
found that a nitro group in the 4 position reduced the cyclisation time to 3 days with 
a similar yield (19%). Reduction of the lactam formed in both instances was 
performed using B2H6 to afford the free ligand. The crystal structure of the ligand 
shows that it possesses three H-bonds; two between nitrogen atoms in the 
macrocycle, and a third between the phenol OH and the nearest nitrogen atom.
161
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Figure 45: Ball and stick representation of the X-ray crystal structure of 
phenolate appended cyclam (Kimura et al).
161
 
The phenol moiety is attached to the macrocyclic ring system through the carbon 
backbone, and when complexed to a metal, forms a six-membered chelate ring. The 
complexation of the couramin derived macrocycle with various transition metal ions 
was then carried out. Analysis of the copper(II) complex shows that the phenolic 
oxygen forms an axial interaction with the copper centre which adopts a five 
coordinate geometry (Figure 46).
161
 An unusually large thermal motion exists 
between C(9) and C(10) in conjunction with a very short C(9)-C(10) distance (1.25 
Å) suggesting the ligand has some flexibility on coordination.  
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Figure 46: Ball and stick representation of the X-ray crystal structure of the 
copper(II) complex with phenolate appended cyclam. Non-hydrogen atoms, a 
perchlorate and a water molecule have been omitted for clarity (Kimura et 
al.).
161
 
It is interesting to note that Fe(OH)3 is taken into solution by this ligand to form a 
stable 1:1 red complex.
162
 The stabilisation of the iron(III) state with respect to the 
iron(II) state was evidenced from cyclic voltammetry. The redox potential observed 
in phenolate free macrocyclic systems such as the 16-membered saturated penta-
amine macrocyclic complex (-0.04 V) or haemoglobin (-0.07 V), is significantly 
lower than the redox potential observed for the iron(III) cyclam complex with 
appended phenol (-0.16 V). However this value is still higher than Fe(III) carriers 
such as mugineic acid (-0.34 V) and enterobactin (-0.99 V).  
The nickel(II) complex of the ligand shown in Figure 45 shows a significantly 
lowered redox potential of +0.35 V vs SCE (0.5 M Na2SO4, pH 7.5, 25 °C) for Ni
III/II
 
with respect to that of nickel(II)-cyclam (+0.50 V vs. SCE).
160
 The phenol moiety 
also becomes harder to oxidise upon coordination to nickel(II) (~+0.5 V 
uncoordinated, ~+0.9 V coordinated). An explanation of these redox potential shifts 
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is suggested by the data obtained from the crystal structure. The nickel(II) ion adopts 
an octahedral geometry with the nickel(II) ion lying in the same plane as the four 
nitrogen atoms.
163
 The oxygen of the phenolate fills one apical site with a Ni-O bond 
length of 2.015 Å. This distance is shorter than the four Ni-N bond lengths (2.072, 
2.051, 2.085 and 2.078 Å) and far shorter than apical bond lengths in octahedral 
nickel(II)-cyclam complexes (2.492 Å for X = Cl, 2.169 Å for X = NO3). The other 
apical site is filled by an oxygen of a perchlorate anion, which has a bond length of 
2.402 Å. 
 
Figure 47: Ball and stick representation of the X-ray crystal structure of the 
nickel(II) complex with phenolate appended cyclam. Non-hydrogen atoms have 
been omitted for clarity (Kimura et al.).
163
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3.1.4. Examples of known thiophenolate complexes 
Thiol and thiophenolate pendent armed azaamacrocycles have also been studied. A 
bis(μ-thiolato)dicopper(II) complex has been synthesised using thiirane to introduce 
the mercaptoethyl group on to a TACN backbone.
164
 The crystal structure of the 
dicopper(II) complex (Figure 48) shows that each sulphur atom bridges the two 
copper centres. 
 
Figure 48: Ball and stick representation of the X-ray crystal structure of the 
bis(μ-thiolato)dicopper(II) complex. H atoms and perchlorate ions omitted for 
clarity (Tolman et al.).
164
 
Welch and co-workers have also studied mercaptoethyl complexes. They have 
reported the synthesis of a tris-mercaptoethyl TACN ligand.
165
 The mercaptoethyl 
group was this time introduced using ethylene sulphide. The indium and gallium 
radiolabelled complexes were prepared and found to be stable in vivo. The 
complexes were less lipophilic than expected, which is believed to be due to the 
facial arrangement of the thiolates around the metal centre, resulting in a substantial 
dipole moment. 
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Figure 49: Ball and stick representation of the X-ray crystal structure of the 
tris(thiophenolate) zinc(II)-nickel(II) dinuclear complex. H atoms omitted for 
clarity (Weighardt et al.).
144
 
Example of complexes incorporating thiophenolate moieties have been reported by 
Weighardt and co-workers. They have produced TACN ligands bearing derivatised 
aromatic thiols which possess tert-butyl groups. Species have been produced with 
tert-butyl groups in the meta
144
 or ortho and para
142
 positions. Hetero dinuclear 
complexes have been produced of a tris(thiophenolate) derivative with a tert-butyl 
group in the meta position. A crystal structure (Figure 49) of a complex of this type 
was obtained where a zinc(II) ion is coordinated by the three nitrogen and sulphur 
atoms in an intermediate octahedral trigonal prismatic arrangement. The sulphur 
atoms also coordinate to a second metal ion (nickel(II)), bridging the two metal 
centres. The nickel(II) ion occupies a tetrahedral geometry with a chloride ion 
capping the tetrahedron. 
  
 98 
3.2. Synthesis of side-bridged cyclam complexes with 
phenolate pendent arms 
The design of the phenolate systems incorporating phenolate arms synthesised in this 
work was based on the tetraaza macrocycle, cyclam (32). The aim was to attach one 
pendent arm, providing a coordination set of N4O1 for the metal centre. Scheme 12 
shows a synthetic scheme in which the reactivity of the amines can be controlled by 
rigidifying the macrocyclic backbone. 
 
Scheme 12: Synthesis of 33. Conditions; i) Nickel(II) perchlorate hexahydrate, 
glyoxal overnight then NaBH4 at 90°C for 1 hr followed by NaCN at reflux for 2 
hr; ii) MeOH, glyoxal, −10°C to RT (100%). 
Cyclam can be synthesised using either a nickel(II) template reaction
166,167
 or by 
using a method reported by Handel and co-workers.
168
 Alternatively it can be 
purchased from Strem Chemicals. The introduction of glyoxal at -10°C forms a 
glyoxal bridge. This has the effect of rigidifying the macrocycle, allowing the 
reactivity of the secondary amines to be controlled. On first inspection of 33, it 
would seem that all four nitrogen atoms are in the same environment and should 
react in a similar fashion. However, this is not the case. Because of the rigidified 
nature of the macrocycle, the lone pairs on the nitrogens fall into two chemically 
different groups. The first is where the lone pair is pointing directly into the 
macrocyclic cleft. The steric hindrance prevents prospective reagents for 
nucleophilic attack from approaching the lone pair. This renders these two sites 
unreactive. The second group where the nitrogen lone pair is pointing away from the 
cleft, can easily participate in nucleophilic attack of appropriate reagents. The 
possibility of both nitrogens reacting in this way is reduced when considering the 
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product formed; an ammonium salt. Reactions using non-polar solvents cause this 
product to precipitate, therefore preventing further reaction from occurring. This 
methodology can be used to selectively alkylate one tertiary amine site, resulting in 
the attachment of only one pendent arm. 
 
Scheme 13: Synthesis of 34. Conditions; i) dry MeCN, RT, (product not 
isolated). 
An attempt was made to attach di-tert-butyl-2-hydroxy-benzylbromide, (2), to 
glyoxal cyclam (33) using this methodology. Upon the addition of dry MeCN to a 
mixture of 2 and 33, an immediate precipitate formed. After three days at RT, the 
reaction mixture was concentrated under reduced pressure before ether was added. 
The material that was insoluble in ether was then collected by filtration. Two 
important points were noted from observations regarding reaction work-up. Firstly 
the amount of recovered solid was approximately the same amount of 33 that was 
used initially. Secondly, the filtrate was UV-active whereas the solid was not. The 
proton and carbon NMR of both products were analysed, and revealed that the 
desired reaction had not occurred. The data for the solid suggested recovery of 
starting material 33. The fact that it was collected as a solid and is ether insoluble 
would suggest that it was protonated. NMR analysis of the filtrate was complicated 
as the number of signals made any structural assignment difficult. However, it was 
evident that no attachment of 2 to 33 had occurred. Instead, it is suggested that 
glyoxal cyclam (33) had acted as a base instead of a nucleophile. By deprotonating 
the phenol, this created a nucleophile which attacked a further molecule of 2 at the 
benzylic position followed by displacement of the bromide. This process creates a 
dimer. Evidence for dimerisation was obtained from mass spectrometry analysis, 
which indicated the presence of di-, tri- and tetramers of 2.  
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Scheme 14: Synthesis of 36 and its complexation to Ni(II), Cu(II), Zn(II) and 
Ga(III). Conditions; i) dry MeCN, RT, 5 days (64%); ii) ethanol, NaBH4, RT, 7 
days (89%); iii) see text; iv) Metal salt, MeOH, reflux, 2 hr - 2 d (Cu=98%, 
Zn=95%, Ni=98%, Ga complex not isolated). 
After the unsuccessful reaction using the unprotected phenolic species, focus was 
switched to protected analogues. Firstly the methyl ether derivative, 5, was 
investigated. The attachment of 5 to glyoxal cyclam, 33, was attempted in a similar 
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fashion to that detailed in Scheme 13 (see Scheme 14). Unlike the previous reaction, 
no precipitate formed. After three days the reaction was worked-up and analysis of 
the solid collected showed that the reaction of 5 with 33 had occurred. In the next 
step the glyoxal bridge was reduced to form the piperazine ring, forming the side-
bridged cyclam species 36. This was achieved using NaBH4 in alcoholic media. In an 
attempt to unmask the phenol, BBr3 was then used. This reagent has been previously 
used to deprotect 3,3‟-dihydroxyphenyl,169 which although not as sterically hindered 
as 36, still highlighted the conditions required to cleave the methyl ether. The 
conditions reported for this deprotection were used in various attempts to effect the 
desired deprotection step. The temperature was initially held at -80°C, and the 
reaction time was varied, between 2 and 4 hours, before allowing the reaction 
mixture to warm to RT o/n. Unfortunately, the desired ether cleavage reaction was 
unsuccessful, the methyl peak was present in the 
13
C NMR after each attempt. The 
steric hindrance surrounding the ether moiety may be the reason for the lack of 
cleavage. A subsequent reaction using the boron-trifluoride ethyl etherate and 
sodium iodide reagent system
170
 was also unsuccessful. However, complex 
formation was still of interest. 
The complexation of 35 was performed using transition and p-block metals. 
Nickel(II), copper(II) and zinc(II) were chosen from the transition elements, and 
gallium(III) was chosen from the p-block. Nickel(II) and copper(II) were of interest 
because they possess a variety of stable oxidation states whereas zinc(II) and 
gallium(III) are redox inactive. The latter are both d
10
 and hence diamagnetic 
enabling NMR data to be collected. Gallium(III) complexes are of particular interest 
because only two related complexes of configurationally restricted 
tetraazamacrocycles have been reported previously. Weisman and Wong have 
reported the synthesis of cross-bridged cyclen
171
 and cyclam
172
 complexes using 
either the gallium nitrate or chloride salts respectively. The complexes were isolated 
by centrifugation after heating at reflux for 2 days. Yields obtained from 
recrystallisation were in the range of 50-60%. These conditions were used when 
synthesising the gallium(III) chloride complex of 36. However, they seemed to be 
unsuitable for the side bridged compound as it was difficult to isolate the metal 
complex. Therefore, a different method for gallium(III) complexation was sought, 
and an alternative method has been reported by Sharma and co-workers. Their 
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investigations into metalloantimalarials lead to them to synthesise an amine phenol 
ligand and study its complexes with gallium(III).
173
 To insert the gallium into the 
acyclic cleft, Ga(acac)3 in MeOH was heated to reflux in the presence of the ligand. 
Then, KClO4 in hot water was added and reflux continued for a further 30 min. 
Crystals could then be collected after recrystallisation from ethanol/acetonitrile (9:1). 
However, this method also proved to be incompatible with this ligand system and the 
gallium(III) complex was not isolated. 
All the metal complexation reactions were carried out in MeOH. Metal perchlorate 
salts were used to maximise the potential for the complexes to crystallise to enable 
structural characterisation. Transition metal complexation reactions were heated to 
reflux for 1.5 to 2 hours whereas attempts at forming the gallium(III) complexes 
were left for 2 days. Products were purified by size exclusion chromatography on a 
Sephadex LH-20 column. Yields for the transition metal complexes of 36 were in the 
range of 95 - 98%. 
Orange crystals of the nickel(II) complex of 36 were grown by evaporating an 
acetone-ether solution at RT. Orange crystals suitable for X-ray analysis were 
obtained. The oxygen atom from the methoxy group of the pendent arm is not used 
in the coordination of the nickel(II) centre, which adopts a distorted square planar 
geometry with the four nitrogen atoms of the macrocyclic ring (bond lengths for the 
nickel(II) ion are given in Table 7). There is disorder in the tert-butyl group para to 
the methoxy group, with each atom occupying two sites ~50% of the time (only one 
site shown in Figure 50). 
The electronic spectrum of [Ni36]
2+
 would also suggest that the ion is square planar 
as a single d-d transition was observed at 477 nm. Lindoy and co-workers
174
 
observed only one band for their N-benzylated cyclam complexes in the region of 
474-488 nm, all of which were square planar. The copper(II) complex of 36 also 
possesses one d-d band in the UV, which is diagnostic of a copper(II)-N4 
chromophore, in which solvent or anion may occupy axial positions.
175
 However, the 
featureless nature of the spectrum results in it being of little use for the assignment of 
a detailed coordination geometry around the copper(II) ion. 
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Figure 50: Ball and stick representation of the X-ray crystal structure of 
[Ni36][(ClO4)2]. Water molecules and perchlorate anions omitted for clarity. 
 Bond length (Å) 
Ni(1)-N(1) 1.941(5) 
Ni(1)-N(2) 1.922(6) 
Ni(1)-N(3) 1.921(5) 
Ni(1)-N(4) 1.953(5) 
Table 7: Selected bond lengths from the X-ray crystal structure of 
[Ni36][(ClO4)2]. 
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Scheme 15: Synthesis of 39 and its complexation to Ni(II), Cu(II), Zn(II) and 
Ga(III). Conditions; i) MeCN, RT, 3 d (66%); ii) MeOH, NaBH4, RT, 2 d 
(80%); iii) see text; iv) metal salt, MeOH, reflux, 2 hr - 2 d (Cu=87%, Ni=42%, 
Zn=47%, Ga complex not isolated). 
Because of the stability of the methyl phenol to cleavage, focus switched to the 
benzylic derivatives. The large number of ways in which these groups can be cleaved 
makes them highly versatile.
133
 The synthesis of the side-bridged cyclam species 
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bearing the benzyl protecting group is outlined in Scheme 15. The synthesis of 39 is 
directly analogous to that of 36. However, problems were again encountered in the 
deprotection step. A range of conditions were used in attempts to cleave the 
protecting group and unmask the phenol. In general, conditions employed for 
aromatic debenzylation fall into categories of (1) catalytic hydrogenolysis, (2) 
reductive cleavage, (3) iodide-mediated debenzylation, (4) metal mediated 
debenzylation, (5) Lewis-acid-mediated debenzylation and (6) acid-mediated 
cleavage. Initial attempts at cleaving the benzyl ether were directed towards catalytic 
hydrogenolysis (1). The problem with this type of deprotection lay in the presence of 
both N-benzylic and O-benzylic moieties in these molecules, with potential for both 
to be cleaved under similar conditions. Belmar and Jiménez, in their pursuit of 
highly hindered polyanionic chelating ligands, used a benzyl group to protect 2,4-di-
tert-butyl phenol which was linked to an aromatic amine by an amide bond. 
Palladium on carbon (10% w/w) in the presence of hydrogen was sufficient to cleave 
the protecting group.
135
 The conditions outlined in this paper were used in an attempt 
to deprotect the phenol in 39. However, only starting material was recovered and so 
a number of further conditions were explored. Firstly, the reaction was attempted at a 
higher pressure using a Parr apparatus. Three different pressures were used in an 
attempt to effect the desired debenzylation; 10, 20 and 40 psi were all used, but 
starting material or a multiple component mixture was always recovered after work-
up. After this laborious process, the catalyst was changed. Several different catalysts 
were used in attempts to cleave the benzyl ether. Firstly, 5% Pd/C was used. This 
was used to circumvent possible N-debenzylation by lowering the amount of active 
catalyst. However, the material recovered after each attempt was either recovered 
starting material or a multi-component mixture. This was also the case when a lead 
poisoned catalyst was used, or Pd 10% on activated carbon, wet, Degussa type E101 
NE/W which is specifically for debenzylation purposes. Following these results, the 
literature was consulted for alternative options. 
Of particular interest was the work reported by Binkley and Hehemann,
176
 which has 
been further developed by Riley and Grindley.
177
 The procedure described is for a 
light-initiated process for the rapid debenzylation of sterically hindered benzyl 
ethers. Given the steric bulk surrounding the benzyl ether in 39, this looked 
promising. Both sets of authors report that the use of CaCO3 and NBS in a biphasic 
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mixture of CCl4 and water can cleave benzyl ethers in greater than 70% yield in the 
presence of light. This set of conditions causes α-bromination of the benzyl ether, 
therefore promoting subsequent cleavage of the ether bond. On reproduction of these 
experimental conditions however, the desired product was not isolated.  
The use of boron trifluoride ethyl etherate in conjunction with NaI has been reported 
as being a suitable reagent system for cleavage of benzyl and methyl ethers.
170
 
Debenzylation of cyclohexanyl benzyl ether using this reagent system gave a 75% 
yield of the corresponding alcohol in just over an hour. The phenol benzyl ether was 
obtained in 84% after 21 hr. Alcohols are therefore more readily cleaved than 
phenols using this reagent system. Using the conditions described, this reagent 
system was used in an attempt to debenzylate 39. The reaction was allowed to 
proceed for 48 hours given the hindered nature of the benzyl ether. However, after 
reaction work-up only the starting material was recovered. 
The use of solid-supported acids has been reported for the debenzylation of aryl 
benzyl ethers.
178
 The use of Amberlyst-15 was reported as being selective towards 
benzyl ethers whilst methyl ethers were left intact. This gave yields of greater than 
70% for debenzylation, but was highly dependent on the stoichiometry of the 
reaction. The authors reported that a 1:1 ratio of reactant to Amberlyst-15 afforded 
the best yield, for 2 hr at a temperature of below 120°C (chosen arbitrarily because 
Amberlyst-15 degrades at temperatures above this). However, it was found that 
Amberlyst-15 did not cleave the benzyl ether in 39. 
Debenzylation has also been reported to occur using Pd(OH)2/C in MeOH in the 
absence of hydrogen. This process is believed to occur via the oxidative cleavage of 
the ether although transfer hydrogenation is a possible competing reaction, with 
MeOH serving as the hydrogen donor. Molar equivalents of the catalyst are used 
because if MeOH does indeed act as a hydrogen donor, then the formaldehyde 
produced will effectively poison the catalyst. However, this reagent system did not 
cleave the benzyl group either.  
Other routes exist for deprotecting this group. One such way is to use ferric chloride. 
This has been reported by the groups of Fraser-Reid and Takeda where they 
investigated the deprotection of a series of benzyl protected oligosaccharides
179
 and 
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monosaccharides.
180
 Using Takeda‟s conditions (RT, dry DCM, 2 equivalents of 
FeCl3) however did not yield the desired deprotected species. It is stated that the end 
point of the reaction is reached when the colour of the mixture is green-blue.
180
 This 
was not observed when reproducing this deprotection method; in fact no colour 
change occurred. 
Acetyl bromide in alcoholic media has been found to be an efficient system for the 
facile removal of various protective groups which are stable to acetyl chloride in 
alcoholic media.
181
 The deprotection of a benzyl ether to give the corresponding 
phenol is reported in greater than 80% yield. However, once again this reaction was 
unsuccessful.  
As a result of being unable to deprotect the phenolic ether, attention turned to the 
complexation of this prochelator to metal ions. Complexation of 39 to the transition 
metals of interest (nickel(II), copper(II) and zinc(II)) was performed in the same way 
as those to 36. However, the gallium(III) complex was not isolated. The nickel(II) 
and copper(II) complexes were analysed by cyclic voltammetry, the data for which is 
reported in section 3.4. Electronic spectra of the copper(II) and nickel(II) complexes 
of 39 were similar to those of 36. Two single d-d bands were observed at 550 and 
481 nm for the copper(II) and nickel(II) complexes respectively. The nickel(II) 
complex is therefore square planar whereas it is again difficult to ambiguously assign 
the coordination around the copper(II) ion. 
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Scheme 16: Synthesis of 41 and its complexation to Ni(II), Cu(II), Zn(II) and 
Ga(III). Conditions; i) MeCN, RT, 4 d (88%); ii) EtOH, NaBH4, 2 weeks, RT 
(97%); iii) see text; iv) metal salt, MeOH, 2 hr - 2 d (Cu=29%, Ni=44%, 
Zn=49%, Ga complex not isolated). 
The p-methoxybenzyl derivatives offered alternative reactions for the deprotection 
step. The synthesis of the protected species was again via the bisaminal intermediate, 
and was directly analogous to the synthesis of previous side-bridged compounds 36 
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and 39. However, the deprotection of the phenol protecting group was again 
problematic. 
Hodgetts and Wallace have reported that p-methoxybenzyl ethers are unstable in 
acetic acid.
182
 The conditions they employed (heating to 90°C in acetic acid for 
between 4 and 72 hr, followed by an aqueous work-up) seemed appropriate for 
unmasking the phenol. Compound 41 was therefore dissolved in acetic acid and 
heated to 90°C for 72 hr. The work-up was modified given that the product is 
zwitterionic in nature and therefore water soluble. The reaction mixture was 
concentrated and the oily residue triturated with ether. The precipitate was then 
collected by filtration. NMR data collected on the precipitate showed that the ether 
functionality was still intact. The reaction was performed again, this time heating to 
reflux but this was also unsuccessful. 
Cerium chloride heptahydrate in conjunction with sodium iodide has been found to 
be an excellent reagent system for deprotection of p-methoxybenzyl ethers.
183
 When 
used to deprotect the p-methoxybenzyl ethers of phenol and p-nitrophenol, yields of 
86 and 89% were obtained respectively. This seemed to be an ideal system for the 
deprotection of compound 41. In using this reagent system, an additional equivalent 
of cerium chloride heptahydrate was used. This was because it was envisaged that 
the cerium could coordinate with the tetraazamacrocyclic ring, and thus would not be 
available for activating the ether bond. Therefore 2.5 equivalents of cerium chloride 
heptahydrate were used, along with one equivalent of sodium iodide. The reaction 
was conducted in MeCN and heated at reflux for 24 hr. The reaction mixture was 
then concentrated and the resulting hygroscopic solid re-dissolved in 6M HCl. The 
reaction mixture was then heated to 55°C for 3 hours. This last step should ensure 
that any formed phenol was protonated and that the cerium chelated by the 
macrocyclic ring was subsequently removed from the cavity. The product obtained 
from this treatment was then transferred to a Sephadex LH-20 column. Two bands 
were obtained; one orange, which eluted first, and one yellow, eluting shortly 
afterwards. Analysis by proton and carbon NMR and mass spectrometry showed that 
neither of these fractions contained the desired deprotected compound. 
The nickel(II), copper(II) and zinc(II) complexes of this chelator (41) were prepared 
but the gallium(III) complex again proved to be problematic and could not be 
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isolated. The cyclic voltammetry data for the nickel(II) and copper(II) complexes are 
reported in section 3.6. Electronic spectra of the copper(II) and nickel(II) complexes 
of 41 were similar to those of 36 and 39. Two single d-d bands were observed at 529 
and 478 nm for the copper(II) and nickel(II) complexes respectively. The nickel(II) 
complex is therefore square planar whereas it is again difficult to ambiguously assign 
the coordination around the copper(II) ion. The different phenolic ethers produced 
would therefore appear to have no effect on the coordination around the metal 
centre; the same geometry is observed for both the nickel(II) and copper(II) 
complexes of 36, 39 and 41. 
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Scheme 17: Synthesis of 37 and its subsequent complexation to Ni(II), Cu(II), 
Zn(II) and Ga(III). Conditions; i) dry MeCN, RT, 3 d (75%); ii) EtOH, NaBH4, 
RT, o/n (98%); iii) 6M HCl, MeOH, o/n (79%); iv) metal salt, MeOH, reflux, 2 
hr - 2 d (Cu=40%, Ni=30%, Zn=29%, Ga complex not isolated). 
The synthesis of the phenol ester compound, 43, was approached in exactly the same 
way as the methyl and benzylic ether derivatives. Unlike the previous derivatives, 
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the acetyl group could be successfully removed to unmask the phenol. As the acetyl 
group is acid labile, deprotection strategies focussed on acid hydrolysis. 2M HCl in 
MeOH was initially used in an attempt to cleave the protecting group under reflux 
conditions overnight. Analysis of the proton and carbon NMR showed that the ester 
was still intact. 3M and 4M HCl in MeOH under the same conditions were also 
ineffective. However, when using 6M HCl, the acetyl group was absent from the 
NMR, showing the phenol had been deprotected. Complexation reactions with the 
ligand were performed in basic media; this was to ensure that both the phenol and 
amines functionalities were deprotonated. Upon addition of triethylamine to a 
methanolic solution of 37, an instant colour change was observable from light yellow 
to a straw colour. It was assumed that this colour change was because of the change 
in delocalisation around the aromatic system due to the formation of the phenolate 
anion. Copper(II), nickel(II) and zinc(II) perchlorate salts were used to form the 
metal complexes. These complexes are very hygroscopic, and were isolated as oils. 
The synthesis of copper(I) complexes was also attempted as these complexes would 
be neutral in terms of charge and hence would not require a counter anion. Two 
attempts at synthesising the copper(I) complexes were made using Schlenk line 
techniques and [Cu(NCMe)4][BF4]. Despite efforts to prevent getting oxygen into 
the reaction vessel, both products were isolated as dark blue solids which quickly 
oiled, implying that the copper(I) had been oxidised to copper(II). 
The cyclic voltammetry for the nickel(II) and copper(II) complexes of 37 are 
reported in section 3.6. These complexes are of interest because they should have 
both ligand and metal centred redox processes. The electronic spectrum of the 
copper(II) complex displayed only a single band due to d-d transitions at 641 nm. 
The shift observed for the copper(II) complex of 37 is indicative of a five-coordinate 
geometry (either distorted square based pyramidal or trigonal bipyramidal) being 
formed around the metal ion.
41
 This would imply that the phenolate tethered to the 
macrocyclic ring is bound to the metal centre in solution. The electronic spectrum of 
the nickel(II) complex of 37 possesses one strong d-d transition at 441 nm. In the 
nickel(II) complex of a phenolate cyclam ligand produced by Kimura and co-
workers,
184
 different absorptions are observed dependent on pH. At acidic and basic 
pH absorptions of 424 and 559 nm were observed respectively, corresponding to a 
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transition from low spin to high spin.
185
 This data suggests that in the nickel(II) 
complex of 37, the nickel(II) ion adopts a square planar geometry with the phenol 
not bound to the metal centre. Support for the presence of a high spin nickel(II), in 
which the phenol is bound to the metal in the axial site, is evidenced by a very weak 
peak at 581 nm. 
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3.3. Synthesis of side-bridged cyclams with thiophenolate 
pendent arms 
The synthesis of the side-bridged cyclam bearing a thiophenol and its subsequent 
complexation is outlined in Scheme 18. The attachment of the thiophenol 18 to 
glyoxal bridged cyclam 33 was achieved in 94%. This ammonium salt was then 
converted to the side-bridged species by use of NaBH4 in alcoholic media. The p-
methoxybenzyl protecting group was then cleaved using mercury(II) acetate and H2S 
under deoxygenated conditions. Because of the propensity of this ligand to form 
disulfide bridged dimers, the ligand was used as quickly as possible and all solvents 
degassed prior to use. Metal insertion was also performed under an inert atmosphere. 
The nickel(II) and zinc(II) complexes were all isolated in this manner and purified 
by collecting the appropriate fraction after loading on to a Sephadex LH-20 column. 
These complexes had a tendency to oil after a few minutes of exposure to air and so 
cyclic voltammetry studies were conducted as soon as possible. The data obtained or 
the nickel(II) complex of 46 is reported in section 3.7. The electronic spectrum of the 
nickel(II) complex of 46 possess two d-d transition bands at 367 and 464 nm. This 
could possibly imply that the nickel(II) centre oscillates between square planar and 
octahedral in solution. It is difficult to ascertain whether or not the thiophenolate 
pendent arm is always bound to the nickel(II) centre. 
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Scheme 18: Synthesis of 46 and complexation with Zn(II), Ni(II) and Ga(III). 
Conditions: i) dry MeCN, RT, 1 week (94%); ii) MeOH, NaBH4, RT, 1 week 
(82%); iii) MeOH, Hg(OAc)2, reflux, 16 hr then H2S bubbled through the 
solution for 20 min (93%); iv) metal salt, reflux 2 hr - 2 d (Ni=92%, Zn=50%, 
Ga complex not isolated). 
The synthesis of the di-tert-butyl thiophenol ligand, 49, was approached in the same 
manner as the thiophenol ligand. 33 was reacted with 24 forming the ammonium salt 
in 95% yield. The glyoxal bridge was then reduced using NaBH4 in alcoholic media. 
The sulphur protecting group was then removed using Hg(OAc)2 in MeOH. As 
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before, because of the propensity of the unprotected thiophenolate species to 
dimerise, the metal complexes of the salt were synthesised as quickly as possible. 
These complexation reactions were performed using degassed solvents and under an 
inert atmosphere. The nickel(II), zinc(II) and copper(II) complexes of 48 were all 
isolated as solids, whereas the gallium(III) complex once again proved to be elusive. 
The nickel(II) and copper(II) complexes were both analysed by cyclic voltammetry, 
the data from which is reported in section 3.7. The electronic spectra of the 
copper(II) and nickel(II) complexes of 48 possess a single d-d band each at 550 and 
550 nm respectively. In the case of the nickel(II) complex this would suggest that the 
ion is square planar; similar values have been reported for nickel(II) complexes of 
cyclam derivatives with a pendent pyridyl arm.
186
 The d-d band for the copper(II) 
complex means that a geometry cannot be ambiguously assigned for the ion. 
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Scheme 19: Synthesis of 49 and complexation with nickel(II), copper(II), 
zinc(II) and gallium(III). Conditions; i) dry MeCN, RT, 3 days (95%); ii) 
MeOH, NaBH4, 5 days, RT (49%); iii) MeOH, Hg(OAc)2, 60°C o/n then H2S 
bubbled through the solution for 20 min (97%); iv) metal salt, MeOH, reflux, 2 
hr - 2 d (Cu=70%, Ni=94%, Zn=87%, Ga complex not isolated). 
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3.4. Cyclic voltammetry data for side-bridged cyclam 
phenolate complexes 
Cyclic voltammetry was conducted on both phenolate and thiophenolate complexes. 
The purpose of these experiments was to probe the redox behaviour of the metal and 
the ligand. The generation of the phenoxyl and thiyl radical can be observed under 
these conditions. The redox potentials for these processes can be compared to other 
known examples to provide an insight into the stability of the complexes formed. 
 
Figure 51: Cyclic voltammograms of [Cu36]
2+
, [Cu39]
2+
 and [Cu41]
2+
 at 0.2 V/s. 
Data collected in acetonitrile with tetra-butyl ammonium perchlorate as a 
supporting electrolyte at RT using a platinum reference electrode.  
Figure 51 shows the cyclic voltammograms for the copper(II) complexes of 36, 39 
and 41. The copper(II) complex of 41 displays different behaviour to the other two 
complexes. This complex possesses a Cu(II)/Cu(III) wave at +1.26 V, whereas for 
the other two complexes this is not observed. The copper(II) reduction consists of 
two species; adsorbed and free. This is evidenced for all three complexes by the 
presence of two small peaks in the cathodic region at −0.79 and −0.56 V. The free 
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and adsorbed species are re-oxidised simultaneously given the presence of one 
oxidation peak at −0.38 V, −0.23 V and −0.13 V for [Cu41]2+, [Cu39]2+, and 
[Cu36]
2+
 respectively. This peak therefore appears to be sensitive to the protecting 
group at the phenolic site. The shift towards anodic potentials occurs in the order p-
methoxybenzyl < benzyl < methyl. The peak at -1.48 V is ascribed to the reduction 
of the copper(II) to copper(0), which is irreversible. Further evidence to support this 
was obtained by performing repetitive scans; the spectra became more inconsistent 
with time as the electrode became fouled by the deposition of copper on the surface. 
 
Figure 52: Consecutive cyclic voltammograms of [Cu37]
+
 at 0.2 V/s. Data 
collected in acetonitrile with tetra-butyl ammonium perchlorate as a supporting 
electrolyte at RT using a platinum reference electrode. 
Figure 52 shows the cyclic voltammagram of the copper(II) complex of 37. At +0.48 
V a fully reversible peak is observed, which is assigned to the formation of the 
phenoxyl radical and subsequent reduction back to the phenolate. Reversibility of 
this wave was tested by plotting the peak current verses the square root of the scan 
rate. This plot gave a straight line; indicative of a reversible process. Previous work 
by Wieghardt and co-workers has been focused on the study of numerous metal 
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complexes with phenolate pendent arms. Their studies have shown that the redox 
potential for the phenoxyl radical/phenolate couple can vary depending on the metal 
centre. For a TACN zinc(II) complex with a di-tert-butyl phenolate and two methyl 
pendent arms, the redox potential for the reversible formation of the phenoxyl radical 
is between -0.09 V and -0.32 V.
132
 When the methyl pendent arms are exchanged for 
acetates, values of 0.63, 0.73 and 0.36 V are obtained for the gallium(III), iron(III) 
and cobalt(III) metal complexes respectively.
142
 The irreversible peak at +1.27 V is 
believed to be metal centred and is due to the formation of copper(III). In the 
cathodic region there are two small reduction peaks at −0.82 and −0.60 V and an 
oxidation peak at −0.37 V. The two reduction peaks are believed to be due to the 
redox couple Cu(II)/Cu(I) for both adsorbed and free species. The oxidation peak 
corresponds to the re-oxidation of both the adsorbed and free species back to 
copper(II). Examples in the literature for cyclam copper complexes which have been 
examined by cyclic voltammetry would seem to support this assignment. For 
example, cyclam copper(II) complexes bearing N-benzyl pendent arms have been 
shown to possess redox potentials of +1.37 to +1.63 V for the Cu(III)/Cu(II) redox 
couple (all irreversible) and potentials of -0.18 to -0.85 V for the Cu(II)/Cu(I) redox 
couple.
174
 Similar values have been obtained for the tris-copper(II) cyclam 
complexes (+1.38 to +1.58 V and −0.64 to −0.85 V respectively).185 
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Figure 53: Cyclic voltammograms of [Ni36]
2+
, [Ni39]
2+
 and [Ni41]
2+
 recorded at 
0.2 V/s. Data collected in acetonitrile with tetra-butyl ammonium perchlorate as 
a supporting electrolyte at RT using a platinum reference electrode..  
Figure 53 shows the cyclic voltammograms of the three nickel(II) complexes of 36, 
39 and 41. The nickel(II) complex of 41 is again different, which is consistent with 
the trends observed for the analogous copper complex. It displays a small oxidation 
peak at +1.22 V which is assigned to Ni(II)/Ni(III) redox couple. All three 
complexes display a Ni(II)/Ni(I) reduction peak between −0.6 and −1.2 V. The peak 
is split between adsorbed and free species, and only the nickel(II) complex of 41 
complex seems to display any reversibility. 
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Figure 54: Consecutive cyclic voltammograms of [Ni37]
+
 0.2 V/s. Data collected 
in acetonitrile with tetra-butyl ammonium perchlorate as a supporting 
electrolyte at RT using a platinum reference electrode.. 
Figure 54 shows the cyclic voltammograms at 0.2 V/s for three consecutive scans. 
The reversible formation of the phenoxyl radical is observed at +0.74 V (reversibility 
of this wave was tested by plotting peak current verses the square root of scan rate; a 
straight line, indicative of a reversible process, was obtained). This is significantly 
more positive than for the copper(II) complex, meaning that the nickel(II) ion must 
be stabilising this redox process to a greater extent (i.e. a more positive potential is 
required to generate the radical species). Kimura and co-workers reported that the 
phenol undergoes oxidation at +0.5V for their nickel(II) complex of phenolate 
appended cyclam.
161
 Therefore the phenol in complex [Ni37]
+
 is more stable to 
oxidation than the corresponding phenol in the non-configurationally restricted 
complex. The oxidative peak at +1.24 V is believed to be due to the formation of 
nickel(III) from nickel(II). Literature values for this transition from other cyclam 
complexes vary between +1.07 and +1.52 V,
174
 and +1.07 to +1.16 V.
185
 An 
interesting feature of the cyclic voltammogram arises in the second and third scans in 
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that the initial oxidation of the phenolate to the phenoxyl radical is no longer clearly 
defined. Previously nickel(II) complexes have been observed to possess two sets of 
quasi-reversible waves which are both part of the Ni(II)/Ni(III) process.
174,185
 The 
relative size of these pairs of waves can vary considerably with the nature of the 
ligand, solvent and electrode. Oxidation potentials for the second set of waves occur 
between ~+0.5 to +1 V. It is therefore possible that a second set of waves for the 
Ni(II)/Ni(III) couple is formed after the initial scan near to the reversible wave of the 
phenoxyl radical. This may well lead to the distortion of the peak shape of the latter 
wave to a slope that is observed in scans two and three. 
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3.5. Cyclic voltammetry data for side-bridged cyclam 
thiophenolate complexes 
 
Figure 55: Cyclic voltammogram of [Ni46]
+
 at 0.01 V/s. Data collected in 
acetonitrile with tetra-butyl ammonium tetrafluoroborate as a supporting 
electrolyte at RT using a platinum reference electrode.  
Figure 55 shows the cyclic voltammogram of [Ni46]
+
 recorded at 0.01 V/s. Two 
peaks are observable. The peak at +0.60 V is assigned to the formation of the thiyl 
radical. Literature data for the formation of this species in other systems has been 
reported as +0.90, +0.65 and +0.60 V respectively for the gallium(III), iron(III) and 
cobalt(III) complexes of TACN ligands bearing a single thiophenolate and two 
acetate pendent arms.
142
 The peak therefore at +1.18 V is not ligand centred but due 
to the Ni(II)/Ni(III) redox couple. This peak appears to be quasi-reversible with there 
being a small back wave present at +1.1 V which could correspond to the reduction 
of nickel(III). 
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Figure 56: Consecutive cyclic voltammograms of [Ni49]
+
 at 0.2 V/s. Data 
collected in MeCN with tetra-butyl ammonium perchlorate as a supporting 
electrolyte at RT using a platinum reference electrode.  
Figure 56 shows three consecutive cyclic voltammograms of [Ni49]
+
 at 0.2 V/s. This 
data can again be compared with other complexes. Gallium(III) and cobalt(III) 
complexes have been reported with TACN ligands bearing one di-tert-butyl 
thiophenolate and two acetate pendent arms. Irreversible waves at +0.82 V and +0.53 
V were assigned to the formation of the thiyl radical. It is thought that after 
formation of the radical species M-SR scission occurs followed by reaction to form a 
disulfide linked dimer. The cyclic voltammograms in Figure 56 display two peaks in 
the anodic region; one at +0.53 V and the other at +1.11 V. From this data, it is 
difficult to make a full assignment, but the waves are due to the formation of the 
thiyl radical and Ni(II)/Ni(III) redox couple. At +1.12 V there is a quasi-reversible 
wave due to the Ni(II)/Ni(I) redox couple. The irreversible peak at −0.2 V only 
appears after the anodic region is scanned first. Wieghardt and co-workers reported a 
similar observation for their cobalt(III) complex. They found that after scanning 
through the oxidation wave, that upon re-reduction, a small wave at −0.5 V was 
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observed. This wave was assigned to the reduction of a disulfide complex. It is 
reasonable to suggest therefore that the wave at −0.2 V in Figure 56 can be similarly 
assigned. 
 
Figure 57: Consecutive cyclic voltammograms of [Cu49]
+
 recorded at 0.2 V/s. 
Data collected in acetonitrile with tetra-butyl ammonium perchlorate as a 
supporting electrolyte at RT using a platinum reference electrode.  
Figure 57 shows three consecutive cyclic voltammograms for [Cu49]
+
 at 0.2 V/s. 
Two waves are observed in the anodic region; one at +0.50 V and the other at +0.8 
V. By comparison with the nickel(II) thiophenolate species and also because the 
wave at higher potential shows quasi-reversibility, the waves are assigned to the 
formation of the thiyl radical and oxidation of copper(II) to copper(III) respectively. 
The wave in the cathodic region at −0.76 V is assigned to the reduction of copper(II) 
to copper(I). This is again split, most likely through the production of adsorbed and 
free species. A further wave is observed in the cathodic region. This peak is not 
observed if the cathodic region is scanned first, suggesting that this species may be 
formed after thiyl radical generation and reaction. As discussed, the homolytic 
coupling between two such species would result in the production of a dimeric 
complex. This wave at −0.25 V could be an oxidation of this dimeric species. 
 127 
3.6. Conclusion 
In this chapter the synthesis of side-bridged cyclam complexes with pendent 
thiophenolate or phenolate arms has been examined. The side-bridged cyclam 
compound bearing an unmasked phenol could not be synthesised directly due to a 
competing reaction. The side-bridged cyclam compounds bearing protected phenol 
pendent arms were synthesised successfully but it was difficult to unmask the 
phenol. The only suitable deprotection strategy for unmasking the phenol was found 
to be using 6M HCl in conjunction with the acetyl protected compound, 43. 
Nickel(II), copper(II) and zinc(II) complexes were produced for the phenolate and 
protected phenol side-bridged cyclam compounds. Gallium(III) complex formation 
was also attempted but was unsuccessful. The crystal structure of the nickel(II) 
complex of 36 was obtained in which the nickel(II) centre adopts a square-planar 
geometry. Cyclic voltammetry of the nickel(II) and copper(II) complexes was 
performed. For the copper complexes, the Cu(II)/Cu(III) redox couple was shifted 
towards anodic potentials in the order p-methoxybenzyl < benzyl < methyl. For 
[Cu37]
+
 a wave corresponding to the formation of the phenoxyl radical was observed 
at +0.48V (reversible). The phenoxyl radical was also observed to form in [Ni37]
+
 at 
+0.74V.  
Metal complexes of the thiophenol side-bridged cyclams were also produced. Again, 
gallium(III) complexes were desired but were not isolated. The thiophenol was 
unmasked by cleaving the p-methoxybenzyl protecting group using mercury acetate 
and hydrogen sulphide. Cyclic voltammetry was performed on the copper(II) and 
nickel(II) complexes. The CV of [Ni46]
+
 possesses a wave at +0.60 V which is 
assigned to the formation of the thiyl radical. In the copper(II) and nickel(II) 
complexes of 49, the formation of the thiyl radical was assigned to peaks at +0.50 
and +0.53 V respectively. These complexes also display evidence for dimerisation 
occurring in solution. Oxidation waves at −0.25 and −0.2 V are assigned to the 
oxidation of the dimer for the copper(II) and nickel(II) complexes of 49 respectively. 
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4. Synthesis of cyclen derived 
macrocyclic systems with 
phenolate, thiophenolate and 
amino-acid pendent arms 
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4.1. Introduction 
This chapter contains a report of the synthesis of cyclen derived macrocyclic 
lanthanide complexes bearing either phenol, thiophenolate or amino-acid pendent 
arms. The cavity size of cyclen means that it is suited towards lanthanide metal ions 
with the metal centre sitting above the plane of the four nitrogen donors. The ligands 
were designed to provide the lanthanide centre with either a N4O4 or N4O3S1 donor 
set. As lanthanides typically prefer coordination numbers of seven to nine, this meant 
that there was possibly a ninth coordination site available. As the compounds could 
have application as MRI contrast agents, the availability of a ninth site would enable 
a water molecule to enter the inner coordination sphere. When complexed to a 
paramagnetic metal centre this would enable the perturbation of the surrounding 
proton nuclei by the paramagnetic centre, thus leading to the enhancement of images 
produced. Specifically, it is the interaction with the proton nuclei of water molecules 
that leads to an enhancement of the image. 
4.1.1. Magnetic resonance contrast agents 
The use of MRI as a worldwide imaging modality has promoted the need for better 
enhancement of the images obtained. Currently, about 40% of MRI scans worldwide 
are performed using contrast agents. The function of the contrast agent is to 
accelerate the relaxation of water protons in the surrounding tissue. This objective 
can be achieved by using paramagnetic substances. This effect was first reported by 
Bloch et al by using ferric nitrate salt to enhance the relaxation of water protons.
187
 
Currently gadolinium(III) complexes are by far the most widely used in contrast 
agents in clinical practice. Some of these contrast agents are shown in Figure 58. 
 
Figure 58: Chemical structures of some of the contrast agents currently used in 
clinical practice. 
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Performing an MR scan requires the use of a strong magnetic field. This has the 
effect of causing the majority of proton nuclei to align in the direction of which the 
magnetic field is applied (see Figure 59). A radio-frequency (RF) pulse, 
perpendicular to the magnetic field, causes the proton nuclei to flip into a transverse 
plane. This can be thought of as a high energy state as the magnetisation of the 
proton nuclei is in a plane perpendicular to that of the external magnetic field. After 
the RF pulse is switched off, the proton nuclei begin to re-align with the external 
magnetic field. As the proton nuclei relax from a high energy state to a low energy 
state, a further RF pulse is emitted as a result. This RF pulse can be detected and 
interpreted in order to produce images of the local area. 
 
Figure 59: Diagram showing the effect on the proton nuclei caused by the 
external magnetic field and RF pulse. 
Relaxation of the nuclei occurs through two relaxation processes; T1 and T2. T1 
relaxation arises because of the longitudinal relaxation of the proton nuclei. This is 
also known as spin-lattice relaxation. This relaxation process is responsible for the 
dissipation of energy from radiofrequency-excited protons into their molecular 
environment or “lattice”. T1 is a measure of time required for the magnetisation in 
the longitudinal direction to return to 63% of its equilibrium magnetisation. 
T2 is responsible for the dissipation of the transverse magnetisation. This is also 
known as spin-spin relaxation. Unlike T1, the T2 process reduces order after an 
excitation pulse. This is because individual components of the magnetisation lose 
their alignment and rotate at various rates in the transverse plane. The T2 relaxation 
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time is a measure of the time required for 63% of the initial magnetisation to 
dissipate.  
T1 contrast agents utilise a paramagnetic metal ion to reduce the time taken for 
proton nuclei to return to their equilibrium magnetisation. This leads to image 
enhancement because of a reduction of line broadening. The paramagnetic relaxation 
of the water protons originates from the dipole-dipole interactions between the 
nuclear spins and the fluctuating local magnetic field caused by the unpaired electron 
spins. This magnetic field around the paramagnetic centre diminishes rapidly with 
distance. Therefore, chemical interactions that bring water protons into the 
immediate proximity of the metal ion play an important role in transmitting the 
paramagnetic effect towards the bulk solvent. For gadolinium(III) complexes, this 
specific interaction corresponds to the binding of the water molecules in the first 
coordination sphere of the metal ion. These inner water-sphere water protons then 
exchange with bulk solvent protons (kex represents the exchange constant for this 
process in Figure 60) and in this way the paramagnetic influence is propagated to the 
bulk. 
 
Figure 60: Diagram showing the exchange of water molecules in the inner 
sphere of a contrast agent complex. 
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4.1.2. Examples of known phenolate complexes  
A Beilstein database search highlights that only two previous examples have been 
reported in which phenol moieties are incorporated into the pendent arms of cyclen 
derived macrocycles. The first example was reported by Heath, Faulkner and co-
workers.
91
 Their paper is concerned with the synthesis of a dinuclear ytterbium(III) 
complex. The ytterbium(III) ions are held in two DO3A macrocyclic units which are 
bound together using a phenol bridging group. The way in which the phenol is 
positioned means that it can be involved in the coordination of either metal centre, 
but the bulk of the DO3A unit prevents both lanthanides from sharing the phenolate 
oxygen donor. Hydration numbers of 1 and 0.3 were obtained, inferring that the 
ytterbium(III) metal centres are eight and seven coordinate respectively. The reason 
for the apparently low hydration numbers was attributed to the lipophilicity of the 
linking phenolate which prevented water molecules from approaching the metal 
centres. The phenol linker group was introduced by reacting 2,6-bis(chloromethyl)-
4-methylphenol with two equivalents of DO3A in the presence of potassium 
carbonate.  
The other example has been reported by Sherry and co-workers.
78
 Their study 
focused on the effect of ligating groups on dissociation of a p-nitrophenolic pendent 
arm. This p-nitrophenolic pendent arm was introduced by reacting 2-hydroxyl-5-
nitrobenzyl bromide with two equivalents of cyclen in dioxane. This gave the mono-
alkylated derivative in 55% yield. Acetate groups were then introduced at the 
remaining three secondary amine sites using bromoacetic acid at pH 8.5 in 49% 
yield. This gave the formation of the chelator in 27% yield. An alternative procedure 
was used in the formation of the triamide derivative. This procedure involved the use 
of six steps to synthesis the chelator in 48% yield. The p-nitrophenolic arm was 
introduced in the ultimate step by reacting it with a stoichometric amount of 
DO3AM in the presence of K2CO3. Recrystallisation from methanol/acetonitrile 
afforded the chelator in 65% from this step. 
Further fourteen membered macrocycles have been synthesised with phenolic 
pendent arms. Much of this work has been focused on monoazacrown macrocycles 
with a pendent spirobenzopyran moiety. A reported synthesis to give a 
spirobenzopyran attached to a monoaza-12-crown has been published by Kimura.
188
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This was synthesised by reacting 2-(3-(chloromethyl)-2-hydroxy-5-
nitrophenyl)acetaldehyde with 1,4,7-trioxa-10-azacyclododecane in the presence of 
triethylamine. This was then further reacted with 1,3,3-trimethyl-2-
methyleneindoline to form the spirobenzyopyran 12-monoazacrown, which can be 
converted to the zwitterionic merocyanine isomer by UV irradiation. In addition, for 
those spirobenzopyran derivatives possessing a piperidinomethyl group at the 8-
position, isomerisation has been shown to proceed in the presence of metal ions such 
as zinc(II) even under dark conditions. This arises because the merocyanine form is 
stabilised to some extent by chelate formation with the metal cation (Scheme 20). 
 
Scheme 20: Equilibrium between the spirobenzopyran and merocyanine 
isomers perturbed by the addition of a zinc(II) salt. 
Kimura and co-workers have also used monoazacrown macrocycles bearing 
spirobenozopyran pendent arms to investigate cation specific isomerisation.
189
 
Selectivity for lithium(I) and sodium(I) was found to be dependent on the ring size; a 
twelve membered ring being selective for the former whilst a fourteen membered 
ring selective for the latter. This was reflected in the isomerisation of the 
spirobenzopyran to the merocyanine form. For the twelve-membered macrocycle, 
lithium(I) selectivity reflected the degree of isomerisation whereas for the fourteen 
membered ring, isomerisation decreased in the order lithium(I) ≥ sodium(I) > 
potassium(I). This would suggest that the complexation of lithium(I) by the crown 
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moieties stabilises the merocyanine isomers significantly more than other group I 
metals. 
Kimura and co-workers have also reported further applications for this ligand type 
with regard to studying the photoresponse profile of poly(vinyl chloride) (PVC) 
membranes.
190
 A lipophilic chain was appended to the spirobenzopran moiety, which 
was then incorporated into the PVC membrane. Upon UV-irradiation, the potential 
was found to increase and then decrease. The photoresponse profile was affected 
considerably by the nature of the metal ion in the monoazacrown cavity and also the 
pH of the aqueous phase. The change in potential was believed to be brought about 
by fast proton exchange, followed by subsequent slow metal–ion exchange into the 
merocyanine form. Further work by Kimura and co-workers in this area has focused 
on incorporating the crowned spirobenzopyran moiety at the side chain of the PVC 
either as one component or being split into its two representative parts.
191
 
Toğrul and co-workers have synthesised borocrytands which bear two 4-tert-butyl 
saligenin units.
192
 Previous borocrytands which utilised catechol pendent arms were 
found to be very oxygen sensitive. This is because of the strong basicity of the 
macrocyclic core, resulting in intramolecular proton transfer from the catechol group 
to the tertiary amines thus generating the catecholate ammonium zwitterion.
193
 The 
propensity to oxidation can be reduced by forming boron complexes and also by 
converting the catechol to saligenine. The boron is complexed by the two saligenine 
units leaving the macrocyclic cavity available to complex a further metal ion. 
Work by Shinkai and Linnane has produced calix-tetra-aza-crowns ether bearing 
phenol pendent arms with the aim of studying interactions with group I metals and 
diammonium cations.
194
 A monoaza-12-crown incorporating an o-methyl phenol 
pendent arm was also synthesised. Both compounds were found to have selectivity 
for potassium(I) and rubidium(I). The increased selectivity of the calix-tetra-aza-
crown-ether is due to the four aza crowns acting in a cooperative manner. 
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4.1.3. Examples of known thiophenolate complexes  
A Beilstein database search reveals, that at present, there is no literature in which a 
thiophenolate pendent arm is appended to a cyclen macrocyclic unit. Examples do 
exist, however, which use monoazacrowns. Kimura‟s group, have reported the 
synthesis and evaluation of two spirobenzothiapyran 12-monoazacrowns similar to 
the ligands already discussed.
195,196
 As a result, when the merocyanine isomer is 
formed, a thiophenolate coordinates to the metal ion instead of a phenolate. The 
spirobenzothiapyran unit is introduced using an analogous methodology to the 
spirobenzopyran. 2-(3-(chloromethyl)-2-hydroxy-5-nitrophenyl)acetaldehyde was 
reacted with 1,4,7-trioxa-10-azacyclododecane in the presence of triethylamine. 
Conversion of the phenol to the thiophenol was achieved by using (CH3)2NCSCl in 
the presence of triethylamine, by treatment with toluene and finally by hydrolysis 
with KOH in H2O-EtOH. The crowned thiosalicyl aldehyde is then reacted with 2-
methylene-1,3,3,trimethylindoline to complete the spirobenzothiapyran unit (see 
Scheme 21). 
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Scheme 21: Synthesis of crowned spirobenzothiapyran
195
. 
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4.2. Synthesis of cyclen ligands with thiophenolate and 
phenolate pendent arms and their lanthanide complexes 
The synthetic methodology used in this work to form chelators and lanthanide 
complexes bearing either a phenolate or thiophenolate pendent arm was designed so 
that complexes of type seen in Figure 61 could be produced (where X = O or S). The 
macrocyclic chelator along with the pendent arms provides the lanthanide centre 
with a coordination number of eight. This leaves the possibility of a ninth 
coordination site which can be filled by a water molecule.  
 
Figure 61: Chemical structure of target lanthanide complexes bearing either a 
thiophenolate or phenolate pendent arm (X = O or S). 
These complexes were designed to have potential as contrast agents for MRI, and so 
the availability of a coordination site which can be filled by a water molecule is 
important. This is because the transmission of the paramagnetic effect towards the 
bulk solvent is more effective when an inner sphere water molecule is present. It was 
proposed that the thiophenolate or phenolate arm could be oxidised, to generate the 
phenoxyl or thiyl radicals respectively. By doing so, the pendent arm would become 
a poor donor for the lanthanide centre and enable a further coordination site to 
become vacant. This could be filled by a further water molecule and as such the 
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effect of the lanthanide ion on the relaxation of proton nuclei on water molecules in 
the vicinity would be increased. This change in the coordination environment of the 
lanthanide can be detected through comparison with the unoxidised complex. In the 
following two sections, the synthesis of the phenolate and thiophenolate ligand 
systems and their complexes will be discussed, which is followed by an analysis of 
their physical and image enhancing properties. 
4.2.1. Synthesis of phenolate bearing macrocyclic ligands 
and their complexes 
The first synthetic strategy that was attempted to prepare the phenolate bearing 
macrocycle is outlined in Scheme 22. This route makes use of the previously 
synthesised tert-butyl ester of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid 
(DO3A-TB).
197
 This compound possesses a single secondary amine which can be 
used to attach a further pendent arm by nucleophilic attack. DO3A-TB was reacted 
with the unmasked phenol pendent arm, 2, which had been synthesised as outlined in 
Chapter 2. However, the desired reaction did not occur. Changing the base from 
potassium carbonate to sodium hydrogen carbonate was not effective, therefore, 
alternative routes were sought. 
Wieghardt and co-workers have published a procedure for the attaching of 2-
hydroxy-3,5-di-tert-butyl-benzyl bromide to 1,4-dimethyl-1,4,7-
triazacyclononane.
132
 This was accomplished by using KOH in dry toluene and 
heating to 70°C for 6 hr. The product from this reaction was suitable for the 
formation of metal complexes without the need for purification. This seemed to be 
very well suited towards the reaction of the same pendent arm with DO3A-TB. 
Using these conditions, however, did not give the target compound 
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Scheme 22: Attempted reaction of 2 with DO3A-TB. 
Mannich condensations have been used for the formation of 
salicylidene(amine)diaminoethane (salen) and substituted salens previously. 
Secondary amines have been reacted with various tert-butyl substituted phenol 
pendent arms to form di-substituted species by Kol et al.
198
 Yields of 71-100% were 
obtained. Another example has been prepared by Gibson and co-workers. An acyclic 
ligand was produced which possessed two 2,4-di-methyl-phenol moieties separated 
by an ethylenediamine chain.
199
 Gibson and co-workers have reported further 
complexes, this time focusing on 2,4-di-tert-butyl phenols.
200
 The ligands bearing 
one phenol pendent arm were obtained in good to excellent yields. 
The literature precedence for the use of Mannich type condensation for attaching 
substituted pendent arms to secondary amines suggested that this could be used for 
producing the target ligand as shown in Scheme 23. DO3A-TB was used for 
attempting such condensations because it only possesses one secondary amine which 
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is available for reaction. Despite the literature precedence for this reaction, it was 
unsuccessful and so alternatives were again sought. 
 
Scheme 23: Attempted Mannich reaction between DO3A-TB and 2,4-di-tert-
butyl-phenol. 
Welch and co-workers have reported the synthesis of cyclen derivatives bearing one, 
two, three or four tert-butyl benzyl pendent arms.
60
 Di-iso-propyl amine was used as 
the base to promote the reaction. This reaction was used in an attempt to mono-
alkylate the cyclen ring with one pendent arm. This was carried out with the 
unmasked phenol compound, 2, but was unsuccessful. The reason for this may lie in 
the formation of the phenolate anion which can form oligomers with other molecules 
of 2, as was observed when performing the same reaction using glyoxal cyclam, 33, 
in Chapter 3.  
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Scheme 24: Attempted reaction between cyclen and 2. 
Further routes to mono-alkylated cyclen compounds have been reported in the 
literature. Gunnlaugsson and co-workers have reported yields of 60 to 75% for the 
mono-alkylation of cyclen with a variety of alkyl halides.
201
 This route uses four 
equivalents of cyclen to one equivalent of alkyl halide and affords the mono-
alkylated product without the need for purification. The excess cyclen can also be 
recovered from the alkaline aqueous layer by firstly concentrating it under reduced 
pressure and then neutralising it. This route was therefore applicable to the 
production of a cyclen species bearing one phenol protected pendent arm. Within the 
Archibald group this approach has been used previously, leading to the synthesis of a 
cyclen bearing a tert-butyl carbamate (BOC) protected ethyl amine (compound 
prepared by Chris Welch). 
The desired reaction proceeded in good yield (89%). It was found that by triturating 
the oily residue with pentane, a yellow solid could be obtained. Interestingly, use of 
this methodology in attaching the same pendent arm to DO3A was not successful. 
Meade and co-workers have reported a similar observation when they were 
investigating the problematic attachment of a glucoronic containing pendent arm.
75
 
In trying to attach the pendent arm, two different reaction pathways were attempted. 
In the first approach, DO3A was used, which gave an incomplete reaction but by 
using cyclen the desired reaction was achieved. The reason for the difference in 
reactivity arises because the nucleophilicity of the macrocyclic units differ. The 
macrocyclic free base is more nucleophilic towards the unactivated alkyl bromide 
electrophile than the DO3A compound. 
Having now appended the phenolate pendent arm, the resulting acetate arms could 
then be tethered as shown in Scheme 25. The attachment of the tert-butyl acetate 
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arms to compound 50 was performed in the presence of potassium carbonate. After 
extraction of the crude product, column chromatography was required to isolate the 
desired product. 
The next step involved the hydrolysis of both types of ester. Wieghardt has reported 
the simultaneous hydrolysis of an acetyl p-tert-butyl phenol pendent arm and an 
ethyl ester using LiOH.H2O in 61% yield.
137
 tert-Butyl esters, however, are resistant 
to basic hydrolysis and so using this methodology would require a further step. 
Using acidic hydrolysis to cleave both types of ester simultaneously was the more 
suitable option. Having previously performed a similar deprotection on compound 
42 using 6M HCl to promote hydrolysis, the same conditions were again employed. 
After heating compound 51 in 6M HCl at reflux overnight, the desired chelator, 52, 
was obtained as the tetra-hydrochloride salt in 94% yield.  
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Scheme 25: Synthesis of 51. Conditions; i) CHCl3, NEt3, reflux, 16hr (89%); ii) 
BrCH2COO
t
Bu, K2CO3, dry MeCN, RT, 48 hr (71%); iii) 6 M HCl, reflux, o/n 
(94%); iv) metal salt, NEt3, MeOH, reflux, 2 hr (La=76%, Eu=83%, Tb=90% 
and Gd=96%). 
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Four metals ions were identified for investigation; lanthanum(III), europium(III), 
gadolinium(III) and terbium(III). Lanthanum(III) was chosen because it is 
diamagnetic and thus the complexes can be used to obtain unshifted 
1
H NMR data. 
Europium(III) and terbium(III) both possess luminescent properties, which were 
thought to be of interest because the phenolate could possibly act as a sensitiser for 
the metal centre. Europium and terbium also flank gadolinium in the periodic table 
and as such can be used to gain further information about the properties of the 
gadolinium complex. Finally, gadolinium(III) was chosen because it possesses seven 
unpaired electrons. Any complexes produced will therefore be highly paramagnetic, 
which is vital to the application of these complexes as contrast agents for use in 
MRI. 
Metal complexation was performed in methanol using a 1:1 ratio of metal salt to 
ligand 51. NEt3, was used to ensure the deprotonation of the eight coordination 
donor atoms. After heating the solution to reflux for 2 hr, the solutions were filtered 
once cool. After evaporation of the filtrate, the oily residue was dissolved in 
methanol and eluted down a Sephadex column with MeOH. The desired fraction was 
collected and concentrated under reduced pressure. The oil collected was triturated 
with diethyl ether to produce the metal complexes as off-white solids. A variety of 
physical techniques were then used to study the properties of the metal complexes. 
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4.2.2. Synthesis of thiophenolate bearing macrocyclic ligands 
and their complexes 
With the successful synthesis of cyclen bearing a phenol and three acetate pendent 
arms, attention now turned to its thiophenolate analogue. The same methodology 
was employed for the synthesis of the thiophenolate analogue. Thus four equivalents 
of cyclen and one equivalent of the thiophenol pendent arm were reacted in the 
presence of triethylamine. The desired compound, 53, was isolated in 83% yield. The 
acetate arms could then be attached to the remaining secondary amine sites to 
complete the synthesis of the fully protected chelator. This step required column 
chromatography to purify the product. The thiol protecting group, p-methoxy benzyl, 
could now be removed by cleaving the thioether bond. This was achieved by the use 
of mercury acetate and hydrogen sulphide. The tert-butyl esters were then cleaved by 
heating a solution of 55 in 6 M HCl to reflux overnight. Performing the deprotection 
steps in this order would also cleave any disulphide bridged dimers formed. 
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Scheme 26: Synthesis of 56. Conditions; i) CHCl3, NEt3, reflux, 15 hr (83%); ii) 
BrCH2COO
t
Bu, K2CO3, dry MeCN, RT, 24 hr (64%); iii) MeOH, Hg(OAc)2, 
H2S, MeOH, (100%); iv) 6 M HCl, reflux, o/n (100%); v) metal salt, NEt3, 
MeOH, reflux, 2 hr (La=76%, Eu=100%, Tb=90%, Gd=87%). 
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The complexation of this prochelator to the four lanthanide ions lanthanum(III), 
europium(III), gadolinium(III) and terbium(III) was performed under an argon 
atmosphere. Triethylamine was used to deprotonate the acetate, tertiary amines and 
thiol functionalities to enable coordination to all eight donors. All solvents used in 
the preparation and work-up were degassed prior to use. The same work-up 
procedure as for the phenolate complexes was used. 
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4.2.3. Images obtained from magnetic resonance imaging T1 
experiments  
Figure 62 shows T1 weighted images produced from gadolinium(III) complexes of 
52 and 56. Images were collected using a flash scan which collected 8 slices of 1 mm 
thickness with a repetition time of 100 ms. The experiments were conducted using a 
small NMR tube inside a larger NMR tube. For A and C, the inner tube contained 
the gadolinium(III) complex of 52 and 56 dissolved in water respectively, with water 
in the outside tube. These images clearly show an enhancement of the image in the 
inner tube compared to the outer tube. The paramagnetic centre accelerates the 
relaxation time of the surrounding water molecules, so that it takes less time for 
water molecules to realign with the external magnetic field. For images B and D, the 
inner tube contains an aqueous solution of [Gd52]
•
 and [Gd56]
•
 respectively, with the 
unoxidised corresponding metal complex in the outer tube. By oxidising the phenol 
or thiophenol bond cleavage between the metal centre and the pendent arm is likely 
to occur enabling a further water molecule to enter the inner coordination sphere. An 
extra water molecule in the coordination sphere, enables the effect of the 
paramagnetic metal centre to be further propagated through to the bulk. However, 
upon oxidation using potassium ferric cyanide , there is no apparent difference in 
voxel intensity between the inner and outer tubes. This may be because although an 
extra coordination site is being made available, the hydrophobic nature surrounding 
this site prevents a water molecule from entering in to it. A similar example has been 
described by Faulkner.
91
 The hydrophobic effect of a bridging phenol between two 
DO3A components each chelating a ytterbium(III) ion meant that coordination 
numbers of only eight and seven were observed. 
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Figure 62: T1 weighted images of [Gd52]
−
 and [Gd56]
−
 relative to water (A and 
C) and relative to their oxidised species (B and D). 
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4.2.4. UV-visible spectra of [Eu52][NHEt3] 
 
Graph 1: UV-visible spectra of [Eu52]
−
 (shown in blue) and [Eu52]
●
 (shown in 
red). 
Graph 1 shows the spectra for [Eu52]
−
 and [Eu52]
●
. The [Eu52]
−
 species possess π-
π* transitions in the 250 – 300 nm range. To oxidise this complex, an aqueous 
solution of potassium ferric cyanide was used. The UV-visible spectrum for the 
oxidised species shows characteristic bands to suggest the presence of the phenoxyl 
radical. The phenoxyl radical is typified by the presence of a fairly weak absorption 
maximum at 500-800 nm and two intense maxima at 380-440 nm.
202
 These features 
have also been identified in proteins such as ribonucleotide reductase and in the 
active form of galactose oxidase.
128
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4.2.5. Fluorescence spectra of the europium(III) and 
terbium(III) complexes of 52 and 56 
 
Graph 2: Graph showing the normalised fluorescence spectra of [Tb52]
−
 and 
[Tb56]
−
. 
Graph 2 shows the normalised fluorescence spectra of [Tb52]
−
 and [Tb56]
−
 excited 
at 250 and 260 nm respectively (spectra normalised to the most intense peak). 
Comparison of the two spectra highlights that both complexes possess four emission 
peaks, with the thiophenolate complex ([Tb56]
−
) being slightly blue shifted 
compared with the phenolate complex ([Tb52]
−
). The four peaks are centred at 490, 
545, 587 and 623 nm for [Tb52]
− 
and 498, 543, 585 and 617 nm for [Tb56]
−
. These 
peaks can be assigned to the following transitions; 
5
D4→
7
F6 (~620 nm), 
5
D4→
7
F5 
(~598 nm), 
5
D4→
7
F4 (~544 nm) and 
5
D4→
7
F3 (~491 nm). The broad peaks centred 
around approximately 390 and 750 nm in [Tb56]
−
 are most likely due to solvent 
effects. 
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Graph 3: Graph showing the normalised fluorescence spectra of [Eu52]
−
 and 
[Eu56]
−
. 
Graph 3 shows the normalised fluorescence spectra of [Eu52]
−
 and [Eu56]
−
 excited 
at 255 and 280 nm respectively (spectra normalised to the most intense peak). 
Compared with the terbium(III) complexes of 52 and 56, the europium(III) 
complexes possess significantly different emission spectra. The europium(III) 
complex of 52 possesses four peaks centred at 521, 595, 612 and 775 nm. The peaks 
at 595 and 612 nm are due to 
5
D0→
7
F1 and 
5
D0→
7
F2 transitions respectively. The 
other two peaks are probably due to solvent effects. The emission spectrum of 
[Eu56]
−
 was collected from 500 nm due to the spectrum being overshadowed by a 
large emission peak centred around 460 nm. The spectrum possesses three peaks at 
573, 619 and 714 nm. The peak at 573 nm is due to a 
5
D0→
7
F0 transition whereas the 
peak at 619 nm is due to a 
5
D0→
7
F2. The peak at 714 nm is most likely again due to 
solvent effects. 
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4.2.6. Cyclic voltammetry of the thiophenolate and phenolate 
europium complexes 
 
Figure 63: Cyclic voltammograms of [Eu52]
−
 measured at various scan rates 
(0.01 – 10 V/s) in acetonitrile using tetrabutylammonium tetrafluoroborate as a 
supporting electrolyte. 
Figure 63 shows cyclic voltammograms for [Eu52]
−
 at scans of 0.01 – 10 V/s. In the 
anodic region there is a set of waves which shows some reversibility. This is 
believed to be ligand centred and is formed because of an oxidative process whereby 
the phenolate is oxidised to the phenoxyl radical. The most likely reason why this 
wave is split is because of adsorbed and free species being oxidised at slightly 
different potentials. In the cathodic region there is only one wave at −1.10 V. This 
wave is quasi-reversible (as shown by a plot of peak current verses the square root of 
scan rate) in nature with the back-wave displaced by 0.38 V. In previous examples 
where the cyclic voltammetry of europium(III) complexes of either macrocyclic and 
linear chelators have been reported,
203
 redox potentials for the 
europium(III)/europium(II) redox couple were given as −1135 mV, −996 mV, −1340 
mV and −585 mV for DOTA, TETA, DTPA and the hydrated ion complexes 
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respectively. Therefore, the wave at −1.10 V is in good agreement with that of other 
literature complexes for the europium(III)/europium(II) couple. It is worth noting 
that the this redox couple is stabilised by 515 mV relative to that of the hydrated 
europium(III) ion.  
 
Figure 64: Consecutive cyclic voltammograms of [Eu56]
−
 measured at 0.2 V/s in 
acetonitrile using tetrabutylammonium tetrafluoroborate as a supporting 
electrolyte at RT. 
Figure 64 shows the consecutive cyclic voltammograms of [Eu56]
−
 at a scan rate of 
0.2 V/s. In the anodic region for the first scan there is one wave which is irreversible 
at +1.14 V. This wave is formed because of the oxidation of the thiophenolate 
generating the thiyl radical. In the cathodic region there is one wave present. This is 
the reduction of the europium(III) to europium(II). Compared with [Eu52]
−
, this 
reduction occurs more readily, being 0.23 V more positively shifted. The reason for 
this may be due to the type of donors that the europium ion prefers. Europium is a 
hard acid and therefore prefers hard donors. A phenolate fulfils this role whereas a 
thiophenolate, being a soft donor does not. The reduction of the europium ion is 
therefore easier to perform using soft donors to the metal centre compared with hard 
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donors. On the second and third scans there is a new wave formed in the anodic 
region. This is believed to arise because of head-to-head coupling between two thiyl 
radical species. The resulting di-sulfide product can participate in an oxidative 
process giving rise to the wave at +0.83 V. The production of the di-sulfide species 
may also explain the small peak at −1.49 V. This could be due to the simultaneous 
reduction of both europium metal ions in the di-sulfide product.  
 
Figure 65: Consecutive cyclic voltammograms of [Eu56]
−
 measured at 0.2 V/s in 
acetonitrile using tetrabutylammonium tetrafluoroborate as a supporting 
electrolyte at −40°C. 
Figure 65 shows consecutive cyclic voltammograms of [Eu56]
−
 with a scan rate of 
0.2 V/s at −40°C. Compared with the same scan at RT, there are notable differences. 
Firstly the oxidation of thiyl radical is shifted to +0.83 V compared with +1.14 V at 
RT. The oxidation of the di-sulfide species is also shifted to a less positive potential 
of +0.32 V, a shift of 0.50 V. The reason for these shifts may be due to the complex 
existing in two isomeric forms which are temperature dependent. DOTA like 
lanthanide complexes are known to exist as four isomers (each isomer exists as a pair 
of enantiomers). The donor atoms are arranged into two parallel planes; one of which 
 156 
is formed from the four nitrogen atoms of the macrocyclic ring and the other being 
formed from the four donor atoms of the pendent arms. In solution four isomers (i.e. 
two pairs of enantiomers) arise from the combination of two chiralities. The first one 
is related to the conformation of the ethylene groups of the macrocyclic ring (λ/δ) 
and the second one is caused by the mutual twist between the two planes arising 
from the orientation of the pendent arms (Λ/Δ).204 The Λδδδδ/Δλλλλ isomer pair is 
called square-antiprismatic (SAP) whereas the Λλλλλ/Δδδδδ pair is called twisted 
square-antiprismatic (TSAP). These two diastereoisomers differ by the sign and 
magnitude of the antiprism tilt angle. Smaller angles are indicative of TSAP 
structures, whilst SAP structures possess larger tilt angles.
205
 The interconversion 
between the two diastereoisomeric forms is believed to occur via two simultaneous 
intramolecular exchanges: ring inversion and rotation of the pendent arms around the 
N-CH2 bond. This is thought to occur through either a concerted twisting process or 
by the detachment of one or more arms.
206
 
 
Scheme 27: Structures of the twisted square-antiprismatic and square-
antiprismatic isomers. 
Comparison of the two cyclic voltammograms at RT and at −40°C, supports the 
presence of two isomeric forms. It is clear that at each temperature, one isomer 
dominates. This is true of other europium(III) complexes, such as 
[Eu(DOTA)(H2O)x]
−
 which exists in an approximate 1:4 ratio of TSAP to SAP 
diastereoisomers at 298 K.
207
 It is also notable that the isomers possess different 
redox potentials caused because of their structural arrangements. For example, the 
 157 
thiyl radical is easier to oxidise at −40°C than at RT. This is further reinforced after 
consulting the cathodic region. In the cathodic region, there are three waves at −0.81, 
−1.40 and −1.64 V. All three waves are irreversible waves. Compared with the scans 
performed at RT, the waves at +0.81 and −1.40 V can be assigned to the reduction of 
the mono-nuclear and di-nuclear species respectively. Both are shifted to more 
positive values compared with those at RT. The remaining wave at −1.64 V is more 
difficult to assign. This may be a component of the wave at −1.40 V, implying that 
this wave comprises of free and adsorbed species. It is unlikely that this wave is 
ligand centred.  
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4.3. Attempted attachment of cyclen derivatives bearing 
amino acid pendent arms to a side-bridged cyclam 
compound 
The cyclen macrocycles synthesised thus far do not possess functional groups for the 
attachment of other units to the complex. The ability to attach further moieties is of 
great interest as biological vectors (such as proteins and antibodies) can be 
incorporated in to the ligand structure, enabling site specific imaging or therapeutic 
action. The pendent arms synthesised in Chapter 2 possess functional groups for the 
attachment of further moieties. In addition, once the pendent arm is attached to the 
macrocycle, the coordination set provided to the metal centre is N4O4. For example, 
27, possesses two carboxylic acid groups which are protected as the tert-butyl and 
benzyl esters. Each carboxylic acid group can be unmasked separately, enabling the 
sites to be reacted in turn. The carboxylic acid group located α to the chiral centre 
can participate in coordination to a metal centre, thus forming a five-membered 
chelate ring. However, the carboxylic acid group in the β position is not orientated 
for coordination to a metal centre and as such, can be used to append further 
moieties, e.g. by forming amide linkages between the pendent arm and other 
molecules. Figure 66 shows the structure of a hetero-dinuclear complex utilising 
fully the amino acid pendent arm 27. In Figure 66, 27 acts as a coordination donor to 
a lanthanide centre and is also used to form a covalent bond with another 
macrocyclic component via the formation of an amide bond.  
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Figure 66: The proposed structure of the hetero-di-nuclear complex. 
In the structure in Figure 66, there are two macrocyclic tetra-aza rings; cyclen and 
cyclam. Cyclam is more suited towards coordination of transition metals whereas 
cyclen is more suited towards coordination of lanthanide metals. This is 
advantageous given that lanthanide and transition metals have a variety of uses for 
biological applications. For example transition metals are used in PET imaging, 
whereas lanthanide metal complexes can be used in MRI as contrast agents and in 
the production of fluorescent complexes. This methodology identified two 
components which would need to be synthesised. Each component contained a 
different macrocyclic element. The side-bridged cyclam complex with a p-nitro 
benzyl arm was supplied by Graeme McRobbie
208
 (compound 60, shown in red in 
Figure 66) and thus only the cyclen containing component (shown in blue in Figure 
66) needed to be synthesised. The cyclen component consists of a DO3A fragment 
which is attached to the amino acid pendent arm, 27. The structure of this ligand is 
therefore analogous to the structures of the phenolate and thiophenolate ligand 
systems already discussed within this chapter. 
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Scheme 28: Attempted synthesis of 58. Conditions; i) CHCl3, 44 hr, RT (32%); 
ii) dry MeCN, K2CO3 (10 equiv), BrCH2COO
t
Bu, 24 hr, RT. 
The first synthetic step would be to either append the tert-butyl acetate arms or the 
amino acid arms. At this point the literature was consulted to see if there were any 
examples of secondary halides being used in this manner. Pagel and Yoo
84
 have 
reported the synthesis of an α-amino-DOTA compound. The α-amino group was 
introduced using α-brominated glycine templates. These were reacted with DO3A in 
the presence of six equivalents of K2CO3 and isolated in excellent yield (90-95%). 
tert-Butyl and benzyl groups were used as protecting groups during the synthesis of 
the glycine templates. After the glycine template was attached to the secondary 
amine site of DO3A, these protecting groups were cleaved in excellent yields, to 
afford the fully deprotected chelator. Another example has been reported by Mäcke, 
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using pendent arm 27.
25
 Considering this literature precedence, it was decided to 
append the amino acid pendent arm first, followed by the addition of the tert-butyl 
acetate arms. Mäcke reports only a 21% mono-alkylation yield of cyclen using 
pendent arm 27. Their previous efforts to introduce succinic acid-di-tert-butylester 
gave yields below 5% for monoalkylation with the elimination product fumaric acid-
di-tert-butylester dominating. Using the di-phenylmethyl ester derivative gave a high 
yield of mono-alkylation (79%), although this cannot be used in a selective 
deprotection strategy. Use of 2-bromoglutaric-1-tert-butyl-5-benzylester gave 83% 
yield of mono-alkylation, with no elimantion product being isolated. The reason 
therefore for low yields of the succinic ester was due to the formation of a 
conjugated π-system formed through an elimination pathway. The yield obtained for 
the attachment of pendent arm 27 to cyclen was reported as being only 21%. In 
reproducing this reaction, the conditions (dropwise addition of 27 to two equivalents 
of cyclen dissolved in CHCl3) were modified. To maximise yield, a syringe pump 
was used, which delivered 27 at a rate of 2 ml per hr (1.99 g of 27 dissolved in 40 ml 
of CHCl3). After stirring at RT for a further 24 hr, the reaction was stopped and the 
crude material subjected to silica gel column chromatography using an eluent of 
EtOH/NH3 (95:5). The desired fraction was isolated giving the mono-alkylated 
product in 32% yield, a 11% increase from the reported yield for this reaction. The 
next step was to react the three secondary amine sites by introducing tert-butyl 
acetate pendent arms at these sites. However, this proved problematic; a 
chromatographic separation could not be found which lead to the clean isolation of 
the desired compound.  
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Scheme 29: Synthesis of 58. Conditions; i) K2CO3 (6 equiv.), dry MeCN, 65°C, 5 
hr (76%); ii) 10% Pd/C, 25 psi, H2, 24 hr, RT (57%). 
The alternative pathway to the production of 59 was to react 27 with DO3A-TB. 
This reaction was performed according to the conditions of Yoo and Pagel.
84
 After 
silica gel column chromatography using an eluent of DCM/MeOH (97:3 (v/v)), 58 
was isolated in 76% yield. The benzyl group was then selectively cleaved in the 
presence of Pd/C in a hydrogen saturated atmosphere at 25 psi over 24 hr and 59 was 
obtained in a yield of 57%. The carboxylic acid group was now unmasked, enabling 
it to be used in a coupling reaction with compound 60.  
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Scheme 30: Attempted coupling of 59 and 60. Conditions; i) DCC, HOBt, dry 
DCM, RT 10 days; ii) 6 M HCl, MeOH, reflux, o/n. 
Couplings between aromatic amines and carboxylic acids have been used in several 
coupling strategies. Zhao and co-workers have produced potent and selective 2-
azepanone inhibitors of human tryptase.
209
 To synthesise such inhibitors, it was 
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necessary to couple a 2-azapanone derivative with biphenyl-4-carboxylic acid to 
form an amide. This coupling reaction was achieved by the use of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC), hydroxybenzotriazole 
(HOBT) and di-isopropyl-ethyl amine in DCM. A yield of 85% was obtained. Seto 
and Xie in their pursuit of bidentate protein tyrosine phosphatase inhibitors produced 
a library of compounds which used diamine benzyl linker groups coupled to two 
identical aryl α-ketocarboxylic acids.210 Coupling of the two different components 
with EDC and DMAP formed the di-amide compounds in yields of between 47 and 
76% after column chromatography. A further example in which aromatic amines are 
involved in the formation of amides has been published by Nagata and co-
workers.
211
 Their investigations into tricyclic indole-2-carboxylic acids required a 
coupling reaction between a di-substituted benzyl amine and a tricyclic component 
with a carboxylic acid. Two different approaches were used; one which used bis(2-
oxo-3-oxazolidinyl)phosphonic chloride (BopCl) and triethylamine, and another 
which used water-soluble carbodiimide (WSC) and HOBt. Yields of 79-88% were 
obtained respectively.  
To couple 58 to 59, dicyclohexylcarbodiimide (DCC) was used as coupling reagent 
in the presence of HOBt. The reaction was allowed to proceed for 10 days before 
concentrating under reduced pressure. Silica and alumina chromatographic 
conditions were found to be unsuitable for the purification of the resulting coupled 
product and because of this, size exclusion chromatography was used. From the 
resulting column, two fractions were produced, which were analysed by NMR 
spectroscopy. This analysis proved inconclusive as to which fraction contained the 
desired product. The two bands were eluted close together and therefore a certain 
degree of overlap could have arisen.  
To obtain better separation using size exclusion chromatography, both fractions from 
the previous step were combined and treated with 6M HCl at reflux to cleave the 
tert-butyl esters. Size exclusion chromatography was performed on the product 
isolated, leading to the collection of three bands. Analysis of all three samples again 
proved inconclusive. It is therefore possible that the desired coupling reaction had 
not occurred. The steric bulk surrounding the two coupling sites could have 
prevented them from being suitably activated by the coupling reagent to enable 
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amide formation. Degradation of 59 could also have occurred. Intramolecular 
cyclisation of the asparatic acid moiety is possible, leading to the formation of a five-
membered ring (a succinic ester). This compound would not be able to participate in 
amide coupling reactions. 
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4.4. Conclusion 
In this chapter the preparation of cyclen derived complexes bearing phenolate, 
thiophenolate and amino acid arms has been described. Ligands were produced 
bearing three acetate arms and either one phenol/ thiophenol pendent arm. The 
phenolate ligand, 52, was synthesised using the acetyl protected di-tert-butyl pendent 
arm, 15. This circumvented previous deprotection problems highlighted in Chapter 
3. The thiophenolate ligand, 56, was produced using pendent arm 24. Lanthanide 
complexes of the ligands were synthesised. For the gadolinium(III) complexes, T1 
weighted images were collected. These images showed that the complexes [Gd52]
−
 
and [Gd56]
−
 enhanced the image relative to water. The oxidised species [Gd52]
●
 and 
[Gd56]
●
 were found to not enhance the image relative to the unoxidised complexes. 
The lipophilic nature surrounding the metal ion is believed to prevent further water 
molecules entering the inner coordination sphere after oxidation, and therefore no 
enhancement of the image is observed.  
Analysis of the europium(III) complexes was conducted using UV-visible 
spectroscopy, CV and fluorescence spectroscopy. The UV-visible spectrum of 
[Eu52]
−
 displays only π-π* transitions, but upon one electron oxidation, the 
characteristic fingerprint of a phenoxyl radical was observed. This was further 
observed in the cyclic voltammogram (peak at ~+0.75 V due to formation of the 
phenoxyl radical). The thiyl radical was also observed in the cyclic voltammogram 
of [Eu56]
−
 (wave at +1.14 V). When cooled to −40°C, this peak shifts to +0.83 V. 
The existence of different isomers was suggested for the ease of this oxidation at 
lower temperatures. Fluorescence spectra for the europium(III) complexes of 52 and 
56 possess two emission peaks each whereas the terbium(III) complexes possess four 
emission peaks each.  
Macrocyclic ligands based on a cyclen framework were also produced with pendent 
arm 27 attached. Subsequent debenzylation, afforded a possible point for a further 
moiety to be attached. This ligand was used in an attempt to couple a further 
macrocycle, a side-bridged cyclam compound with a pendent p-aminobenzyl arm 
(60). Although unsuccessful, this route does highlight a possible synthetic strategy 
for the production of dual-imaging probes using amino acid linker moieties. 
 167 
 
 
 
5. Porphyrin complexes bearing 
hydroxyl and polyethylene 
glycol chains towards 
photodynamic therapy 
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5.1. Introduction 
In this chapter, the design and synthesis of porphyrins bearing hydroxyl or 
polyethylene glycol (PEG) pendent arms for photodynamic therapy (PDT) is 
described. PDT is an emerging anticancer therapy which uses light to stimulate a 
photosensitiser in order to generate singlet oxygen, a highly potent cytotoxic agent. 
Porphyrins are commonly used in this role.
212,213
 In the pursuit of PDT agents, the 
design of the porphyrin sensitisers was centred upon maximising their water 
solubility whilst still retaining their therapeutic effect.  
The introduction will focus on PDT and also cover target molecule design. 
5.1.1. Photodynamic therapy 
PDT is based on the accumulation of a photosensitiser in malignant tissue after the 
administration of the photosensitiser. Subsequent illumination with light of an 
appropriate wavelength creates a photochemical reaction, the so-called 
photodynamic effect, which produces singlet oxygen. The process whereby singlet 
oxygen is generated is shown in the Jablonski diagram in Figure 67. 
 
Figure 67: Jablonski diagram showing the process whereby singlet oxygen is 
generated.  
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The first step in the generation of singlet oxygen is where the sensitiser is 
transformed from its ground singlet state (S0) into a short-lived excited singlet state 
[(S1, (~10
-6
s)] by illumination with light of an appropriate wavelength (1 in Figure 
67).
212
 The sensitiser can then relax to the ground state through either nonradiative 
decay (2) or fluorescence (3). Alternatively the sensitiser can undergo intersystem 
crossing (4) to the longer lived triplet state [(T1, (~10
-2
s)]. A sensitiser in the triplet 
state can still relax to the ground state by either phosphorescence (5) or internal 
conversion (6). Alternatively the excited triplet state can undergo two types of 
reaction. Firstly, it can participate in an electron-transfer process with a biological 
substrate to form radicals and radical ions which, after interaction with oxygen, can 
produce oxygenated products such as the superoxide ion, O2
−
 (type I reaction). 
Alternatively it can undergo a photochemical process known as a type II reaction, 
which results in the conversion of stable triplet oxygen (
3
O2) to the short lived but 
highly reactive singlet oxygen (
1
O2), the putative cytotoxic agent.
213
 In water the 
lifetime of 
1
O2 is approximately 1-3 μs, whereas in most organic solvents the lifetime 
is 4-50 times longer. However, the lifetime of 
1
O2 is considerably shorter in cellular 
systems, ranging from 100 ns in the lipid regions of membranes to 250 ns in the 
cytoplasm. The diffusion range of 
1
O2 is predicted to be limited to approximately 45 
nm in cellular media. Because of the diameter of human cells (10 to 100 μm), they 
cannot diffuse more than a single cell length. Thus, the site of the primary generation 
of 
1
O2 determines which subcellular structures may be accessed and subject to free 
radical attack. Singlet oxygen is a powerful, fairly indiscriminate oxidant that reacts 
with a variety of biological molecules and assemblies. For this reason, the Type II 
reaction predominates over Type I, although there is some indication that the 
superoxide ion may also be involved in some aspects of PDT damage. 
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5.1.2. Synthetic targets 
The structures of the two synthetic targets are shown in Figure 68. Both are designed 
to give water solubility of the compound and its complexes. Hydroxy and 
polyethylene glycol (PEG) chains are both used for this purpose. Both types of 
compound can form metal complexes. For the hydroxy compound (Figure 68, left 
compound), it was decided to focus on the production of gallium(III) complexes, 
whereas for the PEGylated porphyrins (Figure 68, right compound), gallium(III), 
nickel(II) and zinc(II) complexes were all synthesised. Gallium(III) complexes of 
tetaphenylporphyrin (TPP) is discussed. This is followed by a discussion of the 
literature on tetra(pentafluorophenyl)porphyrins, which can be used for the synthesis 
of PEGylated porphyrin derivatives. The synthesis of both target molecules is then 
presented. 
 
Figure 68: Target molecules that are potential PDT agents. 
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5.1.3. Tetraphenylporphyrin gallium complexes 
Gallium(III) complexes of tetraphenylporphyrin (TPP) possess interesting properties 
which make them appealing to study. Firstly, gallium(III) typically adopts square 
based pyramidal geometries within the porphyrin cleft, with an anion occupying the 
axial position. This anion can be readily substituted or reacted enabling complexes 
with different anions or organometallic complexes to be produced. The 
electrochemistry and photolysis properties of compounds of this type have been 
studied. Incorporation of gallium can result in an increase in quantum yields of 
singlet oxygen due to the “heavy atom effect”.214 This property is desirable in the 
production of PDT agents.  
The synthesis of [Ga(TPP)Cl] has been reported by Guilard and co-workers.
215
 The 
gallium(III) is inserted into the macrocyclic cleft using the chloride salt dissolved in 
acetic acid and heating to reflux for 12 hr in the presence of sodium acetate. A yield 
of 71% was obtained whilst insertion into 2,3,7,8,12,13,17,18-octaethylpoprhyrin 
(OEP) and 2,3,7,8,12,13,17,18-octamethylpoprhyrin (OMP) gave yields of 75 and 
86% respectively. Single crystals of [Ga(TPP)]Cl were grown via recrystallisation 
from toluene. The crystal structure is shown in Figure 69.
215
 Other halogen 
complexes were synthesised by reacting the chloride complex with either 
hydrofluoric or hydroiodic acid in toluene yielding the fluoride and iodide 
complexes respectively. 
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Figure 69: Ball and stick representation of the X-ray crystal structure of 
[Ga(TPP)Cl] (Guilard and Coutsolelos).
215
 
A further two methods are reported for the insertion of gallium(III) into the 
porphyrin cleft. Eaton and co-workers investigated ring rotation in gallium 
complexes of para-substituted tetraphenylporphyrins.
216
 The use of 
(NH4)Ga(SO4)2.12H2O in refluxing acetic acid containing excess sodium acetate 
affords the gallium complex with a single axial hydroxyl group in 75 to 84% yield. 
The hydroxyl can be exchanged for a chloride by boiling in either tetrachloroethane 
or trichloroethene. Yields obtained for this conversion were in the range of 57 to 
100%. The other method, reported by Buchler and co-workers uses the gallium(III) 
acetylacetonate salt in refluxing phenol.
217
 This produces a gallium-porphyrin 
complex in which the gallium bears an axial phenoxide substituent. A yield of 92% 
was achieved when using this methodology to complex OEP with gallium(III). 
Feng and co-workers have synthesised a gallium(III) TPP complex with an axially 
coordinated hydride.
218
 This was synthesised by the reaction of the gallium(III) 
chloride complex with NaBH4. The presence of the hydride coordinated to gallium 
was confirmed by IR, NMR and crystallographic data. The electronic spectrum of 
the complex shows that the complex belongs to the „hyperclass‟ of porphyrins as the 
Soret is split into two peaks. Other axial substituents have also been investigated. For 
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example Guilard and co-workers have reported the synthesis and characterisation of 
gallium porphyrin complexes with thiocyanate or azide substituents.
219
 Acetylide 
complexes have been prepared by Balch and co-workers.
220
 
DiPasquale and Mayer investigated the interaction of TPP gallium(III) complexes 
with hydrogen peroxide.
221
 The TPP gallium complex was used as a model for iron-
heme. The hydrogen peroxide-iron-heme complex is a suggested intermediate in the 
following reaction 
 Fe𝐼𝐼𝐼 𝐻2𝑂2  
+ +RH→ 𝐹𝑒III OH  + RO𝐻2
+ 
Gallium(III) was used as a substitute for iron in these model complexes as it is redox 
inactive and has a similar size to iron(III). TPP gallium(III) complexes, with weakly 
coordinating anions, were produced. Those synthesised included gallium complexes 
with triflate, hydroxide, methyl or perchlorate as axial donors. Hydrogen peroxide 
was found to be a very poor ligand to the gallium in the TPP complex. An excess of 
hydrogen peroxide in deuterated DCM did not displace water or perchlorate from the 
gallium centre. 
The electrochemistry of gallium(III) tetraphenyl and octaethyl porphyrin complexes 
has been investigated.
222
 Each gallium(III) complex shows two reversible oxidations 
and two reversible reductions (see Table 8). Thin layer spectra recorded during the 
first reduction and first oxidation reveal spectra that are characteristic of anion and 
cation radicals. 
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  Oxidation Reduction 
Porphyrin Anion 1
st
 2
nd
 1
st
 2
nd
 
TPP Cl
-
 1.16 1.40 -1.12 -1.52 
 OAc
-
 1.17 1.41 -1.14 -1.53 
 F
-
 1.18 1.42 -1.15 -1.54 
 OH
-
 1.17  -1.16 -1.54 
OEP Cl
-
 1.00 1.44 -1.38 -1.81 
 OAc
-
 1.01 1.44 -1.36 -1.87 
 F
-
 1.00 1.45 -1.38 -1.82 
 OH
-
 1.01 1.44 -1.37 -1.88 
Table 8: Oxidation and redox potentials of gallium(III) TPP and OEP 
complexes with different anions. 
Further research has been conducted again by Kadish and co-workers, this time 
focusing on five coordinate ionic and ζ-bonded gallium complexes.223 The oxidation 
and reduction potentials for the OEP complexes are shown in Table 9.  
 Oxidation Reduction 
Axial ligand 1
st
 2
nd
 3
rd
  1
st
 2
nd
  
C(CH3)3 0.76 1.20 1.47 -1.31 -1.74 
C4H9 0.79 1.19 1.47 -1.29 -1.73 
C2H5 0.80 1.20 1.46 -1.27 -1.70 
CH3 0.86 1.19 1.46 -1.29 -1.71 
C2H2C6H5 0.99 1.21 1.48 -1.24 -1.67 
C6H5 1.05 1.22 1.48 -1.22 -1.66 
C2C6H5 1.27 1.47  -1.19 -1.59 
Table 9: Oxidation and redox potentials of gallium(III) TPP complexes with 
different hydrocarbon axial ligands. 
Subsequent research has involved the laser-flash photolysis of the ζ-bonded gallium 
complexes.
224
 Steady-state photolysis was shown to lead to the photodissociation of 
the metal-carbon-bond. This occurs when the axial group is CH3, C2H5, C4H9, 
CH(CH2)2 or C(CH3)3. However, when the axial group is CH=CHC6H5 or C≡CC6H5, 
photodissociation does not occur. The difference in the photoreactivity arises 
because of the nature of the metal-carbon bond. The compounds which undergo 
photodissociation display purely ζ–bond character, whereas those that didn‟t 
photodissociate possess ionic character. Laser photolysis studies conducted in the 
presence and absence of ferrocene indicate that the reaction proceeds through a 
triplet state originating from the porphyrin macrocycle.  
Balch and co-workers have prepared gallium complexes of TPP with both 5-hexenyl 
and cyclopentylmethyl axial ligands in order to study the cyclization of the 5-
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hexenyl radical.
225
 When the reaction was performed in the presence of 
nitrosobenzene, a radical trap, no cyclization was observed. The ESR spectrum of 
the 5-hexenyl complex and nitrosobenzene after irradiation for 2 hr is typical for that 
of a nitroxide Ph(R)NO
•
. 
A novel cyclic trimer of a gallium(III) porphyrin has been reported.
226
 To prepare 
this complex, TPP was benzoylated in the β position. The gallium(III) was then 
readily inserted to form the monomer complex. Cleavage of the benzoyl ester using a 
basic hydrolysis resulted in the formation of the cyclic trimer. In this complex, each 
gallium ion is square-based pyramidal, with the four nitrogens of the porphyrin ring 
forming the base and the hydroxyl group of a neighbouring porphyrin filling the 
apical position. Addition of the acids HCl, HBr and trifluoroacetic acid (TFA) 
cleaved the trimer to form the monomeric species (2-OH-TPP)GaX, where X = Cl, 
Br or triflate). This process can be reversed by the addition of a proton scavenger, 
2,4,6-collidine. 
To summarise, the published work on gallium(III) TPP complexes and their 
derivatives includes at least three routes of metal insertion. On complete formation, 
the gallium ion prefers to adopt a square-based pyramidal geometry in all the 
examples discussed. The anion filling the apical position can be substituted enabling, 
for example, the formation of organometallic compounds. The gallium(III) porphyrin 
complexes have also been shown to possess electrochemical behaviour which is 
dependent on the nature of the anion in the apical position.  
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5.1.4. Tetra(pentafluorophenyl)porphyrin compounds 
Tetra(pentafluorophenyl)porphyrins have been studied widely because of the readily 
substituted p-fluoride on the pentafluorophenyl rings. This enables a range of 
substituents to be incorporated into the porphyrin backbone and its resulting 
complexes. Furthermore, all of the fluorine atoms can be substituted by adjusting the 
reaction conditions. Examples of these reactions are now discussed along with the 
synthesis of tetra(pentafluorophenyl)porphyrin. 
The synthesis of 5,10,15,30-tetrakis(pentafluorophenyl)porphine (TF5PP), 62, was 
first reported in 1969 by Longo and co-workers.
227
 Subsequent complexation studies 
were also conducted. The attempted preparation of silver(II) complexes using the 
nitrate salt in acetic acid does not result in the formation of the expected (TF5PP)Ag 
product but instead forms the porpholactone deriviative.
228
 Copper and nickel 
porpholactone deriviatives have also been produced in a similar fashion. Further 
investigation in to the metallation of TF5PP, also demonstrated that DMF was not a 
suitable solvent.
229
 Use of DMF led to the formation of meso-tetrakis(o,o,m,m-tetra-
fluoro-p-(dimethylamino)phenylporphinato complexes. The proposed pathway for 
this was via the degradation of DMF at reflux to form dimethylamine. This amine 
can substituent a p-fluorine atom on one or more of the phenyl rings via an activated 
aromatic substitution reaction. This reaction is known to occur under-mild conditions 
when a phenyl ring bears both strongly electron withdrawing groups and good 
leaving groups such as fluorine anions. Substitution of the p-fluorine was shown to 
be almost quantitative from experimental data. Interestingly, when heating the free 
base porphyrin, one or two of the four p-fluorine atoms are substituted. Clearly the 
reaction mechanism for this substitution differs from when there is a metal residing 
in the cavity. 
Nickel(II) meso-tetrakis(polyfluorophenyl)porphyrins have been synthesised with 
pyrrole groups in order to form electropolymerized films.
230
 From the reaction of 1-
(3-hydroxypropyl)pyrrole in THF with sodium followed by subsequent reaction with 
(TF5TP)Ni, resulted in a five component mixture from which mono-, di-, tri- and 
tetra-substituted products were obtained along with starting material. The 
electropolymerisation of these compounds led to the isolation of films which 
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exhibited the regular electroactivity of N-substituted polypyrroles as well as the 
spectroscopic and electrochemical features of the nickel(II) porphyrins. 
Drain and co-workers have developed an efficient microwave-assisted synthesis of 
amine-substituted tetra(pentafluorophenyl)porphyrin.
231
 The porphyrin and ten 
equivalents of the relevant amine are irradiated with 1100 W microwaves for 
between 10 and 30 minutes to afford the tetra-substituted porphyrin in 72 to 96% 
yield. The reaction uses N-methylpyrrolidone as a solvent to avoid problems with the 
decomposition of DMF. The crystal structure of the tetra-substituted 
tetraethylenediamine mono-N-t-Boc (Por-EDA4) was also reported (Figure 70). In 
this structure the ethylenediamine chains are arranged into two different 
conformations; bent and extended. The bent conformation is organised by an 
intramolecular bond.  
 
Figure 70: Ball and stick representation of the X-ray crystal structure of Por-
EDA4 (Drain and co-workers).
231
 
Weiss and co-workers have prepared porphyrin derivatives with cationic pendent 
arms by substituting all of the fluorine atoms in 
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tetra(pentafluorophenyl)porphyrin.
232
 The pendent arms, DMAP and 
triethylphosphane, were introduced using self-activated silyl-assisted polyonio 
substitution (SASAPOS) type reactions. Yields of 99 and 97% were obtained 
respectively. 
Tetra(pentafluorophenyl) porphyrin was used to form the PEGylated target molecule 
as shown in Figure 68. The ability to displace the p-fluoride atom selectively was 
utilised to attach PEG chains to the porphyrin backbone. Addition of these PEG 
chains will aid solubility of the resulting compound and its complexes. 
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5.2. Synthesis of tetra(3,5-di-hydroxyphenyl)porphyrin and 
its gallium complex 
 
Scheme 31: Synthesis of 61 and 62. Conditions; i) propionic acid, reflux, 30 min, 
19%; ii) BBr3, DCM, RT, 72 hr, 84%; iii) gallium(III) chloride, sodium acetate, 
acetic acid, reflux, 81%; iv) BBr3, DCM, RT, 24 hr, 100% 
Scheme 31 shows the synthesis of the tetra(3,5-di-methoxyphenyl)porphyrin, 61, and 
tetra(3,5-di-hydroxyphenyl)porphyrin, 62, and their gallium(III) complexes. The first 
step in the synthesis was to produce the porphyrin ring system from pyrrole and 3,5-
di-methoxy-benzaldehyde in propionic acid. This reaction has been reported 
previously by Nolte and co-workers
233
 using a modified methodology developed by 
Tsuchida and co-workers.
234
 The product can be obtained from the crude mixture by 
filtration, resulting in the isolation of the desired material in 19% yield as a purple 
crystalline material. 
Crystals of 61 suitable for X-ray crystallographic analysis were grown from a 
toluene solution left to evaporate at RT and the structure was determined as shown in 
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Figure 71. The porphyrin core is planar with the dimethoxyphenyl rings arranged in 
a perpendicular fashion (see Figure 72). 
 
Figure 71: Ball and stick representation of the X-ray crystal structure of 61. 
Water molecules are omitted for clarity. 
 
Figure 72: Ball and stick representation of the X-ray crystal structure of 61 
viewed along the horizontal axis.  
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The next step in the synthesis of the free base porphyrin involves the cleavage of the 
methoxy ethers. This deprotection has been reported previously, using boron 
tribromide.
233,234
 This reaction was carried out with asymmetric porphyrin 
derivatives which have three 3,5-dimethoxybenzene rings decorating the periphery, 
affording the hexa-hydroxy porphyrin in 75% yield after column chromatography.
235
 
Using boron tribromide to cleave the methyl ethers gave 62 as a dark purple solid in 
84% yield. 
Synthesis of the gallium(III) complexes was performed using 61 by Guilard‟s 
method of gallium insertion,
215
 to give the gallium complex in 81% yield as a violet 
solid. 62 was not used for this complexation reaction because it was thought that the 
hydroxyl groups on the periphery of the porphyrin may act as coordination donors to 
the gallium(III). This could possibly lead to the formation of porphyrin complexes 
were molecules of 62 are bridged by a single gallium(III) ion. Crystals of [Ga61]Cl 
were grown from a toluene solution which was left to evaporate at RT. The X-ray 
structure was determined as shown in Figure 73. The gallium(III) ion adopts a 
square-based pyramidal geometry, with a chloride in the apical position (bond 
lengths shown in Table 10). The gallium ion is elevated out of the porphyrin cleft by 
an angle of 10° as determined by the angle between two adjacent nitrogen atoms and 
the gallium ion.  
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Figure 73: Ball and stick representation of the X-ray crystal structure of 
[Ga61]Cl. Water molecule and H-atoms omitted for clarity. 
Of particular note is the deformation from planarity shown in this structure which is 
clearly noticeable when viewing along the horizontal axis, with the porphyrin core in 
the plane (Figure 74). Compared with the free-base derivative there is considerable 
saddle strain. This coincides with the dimethoxyphenyl rings becoming further 
distorted from being perpendicular to the porphyrin ring system. The insertion of the 
gallium ion into the porphyrin cleft is the most likely cause for this distortion. 
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Figure 74: Ball and stick representation of the X-ray crystal structure of 
[Ga61]Cl viewing along the horizontal axis. 
 Bond length (Å) 
Ga(1)-N(1)  2.0213(18) 
Ga(1)-N(2) 2.0144(17) 
Ga(1)-N(3) 2.0316(18) 
Ga(1)-N(4) 2.0217(17) 
Ga(1)-Cl(1) 2.2067(9) 
Table 10: Selected bond lengths from the X-ray crystal structure of [Ga61]Cl. 
The next step was to cleave the methyl ethers. This cleavage was performed using 
boron tribromide in an analogous way to the preparation of 62, and [Ga62]Cl was 
isolated as a very dark purple powder in quantitative yield. 
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5.2.1. Electrochemistry 
 
Figure 75: Cyclic voltammogram of 61 at a scan rate of 0.2 V/s in 
dichloromethane with tetrabutylammonium tetrafluoroborate as a supporting 
electrolyte. 
Figure 75 shows the cyclic voltammogram of 61. In the anodic region there are two 
waves at +1.19 V and +1.44 V, which are both reversible. These waves correspond 
to the formation of the radical cation and cation species respectively. In the anodic 
region there are also two waves, which appear at −1.12 and −1.51 V. These waves 
indicate the formation of the radical anion and anion species respectively. Both 
waves are again reversible. A plot of peak current verses the square root of scan rate 
gives a straight line which passes through the origin for all four waves; this is 
indicative that each wave is reversible in nature. The wave at −1.12 V appears to 
consist of two components; this is ascribed to the presence of both adsorbed and free 
species. Diagnostic criteria for metal complexes of porphyrins have been developed 
by Fuhrhop et al.
236
 These criteria are as follows; i) the difference in E½‟s for the 
first ring oxidation and the first ring reduction is equal to 2.25 ± 0.15 V; ii) ΔE½ 
(reduction) = 0.42 ± 0.05 V; and iii) ΔE½ (oxidation) = 0.29 ± 0.05 V. Values 
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obtained for 61 for these criteria are i) 2.26 V, ii) 0.39 V and iii) 0.24 V. Compound 
61 therefore fulfils all criteria, and therefore the four redox waves can be assigned as 
porphyrin ring centred. 
 
Figure 76: Repetitive cyclic voltammograms of 62 in water using potassium 
chloride as a supporting electrolyte at a scan rate of 0.1 V/s 
Figure 76 shows the successive cyclic voltammograms of 62 measured in water at 
0.1 V/s. Compared with 61, the porphyrin possesses different behaviour. Only the 
anodic region is shown as the cathodic region is featureless. In the first scan a small 
broad peak is observable at ~+1 V. This peak is not present in further scans. It is 
interesting to note that after the first scan, the height of the peak at 1.39 V increases. 
This coincides with a complete disappearance of the peak at +1 V. It is proposed that 
the peak at ~+1 V is the formation of a radical species; a phenoxyl radical. The 
phenoxyl radical could result in dimerisation as shown in Scheme 32. 
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Scheme 32: Proposed reaction pathway for the formation of the porphyrin 
polymer formed from 62. 
Scheme 32 shows the proposed pathway to form the porphyrin polymer of 62. In the 
first step, one of the hydroxyl groups undergoes oxidation, generating the radical 
cation. Subsequent lose of a proton leaves a phenoxyl radical species. Through 
resonance, the radical can move through the conjugated π system, and by doing so, 
the radical can reside at the para position on the ring. Two such radicals can react 
with one another to form a dimer by forming a new C-C bond via radical fusion. The 
resulting dimer then regains its aromaticity by intermolecular hydrogen transfer. This 
same reaction can proceed at the other three di-hydroxy-phenyl positions on 62 
therefore resulting in a polymer that extends both vertically and horizontally. 
Reaction of 3,5-dihydroxy-toluene in the presence of potassium ferricyanide is 
known to lead to the formation of 2,2‟,6,6‟-tetrahydroxy-4,4‟-
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dimethylbiphenyl.
237,238
 The dimerisation was shown to occur through a radical 
mechanism caused by one electron oxidation by potassium ferricyanide. This lends 
support to the notion of the porphyrin polymer being formed as outlined in Scheme 
32. 
The formation of the poprhyrin polymer is further evidenced by the presence of a 
large amount of adsorbed species on the platinum electrode. Also, from Figure 76, 
the peak at +1.39 V in the first scan shifts to +1.46 V on subsequent scans. This may 
suggest that on scans 2 and 3, a different species is responsible for this oxidative 
wave. This peak may originate from the oxidation of the polymerised porphyrin. 
To further probe this reaction, the platinum working electrode was exchanged for a 1 
cm wide 190 μm thick strip of Toray™ Carbon Paper. The experiment was then 
conducted again using the same conditions. The cyclic voltammogram recorded at 
the new electrode surface is shown in Figure 77. If repetitive cyclic voltammograms 
are collected, a deposit can be seen to form on the graphite surface which coincides 
with the solution gradually becoming clearer. The porphyrin polymer being formed 
must therefore become impregnated into the carbon paper. A similar type of 
procedure has been reported by Mosinger and co-workers.
239
 They report the 
synthesis of immobilised TPP photosensitisers into polymeric nanofibres. These 
nanofibres were placed in bacterial cultures of E. coli. Upon irradiation, the 
bactericidal effect is clearly observable due to the absence of bacterial colonies. The 
generation of singlet oxygen by illumination with red light provided the cyctotoxic 
species. To investigate further the composition of material on the surface of the 
carbon paper, SEM coupled with X-ray emission spectroscopy was used. 
 188 
 
Figure 77: Cyclic voltammogram of 62 recorded at a graphite electrode at a 
scan rate of 0.2 V/s. 
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5.2.2. Scanning electron microscopy studies 
 
Figure 78: SEM images of the carbon paper and of the carbon paper 
impregnated with the porphyrin polymer formed from 62. 
Scanning electron microscopy (SEM) was used to analyse the surface of the 
electrode impregnated with material produced from cyclic voltammetry experiments. 
Figure 78 shows the images of the carbon paper material (A), the carbon paper 
coated with material produced from cyclic voltammetry (B) and the carbon paper 
with material produced from cyclic voltammetry after washing with water (C). The 
SEM image of the clean electrode (A) was collected using a secondary electron 
detector. This enabled the tomography of the surface of the substrate to be observed. 
Electrodes with material impregnated into the graphite sheets (B and C) were 
analysed by using a backscattered electron detector. This enabled elemental contrast 
to be obtained. There is a clear difference between B and C in terms of the material 
impregnated into the carbon paper. B possesses both crystalline and powder phases, 
whereas C just has a powder phase. The chemical composition of the treated and 
non-treated carbon paper was probed by X-ray emission spectroscopy.  
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Graph 4: X-ray emission lines of the carbon paper impregnated with the 
porphyrin polymer formed from 62 before and after treatment. 
Graph 4 shows the difference in the composition of the material deposited on the 
surface of the carbon graphite. Pre-washing, the surface is contaminated with large 
quantities of KCl, which was used as the supporting electrolyte during cylic 
voltammetry studies. This is evidenced by the presence of peaks at 2.63 and 3.32 
keV. These are both generated due to chlorine (Kα emission line with a Kβ emission 
line as shoulder to this peak) and potassium (Kα emission line with a Kβ emission 
line as shoulder to this peak) respectively. A further smaller peak is present at 1.5 
keV which is due to the presence of bromine (Lα emission line). The carbon paper 
was treated by leaving it in distilled water overnight. After washing, the spectrum 
now only possessed one major peak, which corresponds to bromine at 1.5 keV. The 
presence of this peak would suggest that during the cleavage of the methyl ethers 
using boron tribromide, the chloride axially attached to the gallium ion is exchanged 
for a bromide ion. This is not quantitative as there is still a small peak for chloride in 
the spectrum whilst there is a complete absence of a potassium peak. Gallium 
possesses K and L lines at around 10 keV and 1.1 keV respectively. The K line was 
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not detected and the L line is not clearly observable. Due to the presence of the other 
elemental emission lines in this area, it is possible that the gallium L line is masked. 
5.2.3. Cytotoxicity studies 
Cytotoxicity studies were conducted on 62 and [Ga62]Cl. These studies are used to 
measure the light induced toxicity of each complex by determining the percentage of 
cells killed after irradiation. The porphyrin compound is incubated in the cells for a 
small amount of time prior to being irradiated with red light. The percentage number 
of cells killed is then calculated. A control is used, whereby the cells are incubated 
with the porphyrin but kept in the dark. A high percentage of cell kill for the control 
is known as “dark toxicity” and has no therapeutic potential. Only the percentage 
number of cells killed upon irradiation with light is a useful measure of how 
effective a compound will be for PDT.  
 
Graph 5: Percentage cell survival of human Caco2 cells in the presence of 62 
and [Ga62]Cl. 
Graph 5 shows the percentage survival of human Caco2 cells in the presence of 
either 62 or [Ga62]Cl. It is clear from the graph that both compounds display the 
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similar cytotoxic effects when non-irradiated and irradiated. 62 and its gallium 
complex are therefore not vey suitable as PDT agents because they possess high 
levels of dark toxicity. 
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5.3. Synthesis of tetra(pentafluorophenyl)porphyrin 
PEGylated derivatives and their nickel(II), zinc(II) and 
gallium(III) complexes 
The synthesis of the PEGylated tetra(pentafluorophenyl)porphyrin derivatives, 64-
66, are shown in Scheme 33. Tetra(pentafluorophenyl)porphyrin, 63, was 
synthesised according to the literature procedure by Longo and co-workers.
227
 This 
involves the heating to reflux of pyrrole and pentafluorobenzaldehyde in propionic 
acid for 6 hr. When made in this way, there are considerable amounts of chlorin 
impurity present, which is difficult to separate by column chromatography. A 
purification method reported by Gouterman and co-workers was therefore used.
228,240
 
The purification they describe utilises a metallation of the free base porphyrin in 
order to separate it from the chlorin impurity. In order to extract the porphyrin from 
the crude material, the product was first put onto a wet-packed neutral alumina 
column. Using an eluent mixture of petroleum ether and hexane (5:8), both green 
(chlorin) and red (porphyrin) bands were collected, whilst a black band remained at 
the top. The green and red bands were then combined and the porphyrin/chlorin mix 
reacted with zinc(II) acetate in refluxing chloroform/methanol. The complex was 
then purified by column chromatography, using a basic alumina column. The green 
chlorin band was then eluted using hexane/DCM (1:1). After the column was clear, 
the desired porphyrin band was brought down using DCM. The porphyrin was then 
demetallated using concentrated HCl, and the free base porphyrin extracted using an 
aqueous work-up.  
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Scheme 33: Synthesis of 63-66. Conditions; i) propionic acid, reflux, 6 hr (4%); 
DMF, 10 equivalents of 29, 30, or 31, RT, 3 d (64=75%, 65=100%, 66=100%). 
Complex formation of porphyrin 63 was accomplished using three different metals; 
nickel(II), zinc(II) and gallium(III). Complexation with zinc(II) and nickel(II) 
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involved dissolving the porphyrin in chloroform or acetic acid respectively, followed 
by the addition of the appropriate metal salt. Complexation with gallium(III) proved 
more difficult however. Initially the methodology developed by Guilard and co-
workers was used.
215
 The porphyrin was dissolved in dry acetic acid and the gallium 
chloride added in the presence sodium acetate. The reaction was heated to reflux and 
allowed to proceed for 12 hr. After this time, TLC showed that the reaction was not 
complete. The mixture was subjected to column chromatography and the desired 
fraction which had a Rf of 0.44 (ethyl acetate/hexane 5/95) was isolated. Using this 
methodology, the gallium complex was obtained in only 5% yield. One possible 
reason for this was the low solubility of porphyrin in acetic acid. 
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Scheme 34: Synthesis of Ni(II), Zn(II) and Ga(III) metal complexes of 63-67. 
Conditions; i) when M=Zn: Zn(II) acetate, DCM, reflux, 4 hr (92%); when 
M=Ni: Ni(II) acetate, acetic acid, reflux, 24 hr (95%); when M=Ga: GaCl3, 
sodium acetate, acetic acid, reflux, 24 hr (6%) or Ga(acac)3, PhOH, 220°C, 30 
min (92%); ii) DMF, 10 equivalents of 29, 30, or 31, RT, 3 d ([M64]=62-94%, 
[M65]=58-94%, [M66]=72-95%, [Zn67]=8%). 
Figure 79 shows the crystal structure of [Ga63]C4H4N obtained from 
crystallographic refinement. Crystals were grown from a toluene solution left to 
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evaporate at RT. The unit cell contains a single molecule of toluene and a pyrrolic 
anion. The pyrrolic anion is not coordinated to the gallium centre. The presence of a 
pyrrolic anion in the unit cell is unlikely due to its high basicity; better quality data is 
needed to ambiguously assign the chemical nature of the anion. The toluene 
molecule is disordered over four sites; the molecule is present either above or below 
the porphyrin plane in which it occupies two different site positions. Figure 79 
shows all four positions for the toluene molecule. The gallium ion sits in the plane of 
the porphyrin and adopts a square planar geometry (bond lengths for the gallium(III) 
ion are shown in Table 11). Figure 80 shows [Ga63]C4H4N viewing perpendicular to 
the horizontal plane. This shows the toluene molecule is directly centred 
above/below the gallium ion. The distance between the gallium centre and the centre 
of toluene molecule is 3.29 Å. The pyrrolic anion could be generated from the 
decomposition of 62 during complexation due to its insolubility in acetic acid, or 
having been carried through from the previous step. 
 
Figure 79: Ball and stick representation of the X-ray crystal structure of 
[Ga63]C4H4N viewed along the horizontal axis. The pyrrolic anion is omitted 
for clarity. 
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Figure 80: Ball and stick representation of the X-ray crystal structure of 
[Ga63]C4H4N viewed along the vertical axis. H-atoms and the pyrrolic anion 
have been omitted for clarity. 
 Bond lengths (Å) for 
[Ga63]C4H4N 
Bond lengths (Å) for 
[Ga63]OPh 
Ga(1)-N(1)  2.038(5) 2.109(7) 
Ga(1)-N(1)#1 2.038(5) 2.108(7) 
Ga(1)-N(2) 2.046(5) 2.086(8) 
Ga(1)-N(2)#1  2.046(5) 2.059(7) 
Ga(1)-O(1)   1.796(11) 
Table 11: Selected bond lengths from the X-ray crystal structures of 
[Ga63]C4H4N and [Ga63]OPh. 
The second metallation procedure used for the insertion of gallium into porphyrin 63 
was that developed by Buchler.
217
 The porphyrin and gallium acetylacetonate were 
dissolved in phenol and heated to 220°C for 20 min. The crude material was then 
purified by column chromatography to remove the excess phenol. This was 
performed using a neutral alumina column, with the red band containing the metal 
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complex being eluted with benzene. Crystals of this material were grown from a 
toluene solution left to evaporate at RT. 
 
Figure 81: Ball and stick representation of the X-ray crystal structure of 
[Ga63]OPh with hydrogen atoms omitted for clarity. 
Figure 81 shows the X-ray structure of [Ga63]OPh. The gallium ion adopts a five 
coordinate geometry, with the oxygen of the bound phenolate anion capping the apex 
of a square based pyramid. The bond lengths of the gallium(III) ion are shown in 
Table 11. 
To PEGylate the porphyrin, a methodology developed by Boyle and co-workers was 
used.
241
 They describe the regio-selective synthesis of monofunctionalised 
porphyrins via the displacement of a p-fluorine atom. These porphyrin derivatives 
possess a single pentafluorophenyl ring. Reactions were conducted in DMF at RT 
using sodium sulphide in the presence of an electrophile. Yields of 57-82% of mono-
functionalised products were obtained after being left to react for 12 hr. This route 
therefore appeared to be applicable to the synthesis of the target compound. 
Using this methodology, the PEGylated porphyrin complexes were prepared by 
attaching the PEG chains. This was performed by dissolving the complex in DMF 
and adding ten equivalents of the relevant PEG (either 29, 30 or 31) chain in the 
presence of ten equivalents of sodium sulphide. After three days the reaction was 
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judged complete by TLC (absence of starting material and also a new single spot 
with an Rf of 0.37) except for the zinc(II) complex of 66. Analysis showed that the 
reaction had not occurred (only one spot visible by TLC which had the same Rf as 
the starting material). The most likely reason for no reaction occurring is the 
aggregation of [Zn62]. Aggregation of [Zn62] is likely to be deterred by longer PEG 
chains (such as 29 and 30), but with 31, the chain length is much shorter and 
therefore unable to disrupt the aggregation. To disrupt aggregation, the reaction 
mixture was heated to 60°C and left for three weeks. Analysis now showed a multi-
component mixture in which starting material was still present but another intense 
spot with an Rf of 0.45 was also present. Other less intense spots were present at 
lower Rf values. The various fractions were isolated using column chromatography 
using a wet packed silica gel column. The starting material was eluted from the 
column using DCM and the remaining products eluted with MeOH/DCM (10/90 
(v/v)). The first spot removed in this way was the major component but it was only 
isolated in 8% yield. Analysis of this component by NMR showed that this was the 
mono-substituted product, [Zn67]. Analysis of the other spots was made difficult by 
the poor separation but these are believed to be the di-, tri- and tetra-substituted 
products. Combined yield of all three of these fractions was less than 5%.  
Clean up of the other metallated tetra-PEGylated porphyrins, [M64]-[M66] (Scheme 
33) was necessary to remove the excess PEG. Column chromatography was found to 
be laborious and in the case of longer PEG chains (29 and 30), particularly 
challenging. Therefore an alternative method for removing the excess PEG was 
sought. One method which appeared appropriate was to use dialysis. Spectrum 
Laboratories Inc. produce a product called a Float-A-Lyzer, which is basically 
dialysis tubing incorporated into a device which floats. This type of device could be 
purchased with a molecular weight cut-off (MWCO) of 1000 Da. This was ideal as 
the PEG chains all weighed less than this and the PEGylated porphyrin complexes 
all weighed considerably more. This appeared to be a very attractive method. The 
Float-A-Lyzers purchased had an internal diameter of 10 mm and a volume of 3ml. 
The tetra-PEGylated porphyrins were then dissolved in water/MeOH and placed 
within the Float-A-Lyzer and left for a period of one week immersed in water to 
enable the excess PEG to diffuse from the internal cavity. The tetra-PEGylated 
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porphyrin was then removed and re-analysed by NMR. This showed that the excess 
PEG had been removed from the samples.  
 
Scheme 35: Synthesis of [Ga63]Cl. Conditions; GaCl3, dry acetic acid, sodium 
acetate, reflux, 18 hr, 100%. 
The problematic insertion of gallium(III) into the porphyrin cleft of 62 was 
investigated further by seeing if the same problems were encountered when using the 
tetra-PEGylated porphyrin 63. The porphyrin was again dissolved in acetic acid and 
the gallium chloride salt added to it in the presence of sodium acetate (see Scheme 
35 for further conditions). After refluxing the mixture for 18 hr, it was analysed by 
TLC which showed that complex formation had proceeded as intended. Subsequent 
silica gel column chromatography (eluent DCM/MeOH 95/5 (v/v)) gave the 
gallium(III) complex in quantitative yield. This implies that 63 is more soluble in 
acetic acid than its analogue 62, thus increasing the yield of the product. 
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5.3.1. Cytotoxicity studies 
Cytotoxcity studies were conducted on the PEGylated porphyrins and their metal 
complexes. The aim of these studies was to ascertain if the light induced cyctotoxity 
was dependent on the length of the PEG chain. A second aim was to see if the metal 
ion had an influence on these properties. Experiments were conducted in the same 
way as those in section 5.2.3.  
 
Graph 6: Percentage cell survival of human Caco2 cells in the presence of 64, 65 
and 66. 
Graph 6 shows the percentage cell survival of human Caco2 cells when exposed to 
differing concentrations of 64, 65 and 66 after irradiation with red light or when kept 
in the dark (non-irradiated). From the graph, one noticeable trend is observable. 
When the PEG chain has an average molecular weight of 550 (65), there is 
negligible effect upon cell survival when either irradiated or non-irradiated. 
However, compared with compounds 64 and 66, a clear difference is noticeable. 
Compounds 64 and 66 have no appreciable effect on cell survival when not 
irradiated but when irradiated, the percentage of cells surviving decreases rapidly 
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with increasing concentration. It is possible that compounds 64 and 66 are able to 
cross the cell membrane using membrane channels, leading to intracellular singlet 
oxygen generation. Within the cell, the singlet oxygen generated can damage cell 
organelles leading to cell kill. The lack of cell kill for compound 65 suggests that 
this may not be able to internalise within the cell. Singlet oxygen is therefore 
generated outside of the cell leading to low levels of cell kill. 
These results differ to the trend observed by Ng and co-workers.
242
 They produced 
1,4-diPEGylated zinc(II) phthalocyanines (ZnPc[O(CH2CH2O)nMe]2). The chain 
length was found to be important with regard to light induced cytotoxicity. When n = 
2, or 8 and above, high IC50 values were obtained (> 0.1 μM against HT29). 
Conversely, those compounds where n = 4 or 6 possessed IC50 values of less than 0.1 
μM. The reason for the differences in these values is that when n = 2 the compounds 
are not very water soluble, and at high values of n (greater than 8), the compounds 
aggregated in the culture medium, probably due to strong dipole-dipole interactions 
among the side chains. Aggregation provides an efficient non-radiative relaxation 
pathway, thereby reducing the population of the triplet state and the singlet oxygen 
generation efficiency. 
The nickel(II) complexes of 64, 65 and 66 were all found to have negligible light 
induced cytotoxicity and high levels of dark toxicity. The same was found for the 
zinc(II) complexes of 65, 66 and 67. In all of these complexes, the metal sits in either 
the plane of the porphyrin ring (zinc) or slightly sitting out of the plane (nickel). 
These complexes can therefore aggregate. This leads to ineffective singlet oxygen 
generation and would also account for the high dark toxicity observed.  
The gallium(III) phenoxide complexes, however, were found to possess light 
induced cytotoxicity (see Graph 7). Compared with the unmetallated derivatives (64, 
65 and 66), a different trend was observed. For the gallium phenoxide complexes, 
the longer length chains are both cytotoxic on exposure to light, whereas the 
complex with the smallest PEG chain (31), were found to be inactive. All three 
complexes possess low levels of dark toxicity. The differences in light induced 
toxicity, suggests that these complexes internalise or localise differently compared 
with the free porphyrins. 
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Graph 7: Percentage cell survival of human Caco2 cells in the presence of the 
gallium(III) phenoxide complexes of 64, 65 and 66. 
Changing the anion in the gallium(III) complexes was found to have a profound 
effect on the light induced toxicity. The percentage cell survival of human Caco2 
cells in the presence of [Ga64]Cl is shown in Graph 8. Compared with [Ga64]OPh, 
the compound exhibits light induced cytotoxicity, which becomes greater with each 
successive experiment. Each experiment was performed using the same stock 
solution of [Ga64]Cl in DMSO. This infers that a more cytotoxic species is being 
generated over time. This could occur by displacement of the chloride attached to the 
gallium(III) centre by a DMSO molecule. 
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Graph 8: Percentage cell survival of human Caco2 cells in the presence of the 
[Ga64]Cl from experiments conducted in triplicate. 
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5.4. Conclusion 
In this chapter, the focus has been on the production of water soluble PDT agents. 
PDT agent design has been based around porphyrin molecules, and two such 
compounds have been synthesised for this purpose. The first porphyrin synthesised 
was based on TPP, and has eight hydroxyl groups decorating the periphery. Insertion 
of gallium(III) into the porphyrin cleft induces saddle strain on the porphyrin which 
is readily seen from the crystal structures obtained. Electrochemistry of the free base, 
61, fulfils the rules outlined by Fuhrlop
236
 whereas compound 62 underwent an 
electrochemical reaction. 62 and its gallium complex are believed to undergo head-
to-head dimerisation, thus forming a polymer. It was possible to coat the surface of a 
carbon paper electrode with this material and study it using SEM. Investigations into 
the cytotoxicity profiles of both the metallated and free base porphyrin of compound 
62 showed that dark toxicity almost mirrored the light induced toxicity. These 
compounds are therefore not suitable as PDT agents but may be suitable as 
antibacterial agents incorporated into fibrous materials. 
The second porphyrin derivative investigated was tetra(pentafluorophenyl)porphyrin 
and its complexes with gallium(III), zinc(II) and nickel(II). The porphyrin was 
synthesised by an Adler method and required a metallation-demetallation procedure 
to isolate the free-base. Insertion of zinc(II) and nickel(II) into the porphyrin gave 
satisfactory yields whereas gallium insertion proved problematic; use of Guilard and 
co-workers method
215
 resulted in only 5% of the desired metal complex being 
isolated. Much more satisfactory yields were obtained by using the method reported 
by Buchler and co-workers.
217
 Compound 63 and its complexes were used to 
produce porphyrins bearing four PEG chains. Each of these chains was attached via a 
thioether linkage following displacement of the para-fluoride. Yields for this 
PEGylation reaction were typically high although one exception was for the zinc(II) 
complex of 67. PEGylation for this complex proved difficult to carry out, a possible 
reason being that the porphyrin was forming aggregates. Heating this reaction 
encouraged the PEGylation reaction to proceed as desired. Cytotoxity studies of the 
free-bases 64, 65 and 66 revealed an interesting trend. 64 and 66 were light induced 
toxic whereas 66 was not. This suggests that 64 and 66 might be able to cross the 
cell membrane whereas 65 cannot. Zinc(II) and nickel(II) complexes were found to 
be ineffective light induced cyctotoxic agents. The gallium(III) phenoxide complexes 
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of 65 and 66 were found to be light induced cytotoxic whereas the complex of 64 
was not. This suggests a different mechanism of cell kill compared with the 
unmetallated tetra-PEGylated compounds. [Ga64]Cl was found to be light induced 
cytotoxic, however, and became more cytotoxic over time when left in solution. 
Displacement of the chloride from the gallium(III) centre in the stock solution by a 
DMSO molecule is believed to form the more potent cytotoxic agent. 
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6. Conclusions and further work 
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6.1. Conclusions 
The goal of this research was to synthesise macrocyclic ligand systems bearing 
pendent arms for potential use in diagnostic and therapeutic applications such as 
magnetic resonance imaging (MRI) and photodynamic therapy (PDT). Tetraaza 
macrocyclic complexes of 1,4,7,10-tetraazacylcododecane (cyclen), 1,4,8,11-
tetraazacyclotetradecane (cyclam) and porphyrins incorporating transition, 
lanthanide and p-block metal ions have been synthesised towards this aim. Novel 
redox active macrocyclic systems with attached pendent arms have been produced 
which has provided insight into the stability of the complexes produced. 
In Chapter 2, the design and synthesis of the pendent arms which were used to attach 
to the macrocycles was discussed. Redox active, amino acid and PEG pendent arms 
were all successfully synthesised. Phenol and thiophenol pendent arms were 
synthesised with the aim of investigating their redox properties when incorporated 
into macrocyclic complexes of cyclen and cyclam. Phenol pendent arms were 
synthesised with methyl, benzyl, p-methoxybenzyl and acetyl protecting groups. In 
addition, an unmasked phenol derivative was also synthesised. Two thiophenol 
pendent arms were synthesised, both utilising a p-methoxybenxyl group to protect 
the thiol. These were synthesised according to a procedure detailed by Wieghardt 
and co-workers.
142
 The phenol and thiophenol pendent arms were synthesised with 
tert-butyl groups in the ortho and para positions of the aromatic ring. These were 
required to stabilise the radical species once generated. A thiophenol derivative was 
synthesised without tert-butyl groups for comparison.  
Amino acid pendent arms were synthesised based on the two amino acids aspartic 
acid and 4-nitro-L-phenylalanine. The amino group of each amino acid was 
converted to a bromide via a diazonium salt intermediate. This gave a point of 
possible attachment to a tetraaza macrocycle. The remaining carboxylic acid groups 
were protected to enable selective deprotection once attached. Finally, polyethylene 
glycol (PEG) chains were synthesised. These chains are of varying length with one 
end of the chain capped as a methoxy group whilst the other is an alcohol. The 
synthesis of the PEG pendent arms uses commercially available materials and 
involves either a bromination or chlorination of the alcohol functional group. This 
activates the PEG chain towards nucleophilic attack. These chains were subsequently 
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used to increase the water solubility of tetra(pentafluorophenyl)porphyrin complexes 
by displacement of a p-fluoride on each phenyl ring. 
In Chapter 3, the preparation of side-bridged cyclam complexes with thiophenolate 
or phenolate pendent arms was discussed. Use of the phenol pendent arms as 
discussed in Chapter 2 led to a library of side-bridged cyclams being produced. 
There were a number of issues with the protecting group strategy and after 
attempting different variations, use of the acetyl protected phenol was identified as 
the most appropriate. This was cleaved using 6M HCl in conjunction with the acetyl 
protected compound, 43. Nickel(II), copper(II) and zinc(II) complexes were 
produced for the phenolate and protected phenol side-bridged cyclam compounds. 
Gallium(III) complexes were also desired but were not isolated for either the 
phenolate or thiophenolate compounds. Cyclic voltammetry of the nickel(II) and 
copper(II) complexes was performed to obtain evidence of the phenoxyl radical 
being generated. For the copper complexes, the Cu(II)/Cu(III) redox couple was 
shifted towards anodic potentials in the order p-methoxybenzyl < benzyl < methyl. 
For [Cu37]
+
, the side-bridged cyclam di-tert-butyl-phenolate copper(II) complex, a 
wave corresponding to the formation of the phenoxyl radical was observed at +0.48 
V (reversible). The phenoxyl radical was also observed to form in [Ni37]
+
 at +0.74 
V.  
Nickel(II) complexes of the thiophenol side-bridged cyclams were produced. The 
thiophenol was unmasked by cleaving the p-methoxybenzyl protecting group using 
mercury acetate and hydrogen sulphide. Cyclic voltammetry was performed on the 
copper(II) and nickel(II) complexes. The cyclic voltammogram (CV) of the 
nickel(II) complex of the side-bridged cyclam with attached thiophenolate arm 
([Ni46]
+
) possesses a wave at +0.60 V which is assigned to the formation of the thiyl 
radical. In the copper(II) and nickel(II) complexes of the side-bridged cyclam 
complex with a di-tert-butyl-thiophenolate arm attached (49), the formation of the 
thiyl radical was assigned to peaks at +0.50 and +0.53 V respectively. These 
complexes also display evidence for dimerisation occurring in solution. Dimerisation 
occurs between two radical species to form a di-sulphide bond. Oxidation waves at 
−0.25 and −0.2 V are assigned to the oxidation of the dimer for the copper(II) and 
nickel(II) complexes of 49 respectively. 
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Chapter 4 details the production of lanthanide macrocyclic complexes using cyclen 
as the tetraazamacrocyclic scaffold. Ligands were produced bearing three acetate 
arms and either one phenol/thiophenol pendent arm or an amino acid pendent arm. 
The phenolate ligand, 52, was synthesised using the acetyl protected di-tert-butyl 
pendent arm, 15. The thiophenolate ligand, 56, was produced using the di-tert-butyl 
thiophenolate pendent arm, 24. Lanthanide complexes of the ligands were 
synthesised. For the gadolinium(III) complexes, T1 weighted images were collected. 
These images showed that the complexes [Gd52]
−
 and [Gd56]
−
 enhanced the image 
relative to water. The oxidised species [Gd52]
●
 and [Gd56]
●
 did not enhance the 
image relative to the starting complexes. The lipophilic nature surrounding the metal 
ion is believed to prevent further water molecules entering the inner coordination 
sphere after oxidation, and therefore no enhancement of the image is observed.  
The UV-visible spectrum of [Eu52]
−
 displays only a π-π* transition, but upon one 
electron oxidation, the characteristic fingerprint of a phenoxyl radical was observed. 
This was further observed in the cyclic voltammogram (peak at ~+0.75 V due to 
formation of the phenoxyl radical). The thiyl radical was also observed in the cyclic 
voltammogram of [Eu56]
−
 (wave at +1.14 V). When cooled to −40°C, this peak 
shifts to +0.83 V. The existence of different isomers was suggested for the ease of 
this oxidation at lower temperatures. Fluorescence spectra of [Eu52]
−
 and [Eu56]
−
 
possess two emission peaks each. For [Eu52]
−
 the peaks are centred at 595 and 612 
nm which corresponds to 
5
D0→
7
F1 and 
5
D0→
7
F2 transitions respectively. The 
emission peaks for [Eu56]
−
 are at 573 and 614 nm and correspond to 
5
D0→
7
F0 and 
5
D0→
7
F2 transitions. In contrast, the terbium(III) complexes of 52 and 56 possess 
four emission peaks each. These peaks correspond to the following transitions; 
5
D4→
7
F6 (~620 nm), 
5
D4→
7
F5 (~598 nm), 
5
D4→
7
F4 (~544 nm) and 
5
D4→
7
F3 (~491 
nm). 
Macrocyclic ligands based on a cyclen framework were also produced with the 
aspartic acid pendent arm, 27, attached. This ligand was used in an attempt to couple 
a further macrocycle, a side-bridged cyclam compound with a pendent p-
aminobenzyl arm (60). Although unsuccessful, this route does highlight a possible 
synthetic strategy for the production of dual-imaging probes using amino acid linker 
moieties. 
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In Chapter 5, the synthesis of porphyrin complexes with either hydroxyl or PEG 
chains on the periphery as potential PDT agents is detailed. The octa-hydroxyl 
porphyrin (62) was synthesised using an Adler condensation of 3,5-dimethoxy-
benzaldehyde and pyrrole. Cleavage of the methoxy ethers was achieved using boron 
tribromide. Gallium(III) complexes were produced of tetra(3,5-
dimethoxyphenyl)porphyrin (61) and 62. Comparison of 61 and [Ga61]Cl 
compounds highlighted that the inclusion of gallium into the cleft of the porphyrin 
induces severe saddle strain, causing the sp
2
 hybridised porphyrin planar core to 
deviate from planarity. An intriguing property arose when analysing 62 and 
[Ga62]Cl by cyclic voltammetry. These compounds do not possess characteristic 
porphyrin behaviour. The cyclic voltammagram for 62 has a broad peak at ~+1 V. 
This is assigned to the formation of a radical species. This radical can react with an 
equivalent radical species, leading to the formation of dimer. Subsequent reaction of 
the porphyrin dimer results in the formation of a porphyrin polymer. Evidence to 
support the porphyrin polymer being formed was gained by performing cyclic 
voltammetry using carbon paper. This resulted in a purple coating being deposited 
on the surface. Analysis using SEM and X-ray emission spectroscopy revealed that 
the surface was heavily contaminated with KCl. A washing procedure was sufficient 
to remove this excess potassium salt but leave the porphyrin polymer intact on the 
surface of the carbon paper. Cytotoxicity of the porphyrins showed that light induced 
cytotoxicity mirrored that of the dark toxicity. No selective PDT effect was 
observed. However, the ability to coat a porphyrin polymer onto the surface of 
carbon paper might suggest a possible use of these compounds as anti-bacterial 
agents. Mosinger and co-workers has reported such an application of a porphyrin 
sensitiser previously.
239
 
Tetra(pentafluorophenyl)porphyrin (63) derivatives whereby the four p-fluorine 
atoms are substituted for polyethylene glycol chains were also synthesised. Crystal 
structures of gallium(III) complexes of 63 were obtained. In one structure the 
gallium(III) ion is in a square based pyramidal geometry with an apical phenolate. In 
the other structure, the gallium(III) ion is square planar; the pyrrolic anion does not 
directly coordinate to the metal centre. Such a geometry with a gallium(III) ion in a 
porphyrin cleft is rare. The attachment of PEG chains (29-31) via displacement of 
the p-fluorines of 63 led to the synthesis of compounds possessing differing light 
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induced cytotoxicity (64-67). Light induced cytotoxicity was examined by using in 
vitro cellular studies with Caco2 cells. The free base porphyrins, 64-66, showed a 
size related light induced cytotoxicity. 64 and 66 were both induced light cytotoxic 
whereas 65 was not. All three were not dark toxic. The nickel(II) and zinc(II) 
complexes of 64-67 were all found to be light and dark toxic, which is believed to be 
caused by aggregation. Light induced cytotoxicity of the gallium(III) phenoxide 
complexes showed that if longer chains were attached to the porphyrin then the 
resulting compounds were light induced cytotoxic. However, if the shortest chain is 
attached to the porphyrin then the resulting compound ([Ga66]OPh) exhibits no light 
induced cytotoxicity. These compounds therefore result in cell death using a 
different mechanism to that of the free ligands. Compared with [Ga64]OPh, which 
possesses both light and dark toxicity, [Ga64]Cl has light induced cytotoxity with 
only minor associated dark toxicity. This suggests that the anion within the complex 
can also affect the light induced cytotoxicity. [Ga64]Cl also becomes increasingly 
more light induced cytotoxic with time when left in solution, suggesting the 
formation of more a cytotoxic species whilst it is stored in DMSO. Dark toxicity of 
this compound also increases with time.  
To summarise, this research has been focused on the design and synthesis of tetraaza 
macrocycles bearing pendent arms towards biological applications. Three different 
macrocycles have been investigated; cyclam, cyclen and porphyrin. These 
macrocycles have been used to form metal complexes of different types of transition, 
lanthanide and p-block metal ions. 
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6.2. Further work 
This research has scope for further development. Several of the key areas highlighted 
within this thesis provide avenues for future research. In this section each area of 
work is discussed relevant to its future research potential. 
6.2.1. Side-bridged cyclams bearing redox active pendent 
arms 
The research detailed within has covered ligand systems in which the redox pendent 
arm is attached through one of the nitrogen atoms. A further way to incorporate this 
moiety would be through the carbon network. Examples of this type have been 
reported previously by Kimura and co-workers,
160,161
 however, they have not been 
synthesised with tert-butyl groups to stabilise the radical species. Furthermore, this 
type of route would still leave the nitrogen atoms available for attaching further 
moieties. This could again be exploited via the use of a bis-aminal intermediate, 
enabling the reactivity of the nitrogens to be controlled. In addition, side-bridged 
cyclens bearing redox pendent arms could also be developed. This would provide a 
comparison for the side-bridged cyclam complexes already produced, while varying 
the geometric parameters around the metal ion. 
A different approach to the synthesis of the phenol pendent arm could also be taken. 
In this work, the phenol has been protected as either an ether or an ester. An 
alternative way could be to use a boronic ester, which can be subsequently cleaved to 
form the phenol when desired. This type of methodology has been used previously 
by Franz and co-workers to produce triggered pro-chelators for iron sequestration.
243
  
6.2.2. Lanthanide complexes bearing redox active pendent 
arms 
The drawback of the lanthanide complexes bearing redox pendent arms already 
synthesised is that upon one electron oxidation, no further water molecules appear to 
access the inner coordination sphere. For these complexes to be effective MRI 
agents, this will need to be improved upon. The current hypothesis is that the 
lipophilic nature of the ligand prevents more than one water molecule from accessing 
the metal centre. To circumvent this problem, it could be possible to introduce 
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hydrophilic groups in close proximity to the metal centre by modification of the 
ligand structure. This would hopefully enable further water molecules to access the 
metal centre when the phenoxyl or thiyl radical is formed. Image enhancement could 
also be achieved by the formation of a disulfide bound between [Gd56]
−
 and a 
protein which has accessible thiol groups on its surface. The resulting protein 
conjugate would have a much longer rotational correlation time which can enhance 
the relaxivity considerably. 
The production of mixed phenol/thiophenol ligand systems would be of interest. 
Having characterised the phenolate and thiophenolate metal systems independently, 
investigations using cyclic voltammetry would highlight the effect on the ease of 
oxidation of the metal centre as well as the pendent arms. It would also be interesting 
to see the effect on the redox properties of the phenolate pendent arms when a dimer 
is formed because of thiyl radical-radical coupling. 
6.2.3. Water soluble porphyrin sensitisers 
Compound 62 and its gallium(III) complex have been shown to be electrochemically 
deposited on to carbon paper. To provide further evidence for the mechanism 
suggested, the synthesis of an asymmetric porphyrin is proposed. This porphyrin will 
possess only one 3,5-di-hydroxy-phenyl ring, and as such, only dimers can be 
formed by the head-to-head coupling pathway. Bulk electrolysis or reactions using 
potassium ferricyanide could be used to form this dimeric product, which could then 
be isolated and characterised.  
PEGylation reactions of 63 deserve further attention. The compounds synthesised 
already possess differing light toxicity dependent on the type of metal ion and also 
the number and length of the PEG chains. This area can be easily expanded upon by 
investigation of further metal centres to attenuate the light induced cytotoxic effect. 
The isolation of [Zn67] as the mono-PEGylated complex warrants further research, 
as this suggests a possible route to producing asymmetric systems from a 
symmetrical porphyrin. 
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7. Experimental 
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7.1. Chemicals 
All materials for synthetic procedures were purchased from Lancaster, Aldrich or 
Strem Chemicals. Exceptions to this were the Toray™ Carbon Paper which was 
purchased from fuelstore.com and the Float-A-Lyzers which were purchased from 
Spectrum Laboratories Inc. All materials were used as received unless otherwise 
stated. The solvents used were of general purpose or HPLC grade and were 
purchased from Fisher Scientific. TLC analysis was performed using aluminium-
backed silica gel 60 F254, 0.2 (Merck plates) or aluminium-backed aluminium oxide 
60 F254, (Merck plates). Silica gel chromatography was performed with silica gel 60 
(Davisil). Alumina gel chromatography was performed using aluminium oxide 150 
(Aldrich). When required diethyl ether, dichloromethane, acetonitrile and acetic acid 
were dried as follows; diethyl ether was dried over sodium metal and benzophenone 
followed by distillation; dichloromethane and acetonitrile were dried over calcium 
hydride for 24 h followed by distillation; acetic acid was dried by adding acetic 
anhydride (3% w/v) and distilling (b.p. 118°C). 
7.2. Instrumentation 
Evaporation of solvents was preformed on a Buchi RE 111 rotary evaporator at 35-
60
o
C equipped with a diaphragm vacuum pump. All NMR spectra were acquired in 
the solvent indicated with chemicals shifts () quoted as parts per million values 
(ppm) and coupling constants (J) quoted in hertz (Hz). NMR spectra were recorded 
using a JOEL JNM-LA400 FT NMR spectrometer at a frequency of 400 MHz for 
1
H 
spectra, 100 MHz for 
13
C spectra and 376 MHz for 
19
F spectra. Mass spectrometry 
was performed using either a Finnegan MAT 900 XLT system to collect electrospray 
ionization (ES-MS) spectra or matrix assisted laser desorption ionization (MALDI). 
Accurate mass spectrometry measurements were obtained using a LTQ Orbitrap XL. 
UV/visible spectra were obtained using an Agilent8453E UV-VIS diode array 
spectrometer using 1 cm
3
 quartz cells. 
Single crystal X-ray diffraction data were collected on a Stöe IPDS-II imaging plate 
diffractometer, using MoKα X-rays of λ=0.71073 Å. Crystals were cooled to 150 K 
during data collection, with the temperature controlled by an Oxford Systems 
Cryostream Cooler. Diffraction data were solved using direct methods (SHELXS), 
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and the refinement was by full-matrix least squares against F
2
 (SHELXL-97) 
method. The WinGX program
244
 was used for refinement and production of data 
tables, and the ORTEP-3 program
245
 was used for structural visualisation. Hydrogen 
atoms were fixed in idealised positions and refined using a riding model, with C-H 
distances of 0.97 Å, N-H distances of 0.91 Å, and Uiso 1.5 times Ueq of the carrier 
atom. All ORTEP representations show ellipsoids at the 50% probability level. Ortep 
representations and crystal data and structure tables are included within this chapter. 
Torsion and bond length tables are included in the appendix on the CD. 
Cyclic voltammetry was performed using a standard three-electrode configuration 
with platinum working (0.2 mm diameter disk) and counter electrodes and a 
Ag/AgCl reference which gave the FeCp/ FeCp+ couple at 0.55 V using an Autolab 
II PGSTAT 30 system. All measurements were made in an argon/nitrogen purged 
solution of either MeCN/ 0.2 mol dm
-3
 [n-Bu4N][BF4] or MeCN/ 0.2 mol dm
-3
 [n-
Bu4N][ClO4] or H2O/ 0.2 mol dm
-3
 KCl over  the scan rates of 0.01 V s
-1
 to 10 V s
-1
. 
Cytotoxicity testing was conducted using the following protocol. Each porphyrin 
compound formulated in DMSO and diluted in medium (DMEM+ 4.5 g/L Glucose + 
NEAA + 2 mM L-glutamine) to give concentrations ranging from 1x10
-4
 to 1 x10
-6
M 
was added to Caco 2 cells (Human Caucasian colon adenocarcinoma) adjusted to a 
concentration of 1x10
6
 cells /ml. The cells were then incubated in the dark for an 
hour at 37°C and 5% CO2 after which they were washed in a 3 fold excess of 
medium to eliminate any unbound porphyrin. The pellets of cells and porphyrin were 
re-suspended in 1 ml medium and 4x100 µl of each concentration was put in two 96 
wells plates. One plate was irradiated with red light to a dose of 3.6 J/cm
2
 while the 
other served as dark control. After irradiation, 5 µl of Fetal Bovine Serum was added 
to each well and the plates were returned to the incubator overnight. After 18 to 24 
hours, an MTT cell viability assay was performed and the results expressed as a 
percentage of cell viability versus porphyrin concentration; an LD 90 (lethal dose 
where 90% of the cells are killed) was determined from the resulting curves. Each 
experiment was repeated in triplicate (minimum). 
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7.3. Pendent arm synthesis 
7.3.1. Synthesis of 2,4-di-tert-butyl-6-(hydroxymethyl)phenol 
(1) 
 
2,4-di-tert-butyl-phenol (20 g, 0.097 mol) was dissolved in methanol (30 ml). To this 
solution was added LiOH.H2O (0.33 g, 0.008 mol) and paraformaldehyde (3 g, 0.1 
mol) in methanol (40 ml) dropwise. After addition was complete, the solution was 
then heated to reflux for 24 hr, before allowing it to cool and concentrating in vacuo. 
The residue was then taken up in ethyl acetate (20 ml) and the inorganic salts filtered 
off. The filtrate was then concentrated and redissolved in hexane and placed in a 
fridge o/n. A crystalline solid formed and was collected to give 1 as fine white 
needles (11.39 g, 50%); 
1
H NMR [CDCl3] 7.54 (br s, 1H, PhOH), 7.29 (d, 1H, 
J=2.5 Hz, ArH), 6.90 (d, 1H, J=2.5 Hz, ArH), 4.83 (s, 2H, CH2OH), 1.44 (s, 9H, 
t
Bu), 1.30 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 153.10, 141.61, 136.52, 124.09, 123.94, 
122.59 (Carom), 65.90 (CH2), 34.93, 34.19 (C(
t
Bu)), 31.59, 29.67 (Me(
t
Bu)). CHN 
data not collected. 
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7.3.2. Synthesis of 2-(bromomethyl)-4,6-di-tert-butylphenol (2) 
 
To a solution of 1 (4.98 g, 0.0211 mol) in CHCl3 (60 ml) at 0°C and under a nitrogen 
atmosphere, was added PBr3 (5.71 g, 0.0211 mol) in CHCl3 (20 ml) over the course 
of 30 min. After addition was completed, stirring was continued at 0°C for a further 
hour. The solution was then poured into brine (200 ml), and the organic layer 
separated. The organic layer was further washed with brine (3 x 200 ml) and then 
dried over MgSO4 and concentrated under reduced pressure to give a yellow oil (6.0 
g, 95%); 
1
H NMR [CDCl3] 7.37 (d, 1H, J=2.53 Hz, ArH), 7.14 (d, 1H, J=2.53 Hz, 
ArH), 5.2 (br s, 1H, PhOH), 4.61 (s, 2H, CH2), 1.47 (s, 9H, 
t
Bu), 1.34 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 153.10, 141.61, 136.52, 124.09, 123.94, 122.59 (Carom), 65.90 
(CH2), 34.93, 34.19 (C(
t
Bu)), 31.59, 29.67 (Me(
t
Bu)); MS (ES-MS): m/z 300 (M
+
), 
219 ((M-Br)
+
); Calcd. for C15O1H23Br1: C, 60.20; H, 7.69. Found: C, 59.76; H, 8.27. 
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7.3.3. Synthesis of 3,5-di-tert-butyl-2-methoxybenzaldehyde 
(3) 
 
K2CO3 (1.5 g, 0.011 mol) was suspended in acetone (30 ml) and stirred at RT for 5 
min before adding 3,5-di-tert-butyl-2-hydroxybenzaldehyde (0.5 g, 0.00214 mol) 
and MeI (1.3 ml, 0.0214 mol). This yellow mixture was then stirred at RT for 15 hr, 
by which time the reaction was judged to be complete by TLC (5 % ethyl acetate in 
hexane). The solution was concentrated in vacuo and the white solid redissolved in 
hexane. The potassium carbonate was then removed by filtration and the filtrate 
concentrated to give 3 as a yellow oil (0.44 g, 83%): Rf=0.5 (5% ethyl acetate in 
hexane); 
1
H NMR [CDCl3] 10.22 (s, 1H, CHO), 7.61 (d, 1H, J=2.5 Hz, ArH), 7.51 
(d, 1H, J=2.5 Hz, ArH), 3.82 (s, 3H, OMe), 1.32 (s, 9H, 
t
Bu), 1.22 (s, 9H, 
t
Bu); 
13
C 
NMR [CDCl3]  190.66 (CHO), 166.19, 146.16, 142.76, 130.60, 128.97, 124.22 
(Carom), 65.88 (OMe), 35.22, 34.58 (C(
t
Bu)), 31.23, 30.76 (CH3(
t
Bu)). CHN data not 
collected. 
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7.3.4. Synthesis of (3,5-di-tert-butyl-2-methoxyphenyl) 
methanol (4) 
 
3 (0.44 g, 1.77 mmol) was dissolved in ethanol (30 ml) to which was added NaBH4 
(0.1 g, 2.63 mmol) portionwise. This yellow solution was then stirred at RT for 2.5 
hr before stripping off the solvent and partitioning between DCM (60 ml) and brine 
(200 ml). The organic layer was collected and dried over MgSO4 before removing 
the solvent in vacuo to give a yellow oil. This was placed in a fridge o/n whereby the 
oil solidified to give a white solid (0.44 g, 100%); 
1
H NMR [CDCl3] 7.30 (d, 1H, 
J=2.5 Hz, ArH), 7.29 (d, 1H, J=2.5 Hz, ArH), 5.26 (s, 1H, OH), 4.74 (s, 2H, CH2), 
3.78 (s, 3H, OMe), 1.40 (s, 9H, 
t
Bu), 1.31 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3]  155.30, 
145.99, 141.83, 133.43, 124.40, 123.88 (Carom), 61.94 (OMe), 61.82 (CH2OH), 
35.26, 34.51 (C(
t
Bu)), 31.47, 31.07 (CH3(
t
Bu)). CHN data not collected. 
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7.3.5. Synthesis of 1-(bromomethyl)-3,5-di-tert-butyl-2-
methoxybenzene (5) 
 
4 (0.44 g, 1.41 mmol) was dissolved in CHCl3 (25 ml) at 0°C. PBr3 (0.38 g, 1.41 
mmol) dissolved in CHCl3 (15 ml) was then added dropwise over 30 min under a 
nitrogen atmosphere. The yellow solution was then stirred at 0°C for a further 1 hr 
before the organic layer was washed with brine (3 x 200 ml). The organic layer was 
collected, dried over Na2SO4 and concentrated in vacuo to give 5 as a yellow oil 
(0.47, 85%); 
1
H NMR [CDCl3] 7.36 (d, 1H, J=2.5 Hz, ArH), 7.34 (d, 1H, J=2.5 Hz, 
ArH), 4.63 (s, 2H, CH2), 3.90 (s, 3H, OMe), 1.45 (s, 9H, 
t
Bu), 1.36 (s, 9H, 
t
Bu13C 
NMR [CDCl3]  155.69, 146.26, 142.27, 130.65, 127.13, 125.11 (Carom), 62.18 
(OMe), 35.39, 34.50 (C(
t
Bu)), 31.40, 31.07 (CH3(
t
Bu)), 29.96 (CH2Br); MS (ES-
MS): m/z 312 (M
+
), 233(M-Br
+
). Satisfactory CHN data not obtained. 
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7.3.6. Synthesis of 2-(benzyloxy)-3,5-di-tert-
butylbenzaldehyde (6) 
 
3,5-di-tert-butyl-2-hydroxybenzaldehyde (4.0 g, 0.0171 mol) and potassium 
carbonate (2.1 g, 0.0171 mol) were dissolved in DMF (25 ml) at 0°C and stirred for 
5 min. To the yellow solution was added benzyl bromidde (2.89 g, 0.0168 mol) and 
the resulting mixture was heated to 75°C for 24 hr before cooling and pouring into 
ice-water (200 ml). The precipitate formed by this process was then collected by 
filtration and washed with water (2 x 10 ml) to give 6 as fine crystals (5.0 g, 90%): 
1
H NMR [CDCl3]  10.34 (s, 1H, CHO), 7.75 (d, 1H, J=2.5 Hz, ArH), 7.66 (d, 1H, 
J=2.5 Hz, ArH), 7.51-7.36 (m, 5H, Bn), 5.04 (s, 2H, CH2), 1.46 (s, 9H, 
t
Bu), 1.34 (s, 
9H, 
t
Bu); 
13
C NMR [CDCl3] 190.81 (CHO), 159.71, 146.64, 143.08, 136.57, 
130.95, 129.3276, 128.63, 128.13, 127.00, 124.03 (Carom), 80.39 (CH2), 35.40, 34.73 
(C(
t
Bu)), 31.31, 30.94 (Me(
t
Bu)). CHN data not collected. 
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Figure 82: ORTEP representation of the X-ray crystal structure of 6 with all 
non-H atoms labelled. 
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Table 12: Crystal data for the structural refinement of 6. 
Identification code  sja55_06 
Empirical formula  C22 H28 O2 
Formula weight  324.44 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.735(3) Å = 80.06(2)°. 
 b = 11.234(3) Å = 85.55(2)°. 
 c = 16.555(4) Å  = 73.12(2)°. 
Volume 1881.2(8) Å3 
Z 4 
Density (calculated) 1.146 Mg/m3 
Absorption coefficient 0.071 mm-1 
F(000) 704 
Crystal size 0.46 x 0.25 x 0.22 mm3 
Theta range for data collection 2.82 to 34.79°. 
Index ranges -17<=h<=12, -17<=k<=17, -26<=l<=26 
Reflections collected 43609 
Independent reflections 15941 [R(int) = 0.1899] 
Completeness to theta = 34.79° 97.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15941 / 0 / 434 
Goodness-of-fit on F2 0.638 
Final R indices [I>2sigma(I)] R1 = 0.0571, wR2 = 0.0909 
R indices (all data) R1 = 0.3237, wR2 = 0.1414 
Extinction coefficient 0.00044(18) 
Largest diff. peak and hole 0.307 and -0.256 e.Å-3 
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7.3.7. Synthesis of (2-(benzyloxy)-3,5-di-tert-
butylphenyl)methanol (7) 
 
To a solution of 6 (4.50 g, 0.0139 mol) dissolved in methanol (50 ml) was added 
NaBH4 (1.05 g, 0.0278 mol) portion wise over 5 min. After addition was complete, 
the yellow solution was stirred at RT for an hour before removing the solvent in 
vacuo. The white solid formed was then partitioned between CHCl3 (50 ml) and 
brine (200 ml). The organic layer was collected and further washed with brine (2 x 
200 ml). The organic extracts were then combined, dried over MgSO4 and 
concentrated in vacuo to give 7 as a pale yellow oil (4.50 g, 99%); 
1
H NMR [CDCl3] 
δ 7.50-7.30 (m, 7H, ArH), 4.97 (s, 2H, CH2, CH2Bn), 4.74 (s, 2H, CH2OH), 1.43 (s, 
9H, 
t
Bu), 1.32 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 153.81, 146.23, 142.06, 137.64, 
133.67, 128.46, 127.64, 126.82, 124.78, 124.14 (Carom), 75.84 (CH2Bn), 61.50 
(CH2OH), 35.41, 34.51 (C(
t
Bu)), 31.46, 31.22 (Me(
t
Bu)). CHN not collected. 
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7.3.8. Synthesis of 2-(benzyloxy)-1-(bromomethyl)-3,5-di-tert-
butylbenzene (8) 
 
To 7 (2.07 g, 0.00635 mol) in CHCl3 (50 ml) at 0°C under nitrogen was added PBr3 
(1.72 g, 1.5 ml, 0.00635 mol) in CHCl3 (30 ml) over 30 min. The solution was then 
stirred at 0°C for 1 hr before pouring into brine (200 ml). The organic layer was 
extracted and then washed further with brine (3 x 200 ml). The organic extracts were 
combined, dried over Na2SO4 and then concentrated in vacuo to give 8 as a white 
solid (2.36 g, 96%); 
1
H NMR [CDCl3] δ 7.56-7.34 (m, 7H, ArH), 5.12 (s, 2H, 
CH2Bn), 4.58 (s, 2H, CH2Br), 1.43 (s, 9H, 
t
Bu), 1.32 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] 
δ 154.15, 146.53, 142.50, 137.61, 130.88, 128.52, 127.73, 127.32, 126.76, 125.31 
(Carom), 75.21 (CH2Bn), 35.57, 34.54 (C(
t
Bu)), 31.41, 31.23 (Me(
t
Bu)), 30.09 
(CH2Br); MS (ES-MS): m/z 388 (M
+
); Calcd for C14H27Br1O1: C, 67.90; H, 7.40. 
Found: C, 68.03; H, 7.63. 
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7.3.9. Synthesis of 4-methoxybenzaldehyde (9) 
 
4-Hydroxybenzaldehyde (5 g, 0.041 mol) and K2CO3 (5.66 g, 0.041 mol) were 
dissolved in acetone (35 ml) and the mixture stirred at RT for 5 min. MeI (29 g, 0.2 
mol) was then added and the reaction heated to 50°C for 24 hr. The solution was 
then allowed to cool and concentrated in vacuo before being taken up into DCM (30 
ml). The suspension was then filtered and the filtrate concentrated to give a yellow 
oil (5.57 g, 100%): 
1
H NMR [CDCl3] 9.74 (s, 1H, CHO), 6.85 (d, 2H, J=8.70 Hz, 
ArH),7.68 (d, 2H, J=8.70 Hz, ArH), 3.73 (s, 3H, OMe); 
13
C NMR [CDCl3]  190.38 
(CHO), 164.27, 131.90, 131.58, 129.60, 113.97 (Carom), 55.18 (OMe). CHN data not 
collected. 
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7.3.10. Synthesis of (4-methoxyphenyl)methyl alcohol 
(10) 
 
To a solution of 9 (5.57 g, 0.041 mol) in propan-2-ol (30 ml) was added NaBH4 (1.57 
g, 0.041 mol) portionwise with stirring. The reaction was then stirred at RT for a 
further 4 hr before removing the solvent in vacuo. The white solid was then 
dissolved in DCM (30 ml) and washed with brine (100 ml). The organic layer was 
separated and dried over MgSO4. It was then filtered and concentrated to give a light 
yellow oil (4.71 g, 84%); 
1
H NMR [CDCl3]  7.16 (d, 2H, J=8.5 Hz, ArH), 6.79 (d, 
2H, J=8.5 Hz, ArH), 4.44 (s, 2H, CH2), 3.85 (s, 1H, OH), 3.68 (s, 3H, OMe); 
13
C 
NMR [CDCl3]  158.46, 132.95, 128.14, 113.65, 113.34 (Carom), 63.80 (CH2), 54.72 
(OMe). CHN data not collected. 
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7.3.11. Synthesis of 1-(bromomethyl)-4-methoxybenzene 
(11) 
 
To a solution of 10 (4.71 g, 0.0341 mol) in CHCl3 (30 ml) at 0°C under a nitrogen 
atmosphere was added PBr3 (9.25g, 0.0341 mol) in CHCl3 (20 ml) dropwise over 0.5 
hr. Stirring was then continued for 1 hr at 0°C. The solution was then washed with 
brine (4 x 100 ml) before drying over MgSO4 and removing the solvent in vacuo to 
give a light orange oil (6.6 g, 96%); 
1
H NMR [CDCl3] 7.55 (d, 2H, J=8.7 Hz, 
ArH), 7.43 (d, 2H, J=8.7 Hz, ArH), 5.12 (s, 2H, CH2Br), 4.58 (s, 3H, OMe); 
13
C 
NMR [CDCl3]  159.36, 130.19, 129.64, 113.90 (Carom), 54.98, (OMe), 33.86 (CH2); 
MS (ES-MS): m/z 202 (M
+
), 121 ((M-Br)
+
). CHN data not collected. 
 232 
7.3.12. Synthesis of 3,5-di-tert-butyl-2-(4-
methoxybenzyloxy)benzaldehyde (12) 
 
3,5-Di-tert-butyl-2-hydroxy benzaldehyde (2 g, 0.0085 mol) and K2CO3 (1.18 g, 
0.0085 mol) in DMF (40 ml) were stirred together for 5 min. 11 (1.89 g, 0.0094 mol) 
was then added and the solution heated to 55
o
C for 24 hr. The reaction mixture was 
allowed to cool before pouring in to ice-water (60 ml). A precipitate formed which 
was removed by filtration. The crude solid was then subjected to hot pentane washes 
(4 x 10 ml). The resulting white solid was then recrystallised from hexane. This gave 
12 as transparent crystals (2.11 g, 70%); 
1
H NMR [CDCl3] δ 10.35 (CHO), 7.75 (d, 
1H, J=2.67 Hz, ArH), 7.67 (d, 1H, J=2.67 Hz, ArH), 7.43 (d, 2 H, J=8.7, ArH), 6.95 
(d, 2 H, J=8.7, ArH), 4.96 (s, 2H, CH2Bn), 3.83 (s, 3H, OMe), 1.46 (s, 9H, 
t
Bu), 1.34 
(s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 190.79 (CHO), 159.69, 159.54, 146.44, 143.02, 
130.86, 129.34, 128.66, 128.62, 123.94, 113.98 (Carom), 80.26 (CH2Bn), 55.21 
(OMe), 35.32, 34.65 (C(
t
Bu)), 31.26, 30.91 (Me(
t
Bu)); MS (ES-MS): m/z 354 (M
+
). 
CHN data not collected. 
 233 
 
Figure 83: ORTEP representation of the X-ray crystal structure of 12 with all 
non-H atoms labelled. 
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Table 13: Crystal data for the structural refinement of 12. 
Identification code  sja19_07 
Empirical formula  C23 H30 O3 
Formula weight  354.47 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/a 
Unit cell dimensions a = 9.0804(17) Å          = 90°. 
 b = 24.181(6) Å            = 105.627(15)°. 
 c = 9.5998(18) Å            = 90°. 
Volume 2030.0(7) Å3 
Z 4 
Density (calculated) 1.160 Mg/m3 
Absorption coefficient 0.075 mm-1 
F(000) 768 
Crystal size 0.35 x 0.30 x 0.20 mm3 
Theta range for data collection 2.36 to 35.02°. 
Index ranges -12<=h<=14, -37<=k<=38, -15<=l<=15 
Reflections collected 27544 
Independent reflections 8771 [R(int) = 0.2187] 
Completeness to theta = 35.02° 97.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8771 / 0 / 236 
Goodness-of-fit on F2 0.632 
Final R indices [I>2sigma(I)] R1 = 0.0574, wR2 = 0.1166 
R indices (all data) R1 = 0.2552, wR2 = 0.1569 
Extinction coefficient 0.0009(4) 
Largest diff. peak and hole 0.261 and -0.296 e.Å-3 
 235 
7.3.13. Synthesis of (3,5-di-tert-butyl-2-(4-
methoxybenzyloxy)phenyl)methanol (13) 
 
To a solution of 12 (1.5 g, 0.0042 mol) in ethanol (40 ml) was added NaBH4 (0.16 g, 
0.0042 mol) portionwise with stirring. The solution was stirred for 3 hours at RT 
before concentrating the mixture under reduced pressure. The residue was then 
partitioned between DCM (100 ml) and water (100 ml). The organic layer was 
collected, dried over MgSO4 and concentrated under reduced pressure. This gave 13 
as a white solid (1.21 g, 81%); 
1
H NMR [CDCl3] δ 7.45 (d, 2H, J=8.42 Hz, ArH), 
7.37 (d, 1H, J=2.53 Hz, ArH), 7.32 (d, 1H, J=2.53 Hz, ArH), 6.95 (d, 2H, J=8.42 Hz, 
ArH), 4.91 (s, 2H, CH2Bn), 4.79 (s, 2H, CH2OH), 3.82 (s, 3H, OMe), 1.45 (s, 9H, 
t
Bu), 1.34 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 159.22, 153.87, 146.20, 142.14, 133.74, 
129.74, 128.67, 124.73, 124.20, 113.92 (Carom), 75.65 (CH2Bn), 61.83 (CH2OH), 
55.21 (OMe), 35.43, 34.52, (C(
t
Bu)), 31.47, 31.28, (Me(
t
Bu)); MS (ES-MS): m/z 356 
(M
+
); Calcd for C23O3H32: C, 77.53; H 8.99. Found C, 77.54; H, 8.73. 
 236 
7.3.14. Synthesis of 1-(bromomethyl)-3,5-di-tert-butyl-2-
(4-methoxybenzyloxy)benzene (14) 
 
13 (1 g, 0.00281 mol) and CBr4 (1.4 g, 0.00421 mol) were dissolved in dry DCM (20 
ml) to which was added triphenylphosphine (1.11 g, 0.00421 mol) in dry DCM (10 
ml) over 5 min. A yellow solution formed which was then stirred at RT for 18 hr. 
Water (150 ml) was then added and the organic layer was extracted. The aqueous 
layer was further extracted with DCM (2 x 50 ml). All the organic extracts were 
combined and dried over MgSO4. The crude product was then purified by silica gel 
chromatography (1:1 DCM/hexane v/v). The fractions containing the desired 
compound were then combined and concentrated under reduced pressure to give a 
light pink solid (0.80 g, 68%); Rf=0.58 (1:1 hexane/DCM v/v); 
1
H NMR [CDCl3] δ 
7.52 (d, 2H, J=8.56 Hz, ArH), 7.38 (s, 2H, ArH), 6.89 (d, 2H, J=8.56 Hz, ArH), 5.18 
(s, 2H, CH2Bn), 4.63 (s, 2H, CH2Br), 3.86 (s, 3H, OMe), 1.47 (s, 9H, 
t
Bu), 1.36 (s, 
9H, 
t
Bu); 
13
C NMR [CDCl3] δ 159.30, 154.24, 146.43, 142.50, 130.90, 129.75, 
128.52, 127.31, 125.98, 113.96 (Carom), 75.05 (CH2Bn), 55.28 (OMe), 35.58, 34.54 
(C(
t
Bu)), 31.59 (CH2Br), 31.41, 31.27 (Me(
t
Bu)); MS (ES-MS) m/z 339 ((M-Br)
+
), 
219 ((MH-C8H9O1, Br)
+
). Satisfactory CHN not obtained. 
 237 
7.3.15. Synthesis of 2-(bromomethyl)-4,6-di-tert-
butylphenyl acetate (15) 
 
To solution of 2 (3.0 g, 0.0100 mol) in acetic anhydride (2.05 g, 0.0201 mol) was 
added H2SO4 (5 drops). The reaction mixture was stirred for 12 hr at which time the 
TLC showed complete consumption of the starting material (silica plate using 5% 
EtOAc in hexane as the eluent). DCM (50 ml) was then added and the mixture 
washed with brine (2 x 100 ml). The organic layer was collected and dried over 
MgSO4 before filtering under reduced pressure. The resulting yellow oil was placed 
in a freezer whereby a solid formed o/n (3.41 g, 100%); 
1
H NMR [CDCl3] δ 7.42 (s, 
1H, ArH), 7.32 (s, 1H, ArH), 4.34 (s, 2H, CH2Br), 2.42 (s, 3H, COMe), 1.37 (s, 9H, 
t
Bu), 1.33 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 169.75 (COMe), 148.70, 145.52, 141.39, 
130.10, 126.40, 125.59 (Carom), 35.12, 34.80 (C(
t
Bu)), 31.50, 30.73 (Me(
t
Bu)), 29.68 
(CH2Br), 21.57 (COCH3); Calcd. for C17O2Br1H25: C, 59.82; H, 7.33. Found: C, 
60.11; H, 7.52; MS (ES-MS): m/z 261 (M
+
), 219.2 ((MH-BrOAc)
+
). 
 238 
Figure 84: ORTEP representation of the X-ray crystal structure of 15. 
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Table 14: Crystal data for the structural refinement of 15. 
Identification code  sja9_08 
Empirical formula  C17 H25 Br O2 
Formula weight  341.27 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 9.8366(12) Å = 90°. 
 b = 18.441(3) Å = 90°. 
 c = 18.750(3) Å  = 90°. 
Volume 3401.2(9) Å3 
Z 8 
Density (calculated) 1.333 Mg/m3 
Absorption coefficient 2.417 mm-1 
F(000) 1424 
Crystal size 0.29 x 0.26 x 0.16 mm3 
Theta range for data collection 2.21 to 29.53°. 
Index ranges -13<=h<=11, -25<=k<=25, -20<=l<=25 
Reflections collected 18419 
Independent reflections 4716 [R(int) = 0.2836] 
Completeness to theta = 29.53° 99.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4716 / 0 / 188 
Goodness-of-fit on F2 0.619 
Final R indices [I>2sigma(I)] R1 = 0.0551, wR2 = 0.1123 
R indices (all data) R1 = 0.2412, wR2 = 0.1459 
Largest diff. peak and hole 0.482 and -1.421 e.Å-3 
  
 240 
7.3.16. Synthesis of 2-(4-
methoxybenzylthio)benzaldehyde (16) 
 
2-Nitro-benzaldehyde (4.56 g, 0.03 mol) was dissolved in DMF (40 ml) at 0°C and 
4-methoxyphenylmethanethiol (4.89 g, 0.035 mol) and K2CO3 (5.43 g, 0.039 mol) 
were added. The mixture was then heated to 80°C for 24 hr. After this time, the 
mixture was allowed to cool before pouring it into ice-water (60 ml) which resulted 
in the formation of a yellow precipitate. This was collected via filtration and then 
recrystallised from petroleum ether 60-80 and chloroform (1:1 v/v), giving 16 as 
yellow crystals (6.89 g, 89%); 
1
H NMR [CDCl3] δ 10.19 (s, 1H, CHO), 7.74 (dd, 1H, 
J=1.3 Hz, 7.6 Hz, ArH), 7.42-7.43 (m, 7H, ArH), 4.01 (s, 2H, CH2), 3.69 (s, 3H, 
OMe); 
13
C NMR [CDCl3]  191.44 (CHO), 158.97, 141.36, 134.59, 133.88, 131.41, 
130.01, 129.86, 127.96, 126.01, 114.00 (Carom), 55.21 (CH2), 38.34 (OMe); Calcd. 
for C15H14O2S1: C, 69.77; H, 5.43; S, 12.40. Found: C, 69.84; H, 5.51; S, 13.49; MS 
(ES-MS): m/z 258 (M
+
).  
 
Figure 85: ORTEP representation of the X-ray crystal structure of 16 with all 
non-H atoms labelled. 
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Table 15: Crystal data for the structural refinement of 16. 
Identification code  sja46_06 
Empirical formula  C15 H14 O2 S 
Formula weight  258.32 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 5.5375(6) Å                = 90°. 
 b = 13.7647(12) Å            = 95.596(8)°. 
 c = 16.6308(18) Å             = 90°. 
Volume 1261.6(2) Å3 
Z 4 
Density (calculated) 1.360 Mg/m3 
Absorption coefficient 0.247 mm-1 
F(000) 544 
Crystal size 0.42 x 0.22 x 0.19 mm3 
Theta range for data collection 2.46 to 34.83°. 
Index ranges -8<=h<=8, -22<=k<=17, -26<=l<=26 
Reflections collected 15809 
Independent reflections 5339 [R(int) = 0.0621] 
Completeness to theta = 34.83° 97.4 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5339 / 0 / 164 
Goodness-of-fit on F2 0.933 
Final R indices [I>2sigma(I)] R1 = 0.0529, wR2 = 0.1381 
R indices (all data) R1 = 0.1150, wR2 = 0.1703 
Extinction coefficient 0.022(3) 
Largest diff. peak and hole 0.677 and -0.664 e.Å-3 
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7.3.17. Synthesis of (2-(4-
methoxybenzylthio)phenyl)methanol (17) 
 
16 (11.3 g, 0.044 mol) was suspended in propan-2-ol (30 ml) to which NaBH4 (1.6 g, 
0.044 mol) was added portionwise. This was stirred at RT under a nitrogen 
atmosphere for 1 hr and then heated to 80°C for a further 1 hr. The solution was then 
allowed to cool to RT resulting in the formation of a white crystalline product. The 
propan-2-ol was then removed in vacuo and the white solid dissolved in DCM (50 
ml) and washed with brine (200 ml). The organic layer was collected and further 
washed with brine (2 x 200 ml). The combined organic extracts were then dried over 
Na2SO4 before being concentrated in vacuo to yield 17 as a white solid (10.04 g, 
88%); 
1
H NMR [CDCl3] δ 7.31-7.26 (m, 2H, ArH), 7.17-7.14 (m, 2H, ArH), 7.03 (d, 
2H, J=8.7 Hz, ArH), 6.71 (d, 2H, J=8.7 Hz, ArH), 4.51 (s, 2H, CH2OH), 3.95 (s, 2H, 
CH2S), 3.72 (s, 3H, OMe); 
13
C NMR [CDCl3]  158.84, 141.59, 134.26, 131.67, 
129.89, 129.24, 128.41, 128.27, 127.21, 113.92 (Carom), 63.67 (CH2OH), 55.24 
(SCH2), 39.25 (OMe); MS (ES-MS): m/z 260 (M
+
). Satisfactory CHN data not 
obtained. 
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Figure 86: ORTEP representation of the X-ray crystal structure of 17 with all 
non-H atoms labelled. 
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Table 16: Crystal data for the structural refinement of 17. 
Identification code  sja54_06 
Empirical formula  C15 H16 O2 S 
Formula weight  260.35 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 14.5448(18) Å        = 90°. 
 b = 4.8986(3) Å            = 107.532(10)°. 
 c = 19.419(2) Å             = 90°. 
Volume 1319.3(2) Å3 
Z 4 
Density (calculated) 1.311 Mg/m3 
Absorption coefficient 0.236 mm-1 
F(000) 552 
Crystal size 0.6 x 0.24 x 0.19 mm3 
Theta range for data collection 2.94 to 34.86°. 
Index ranges -23<=h<=16, -7<=k<=6, -30<=l<=30 
Reflections collected 20507 
Independent reflections 5667 [R(int) = 0.0835] 
Completeness to theta = 34.86° 98.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5667 / 0 / 167 
Goodness-of-fit on F2 0.785 
Final R indices [I>2sigma(I)] R1 = 0.0405, wR2 = 0.0914 
R indices (all data) R1 = 0.1238, wR2 = 0.1143 
Extinction coefficient 0.0082(13) 
Largest diff. peak and hole 0.372 and -0.712 e.Å-3 
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7.3.18. Synthesis of (2-(bromomethyl)phenyl)(4-
methoxybenzyl)sulfane (18) 
 
17 (8.16 g, 0.0314 mol) was dissolved in CHCl3 (100 ml) and stirred under a 
nitrogen atmosphere at −5°C. To this was added PBr3 (5.75 g, 0.02123 mol) 
dissolved in CHCl3 (50 ml) over a period of 25 min. After the addition was complete 
stirring continued for a period of 30 min before warming to RT and washing the 
CHCl3 layer with brine (4 x 500 ml). The organic layer was collected and dried over 
Na2SO4 before removing the solvent under reduced pressure to yield a yellow oil. 
Hexane (100 ml) was layered over the top of this oil and it was placed in a freezer 
for 48 hr. After this time methanol (20 ml) was added and the mixture sonicated. The 
milky white suspension formed by this process was then filtered, yielding 18 as a 
white powder (6.86g, 68%); 
1
H NMR [CDCl3] δ 7.29-7.09 (m, 6H, ArH), 6.73 (d, 
2H, J=8.4 Hz, ArH), 4.53 (s, 2H, CH2), 3.98 (s, 2H, CH2), 3.69 (s, 3H, OMe); 
13
C 
[CDCl3] δ 158.95, 138.62, 136.28, 132.09, 130.68, 130.17, 129.24, 129.12, 127.38, 
114.01 (Carom), 55.37 (CH2S), 39.16 (OMe), 32.29 (CH2OH); MS (ES-MS): m/z 324 
(MH
+
). Satisfactory CHN data not obtained. 
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7.3.19. Synthesis of 2-bromo-3,5-di-tert-butyltoluene (19) 
 
3,5-Di-tert-butyltoluene (20.15 g, 0.0986 mol) was dissolved in trimethylphosphate 
(150 ml) and heated to 65-70°C. Bromine (19.2 g, 0.12 mol) was then added in 
trimethylphosphate (100 ml). Heating continued for a further 16 hr before adding 
further bromine (9.6 g, 0.06 mol). Heating was continued for a further 24 hr before 
extracting the product with petroleum ether (bp 60-80°C, 150 ml). The ether layer 
was then washed with saturated NaHCO3 solution (100 ml) followed by water (200 
ml). It was separated, dried over MgSO4 and concentrated under reduced pressure. 
The crude product was then purified by distillation under reduced pressure with the 
distillate with a bp of 112-114°C being collected. This gave the title compound as a 
transparent oil which crystallised after a week at RT (18.27 g, 65%); 
1
H NMR 
[CDCl3] δ 7.37 (d, 1H, J=1.76 Hz, ArH), 7.17 (d, 1H, J=1.76 Hz, ArH), 2.47 (s, 3H, 
CH3), 1.58 (s, 9H, CH3(
t
Bu)), 1.34 (s, 9H, CH3(
t
Bu); 
13
C NMR [CDCl3] δ 139.18, 
138.11, 126.45, 125.92, 122.87, 122.59 (Carom), 36.78, 36.70 (C(
t
Bu)), 31.19, 29.99 
(Me(
t
Bu)), 25.66 (CH3); MS (ES-MS): m/z 282 (M
+
), 267 (M-Me)
+
). CHN data not 
collected. 
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Figure 87: ORTEP representation of the X-ray crystal structure of 19 with all 
non-atoms labelled. 
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Table 17: Crystal data for the structural refinement of 19. 
Identification code  sja_02 
Empirical formula  C15 H23 Br 
Formula weight  283.24 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 9.8553(12) Å            = 90°. 
 b = 11.6024(13) Å          = 104.440(8)°. 
 c = 13.1040(13) Å            = 90°. 
Volume 1451.0(3) Å3 
Z 4 
Density (calculated) 1.945 Mg/m3 
Absorption coefficient 4.212 mm-1 
F(000) 888 
Crystal size 0.26 x 0.18 x 0.15 mm3 
Theta range for data collection 2.76 to 34.74°. 
Index ranges -15<=h<=15, -17<=k<=18, -19<=l<=20 
Reflections collected 16678 
Independent reflections 6110 [R(int) = 0.0907] 
Completeness to theta = 34.74° 97.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6110 / 0 / 146 
Goodness-of-fit on F2 0.879 
Final R indices [I>2sigma(I)] R1 = 0.0581, wR2 = 0.1482 
R indices (all data) R1 = 0.1159, wR2 = 0.1751 
Extinction coefficient 0.0047(16) 
Largest diff. peak and hole 2.411 and -1.453 e.Å-3 
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7.3.21. Synthesis of 2-bromo-3,5-di-tert-butylbenzyl 
bromide (20) 
 
19 (37.40 g, 0.132 mol), NBS (0.147 mol, 26.1 mol) and AIBN (0.87 g, 5.3 mmol) 
were dissolved in CCl4 (375 ml) with stirring. The solution was heated gently to 
reflux and left for 1 hr. The solution was then allowed to cool before filtering at 
−10°C. The filtrate was concentrated to give 20 as a yellow oil (45.24 g, 95%); 1H 
NMR [CDCl3] δ 7.44 (d, 1H, J=1.89 Hz, ArH), 7.25 (d, 1H, J=1.89 Hz, ArH), 4.69 
(s, 2H, CH2Br), 1.53 (s, 9H, CH3(
t
Bu)), 1.34 (s, 9H, CH3(
t
Bu)); 
13
C NMR [CDCl3] δ 
146.84, 137.73, 126.89, 126.47, 122.98 (Carom), 36.81 (CH2Br), 36.98, 34.42 
(C(
t
Bu)), 31.15, 30.12 (CH3(
t
Bu)); MS (ES-MS): m/z 362 (M
+
), 282 ((M-Br)
+
), 267 
((M-CH2Br)
+
). CHN data not obtained. 
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7.3.22. Synthesis of 2-bromo-3,5-di-tert-butylbenzaldeyde 
(21) 
 
20 (47.84 g, 0.132 mol) and hexamethylenetetramine (52.57 g, 0.375 ml) were 
dissolved in CHCl3 (400 ml) and heated to 75°C for 24 hr. The yellow oil was then 
concentrated in vacuo and the liquid taken up in 50% acetic acid (400 ml) and more 
hexamethylenetetramine (52.57 g, 0.375 mol) added. The solution was heated to 
102°C for 24 hr before adding concentrated HCl (60 ml). Heating was continued for 
a further 15 min before allowing to cool. Ether (200 ml) was then added to the 
solution, and the organic layer was extracted. The aqueous layer was further washed 
with ether (2 x 200 ml) before combining the organic extracts which were then 
washed with 2M HCl (3 x 500 ml) and saturated NaHCO3 solution (3 x 500 ml). The 
organic phase was then dried over Na2SO4 before concentrating under reduced 
pressure. The crude product was purified by silica column chromatography (using 
100:1 n-hexane: ether (v/v) as the eluent). This gave the desired compound as a 
yellow oil (11.79 g, 30%); Rf=0.32 (100:1 n-hexane: ether (v/v)); 
1
H NMR [CDCl3] 
δ 10.54 (s, 1H, CHO), 7.24 (quasi-d, 2H, ArH), 1.51 (s, 9H, CH3(
t
Bu)), 1.31 (s, 9H, 
CH3(
t
Bu)); 
13
C NMR [CDCl3] δ 194.17 (CHO), 150.36, 148.42, 135.28, 131.07, 
124.92, 124.62 (Carom), 37.50, 34.89 (C(
t
Bu)), 30.90, 30.08 (Me(
t
Bu); MS (ES-MS): 
m/z 296 (M
+
). CHN data not obtained. 
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7.3.23. Synthesis of (2-bromo-3,5-di-tert-
butylphenyl)methanol (22) 
 
To a solution of 21 (4.23 g, 14.2 mmol) in propan-2-ol (80 ml) was added NaBH4 
(0.44 g, 11.6 mmol) portion wise at RT. Stirring continued for 2 hr before 
concentrating under reduced pressure. The residue was extracted with Et2O (120 ml) 
and washed with brine (3 x 100 ml). The resulting solution was dried over MgSO4 
and the filtrate concentrated in vacuo to afford a white powder (3.68 g, 86%); 
1
H 
NMR [CDCl3] 7.44 (d, 1H, J=2.39 Hz, ArH), 7.36 (d, 1H, J=2.39 Hz, ArH), 4.76 (br, 
2H, CH2), 2.37 (s, 1H, OH), 1.54 (s, 9H, CH3(
t
Bu)), 1.32 (s, 9H, CH3(
t
Bu)); 
13
C 
NMR [CDCl3] 149.99, 147.51, 140.83, 124.76, 124.38, 120.41 (Carom), 66.92 (CH2), 
37.31, 34.82 (C(
t
Bu)), 31.34, 30.13 (CH3(
t
Bu)); MS (ES-MS): m/z 298 (M
+
). CHN 
data not obtained. 
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7.3.24. Synthesis of (3,5-di-tert-butyl-2-(4-
methoxybenzylthio)phenyl)methanol (23) 
 
To a solution of 22 (3.68 g, 12.3 mmol) in dry Et2O (25 ml) was added 2.5 M BuLi 
in n-hexane (10.6 ml, 17.0 mmol) under an argon atmosphere with ice cooling. The 
solution was stirred at 0°C for 10 mins and then at RT for 3 hrs. Toluene-4-
thiosulfonic acid S-(4-methoxybenzyl) ester (3.92 g, 12.7 mmol) in dry Et2O (45 ml) 
was then added at −75°C. The solution was stirred at −75°C for 1 hr, and then at 
−30°C for a further 4 hr. To this mixture was then added 2M HCl(aq) (105 ml), and 
the organic layer was collected. The aqueous layer was then extracted with Et2O (2 x 
50 ml). The organic layers were then combined and washed with 2M HCl(aq) (2 x 100 
ml) followed by saturated NaCl(aq) (3 x 100 ml). The organic layer was again 
collected and then dried over MgSO4. The solution was then filtered to remove 
solids and the filtrate concentrated under reduced pressure to give a crude oil (7.31 
g). The crude oil was subjected to silica gel chromatography (eluting with 
toluene/Et2O 20/1 (v/v)). The fractions containing the desired compound were 
collected and concentrated in vacuo to give a pale yellow oil (2.13 g, 47%); 
1
H NMR 
[CDCl3] δ 7.25 (d, 1H, J=2.27 Hz, ArH), 7.22 (d, 1H, J=2.27 Hz, ArH), 7.21 (m, 2H, 
ArH), 6.84 (m, 2H, ArH), 4.97 (d, 2H, CH2OH, J=6.48 Hz), 3.87 (s, 2H, CH2), 3.80 
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(s, 3H, OCH3), 2.69 (t, 1H, OH, J=6.48 Hz), 1.59 (s, 9H, CH3(
t
Bu)), 1.33 (s, 9H, 
CH3(
t
Bu)); 
13
C NMR [CDCl3] δ 158.94, 153.80, 151.73, 146.75, 130.11, 129.02, 
124.54, 123.91, 114.06 (Carom), 65.52 (CH2OH), 55.29 (OCH3), 42.86 (SCH2), 37.69, 
34.85 (C(
t
Bu)), 31.64, 31.25 (CH3(
t
Bu)); MS (ES-MS): m/z 372 (M
+
). CHN data not 
obtained. 
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7.3.25. Synthesis of (2-(bromomethyl)-4,6-di-tert-
butylphenyl)(4-methoxybenzyl)sulfane (24) 
 
To a solution of 23 (2.13g, 5.72 mmol) in CHCl3 (25 ml) was added PBr3 (3.52 ml, 
3.81 mmol) in CHCl3 (10 ml) over a period of 10 min. The solution was stirred at 
0°C for 90 min and then washed with brine (4 x 200 ml). The organic layer was 
collected and dried over MgSO4 before concentrating under reduced pressure. The 
crude material obtained by this process was then purified by column chromatography 
(silica gel 60, eluent: n-hexane/ ether 5/1 (v/v)). This gave 24 as a yellow oil (1.60 g, 
64%); Rf=0.69 (n-hexane/ ether 5/1 (v/v)); 
1
H NMR [CDCl3] δ 7.45 (m, 2H, ArH), 
7.23 (m, 2H, ArH), 6.84 (m, 2H, ArH), 5.03 (s, 2H, CH2Br), 3.98 (s, 2H, SCH2), 
3.80 (s, 3H, OCH3), 1.58 (s, 9H, CH3(
t
Bu)), 1.32 (s, 9H, CH3(
t
Bu)); 
13
C NMR 
[CDCl3] δ158.89, 153.84, 151.28, 143.92, 130.80, 130.21, 129.14, 126.86, 124.86, 
113.99, (Carom), 55.27 (OCH3), 42.47 (SCH2), 37.92, 34.84 (C(
t
Bu)), 34.64(CH2Br), 
31.59, 31.16 (CH3(
t
Bu)); MS (ES-MS): m/z 434 (M
+
). CHN data not collected. 
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7.3.26. Synthesis of 5-(benzyloxy)-2-bromo-5-oxobutanoic 
acid (25) 
 
L-Aspartic acid  benzyl ester (4.59 g, 20.56 mmol) and NaBr (7.4 g, 71.96 mmol) 
in 1N HBr (45 ml) was cooled to 0°C under a blanket of N2. To this was added 
NaNO2 (2.41 g, 34.95 mmol) portion wise. The reaction was then stirred for a further 
2 hr at 0
o
C before H2SO4 (1.7 ml) was added followed by diethyl ether (50 ml). The 
organic layer was extracted using portions of diethyl ether (3 x 50 ml), which were 
combined and then washed with brine (4 x 50 ml). The ether layer was then dried 
over NaSO4 before filtering and concentrating in vacuo to give a yellow oil. 
Purification of the crude product by silica gel chromatography (hexane: ethyl acetate 
75:25 to 25:75 v/v) gave 25 as a yellow oil (2.93 g, 50%); 
1
H NMR [CDCl3] 9.00 
(br s, 1H, COOH), 7.31-7.25 (m, 5H, ArH), 5.09 (s, 2H, CH2Ph), 4.54 (dd, 1H, 
3
J=6.17, 8.71 Hz, CH), 3.24 (dd, 1H, 
3
J=8.71, 
2
J=17.27 Hz, CH2), 2.97 (dd, 1H, 
3
J=6.17, 
2
J=17.27, CH2)
13
C NMR [CDCl3] δ 168.69, 167.42 (COOH and COOBz), 
135.19, 128.68, 128.34, 128.02 (Carom), 65.87 (CH2Ph), 51.71 (CH), 38.62 (CH2); 
MS (MALDI): m/z 286 (M
+
). Satisfactory CHN not obtained. 
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7.3.27. Synthesis of 2-bromo-3-(4-nitrophenyl)propanoic 
acid (26) 
 
4-Nitro-L-phenylalanine (5.18 g, 22.69 mmol) and NaBr (8.2 g, 79 mmol) in 1N 
HBr (45 ml) was cooled to 0°C under a blanket of nitrogen. To this was added 
NaNO2 (2.66 g, 38.6 mmol) portion wise. The reaction was then stirred for a further 
2 hr at 0°C before H2SO4 (2 ml) was added followed by diethyl ether (50 ml). The 
organic layer was extracted using diethyl ether (3 x 50 ml), which were combined 
and then washed with water (4 x 50 ml). The ether layer was then dried over MgSO4 
before filtering and concentrating in vacuo to give a yellow oil, from which a 
crystalline product formed (5.71 g, 86%); Rf=0.36 (1:1 ethyl acetate/hexane v/v), 
Rf=0.36 (5:95 MeOH/DCM v/v); 
1
H NMR [CDCl3] 8.11 (d, 2H, J=8.70 Hz, ArH), 
7.34 (d, 2H, J=8.70 Hz, ArH), 4.38 (t, 1H, J=7.58, CH), 3.58 (dd, 1H, 
3
J=7.58, 
2
J=14.32 Hz, CH2), 3.36 (dd, 1H, 
3
J=7.58, 
2
J=14.32 Hz, CH2); 
13
C NMR [CDCl3] δ 
169.64 (COOH), 146.87, 144.32, 132.67, 124.43 (Carom), 46.09 (CH2), 41.36 (CH); 
MS (ES-MS): m/z 258 (M
+
). Satisfactory CHN not obtained. 
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7.3.28. Synthesis of 4-benzyl 1-tert-butyl 2-
bromosuccinate (27) 
 
25 (2.93 g, 0.01 mol) was dissolved in chloroform (20 ml) to which was added a 
solution of tert-butyltrichloroacetimidate (4.47 g, 0.02 mol) in cyclohexane (20 ml) 
drop wise over a period 20 min. During this addition a white precipitate formed 
which was dissolved by the drop wise addition of DMA (~3 ml). Boron trifluoride 
ethyl etherate (320 L) was then added as a catalyst and the solution stirred at RT for 
a period of 5 d. The mixture was then concentrated and hexane (30 ml) and water (50 
ml) were then added. The hexane layer was collected and the solvent removed under 
reduced pressure to afford a light yellow oil (2.63 g, 77%); Rf=0.42 (20:1 
hexane/ethylacetate (v/v)); 
1
H NMR [CDCl3] 7.38-7.30 (m, 5H, ArH), 5.14 (s, 2H, 
CH2), 4.48 (dd, 1H, 
3
J=6.18, 8.84 Hz, CH), 3.26 (dd, 1H, 
3
J=8.84, 
2
J=17.12 Hz, 
CH2), 2.98 (dd, 1H, 
3
J=6.18, 
2
J=17.12 Hz, CH2), 1.40s, 9H, 
t
Bu); 
13
C NMR 
[CDCl3] δ 169.39, 167.69 (COO
t
Bu and COOBz), 135.17, 128.43, 128.27, 128.16 
(Carom), 82.57 (C(
t
Bu)), 66.46 (CH2Ph), 52.31 (CH), 39.72 (CH2), 27.63 (Me(
t
Bu)); 
MS (ES-MS): m/z 343 (M
+
), 287 ((M-
t
Bu)
+
). Satisfactory CHN not obtained due to 
trace DMA impurity. 
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7.3.29. Synthesis of tert-butyl 2-bromo-3-(4-
nitrophenyl)propanoate (28) 
 
26 (5.71 g, 0.021 mol) was dissolved in chloroform (20 ml) to which was added a 
solution of tert-butyltrichloroacetimidate (8.53 g, 0.039 mol) in cyclohexane (20 ml) 
drop wise over a period 20 min. During this addition a white precipitate formed 
which was dissolved by the drop wise addition of DMA (~4 ml). Boron trifluoride 
ethyl etherate (320 L) was then added as a catalyst and the solution stirred at RT for 
a period of 5 d. The mixture was then concentrated and hexane (50 ml) and water (50 
ml) were then added. The hexane layer was collected and the solvent removed under 
reduced pressure to afford a dark yellow crystalline solid (2.86 g, 41%); 
1
H NMR 
[CDCl3] 8.16 (d, 2H, J=7.88 Hz, ArH), 7.40 (d, 2H, J=7.88 Hz, ArH), 4.31 (t, 1H, 
3
J=7.52 Hz, CH), 3.51 (dd, 1H, 
3
J=7.52 Hz, 
2
J=14.30 Hz, CH2), 3.29 (dd, 1 H, 
3
J=7.52 Hz, 
2
J=14.30 Hz, CH2), 1.41 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 167.78 
(COO
t
Bu), 147.14, 144.41, 130.15, 123.70 (Carom), 83.07 (C(
t
Bu)), 45.72 (CH2), 
40.49 (CH), 27.61 (Me(
t
Bu)); MS (ES-MS): m/z 347 ((M+NH4)
+
). Satisfactory CHN 
not obtained due to trace DMA impurity. 
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Figure 88: ORTEP representation of the X-ray crystal structure of 28 with all 
non H-atoms labelled.  
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Table 18: Crystal data for the structural refinement of 28. 
Identification code  sja9_06 
Empirical formula  C13 H16 Br1 N1 O4 
Formula weight  430.19 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 11.578(5) Å = 90°. 
 b = 12.033(4) Å = 91.24(3)°. 
 c = 10.686(4) Å  = 90°. 
Volume 1488.4(10) Å3 
Z 4 
Density (calculated) 1.473 Mg/m3 
Absorption coefficient 2.771 mm-1 
F(000) 672 
Crystal size 0.61 x 0.12 x 0.05 mm3 
Theta range for data collection 3.07 to 34.83°. 
Index ranges -18<=h<=18, -19<=k<=19, -14<=l<=17 
Reflections collected 35589 
Independent reflections 6382 [R(int) = 0.5047] 
Completeness to theta = 34.83° 98.5 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6382 / 0 / 189 
Goodness-of-fit on F2 0.728 
Final R indices [I>2sigma(I)] R1 = 0.0632, wR2 = 0.0741 
R indices (all data) R1 = 0.3576, wR2 = 0.1235 
Extinction coefficient 0.00084(16) 
Largest diff. peak and hole 0.903 and -1.376 e.Å-3 
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7.3.30. Synthesis of mono-methoxy PEG (average 
MW=550) chains with a primary bromide (29) 
 
Mono methoxy capped PEG (10 g, ~0.013 mol) with an average MW of 550 was 
dissolved in DCM (30 ml) at 0°C under nitrogen, to which was added PBr3 (14.4 g, 
0.053 mol) in DCM (10 ml) over 30 min. Stirring was then continued for a further 
hour at 0°C before adding brine (200 ml). The organic layer was separated, further 
washed with brine (2 x 200 ml) and concentrated to give 29 as a yellow oil (4g, 
~40%); 
1
H NMR [CDCl3] δ 3.63 (t, J=7.87 Hz, nH), 3.57-3.41 (m, 8nH), 3.32 (t, 
J=9.64 Hz, nH). CHN data not obtainable. 
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7.3.31. Synthesis of mono-methoxy PEG (average 
MW=750) chains with a primary bromide (30)  
 
Mono methoxy capped PEG (10g, ~0.018 mol) with an average MW of 750 was 
dissolved in DCM (30 ml) at 0°C under nitrogen, to which was added PBr3 (19.69 g, 
0.072 mol) in DCM (10 ml) over 30 min. Stirring was then continued for a further 
hour at 0
o
C before adding brine (200 ml). The organic layer was separated, further 
washed with brine (2 x 200 ml) and concentrated in vacuo to give 30 as a yellow oil 
(8.44g, ~76%); 
1
H NMR [CDCl3] δ 3.65 (t, J=7.58 Hz, nH), 3.56-3.47 (m, 11nH), 
3.35 (t, J=6.32 Hz, nH). CHN data not obtainable. 
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7.3.32. Synthesis of 1-[2-(2-chloro-ethoxy)-ethoxy]-2-
methoxy-ethane (31) 
 
Monomethoxy triethylene PEG (2 g, 12.2 mmol) was dissolved in pyridine (0.98 ml, 
12.2 mol) under nitrogen. To this was added thionyl chloride (1.74 g, 14.6 mmol) 
over 10 min. The slightly yellow solution was then heated to reflux for 3 hr. The 
solution was allowed to cool before washing with water (100 ml). The organic layer 
was collected and dried over magnesium sulphate before concentrating the filtrate in 
vacuo. This gave the compound as a yellow oil (1.98 g, 89%); 
1
H NMR [CDCl3] δ 
3.57 (t, 2H, J=5.88 Hz, CH2), 3.51-3.44 (m, 8H, CH2), 3.38-3.35 (m, 2H, CH2), 3.19 
(s, 3H, OMe); 
13
C NMR [CDCl3] δ 71.40, 70.81, 70.09, 70.06, 70.03 (CH2), 58.41 
(OMe), 42.25 (CH2Cl); MS (ES-MS): m/z 59 (MeOCH2CH2
+
) [no higher fragments 
observed due to heavy fragmentation of PEG chain]. CHN data not collected. 
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7.4. Cyclam compounds and complexes 
7.4.1. Synthesis of cyclam (32) 
 
Nickel(II) perchlorate hexahydrate (54.7 g, 0.15 mol) was dissolved in water (400 
ml). 1,5,8,12-tetraazadodecane (24 g, 0.15 mol) was added with stirring before 
cooling to 5°C and adding glyoxal (22.5 ml). The dark purple solution was left to stir 
o/n. The solution was then cooled to 5°C, and NaBH4 (11 g, 0.3 mol) was added 
portionwise over 1 hr with rapid stirring. The solution was then heated to 90°C and 
filtered whilst still hot. To the filtrate was added NaCN (29 g, 0.6 mol) and the 
solution heated to reflux for 2 hr. The orange solution was concentrated under 
reduced pressure until the volume was ~100 ml. NaOH (15 g, 0.38 mol) was then 
added and the aqueous layer washed repeatedly with CHCl3 (5 x 100 ml). The 
organic fractions were collected and dried over MgSO4. The solution was filtered 
and the filtrate concentrated under reduced pressure to give the crude product (17.07 
g). The crude product was recrystallised from chlorobenzene to afford 32 as thin 
white needles (10.89 g, 36%); 
1
H NMR [CDCl3] δ 2.73 (t, 8H, J=5.19 Hz, 
NCH2CH2CH2N), 2.66 (s, 8H, NCH2CH2N), 2.51 (br s, 4H, NH), 1.71 (quin, 4H, 
J=5.19 Hz, NCH2CH2CH2N). CHN data not collected. 
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7.4.2. Synthesis of cis-3a,5a,8a,10a-tetraazaperhydropyrene 
(33) 
 
Cyclam (1.08 g, 5 mmol) in methanol (40 ml) was cooled to −10°C and glyoxal 
(0.78 g, 5 mmol) in methanol (30 ml) was added dropwise over a period of 1.5 hr. 
The solution was stirred for a further 30 min at −10°C before stirring at RT for 4 hr. 
The methanol was then removed under reduced pressure before treating the product 
using diethyl ether (30 ml). The diethyl ether extracts were collected and combined 
and the solvent removed under reduced pressure. This afforded a yellow oil which, 
on drying in vacuo, yielded a cream solid (1.11 g, 100%); 
1
H NMR [CDCl3] δ 3.46 
(t, 2H, J=11 Hz, NCHN), 3.01 (s, 2H, CH2), 2.92-2.83 (m, 6H, CH2), 2.66 (d, 2H, 
J=11 Hz, CH2), 2.26 (d, 2H, J=11 Hz, CH2), 2.20-2.04 (m, 6H, CH2), 1.14 (dquin, 
2H, J=2.25 Hz, 13 Hz, CH2); 
13
C NMR [CDCl3]  55.69 (NCHN), 53.98, 52.11, 
44.39 (CH2), 19.22 (NCH2CH2CH2N); MS (ES-MS): m/z 222 (M
+
). CHN data not 
collected. 
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7.4.3. Synthesis of N-3,5-di-tert-butyl-2-methoxy-benzyl-cis-
3a,5a,8a,10a-tetraazaperhydropyrene bromide (35) 
 
33 (0.21g, 0.959 mmol) and 5 (0.3g, 0.958 mmol) were dissolved in dry MeCN (20 
ml) and stirred at RT for 5 days. The solvent was removed in vacuo and the residue 
washed with diethyl ether (30 ml). A precipitate formed which was collected by 
filtration and washed with further ether (3 x 10 ml). This gave the product as a white 
solid (0.33 g, 64%); 
1
H NMR [CD3OD] δ 7.52 (d, 1H, J=2.2 Hz, ArH), 7.33 (d, 1H, 
J=2.2 Hz, ArH), 4.76 (s, 5H, CH2), 4.21-4.15 (m, 2H, CH2), 3.72-3.49 (m, 1H, CH2), 
3.40-3.33 (m, 1H, CH2), 3.21-2.87 (m, 12H, CH2 and OMe), 2.55-2.15 (m, 6H, 
CH2), 1.33 (s, 9H, 
t
Bu), 1.24 (s, 9H, 
t
Bu);
13
C NMR [CD3OD] δ 155.07, 143.81, 
140.55, 126.73, 124.85, 117.05 (Carom), 80.13, 73.10 (NCHN), 67.33 (OMe), 60.02 
(NCH2Ph), 55.89, 55.56, 51.47, 50.92, 49.09, 48.91, 45.93, 39.27 (CH2), 31.96, 
30.98 (C(
t
Bu)), 27.16, 27.13 (Me(
t
Bu)), 15.66, 15.56 (NCH2CH2CH2N). CHN data 
not satisfactory. 
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7.4.4. Synthesis of 5-(3,5-di-tert-butyl-2-methoxybenzyl)-
1,5,8,12-tetraazabicyclo[10.2.2]hexadecane (36) 
 
35 (250 mg, 0.467 mmol) was dissolved in ethanol (100 ml) to which was added 
NaBH4 (0.36 g, 9.3 mmol) portionwise. The solution was then stirred for 7 days at 
RT before removing the solvent in vacuo. The white solid formed was partitioned 
between DCM (60 ml) and water (pH 14, 200 ml). The organic layer was collected 
and dried over Na2SO4. The solution was then filtered and the filtrate concentrated 
under reduced pressure to give 36 as a yellow oil (190 mg, 89%); 
1
H NMR [CDCl3] 
δ 7.16 (d, 1H, J=2.5 Hz, ArH), 7.11 (d, 1H, J=2.5 Hz, ArH), 3.65 (s, 3H, OMe), 
3.00-2.13 (m, 26H, CH2), 1.32 (s, 9H, 
t
Bu), 1.23 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 
156.65, 145.04, 141.78, 126.61, 123.10 (Carom), 62.39 (OMe), 57.08 (NCH2Ph), 
56.96, 54.52, 54.34, 53.70, 53.38, 51.66, 51.14, 49.80, 48.57, 48.12 (CH2), 35.27, 
34.44 (C(
t
Bu)), 31.64, 31.29 (Me(
t
Bu)), 24.04, 19.56 (NCH2CH2CH2N); MS (ES-
MS): m/z 460.5 (M
+
). CHN data not satisfactory. 
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7.4.5. Synthesis of copper(II) 5-(3,5-di-tert-butyl-2-
methoxybenzyl)-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane 
perchlorate ([Cu36][(ClO4)2] 
 
To a solution of 36 (100 mg, 0.218 mmol) in MeOH (10 ml) was added copper(II) 
perchlorate hexahydrate (0.08 g, 0.218 mmol) in MeOH (3 ml). The blue solution 
was then heated to reflux for 2 hr. After this time the solution was allowed to cool, 
filtered and concentrated under reduced pressure to give a blue-purple crystalline 
solid (154 mg, 98%); HRMS (ES-MS) expected for C28N4H50O5Cl1Cu1: 620.2760, 
found 620.2767; ε (MeOH): 547 nm (331 mol-1dm3cm-1). CHN not collected due to 
risk of explosion. 
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7.4.6. Synthesis of zinc(II) 5-(3,5-di-tert-butyl-2-
methoxybenzyl)-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane 
perchlorate ([Zn36][(ClO4)2] 
 
To a solution of 36 (100 mg, 0.218 mmol) in MeOH (10 ml) was added zinc(II) 
perchlorate hexahydrate (0.08 g, 0.218 mmol) in MeOH (3 ml). The yellow solution 
was then heated to reflux for 2 hr. After this time the solution was allowed to cool, 
filtered and concentrated under reduced pressure to give a white crystalline solid 
(150 mg, 95%); 
1
H NMR [CD3CN] δ 7.14 (d, 1H, J=2.52 Hz, ArH), 7.10 (d, 1H, 
J=2.52 Hz, ArH), 3.64 (s, 3H, OMe), 2.99-2.11 (m, 26H, CH2), 1.33 (s, 9H, 
t
Bu), 
1.25 (s, 9H, 
t
Bu); 
13
C NMR [CD3CN] δ 157.45, 145.09, 141.48, 125.71, 124.30 
(Carom), 62.89 (OMe), 57.78 (NCH2Ph), 56.54, 54.44, 54.27, 53.65, 53.34, 51.58, 
51.18, 49.75, 48.67, 48.13 (CH2), 35.45, 34.65 (C(
t
Bu)), 31.62, 31.56 (Me(
t
Bu)), 
24.12, 19.64 (NCH2CH2CH2N); HRMS (ES-MS) expected for C28H50O5N4Cl1Zn1: 
621.2756, found 621.2763. CHN not collected due to risk of explosion. 
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7.4.7. Synthesis of nickel(II) 5-(3,5-di-tert-butyl-2-
methoxybenzyl)-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane 
perchlorate ([Ni36][(ClO4)2]) 
 
To a solution of 36 (100 mg, 0.218 mmol) in MeOH (10 ml) was added nickel(II) 
perchlorate hexahydrate (0.08 g, 0.218 mmol) in MeOH (3 ml). The orange solution 
was then heated to reflux for 2 hr. After this time the solution was allowed to cool, 
filtered and concentrated under reduced pressure to give a orange crystalline solid 
(152 mg, 98%); HRMS (ES-MS) expected for C28H50N4ONi: 258.1664 (M
2+
) found 
258.1665; HRMS (ES-MS) expected for C28H50N4ONi: 615.2818 (M
+
) found 
615.2808; ε (MeOH): 477 nm (197 mol-1dm3cm-1). CHN not collected due to risk of 
explosion. 
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Figure 89: ORTEP representation of the X-ray structure of [Ni36][(ClO4)2] with 
all non-H atoms labelled. 
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Table 19: Crystal data for the structural refinement of [Ni36][(ClO4)2]. 
Identification code  sja38_08 
Empirical formula  C120 H164 Cll8 N16 Ni4 O39 
Formula weight  2973.03 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 25.066(4) Å               = 90°. 
 b = 11.2561(17) Å           = 96.911(14)° 
 c = 12.752(2) Å                = 90°. 
Volume 3571.8(10) Å3 
Z 1 
Density (calculated) 1.378 Mg/m3 
Absorption coefficient 0.752 mm-1 
F(000) 1556 
Crystal size 0.39 x 0.36 x 0.27 mm3 
Theta range for data collection 2.49 to 34.90°. 
Index ranges -40<=h<=40, -17<=k<=18, -20<=l<=20 
Reflections collected 103581 
Independent reflections 15376 [R(int) = 0.2890] 
Completeness to theta = 34.90° 98.4 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15376 / 3 / 421 
Goodness-of-fit on F2 0.903 
Final R indices [I>2sigma(I)] R1 = 0.1256, wR2 = 0.3045 
R indices (all data) R1 = 0.2736, wR2 = 0.3472 
Extinction coefficient 0.0028(8) 
Largest diff. peak and hole 1.633 and -0.963 e.Å-3 
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7.4.8. Synthesis of N-3,5-di-tert-butyl-2-benzyl ether-benzyl-
cis 3a,5a,8a,10a-tetraazaperhydropyrene (38) 
 
33 (0.45 g, 0.002 mmol) and 8 (0.78 g, 0.002 mmol) were dissolved in MeCN (30 
ml) and stirred at RT for 3 days. The MeCN was then removed in vacuo and the 
isolated oil was triturated diethyl ether (30 ml) to yield a white solid. This white 
solid was then filtered off and further washed with ether (2 x 30 ml) to give 38 as a 
white solid (0.38 g, 66%); 
1
H NMR [CD3OD] δ 7.67-7.35 (m, 7H, ArH), 4.13-4.05 
(m, 1H, CH2), 3.59-2.80 (m, 12H, CH2), 3.04-2.80 (m, 9H, CH2), 2.52-2.03 (m, 4H, 
CH2), 1.34 (s, 9H, 
t
Bu), 1.26 (s, 9H, 
t
Bu); 
13
C NMR [CD3OD] δ 153.22, 143.92, 
140.43, 133.41, 126.91, 125.32, 124.91, 124.83, 123.88, 117.04 (Carom), 80.32, 74.66 
(NCHN), 72.91 (OCH2Ph), 66.93 (NCH2Ph), 56.13, 55.88, 50.80, 50.70, 49.00, 
48.43, 38.96 (CH2), 31.98, 30.86 (C(
t
Bu)), 27.25, 26.98 (Me(
t
Bu)), 15.48, 15.15 
(NCH2CH2CH2N); MS (ES-MS): m/z 532.4 (M
+
). CHN not satisfactory. 
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7.4.9. Synthesis of 5-(2-(benzyloxy)-3,5-di-tert-butylbenzyl)-
1,5,8,12-tetraazabicyclo[10.2.2]hexadecane (39) 
 
38 (1.09 g, 0.00178 mol) was dissolved in methanol (40 ml) to which NaBH4 (1.36 
g, 0.03568 mol) was added portionwise over 5 min. The mixture was then stirred at 
RT for 2 days before heating to reflux for 2 hr. The solvent was removed under 
reduced pressure and KOH(aq) (pH 14, 200 ml) added. DCM (100 ml) was used to 
extract the organic product which was then dried over MgSO4 and evaporated in 
vacuo to afford 39 as a yellow oil (0.76 g, 80%); 
1
H NMR [CDCl3] δ 7.44-7.20 (m, 
7H, ArH), 5.19 (s, 2H, NCH2Bn), 4.82 (s, 2H, OCH2Bn), 3.70-3.68 (m, 2H, CH2), 
3.28-3.24 (m, 7H, CH2), 3.12-2.84 (m, 5H, CH2), 2.56-2.39 (m, 11H, CH2), 1.36 (s, 
9H, 
t
Bu), 1.23 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] 155.04, 145.35, 141.97, 137.87, 
129.86, 128.47, 127.62, 126.72, 126.63, 123.34 (Carom), 77.00 (OCH2Ph), 56.86 
(NCH2Ph), 54.50, 53.95, 53.63, 50.99, 50.66, 49.73, 48.15, 47.83 (CH2), 35.41, 
34.45 (C(
t
Bu)), 31.64, 31.32 (Me(
t
Bu)), 25.64, 23.84 (NCH2CH2CH2N); MS (ES-
MS): m/z 536.4 (MH
+
). CHN not satisfactory. 
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7.4.10. Synthesis of copper(II) 5-(2-(benzyloxy)-3,5-di-tert-
butylbenzyl)-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane 
perchlorate ([Cu39][(ClO4)2]) 
 
To 39 (100 mg, 0.187 mmol) dissolved in MeOH (10 ml) was added copper(II) 
perchlorate hexahydrate (0.07 g, 0.187 mmol) in MeOH (3 ml). The blue solution 
was then heated to reflux for 2 hr. After this time the solution was allowed to cool, 
filtered and concentrated under reduced pressure to give a purple crystalline solid 
(130 mg, 87%); HRMS (ES-MS) expected for C34H54O5N4Cl1Cu1: 696.3073, found 
696.3075; ε (MeOH): 550 nm (286 mol-1dm3cm-1). CHN not collected due to risk of 
explosion. 
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7.4.11. Synthesis of zinc(II) 5-(2-(benzyloxy)-3,5-di-tert-
butylbenzyl)-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane 
perchlorate ([Zn39][(ClO4)2]) 
 
To 39 (100 mg, 0.187 mmol) dissolved in MeOH (10 ml) was added zinc(II) 
perchlorate hexahydrate (0.0822 g, 0.187 mmol) in MeOH (3 ml). The yellow 
solution was then heated to reflux for 2 hr. After this time the solution was allowed 
to cool, filtered and concentrated under reduced pressure to give a white crystalline 
solid (0.0702 mg, 47%); 
1
H NMR [CD3CN] δ 7.46-7.22 (m, 7H, ArH), 5.21 (s, 2H, 
NCH2Bn), 4.79 (s, 2H, OCH2Bn), 3.72-3.66 (m, 2H, CH2), 3.29-3.22 (m, 7H, CH2), 
3.13-2.82 (m, 5H, CH2), 2.57-2.33 (m, 11H, CH2), 1.34 (s, 9H, 
t
Bu), 1.26 (s, 9H, 
t
Bu); 
13
C NMR [CD3CN] 156.13, 144.39, 142.04, 137.62, 129.56, 128.82, 127.54, 
126.59, 126.36, 123.28 (Carom), 77.13 (OCH2Ph), 56.44 (NCH2Ph), 54.47, 53.82, 
53.59, 51.07, 50.68, 49.57, 48.21, 47.91 (CH2), 35.26, 34.67 (C(
t
Bu)), 31.56, 31.29 
(Me(
t
Bu)), 25.58, 23.78 (NCH2CH2CH2N); HRMS (ES-MS) expected for 
C34H54N4O5ZnCl: 697.3069, found 697.3060. CHN not collected due to risk of 
explosion. 
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7.4.12. Synthesis of nickel(II) 5-(2-(benzyloxy)-3,5-di-tert-
butylbenzyl)-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane 
perchlorate ([Ni39][(ClO4)2]) 
 
To 39 (150mg, 0.281 mmol) dissolved in MeOH (10 ml) was added nickel(II) 
perchlorate hexahydrate (102 mg, 0.281 mmol) in MeOH (3 ml). The yellow/brown 
solution was then heated to reflux for 2 hr. After this time the solution was allowed 
to cool, filtered and concentrated under reduced pressure to give an orange 
crystalline solid (0.0925 g, 42%); HRMS (ES-MS) expected for C34H54N4O5NiCl: 
691.3131 (M
+
), found 691.3122; ε (MeOH): 481 nm (100 mol-1dm3cm-1). CHN not 
collected due to risk of explosion. 
 278 
7.4.13. Synthesis of 3a-3,5-di-tert-butyl-2-(4-methoxy-
benzyloxy)-benzyl-decahyro-5a, 8a, 10a-triaaza-3a-azonia-
pyrene bromide (40) 
 
33 (0.53 g, 2.4 mmol) and 14 (1 g, 2.4 mmol) were dissolved in dry MeCN (20 ml) 
and stirred for 4 days at RT. After this time, a precipitate had formed. The reaction 
mixture was then concentrated under reduced pressure and filtered. The solid was 
then washed with pentane (3 x 20 ml), and the product was isolated as a orange solid 
(1.35g, 88%); 
1
H NMR [CD3OD] δ 7.57 (d, 1H, J=2.38 Hz, ArH), 7.42 (d, 2H, 
J=8.56 Hz, ArH), 7.39 (d, 1H, J=2.38 Hz, ArH), 6.94 (d, 2H, J=8.56 Hz, ArH), 4.78 
(s, 2H, NCH2Phen); 3.73 (s, 3H, OMe), 3.50-3.20 (m, 6H, CH2), 3.01- 2.66 (m, 12H, 
CH2), 2.37-1.94 (m, 6H, CH2), 1.41 (s, 9H, 
t
Bu), 1.26 (s, 9H, 
t
Bu);
13
C NMR 
[CD3OD] δ 161.52, 158.18, 148.52, 131.4105, 130.59, 130.16, 129.63, 121.76, 
115.51 (Carom), 85.13, 79.53 (NCHN), 77.69 (OCH2Phen), 71.63 (NCH2Phen), 
60.64, 55.92, 55.41, 53.72, 53.14, 52.77, 44.79, 43.68 (CH2 and OMe), 36.70, 35.56 
(C(
t
Bu)), 31.92, 31.71 (Me(
t
Bu)), 20.18, 19.90 (CH2CH2CH2); MS (ES-MS): m/z 
562.4 (M
+
), 222 ((macrocycle)
+
). CHN not collected. 
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7.4.14. Synthesis of 5-[3,5-di-tert-butyl-2-(4-methoxy-
benzyloxy)-benzyl]-1,5,8,12-tetraaza-
bicyclo[10.2.2]hexadecane (41) 
 
To 40 (1 g, 1.56 mmol) dissolved in EtOH (50 ml) was added NaBH4 (1.18 g, 31.20 
mmol) portionwise. A colour change from yellow to colourless occurred during this 
addition. The mixture was then left for 2 weeks stirring at RT, before concentrating 
under reduced pressure. The residual solid was then partitioned between DCM (50 
ml) and water (200 ml). The pH of the aqueous layer was adjusted to 14 by the 
addition of KOH. The organic layer was then collected and dried over MgSO4 before 
concentrating under reduced pressure. The product was obtained as a yellow oil 
(0.85 g, 97%); 
1
H NMR [CDCl3] δ 7.37 (d, 2H, J=8.42 Hz, ArH), 7.32 (s, 1H, ArH), 
7.23 (s, 1H, ArH), 6.86 (d, 2H, J=8.42 Hz, ArH), 4.73 (s, 2H, OCH2Phen), 3.70 (s, 
3H, OMe), 3.65 (s, 2H, NCH2Phen), 3.05-2.99 (m, 1H, CH2), 2.78 (br s, 6H, CH2), 
2.56-2.35 (m, 12H, CH2), 2.21-1.94 (m, 6H, CH2), 1.37 (s, 9H, 
t
Bu), 1.29 (s, 9H, 
t
Bu);
13
C NMR [CDCl3] δ 163.56, 159.21, 149.49, 145.88, 135.55, 134.29, 132.75, 
130.64, 127.14, 117.83 (Carom), 81.47 (OCH2Phen), 61.36, 59.44, 58.19, 58.07, 
57.79, 57.52, 55.56, 53.64, 52.44, 49.27 (CH2 and OMe), 39.58, 38.71 (C(
t
Bu)), 
35.83, 35.52 (Me(
t
Bu)), 24.28, 23.01 (CH2CH2CH2); MS (ES-MS): m/z 566.3 
(MH
+
). CHN not collected. 
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7.4.15. Synthesis of copper(II) 5-[3,5-di-tert-butyl-2-(4-
methoxy-benzyloxy)-benzyl]-1,5,8,12-tetraaza-
bicyclo[10.2.2]hexadecane perchlorate ([Cu41][(ClO4)2] 
 
To 41 (0.1 g, 0.1773 mmol) dissolved in MeOH (8 ml) was added copper(II) 
perchlorate hexahydrate (0.657g, 0.1773 mmol) in MeOH (2 ml). The blue solution 
was heated to reflux for 2 hr before allowing to cool to RT. The solution was then 
concentrated under reduced pressure before redissolving in the minimal amount of 
MeOH. This solution was then eluted down a Sephadex LH-20 column with MeOH. 
The blue fraction was isolated and concentrated under reduced pressure. The oily 
residue was triturated with ether (3 x 5 ml) to afford the title compound as a blue 
solid (0.0430 g, 29%); HRMS (ES-MS) expected for C35H56O2N4CuClO4: 726.3179, 
found 726.3183; ε (MeOH): 529 nm (154 mol-1dm3cm-1). CHN not collected due to 
risk of explosion. 
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7.4.16. Synthesis of nickel(II) 5-[3,5-di-tert-butyl-2-(4-
methoxy-benzyloxy)-benzyl]-1,5,8,12-tetraaza-
bicyclo[10.2.2]hexadecane perchlorate ([Ni41][(ClO4)2]) 
 
To 41 (0.1 g, 0.1773 mmol) dissolved in MeOH (8 ml) was added nickel(II) 
hexahydrate (0.0648 g, 0.1773 mmol) in MeOH (2 ml). The orange solution was 
heated to reflux for 2 hr before allowing to cool to RT. The solution was then 
concentrated under reduced pressure before redissolving in the minimal amount of 
MeOH. This solution was then eluted on a Sephadex LH-20 column with MeOH. 
The orange fraction was isolated and concentrated under reduced pressure. The oily 
residue was triturated with ether (3 x 5 ml) to afford the title compound as an orange 
solid (0.0640g, 44%); HRMS (ES-MS) expected for C35H56O2N4NiClO4: 721.3236, 
found 721.3237; ε (MeOH): 478 nm (96 mol-1dm3cm-1). CHN not collected due to 
risk of explosion. 
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7.4.17. Synthesis of zinc(II) 5-[3,5-di-tert-butyl-2-(4-
methoxy-benzyloxy)-benzyl]-1,5,8,12-tetraaza-
bicyclo[10.2.2]hexadecane perchlorate ([Zn41][(ClO4)2]) 
 
To 41 (0.1 g, 0.1773 mmol) dissolved in MeOH (8 ml) was added zinc(II) 
hexahydrate (0.066 g, 0.1773 mmol) in MeOH (2 ml). The yellow solution was 
heated to reflux for 2 hr before allowing to cool to RT. The solution was then 
concentrated under reduced pressure before re-dissolving in the minimal amount of 
MeOH. This solution was then eluted on a Sephadex LH-20 column with MeOH. 
The light yellow fraction was isolated and concentrated under reduced pressure. The 
oily residue was triturated with ether (3 x 5 ml) to afford the title compound as a 
white solid (0.0720g, 49%); 
1
H NMR [CD3CN] δ 7.35 (d, 2H, J=8.67 Hz, ArH), 7.29 
(s, 1H, ArH), 7.21 (br s, 1H, ArH), 6.86 (d, 2H, J=8.67 Hz, ArH), 4.77 (s, 2H, 
OCH2Phen), 3.69 (s, 3H, OMe), 3.63 (s, 2H, NCH2Phen), 3.11-3.01 (m, 1H, CH2), 
2.78 (br s, 6H, CH2), 2.56-1.92 (m, 18H, CH2), 1.34 (s, 9H, 
t
Bu), 1.26 (s, 9H, 
t
Bu);
13
C NMR [CDCl3] δ 164.01, 158.87, 149.24, 146.13, 135.77, 134.34, 132.68, 
130.23, 127.35, 117.57 (Carom), 81.51 (OCH2Phen), 60.49, 59.29, 58.23, 58.01, 
57.81, 56.26, 55.78, 54.57, 52.81, 49.37 (CH2 and OMe), 39.46, 38.58 (C(
t
Bu)), 
35.71, 35.46 (Me(
t
Bu)), 24.67, 23.19 (CH2CH2CH2); HRMS (ES) expected for 
C34H54O2N4ZnO4Cl: 713.3804, found 713.3807. CHN not collected due to risk of 
explosion. 
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7.4.18. Synthesis of 3a-(2-acetoxy-3,5-di-tert-butyl-
benzyl)-decahydro-5a,8a,10a-triaza-3a-azonia-pyrene 
bromide (42) 
 
33 (1.36 g, 6.13 mmol) and 15 (2.09 g, 6.13 mmol) were dissolved in dry MeCN (15 
ml) and stirred at RT for 3 days. After this period, the reaction mixture was 
concentrated under reduced pressure and the residue taken up in to diethyl ether (40 
ml). A white solid formed which was collected by filtration (2.60 g, 75%); 
1
H NMR 
[CD3OD] δ 7.70 (d, 1H, J=2.52 Hz, ArH), 7.48 (br s, 1H, ArH), 4.85 (s, 2H, 
NCH2Ph), 4.30 (br s, 2H, CH2), 3.65-3.59 (m, 2H, CH2), 3.15-2.96 (br m, 8H, CH2), 
2.69-2.47 (m, 6H, CH2), 2.38-2.25 (m, 4H, CH2), 2.02 (s, 3H, COMe), 1.23 (s, 9H, 
t
Bu), 1.22 (s, 9H, 
t
Bu); 
13
C NMR [CD3OD] δ 170.53 (CO), 149.69, 147.94, 143.19, 
128.38, 120.87, 117.15 (Carom), 70.84 (NCHN), 59.71 (NCH2Ph), 54.83, 54.56, 
52.66, 52.53, 42.90 (CH2), 35.29, 34.85 (C(
t
Bu)), 30.71, 30.15 (Me(
t
Bu)), 21.35 
(COOMe), 19.32, 19.16 (CH2CH2CH2); MS (ES-MS): m/z 483.3 (M
+
). CHN not 
satisfactory. 
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7.4.19. Synthesis of acetic acid 2,4-di-tert-butyl-6-
(1,5,8,12-tetraaza-bicyclo[10.2.2]hexadec-5-ylmethyl)phenyl 
ester (43) 
 
42 (2.6 g, 4.62 mmol) was dissolved in ethanol (150 ml) to which was added NaBH4 
(3.51 g, 92.4 mmol) portion wise. The reaction mixture was stirred at RT o/n at 
which time hydrogen evolution had ceased. The reaction mixture was then 
concentrated under reduced pressure and the residue partitioned between DCM (100 
ml) and water (250 ml). The pH of the aqueous layer was then adjusted to 14 with 
the addition of KOH. The organic layer was then collected and dried over MgSO4. 
The filtrate was then concentrated under reduced pressure before dissolving in the 
minimal amount of acetone (~10 ml) which was triturated with pentane (150 ml) to 
give a cream solid which was collected by filtration (2.20 g, 98%); 
1
H NMR [CDCl3] 
δ 7.37 (d, 2H, J=2.50 Hz, ArH), 7.24 (d, 2H, J=2.50 Hz, ArH), 5.23 (s, 2H, CH2), 
3.33-2.37 (m, 28H, CH2 and NH), 2.25 (s, 3H, COOMe), 1.27 (s, 9H, 
t
Bu), 1.25 (s, 
9H, 
t
Bu); 
13
C NMR [CDCl3] δ 166.07 (CO), 144.12, 142.26, 136.81, 127.90, 122.03, 
119.27 (Carom), 53.80, 53.39, 51.38, 49.94, 48.25, 47.86, 46.99, 45.95, 45.47, 44.78, 
43.52 (CH2), 31.16, 31.05 (C(
t
Bu)), 27.74, 26.78 (Me(
t
Bu)), 23.09, 22.78, 
(CH2CH2CH2), 20.83 (COOMe); HRMS (ES-MS) expected for C29H50N4O2H: 
487.4007, found 487.3996. CHN not satisfactory. 
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7.4.20. Synthesis of 2,4-di-tert-butyl-6-(1,5,8,12-tetraaza-
bicyclo[10.2.2]hexadec-5-ylmethyl)-phenol hydrochloride salt 
(37) 
 
To 43 (1.5 g, 3.09 mmol) dissolved in MeOH (10 ml) was added 6M HCl(aq) (10 
ml). This induced a colour change from yellow to colourless. The solution was then 
heated to reflux for 24 hr before cooling to room temperature. The solution was 
concentrated under reduced pressure, and the addition of acetone (30 ml) caused a 
yellow precipitate to form. This was collected by filtration and dried in vacuo (1.44 
g, 79%); 
1
H NMR [D2O] δ 7.24 (s, 1H, ArH), 7.16 (s, 1H, ArH), 3.40-3.14 (m, 15H, 
CH2 and NH), 2.02-1.80 (m, 10H, CH2), 1.11 (s, 9H, 
t
Bu), 1.01 (s, 9H, 
t
Bu); 
13
C 
NMR [D2O] δ 151.65, 144.37, 140.08, 127.67, 125.56, 120.51 (Carom), 74.31 
(NCH2Phen), 49.16, 48.81, 48.18, 47.97, 47.76, 46.83, 45.95 (CH2), 34.55, 33.92 
(C(
t
Bu)), 30.67, 29.47 (Me(
t
Bu)), 21.49, 20.72 (CH2CH2CH2); HRMS (ES-MS) 
expected for C27H48N4OH: 445.3901, found 445.3891. CHN not collected. 
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7.4.21. Synthesis of copper(II) 2,4-di-tert-butyl-6-(1,5,8,12-
tetraaza-bicyclo[10.2.2]hexadec-5-ylmethyl)-phenolate 
perchlorate ([Cu37]ClO4) 
 
To 37 (180 mg, 0.305 mmol) in MeOH (8 ml) was added NEt3 (150 mg, 1.5 mmol). 
The reaction mixture was stirred for 5 min, by which time the colour of the solution 
had changed from yellow to straw colour. To this solution was then added copper(II) 
perchlorate hexahydrate (113 mg, 0.305 mmol) in MeOH (3 ml). The royal blue 
solution was then heated to reflux for 2 hr before allowing to cool. The reaction 
mixture was concentrated under reduced pressure to the minimal volume before 
eluting down a Sephadex LH-20 column using MeOH. The blue fraction was 
collected and concentrated under reduced pressure. The oil obtained was triturated 
with ether (3 x 5 ml) to give a hygroscopic blue solid (0.0737 g, 40%); HRMS (ES-
MS) expected for (cation-2H)
+
 C27H45N4O1Cu1: 504.2884 found 504.2875; ε 
(MeOH): 641 nm (27 mol
-1
dm
3
cm
-1
). CHN not collected due to risk of explosion. 
 287 
7.4.22. Synthesis of nickel(II) 2,4-di-tert-butyl-6-(1,5,8,12-
tetraaza-bicyclo[10.2.2]hexadec-5-ylmethyl)-phenolate 
perchlorate ([Ni37]ClO4) 
 
To 37 (180 mg, 0.305 mmol) in MeOH (8 ml) was added NEt3 (150 mg, 1.5 mmol). 
The reaction mixture was stirred for 5 min, by which time the colour of the solution 
had changed from yellow to straw colour. To this solution was then added nickel(II) 
perchlorate hexahydrate (112 mg, 0.305 mmol) in MeOH (3 ml). The orange 
solution was then heated to reflux for 2 hr before allowing to cool. The reaction 
mixture was concentrated under reduced pressure to the minimal volume before 
eluting down a Sephadex LH-20 column using MeOH. The orange fraction was 
collected and concentrated under reduced pressure. The oil obtained was triturated 
with ether (3 x 5 ml) to give a hygroscopic orange solid (0.0541 g, 30%); HRMS 
(ES) expected for C27H47N4ONi: 501.3098, found 501.3093; ε (MeOH): 441 nm (12 
mol
-1
dm
3
cm
-1
). CHN not collected due to risk of explosion. 
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7.4.23. Synthesis of zinc(II) 2,4-di-tert-butyl-6-(1,5,8,12-
tetraaza-bicyclo[10.2.2]hexadec-5-ylmethyl)-phenolate 
perchlorate ([Zn37]ClO4) 
 
To 37 (180 mg, 0.305 mmol) in MeOH (8 ml) was added NEt3 (150 mg, 1.5 mmol). 
The reaction mixture was stirred for 5 min, by which time the colour of the solution 
had changed from yellow to straw colour. To this solution was then added zinc(II) 
perchlorate hexahydrate (113 mg, 0.305 mmol) in MeOH (3 ml). The straw coloured 
solution was then heated to reflux for 2 hr before allowing to cool. The reaction 
mixture was concentrated under reduced pressure to the minimal volume before 
eluting down a Sephadex LH-20 column using MeOH as the eluent. The yellow 
fraction was collected and concentrated under reduced pressure. The oil obtained 
was triturated with ether (3 x 5 ml) to give a hygroscopic white solid (0.0530 g, 
29%); 
1
H NMR [CD3CN] δ 7.63 (s, 1H, ArH), 7.53 (s, 1H, ArH), 4.10-4.09 (m, 2H, 
CH2Ph), 3.26-2.09 (m, 25H, NH and CH2), 1.31 (s, 9H, 
t
Bu), 1.22 (s, 9H, 
t
Bu); 
13
C 
NMR [CD3CN] δ 152.43, 138.58, 138.03, 136.39, 132.56, 129.65 (Carom), 68.76 
(CH2Ph), 51.17, 50.35, 48.26, 48.21, 48.18, 48.11, 47.93 (CH2), 31.57, 31.03 
(C(
t
Bu)), 30.30, 29.94 (Me(
t
Bu)); HRMS (ES) expected for C27H47N4OZn: 
507.3036, found 507.3036. CHN not collected due to risk of explosion. 
 289 
7.4.24. Synthesis of N-2-(4-methoxybenzylsulphonyl)-
benzyl-cis 3a,5a,8a,10a-tetraazaperhydropyrene (44) 
 
33 (0.2 g, 0.901 mmol) and 18 (290 mg, 0.901 mmol) were dissolved in dry MeCN 
(20 ml). The resulting yellow solution was then stirred at RT for 1 week before 
removing the solvent in vacuo and washing with ether (30 ml). The solid formed by 
this process was then further washed with ether (2 x 30 ml) to give the desired 
product as a yellow solid (0.46 g, 94%); 
1
H NMR [CDCl3] δ 7.83 (d, 1H, J=7.8 Hz, 
ArH), 7.56 (t, 1H, J=7.6 Hz, ArH), 7.43 (t, 1H, J=7.6 Hz, ArH), 7.36 (d, 1H, J=7.8 
Hz, ArH), 6.93 (d, 2H, J=8.6 Hz, Ar), 6.83 (d, 2H, J=8.6 Hz, Ar), 4.30-3.93 (m, 6H, 
CH2), 3.76 (s, 3H, OMe), 3.03-2.89 (m, 14H, CH2), 2.44-2.37 (m, 4H, CH2), 2.11-
2.08 (m, 2H, CH2); 
13
C NMR [CDCl3] δ 158.45, 137.74, 136.74, 134.30, 132.25, 
130.70, 130.47, 130.03, 129.25, 114.35 (Carom), 82.50, 75.56 (NCHN), 59.76 (OMe), 
59.25, 55.63, 54.36, 53.35, 51.89, 51.60, 49.75, 46.79 (CH2), 40.92 (SCH2), 18.46, 
18.15 (NCH2CH2CH2N); MS (ES-MS): m/z 465.3 (M
+
), 224 ((macrocycle)
+
). CHN 
not collected. 
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7.4.25. Synthesis of 5-(2-(4-methoxybenzylthio)benzyl)-
1,5,8,12-tetraazabicyclo[10.2.2]hexadecane (45) 
 
To 44 (0.2 g, 0.367 mmol) dissolved in MeOH (40 ml) was added NaBH4 (280 mg, 
7.368 mmol) portionwise. The solution was then stirred at RT for a week before 
removing the solvent in vacuo. The residue was taken up into DCM (100 ml) and 
washed with KOH(aq) (pH 14, 200 ml). The organic layer was collected, dried and 
evaporated to dryness to afford 45 as a light yellow oil (0.14 g, 82%); 
1
H NMR 
[CDCl3] δ 7.38-7.08 (m, 6H, ArH), 6.77-6.69 (m, 2H, ArH), 5.23 (s, 2H, CH2), 4.04-
3.32 (m, 13H, CH2 and OMe), 3.03-2.74 (m, 8H, CH2), 2.55-1.93 (m, 8H, CH2); 
13
C 
NMR [CDCl3] δ 159.20, 137.32, 131.38, 130.37, 130.24, 128.73, 128.68, 125.92, 
114.04, 113.82 (Carom), 67.58, 59.46 (CH2), 57.89 (NCH2Ph), 56.50 (OMe), 55.57, 
55.39, 50.28, 50.18, 48.24, 47.17 (CH2), 38.44 (SCH2), 19.66, 18.51 
(NCH2CH2CH2N); MS (ES-MS): m/z 469.4 (MH
+
). CHN not collected. 
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7.4.26. Synthesis of 2-(1,5,8,12-
tetraazabicyclo[10.2.2]hexadecane-5-ylmethyl)benzenethiol 
(46) 
 
To 45 (0.14 g, 0.299 mmol) dissolved in methanol (10 ml) was added mercury 
acetate (0.19 g, 0.598 mmol) in methanol (5 ml). The suspension was then heated to 
60°C for 14 hr. After this period a white precipitate had formed and the solvent was 
removed under reduced pressure. The white powder obtained was washed with 
pentane (2 x 10 ml) and then redissolved in methanol (20 ml). The solution was 
bubbled with nitrogen for 10 min followed by passing hydrogen sulphide through the 
solution for 20 min. The solution was then bubbled with nitrogen for a further 30 
min. The black mercury sulphide was filtered off and the yellow solution was 
concentrated in vacuo. The crude product was used without further purification and 
used immediately for complexation reactions (100 mg, 93%). CHN not collected. 
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7.4.27. Synthesis of nickel(II) 2-(1,5,8,12-
tetraazabicyclo[10.2.2]hexadecane-5-ylmethyl)benzenethiol 
perchlorate ([Ni46]ClO4) 
 
46 (0.034 g, 0.0996 mmol) was dissolved in degassed methanol (5 ml) to which was 
added [Ni(ClO4)2].6H2O (0.05 g, 0.1296 mmol) in degassed methanol (2 ml) with 
stirring. The clear solution was heated to reflux under argon for 2 hr and then stirred 
at RT for 14 hr. The solution was removed in vacuo and the brown solid redissolved 
in acetone (2 ml). This was then passed down a short Sephadex LH-20 column, 
eluting with acetone to remove remaining inorganic salts, and the eluent 
concentrated in vacuo. This gave the product as a brown powder (37 mg, 92%); 
HRMS (ES-MS) expected for Ni1C19N4S1H33: 405.1617, found 405.1610, ε 
(acetone): 367 nm (149 mol
-1
dm
3
cm
-1
), 464 nm (68 mol
-1
 dm
3
 cm
-1
). CHN not 
collected due to risk of explosion. 
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7.4.28. Synthesis of zinc(II) 2-(1,5,8,12-
tetraazabicyclo[10.2.2]hexadecane-5-ylmethyl)benzenethiol 
perchlorate ([Zn46]ClO4) 
 
46 (0.034 g, 0.0996 mmol) was dissolved in degassed methanol (5 ml) to which was 
added [Zn(ClO4)2].8H2O (0.05 g, 0.1295 mmol) in degassed methanol (1 ml) with 
stirring. The clear solution was then heated to reflux under argon for 2 hr and then 
stirred at RT for 14 hr. The solution was then removed in vacuo and the white solid 
redissolved in acetone (2ml). This was passed down a short Sephadex LH-20 
column, eluting with acetone to remove remaining inorganic salts, and the eluent 
concentrated in vacuo. This gave the product as a white powder (20 mg, 50%); 
1
H 
NMR [CDCl3] δ 7.05-6.80 (m, 4H, Ar), 3.91-2.17 (m, 27H, CH2 and NH); 
13
C NMR 
[CDCl3] δ 134.74, 132.43, 130.84, 128.52, 123.14, 114.17 (Carom), 67.94, 60.79 
(CH2), 58.49 (NCH2Ph), 56.64, 55.87, 54.02, 53.71, 53.64, 53.10, 51.49, 50.49 
(CH2), 24.11 (NCH2CH2CH2N); HRMS (ES-MS) expected for Zn1C19N4S1H33: 
411.1554, found 411.1555. CHN not collected due to risk of explosion. 
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7.4.29. Synthesis of 3a-[3,5-di-tert-butyl-2-(4-methoxy-
benzylsulfanyl)-benzyl-decahyro-5a, 8a, 10a-triaaza-3a-
azonia-pyrene bromide (47) 
 
33 (0.39 g, 1.77 mmol) and 24 (0.72 g, 1.77 mmol) were dissolved in dry MeCN (15 
ml) and stirred at RT for 3 days. After this period of time a precipitate had formed. 
The mixture was concentrated under reduced pressure, before suspending in ether. 
The yellow/ cream solid was then collected by filtration and washed repeatedly with 
ether (4 x 5 ml) to afford the title compound (1.10g, 95%); 
1
H NMR [D2O] δ 7.58 (br 
s, 1H, ArH), 7.27 (br s, 4H, ArH), 6.73 (br s, 1H, ArH), 4.21 (s, 2H, NCH2Ph), 3.56-
1.98 (m, 27H, CH2, NCHN and OMe), 1.39 (s, 9H, 
t
Bu), 1.20 (s, 9H, 
t
Bu); 
13
C NMR 
[D2O] δ 169.64, 158.97, 152.74, 136.89, 133.04, 131.35, 127.69, 125.79, 125.01, 
114.33 (Carom), 83.15, 75.71 (NCHN), 69.88 (NCH2Phen), 63.09, 60.18 (CH2), 55.77 
(OMe), 54.20, 52.99, 52.22, 51.31, 48.09, 46.75, 43.71, 42.13 (CH2), 37.91 
(SCH2Phen), 34.85, 34.63 (C(
t
Bu)), 31.74, 30.74 (Me(
t
Bu)), 18.81, 18.19 
(CH2CH2CH2); MS (ES-MS): m/z 577 (M
+
), 222 ((macrocycle)
+
). CHN not 
satisfactory. 
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7.4.30. Synthesis of 5-[3,5-di-tert-butyl-2-(4-methoxy-
benzylsulfanyl)-benzyl]-1,5,8,12-tetraaza-
bicyclo[10.2.2]hexadecane (48) 
 
To 47 (1.10 g, 16 .7 mmol) dissolved in MeOH (50 ml) was added NaBH4 (1.34 g, 
35.3 mmol) portion wise with stirring. Stirring continued for 5 days before 
concentrating under reduced pressure. The residue was then partitioned between 
DCM (100 ml) and water (200 ml). The pH of the aqueous layer was adjusted to 14 
by addition of KOH. The organic layer was separated and dried over MgSO4. The 
solid was then removed by filtration and the filtrate concentrated in vacuo to afford a 
yellow oil (0.52 g, 49%); 
1
H NMR [CDCl3] δ 7.68 (d, 1H, J=2.02 Hz, ArH), 7.61 (d, 
1H, J=2.02 Hz, ArH), 7.38 (d, 2H, J=8.76 Hz, ArH), 7.03 (d, 2H, J=8.76 Hz, ArH), 
3.98 (s, 2H, SCH2Phen), 3.87 (s, 3H, OMe), 3.46-3.13 (m, 8H, CH2), 2.87-2.73 (m, 
12H, CH2), 2.46-2.36 (m, 5H, CH2), 1.99-1.89 (m, 2H, CH2), 
13
C NMR [CDCl3] δ 
158.52, 152.77, 149.98, 144.34, 135.80, 130.52, 125.40, 122.48, 120.41, 113.58 
(Carom), 56.63 (NCH2Phen), 56.26 (OMe), 54.72, 54.10, 53.39, 53.12, 50.88, 49.88, 
47.92, 47.77 (CH2), 37.34 (SCH2Phen), 34.49, 34.34 (C(
t
Bu)), 31.37, 31.23 
(Me(
t
Bu)), 26.03, 23.43 (CH2CH2CH2); HRMS (ES-MS) expected for 
C35H57O1N4S1: 581.4248 found 581.4248. CHN not satisfactory. 
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7.4.31. Synthesis of 2,4-di-tert-butyl-6-(1,5,8,12-tetraaza-
bicyclo[10.2.2]hexadec-5-ylmethyl-benzenethiol (49) 
 
To 48 (0.40 g, 0.69 mmol) dissolved in MeOH (7 ml) was added Hg(OAc)2 (0.44 g, 
1.38 mmol). The solution was then heated to 60°C o/n before allowing to cool. The 
mixture was then concentrated under reduced pressure and the resulting white solid 
washed twice with pentane (2 x 10 ml). The solid was then redissolved in MeOH (10 
ml) and the solution purged with nitrogen for 10 min. H2S was then bubbled through 
the solution for 20 min before re-purging the solution with nitrogen again for 1 hr. 
The black HgS was then filtered off using a bed of celite, which was washed with 
degassed MeOH (20 ml). The filtrate was concentrated affording a dark yellow oil 
(0.31 g, 97%). This was used without any further purification for the immediate 
preparation of the metal complexes. HRMS (ES-MS) expected for C27H48N4H: 
429.3952 found 429.3944 (M-S
+
). CHN not collected to likelihood of oxidising 
thiolphenol group. 
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7.4.32. Synthesis of copper(II) 2,4-di-tert-butyl-6-(1,5,8,12-
tetraaza-bicyclo[10.2.2]hexadec-5-ylmethyl-benzenethiolate 
perchlorate ([Cu49]ClO4) 
 
To 49 (0.06 g, 0.13 mmol) dissolved in degassed MeOH (8 ml) under a nitrogen 
atmosphere was added NEt3 (50 μl) at RT with stirring. After 5 min, a solution of 
copper(II) perchlorate hexahydrate (0.05 g, 0.13 mmol) in degassed MeOH (3 ml) 
was added. This resulted in an instant violet colour forming in solution. The solution 
was then heated to reflux for 1.5 hr before allowing to cool. The solution was 
reduced in volume under reduced pressure before eluting down a Sephadex LH-20 
column with MeOH. The blue fraction was collected and concentrated under reduced 
pressure to give a blue powder (0.0563g, 70%); HRMS (ES-MS) expected for 
C27H47N4SCu: 522.2812, found 522.2815; ε (MeOH): 550 nm (185 mol
-1
dm
3
cm
-1
). 
CHN not collected due to risk of explosion. 
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7.4.33. Synthesis of nickel(II) 2,4-di-tert-butyl-6-(1,5,8,12-
tetraaza-bicyclo[10.2.2]hexadec-5-ylmethyl-benzenethiolate 
perchlorate ([Ni49]ClO4) 
 
To 49 (0.06 g, 0.13 mmol) dissolved in degassed MeOH (8 ml) under a nitrogen 
atmosphere was added NEt3 (50 μl) at RT with stirring. After 5 min, a solution of 
nickel(II) perchlorate hexahydrate (0.049 g, 0.13 mmol) in degassed MeOH (3 ml) 
was added. This resulted in an instant yellow colour forming in solution. The 
solution was then heated to reflux for 1.5 hr before allowing to cool. The solution 
was reduced in volume under reduced pressure before eluting down a Sephadex LH-
20 column with MeOH. The orange fraction was collected and concentrated under 
reduced pressure to give a orange powder (0.0765g, 94%); HRMS (ES-MS) 
expected for C27H47N4SNi: 517.2869, found 517.2859; ε (MeOH): 550 (91 mol
-1
 dm
3
 
cm
-1
). CHN not collected due to risk of explosion. 
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7.4.34. Synthesis of zinc(II) 2,4-di-tert-butyl-6-(1,5,8,12-
tetraaza-bicyclo[10.2.2]hexadec-5-ylmethyl-benzenethiolate 
perchlorate ([Zn49]ClO4) 
 
To 49 (0.06 g, 0.13 mmol) dissolved in degassed MeOH (8 ml) under a nitrogen 
atmosphere was added NEt3 (50 μl) at RT with stirring. After 5 min, zinc(II) 
perchlorate hexahydrate (0.047 g, 0.13 mmol) in degassed MeOH (3 ml) was added. 
This resulted in an instant yellow colour forming in solution. The solution was then 
heated to reflux for 1.5 hr before allowing to cool. The solution was reduced in 
volume under reduced pressure before eluting down a Sephadex LH-20 column, 
eluting with MeOH. The light yellow fraction was collected and concentrated under 
reduced pressure to give a white powder (0.0705g, 87%); 
1
H NMR [CD3CN] 7.43 (s, 
1H, ArH), 7.05 (s, 1H, ArH), 4.11 (s, 2H, NCH2Ph), 3.79-3.27 (m, 6H, CH2), 2.98-
2.04 (m, 13H, CH2 and NH), 1.94-1.54 (m, 6H, CH2), 1.29 (s, 9H, 
t
Bu), 1.24 (s, 9H, 
t
Bu); 
13
C NMR [CD3CN] δ 131.39, 130.86, 129.40, 128.48, 125.42, 124.96 (Carom), 
58.86 (CH2), 57.50 (NCH2Ph), 53.17, 52.42, 50.41, 48.77, 47.16, 45.51 (CH2), 
35.63, 35.42 (C(
t
Bu)), 31.75, 31.64 (Me(
t
Bu)), 25.30, 22.28 (CH2CH2CH2); HRMS 
(ES-MS) expected for C27H47N4SZn: 523.2807, found 523.2798. CHN not collected 
due to risk of explosion. 
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7.5.  Cyclen compounds and complexes 
7.5.1. Synthesis of 1,4,7,tris(tert-butoxycarboxymethyl)-
1,4,7,10-tetraazacyclododecane (DO3A-TB) 
 
Cyclen (3.07 g, 0.0178 mol) and NaHCO3 (4.49 g, 0.0535 mol) was dissolved in 
MeCN (900 ml) to which was added tert-butylbromoacetate (10.43 g, 0.0535 mol) in 
MeCN (300 ml) over 5 hours at RT with vigorous stirring. Stirring was then 
continued for a further 72 hr. The solution was then filtered and the filtrate 
concentrated under reduced pressure. The crude mixture was then purified via silica 
column chromatography using DCM rising to 2% MeOH in DCM. The fractions 
containing the desired product were combined and concentrated under reduced 
pressure. This gave DO3A-TB as a cream solid (5.22 g, 57%); Rf=0.2 (2% MeOH in 
DCM); 
1
H NMR [CDCl3] δ 3.29 (4H, NCH2COO
t
Bu) 3.20 (s, 2H, NCH2COO
t
Bu), 
3.01 (s, 4H, CH2NHCH2), 2.83 (m, 12H, NCH2CH2N); 
13
C NMR [CDCl3] δ 170.35, 
169.46 (COO
t
Bu), 81.63, 81.47 (C(
t
Bu)), 57.98, 51.15, 49.01, 47.33 (CH2), 28.05, 
28.01 (CH3(
t
Bu)); MS (ES-MS): m/z 515 (MH
+
). CHN not collected. 
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7.5.2. Synthesis of 2-((1,4,7,10-tetraazacyclodecane-1-
yl)methyl)-4,6-di-tert-butylphenyl acetate (50) 
 
Cyclen (5 g, 0.0289 mol) and NEt3 (0.88 g, 8.72 mmol) were dissolved in CHCl3 (80 
ml). To this solution was added 15 (2.48 g, 7.3 mmol). The yellow solution was 
heated to a gentle reflux for 16 hr. At this point, TLC analysis showed complete 
consumption of the starting material. The solution was then washed with 1M NaOH 
(4 x 100 ml) before the organic layer was collected and dried over MgSO4. The 
solution was then filtered and the filtrate concentrated under reduced pressure. The 
yellow oil obtained was then triturated with pentane (50 ml) affording a yellow solid 
(2.78 g, 89% based on starting moles of 15); 
1
H NMR [CDCl3] δ 7.40 (d, 1H, J=2.10 
Hz, ArH), 7.20 (d, 1H, J=2.10 Hz, ArH), 2.75-2.36 (m, 18H, CH2), 2.29 (s, 3H, 
OMe), 1.25 (s, 9H, 
t
Bu), 1.24 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] 169.63 (COAc), 
147.73, 145.45, 139.89, 131.52, 125.46, 123.03 (Carom), 54.14 (NCH2Ph), 47.04, 
46.44, 46.24, 45.10 (CH2), 34.74, 34.63 (C(
t
Bu)), 31.42, 30.51 (Me(
t
Bu)), 21.47 
(COOMe); MS (ES-MS): m/z= 433.3 (MH
+
). CHN not satisfactory. 
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7.5.3. Synthesis of tert-butyl 2,2’,2”-(10-(2-acetoxy-3,5-di-tert-
butylbenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetate (51) 
 
50 (0.5 g, 1.16 mmol) was dissolved in dry MeCN (20 ml) to which was added 
K2CO3 (1.60 g, 11.56 mmol). After stirring for 5 min, tert-butyl-bromo acetate (0.56 
g, 2.89 mmol) was added dropwise over 5 min with stirring. The solution was then 
stirred for a further 48 hrs before concentrating under reduced pressure. The residue 
was taken up into DCM (40 ml) and the remaining solids filtered off. The filtrate was 
reduced and the residue purified on activated alumina (eluent 5% MeOH in DCM). 
The fractions containing the desired product were combined and concentrated under 
reduced pressure to give a yellow oil (0.64 g, 71%); Rf=0.34 (5% MeOH in DCM); 
1
H NMR [CDCl3] δ 7.45 (d, 1H, J=2.58 Hz, ArH), 7.42 (d, 1H, J=2.58 Hz, ArH), 
3.59-3.13 (m, 8H, CH2), 2.95-2.48 (m, 16H, NCH2CH2N), 2.23 (s, 3H, OMe), 1.39 
(s, 9H, 
t
Bu), 1.38 (s, 18H, 
t
Bu), 1.37 (s, 9H, 
t
Bu), 1.34 (s, 9H, 
t
Bu); 
13
C NMR 
[CDCl3] δ 170.86, 170.55 (COO
t
Bu), 150.39, 145.48, 139.78, 137.94, 137.17, 
136.40 (Carom), 80.88, 80.79 (COOC(Me3)), 58.56, 57.10, 56.06, 55.54, 54.78, 54.25 
(NCH2CH2N), 34.84, 34.04 (C(
t
Bu)), 31.65, 31.44, 30.59, 29.63 (Me(
t
Bu)), 21.51 
(OMe); HRMS (ES-MS) expected for C43H75O8N4: 775.5579 found 775.5586. CHN 
not satisfactory. 
 303 
7.5.4. Synthesis of 2,2’,2”-(10-(2-acetoxy-3,5-di-tert-
butylbenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid (52) 
 
To 51 (0.64 g, 0.827 mmol) dissolved in MeOH (10 ml) was added 6M HCl (15 ml). 
The yellow/ orange solution was then heated to reflux for 24 hr. The solution was 
then allowed to cool before concentrating under reduced pressure. The residue was 
then triturated with acetone (3 x 10 ml) to afford a light orange solid (0.55 g, 94%); 
1
H NMR [D2O] 7.35 (br s, 2H, ArH), 3.78-3.02 (m, 24H, CH2); 
13
C NMR [D2O] 
173.69, 167.86 (COOH), 151.24, 146.10, 145.61, 140.37, 139.42, 126.87 (Carom), 
52.54 (NCH2Ph), 52.11, 48.28, 47.46 (CH2), 34.52, 34.25 (C(
t
Bu)), 31.03, 30.00 
(Me(
t
Bu)). CHN not collected. Mass spec obtained but no peaks discernable from 
spectrum. Peaks at 500 and 149. 
 304 
7.5.5. Synthesis of lanthanum(III) 2,2’,2”-(10-(2-acetoxy-3,5-di-
tert-butylbenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid triethylammonium ([La52][NHEt3]) 
 
To 52 (0.10 g, 0.141 mmol) dissolved in degassed MeOH (5 ml) was added NEt3 
(0.11 g, 1.13 mmol) and the solution was stirred at RT for 5 min. After this time 
lanthanum(III) trifluoromethanesulfonate hydrate (0.0823 g, 0.141 mmol) in MeOH 
(1 ml) was added and the solution was heated to reflux for 2 hr. Allowed to cool to 
RT before concentrating under reduced pressure to the minimal volume. The solution 
was then eluted down a Sephadex LH-20 column with MeOH. The orange band was 
collected and concentrated under reduced pressure. The oily residue was washed 
with ether (3 x 5 ml) to give a white solid (0.06 g, 76%); 
1
H NMR [D2O] 7.37-7.28 
(m, 2H, ArH), 3.84-3.08 (m, 24H, CH2); 
13
C NMR [D2O] 174.31, 166.98 (COOH), 
152.07, 147.38, 145.87, 141.67, 140.57, 131.67 (Carom), 53.01 (NCH2Ph), 54.56, 
49.69, 48.62, 48.59 (CH2), 34.73, 33.94 (C(
t
Bu)), 31.17, 30.48 (Me(
t
Bu)); HRMS 
(ES-MS) expected for C29H44O7N4La: 699.2279, found 699.2268. CHN not 
collected. 
 305 
7.5.6. Synthesis of europium(III) 2,2’,2”-(10-(2-acetoxy-3,5-di-
tert-butylbenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid triethylammonium ([Eu52][NHEt3]) 
 
To 52 (50 mg, 0.0705 mmol) dissolved in MeOH (5 ml) was added NEt3 (0.06 g, 0. 
564 mmol). The orange solution was stirred for 5 min before adding europium(III) 
trifluoromethane sulfonate hydrate (0.04 g, 0.0705 mmol). The solution was then 
heated to reflux for 2 hr before allowing to cool to RT and then concentrated under 
pressure. The oily residue was redissolved in the minimium amount of MeOH 
(~1ml) and eluted down a Sephadex LH-20 column with MeOH. The yellow fraction 
was collected and concentrated under reduced pressure. The oily residue was 
triturated with ether (3 x 5 ml) to afford a white solid (0.497g, 82%), HRMS (ES-
MS) expected for C29H44O7N4
151
Eu1: 711.2412, found 711.2422; Fluoresence 
(MeOH): 521 nm, 595 nm (
5
D0→
7
F1), 612 nm (
5
D0→
7
F2), 775 nm; UV-Vis 
(MeOH): 250-300 nm (π-π*); UV-Vis (MeOH) after oxidation with ferric cyanide: 
250-300 nm (π-π*), 380-440 nm (phenoxyl radical). CHN not collected. 
 306 
7.5.7. Synthesis of terbium(III) 2,2’,2”-(10-(2-acetoxy-3,5-di-
tert-butylbenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid triethylammonium ([Tb52][NHEt3]) 
 
To 52 (0.085 g, 0.141 mmol) dissolved in MeOH (5 ml) was added NEt3 (0.11 g, 
1.13 mmol) and the solution was stirred at RT for 5 min. After this time, terbium(III) 
trifluoromethanesulfonate hydrate (0.085 g, 0.141 mmol) in MeOH (1 ml) was added 
and the resulting solution was heated to reflux for 2 hr. The solution was allowed to 
cool to RT before concentrating under reduced pressure to the minimium volume. 
The solution was then eluted down a Sephadex LH-20 column with MeOH. The 
orange band was collected and concentrated under reduced pressure. The oily residue 
was washed with ether (3 x 5 ml) to give a white solid (0.07 g, 90%); HRMS (ES-
MS) expected for C29H44O7N4Tb: 719.2469 found 719.2455; Fluoresence (MeOH): 
490 nm (
5
D4→
7
F3), 545 nm (
5
D4→
7
F4), 587 nm (
5
D4→
7
F5), 623 nm
 
(
5
D4→
7
F6). 
CHN not collected. 
 307 
7.5.8. Synthesis of gadolinium(III) 2,2’,2”-(10-(2-acetoxy-3,5-di-
tert-butylbenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid triethylammonium ([Gd52][NHEt3]) 
 
To 52 (70 mg, 0.0985 mmol) in MeOH (10 ml) was added NEt3 (0.11 ml, 0.787 
mmol). The dark orange solution was allowed to stir for 5 min before the addition of 
gadolinium(III) nitrate hexahydrate (0.0454 g, 0.0985 mmol) in MeOH (1 ml). The 
solution was heated to reflux with stirring for 2 hr. The solution was allowed to cool 
before concentrating under reduced pressure. The oily residue was redissolvd in the 
minimium amount of MeOH (~1ml) and eluted down a Sephadex LH-20 column 
with MeOH. The yellow fraction was collected and concentrated under reduced 
pressure. The oily residue was triturated with ether (3 x 5ml) to give a white powder 
(0.0775 g, 96%); MS (MS-ES): m/z 718.3 ((M-[NHEt3])
+
). CHN not collected. 
 308 
7.5.9. Synthesis of 1-[3,5-di-tert-butyl-2-(4-methoxy-
benzylsulfanyl)-benzyl]-1,4,7,10-tetraaza-cyclodecane (53) 
 
To cyclen (0.80 g, 1.84 mmol) in CHCl3 (10 ml) was added a solution of 24 (1.26 g, 
7.35 mmol) and triethylamine (0.22 g, 2.20 mmol) in CHCl3 (40 ml). The resulting 
solution was then heated to a gentle reflux for 15 hrs before being allowed to cool to 
RT. The solution was then washed with 1 M NaOH(aq) (3 x 15 ml), followed by 
water (3 x 15 ml). The organic layer was collected and dried over MgSO4 before 
being concentrated under reduced pressure to give 53 as a viscous yellow oil (0.80 g, 
83%); 
1
H NMR [CDCl3] δ 7.51 (m, 2H, ArH), 7.08 (m, 2H, ArH), 6.71 (m, 2H, 
ArH), 3.67 (s, 2H, PhCH2N), 3.60 (s, 2H, SCH2), 3.48 (s, 3H, OCH3), 2.71 (s, 4H, 
HNCH2), 2.58 (s, 4H, NCH2), 2.47 (s, 8H, HNCH2), 1.47 (s, 9H, CH3(
t
Bu)), 1.24 (s, 
9H, CH3(
t
Bu)); 
13
C NMR [CDCl3] 158.49, 152.27, 150.07, 144.77, 138.19, 129.76, 
124.95, 122.49, 120.52, 113.58 (Carom), 54.89 (OCH3), 51.12, 46.86, 46.23 (HNCH2), 
44.81 (NCH2), 42.14 (SCH2), 34.43 (PhCH2N), 37.42, 34.41 (C(
t
Bu)), 31.23, 31.05 
(CH3(
t
Bu)). CHN not collected. 
 309 
7.5.10. Synthesis of tert-butyl 2,2’,2”-(10-(3,5-di-tert-butyl-
2-(4-methoxybenzylthio)benzyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (54) 
 
53 (0.80 g, 1.52 mmol) and potassium carbonate (2.10 g, 15.03 mmol) were 
dissolved in dry MeCN (30 ml). Tert-butyl bromo acetate was then added to this 
solution over a period of 5 min with stirring. The solution was then stirred at RT for 
a further 24 hr. The mixture was then concentrated under reduced pressure, 
redissolved in DCM and then filtered to remove any undissolved solids. The organic 
layer was concentrated under reduced pressure to give the crude material. The crude 
material was purified by column chromatography (silica 60, eluent DCM/ MeOH 
10/1 (v/v)). The fraction with an Rf=0.43 was collected, concentrated under reduced 
pressure and triturated with ether (3 x 10 ml) to give a pale yellow powder (0.70 g 
64%); Rf=0.43 (DCM/ MeOH 10/1 (v/v)); 
1
H NMR [CDCl3] δ 7.32 (d, 1H, J=2.11 
Hz, ArH), 7.24 (d, 1H, J=2.11 Hz, ArH), 6.98 (d, 2H, J=8.91 Hz, ArH), 6.72 (d, 2H, 
 310 
J=8.91 Hz, ArH), 5.24 (s, 2H, PhCH2N), 3.73-2.11 (m, 24H, CH2) 1.41 (s, 9H, 
CH3(
t
Bu)), 1.38 (s, 9H, CH3(
t
Bu)), 1.37 (s, 9H, CH3(
t
Bu)), 1.35 (s, 9H, CH3(
t
Bu)), 
1.25, (s, 9H, CH3(
t
Bu)); 
13
C NMR [CDCl3] δ 173.09, 172.60 (CO), 151.18, 142.73, 
136.02, 130.22, 129.96, 124.55, 123.32, 121.06, 113.95, 113.75 (Carom), 82.45, 82.25 
(COOC(Me)3), 55.16 (OCH3), 51.12, 50.97, 49.62 (HNCH2), 43.41 (NCH2), 37.60 
(SCH2), 34.72 (PhCH2N), 34.85, 31.34, (PhC(
t
Bu)), 27.98, 27.94, 27.92, 27.72, 
27.52 (CH3(
t
Bu)); HRMS (ES-MS) expected for C49H81O7N4S1 869.5820, found 
869.5818. CHN not collected. 
  
 311 
7.5.11. Synthesis of tert-butyl 2,2',2”-(10-(3,5-di-tert-butyl-
2-mercaptobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetate (55) 
 
To 54 (0.35 g, 0.40 mmol) dissolved in methanol (12 ml) was added mercury acetate 
(0.26 g, 0.80 mmol) under a nitrogen atmosphere. The resulting solution was stirred 
at 60°C for 6 hr and then concentrated under reduced pressure. The residue was then 
washed with n-pentane (2 x 10 ml) and concentrated under reduced pressure to yield 
a yellow oil. To this oil was added methanol (12 ml) and the resulting mixture 
degassed for 5 min. H2S was then bubbled through the solution for 20 mins before 
purging the solution with nitrogen for 25 min. The solution was then filtered through 
celite and the filtrate concentrated under reduced pressure to yield a yellow oil (0.30 
g, 100%); 
1
H NMR [CDCl3] δ 7.42 (d, 1H, J=1.88 Hz, ArH), 7.31 (d, 1H, J=1.88 Hz 
ArH), 4.50 (s, 1H, SH), 3.74-2.56 (m, 24H, CH2), 1.44 (s, 9H, CH3(
t
Bu)), 1.38 (s, 
9H, CH3(
t
Bu)), 1.36 (s, 9H, CH3(
t
Bu)), 1.27 (s, 9H, CH3(
t
Bu)), 1.25 (s, 9H, 
CH3(
t
Bu)); 
13
C NMR [CDCl3] δ 169.72, 169.64 (CO), 151.95, 151.83, 130.16, 
129.34, 125.85, 124.01 (Carom), 83.85, 81.94, 77.32 (COOC(Me)3), 56.15, 54.37, 
52.08, 51.02 (NCH2), 34.91, 31.48 (PhC(
t
Bu)), 31.41, 28.17, 28.06 (CH3(
t
Bu)). CHN 
not collected due to oxidisable thiophenol. 
 312 
7.5.12. Synthesis of 2,2’,2”-(10-(3,5-di-tert-butyl-2-
mercaptobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid (56) 
 
To 55 (0.30 g, 0.40 mmol) in methanol (12 ml) was added 6M HCl (15 ml). The 
resulting solution was heated to 95°C with stirring for 18 hr, before allowing to cool. 
The resulting solution was then concentrated, and the residue washed with acetone (3 
x 25 ml) to afford a white solid (0.29 g, 100%); 
1
H NMR [CDCl3] δ 7.45-7.40 (m, 
2H, ArH), 3.68-2.86 (m, 24H, CH2), 1.12 (br s, 18H, CH3(
t
Bu)); 
13
C NMR [CDCl3] 
173.19, 168.73 (CO), 158.19, 153.32, 138.00, 128.92, 125.75, 124.93 (Carom) 52.98, 
49.22, 48.51, 48.11 (NCH2), 34.24, 33.98 (C(
t
Bu)), 31.60, 30.57 (CH3(
t
Bu)). CHN 
not collected due to oxidisable thiophenol. 
 313 
7.5.13. Synthesis of lanthanum(III) 2,2’,2”-(10-(3,5-di-tert-
butyl-2-mercaptobenzyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid ammonium ([La56][NHEt3]) 
 
To 56 (0.07 g, 96 μmol) dissolved in degassed MeOH (5 ml) was added NEt3 (0.1 
ml, 0.77 mmol) and the solution was stirred at RT for 5 min. After this time 
lanthanum(III) trifluoromethanesulfonate hydrate (0.0564 g, 96 μmol) in MeOH (1 
ml) was added and the resulting solution was heated to reflux for 2 hr. It was allowed 
to cool to RT before concentrating under reduced pressure. The concentrated 
solution was then eluted down a Sephadex LH-20 column with MeOH. The orange 
band was collected and concentrated under reduced pressure. The oily residue was 
washed with ether (3 x 5 ml) to give a white solid (0.06 g, 76%); 
1
H NMR [CDCl3] δ 
7.44-7.39 (m, 2H, ArH), 3.67 (s, 2H, PhCH2N), 3.49-2.77 (m, 22H, CH2), 1.24 (s, 
9H, CH3(
t
Bu)), 1.16 (s, 9H, CH3(
t
Bu)); 
13
C NMR [CDCl3] 174.42, 169.32 (CO), 
157.65, 154.44, 141.53, 139.81, 126.67, 124.87 (Carom) 53.09, 50.65, 48.97, 48.19 
(NCH2), 35.57, 34.08 (C(
t
Bu)), 31.54, 31.12 (CH3(
t
Bu)); MS (MS-ES): m/z 715.2 
((M-[NHEt3])
+
). CHN not collected due to oxidisable thiophenol. 
 314 
7.5.14. Synthesis of europium(III) 2,2’,2”-(10-(3,5-di-tert-
butyl-2-mercaptobenzyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid ammonium ([Eu56][NHEt3]) 
 
To 56 (0.0413 g, 57 μmol) in degassed methanol (5 ml) was added europium(III) 
trifluoromethanesulfonate (0.0379 g, 63 μmol) in MeOH (1 ml) with stirring. To this 
mixture was added triethylamine (0.0489 g, 0.48 mmol) dropwise over 5 min. The 
resulting solution was then heated to 80°C for 2 hr. The resulting solution was then 
concentrated under reduced pressure before re-dissolving in the minimal amount of 
degassed MeOH. This solution was then eluted down a Sephadex LH-20 column. 
The yellow fraction was collected and concentrated under reduced pressure. The oily 
product was then triturated with ether (3 x 5 ml) to afford a brown powder (0.0471g, 
100%); MS (ES-MS): m/z 729.1 ((M-[NHEt3])
+
); Fluoresence (MeOH): 573 nm 
(
5
D0→
7
F0), 619 nm (
5
D0→
7
F2), 714 nm. CHN not collected due to oxidisable 
thiophenol. 
 315 
7.5.15. Synthesis of terbium(III) 2,2’,2”-(10-(3,5-di-tert-
butyl-2-mercaptobenzyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid ammonium ([Tb56][NHEt3]) 
 
To 56 (0.07 g, 96 μmol) dissolved in degassed MeOH (5 ml) was added NEt3 (0.1 
ml, 0.77 mmol) and the solution was stirred at RT for 5 min. After this time 
terbium(III) trifluoromethanesulfonate hydrate (0.0584, 96 μmol) in degassed MeOH 
(1 ml) was added and the resulting solution was heated to reflux for 2 hr. Allowed to 
cool to RT before concentrating under reduced pressure to the minimal volume. The 
solution was then eluted down a Sephadex LH-20 column with MeOH. The orange 
band was collected and concentrated under reduced pressure. The oily residue was 
washed with ether (3 x 5 ml) to give a white solid (0.07 g, 90%); MS (MS-ES): m/z 
735.2 ((M-[NHEt3])
+
); Fluoresence (MeOH): 498 nm (
5
D4→
7
F3), 543 nm 
(
5
D4→
7
F4), 585 nm (
5
D4→
7
F5), 617 nm
 
(
5
D4→
7
F6). CHN not collected due to 
oxidisable thiophenol. 
 316 
7.5.16. Synthesis of gadolinium(III) 2,2’,2”-(10-(3,5-di-tert-
butyl-2-mercaptobenzyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid ammonium ([Gd56][NHEt3]) 
 
To 56 in degassed methanol was added gadolinium(III) nitrate hexahydrate (0.0372 
g, 0.0825 mmol) with stirring. To this mixture was added triethylamine (0.1 ml, 0.77 
mmol) dropwise over 5 min. The resulting solution was then heated to 80°C for 2 hr. 
The resulting solution was then concentrated under reduced pressure before re-
dissolving in the minimal amount of degassed MeOH. This solution was then eluted 
down a Sephadex LH-20 column with MeOH. The yellow fraction was collected and 
concentrated under reduced pressure. The oily product obtained was triturated with 
ether (3 x 5 ml) to afford a cream powder (0.0602 g, 87%); MS (MS-ES): m/z 734.2 
((M-[NHEt3])
+
). CHN not collected due to oxidisable thiophenol. 
 317 
7.5.17. Synthesis of 1-benzyl 3-tert-butyl 2-((1,4,7,10-
tetraazacyclododecane-1-yl)methyl)malonate (57) 
 
Cyclen (1 g, 5.80 mmol) was dissolved in CHCl3 (100 ml) to which was added 27 
(1.99 g, 5.80 mmol) in CHCl3 (40 ml) with stirring over 20 hr using a syringe pump 
set to deliver 2 ml/ hr. Stirring continued for a further 24 hr before the reaction 
mixture was concentrated under reduced pressure. The crude product was purified by 
silica gel chromatography (eluent EtOH/ NH3 (95/5)). The fractions containing the 
desired product were combined and concentrated under reduced pressure to afford a 
colourless oil (0.81 g, 32%); Rf=0.2 (EtOH/NH3 (95/5));
 1
H NMR [CDCl3] δ 7.13-
7.04 (m, 5H, Ph), 4.93 (s, 2H, CH2Ph), 3.63-3.57 (m, 2H, NCH2CH), 3.23-3.21 (m, 
1H, CH), 2.60-2.44 (m, 19H, NCH2CH2N and NH), 1.21 (s, 9H, 
t
Bu); 
13
C NMR 
[CDCl3] 172.17, 168.66 (COO
t
Bu), 137.66, 131.06, 123.72, 123.23 (Carom), 77.06 
(C(Me)3), 61.68 (NCHCOO
t
Bu), 60.99 (COOCH2Ph), 56.24, 44.09, 42.89, 40.75 
(CH2),30.31 (CHCH2COOBn), 23.41 (Me(
t
Bu)); HRMS (ES-MS) expected for 
C23H39O4N4: 435.2966 found 435.2962. CHN not satisfactory. 
 318 
7.5.18. Synthesis of 1-benzyl 3-tert-butyl 2-((4,7,10-tris(2-
tert-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1-
yl)methyl)malonate (58) 
 
To DO3A-TB (0.82 g, 1.6 mmol) and potassium carbonate (1.21 g, 8.75 mmol) in 
MeCN (100 ml) was added 27 (0.50 g, 1.46 mmol) dropwise over 5 min. The 
solution was then heated to 65°C for 5 hr before allowing to cool. The solution was 
then concentrated and re-dissolved in DCM (40 ml) before filtering off any insoluble 
solids. The filtrate was again concentrated in vacuo before purifying using a short 
silica plug (eluent DCM/MeOH 97/3). The fractions containing the desired product 
were combined and concentrated under reduced pressure to afford a golden yellow 
oil (0.86 g, 76%); Rf=0.19 (hexane/EtOAc 20/1); Rf=0.54 (DCM/MeOH 95/5); 
1
H 
NMR [CDCl3] δ 7.31-7.21 (m, 5H, Ph), 5.22 (s, 2H, COOCH2Ph), 4.09-4.06 (m, 1H 
NCHCOOtBu), 3.35-3.08 (m, 8H, CH2), 2.78-2.02 (m, 16H, CH2), 1.41 (s, 9H, 
t
Bu), 
1.40 (s, 27H, 
t
Bu); 
13
C NMR [CDCl3] 172.69, 172.17, 168.66 (CO), 141.37, 135.16, 
128.27, 126.65 (Carom), 82.48, 81.44 (COO
t
Bu), 68.14 (NCHCOO
t
Bu), 66.46 
(COOCH2Ph), 58.43, 55.46, 53.24, 52.19 (CH2), 47.37 (CH2), 44.53 
(NCHCH2COOBn), 29.30, 28.79 (C(
t
Bu)), 27.73, 27.56 (Me(
t
Bu)); HRMS (ES-MS) 
expected for C41H66N4O10H: 775.4852 found 775.4851. CHN not satisfactory. 
 319 
7.5.19. Synthesis of 2-(4,7,10-tris-tert-butoxycarbonyl-
1,4,7,10-tetraaza-cyclododec-1-yl)-succinic acid 1-tert-butyl 
ester (59) 
 
58 (0.28 g, 0.361 mmol) in MeOH (40 ml) was added 10% Pd/C (0.02 g) in H2O (1 
ml). The solution was transferred to a Parr shaker bottle where it was shaken under a 
hydrogen atmosphere at 25 psi for 1 d. The solution was filtered through celite, 
washing with MeOH (20 ml). The filtrate was collected and concentrated under 
reduced pressure. The oily residue was triturated with pentane (3 x 10 ml) to afford a 
white solid (0.14 g, 57%); 
1
H NMR [CDCl3] δ 3.38-2.10 (m, 25H), 1.38 (s, 21H, 
t
Bu), 1.35 (s, 9H, 
t
Bu); 
13
C NMR [CDCl3] δ 168.40, 166.20, 165.48 (COO
t
Bu), 
77.44, 75.19 (C(
t
Bu)), 53.29 (NCHCO2
t
Bu), 51.16, 48.07, 46.86, 46.70, 44.92, 44.03 
(CH2), 42.54 (NCHCH2COOH), 23.67, 23.38 (Me(
t
Bu)); HRMS (ES-MS) for 
C34H58N4O8H: 651.4327 found 651.4321 ((M-2H2O+H)
+
). CHN not satisfactory. 
 320 
7.5.20. 4-(1,5,8,12-tetraaza-bicyclo[10.2.2]hexadec-5-
ylmethyl)-phenylamine (60) 
 
Compound 60 was supplied by Graeme McRobbie, The University of Hull.
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 321 
7.6. Porphyrin derivative synthesis 
7.6.1. Synthesis of 5,10,15,20-tetrakis(3,5-dimethoxy-phenyl)-
porphyrin (61) 
 
3,5-Dimethoxybenzaldehyde (2.5 g, 0.025 mol) and propionic acid (50 ml) were 
heated to reflux. To this solution was added pyrrole (1.01 g, 0.015 mol) over 5 min, 
which caused a colour change in the reaction mixture from light yellow to dark 
purple. The solution was allowed to reflux for a further 30 min before cooling to RT. 
The resulting black tarry solution was then filtered and a purple solid was collected. 
The solid was washed with methanol (25 ml) and hot water (60 ml). The compound 
was then dissolved in CHCl3 (10 ml) and eluted down a basic alumina column. The 
fraction containing 61 was collected and concentrated under reduced pressure to 
afford a purple solid (0.60 g, 19%); Rf=0.50 (50% hexane in ethyl acetate), Rf=0.29 
(DCM); 
1
H NMR [CDCl3] 8.93 (s, 8H, βH), 7.41 (d, 8H, J=2.18 Hz, ArH), 6.91 (t, 
4 H, J=2.18 Hz, ArH), 3.96 (s, 24H, OMe), −2.84 (s, 2H, NH); 13C NMR [CDCl3] 
158.84, 144.01, 131.01, 113.83, 100.16 (Carom), 55.63 (OMe); MS (MALDI): m/z 
855 (MH
+
); UV-Vis (DCM): 419 nm, 514 nm, 549 nm, 588 nm, 645 nm. CHN not 
collected. 
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Figure 90: ORTEP representation of the X-ray structure of 61 with all atoms 
labelled. 
  
 323 
Table 20: Crystal data for the structural refinement of 61. 
Identification code  sja35_06 
Empirical formula  C26 H26 N2 O7 
Formula weight  478.49 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.2795(17) Å        = 109.310(11)°. 
 b = 11.3173(17) Å        = 100.963(12)°. 
 c = 11.8705(17) Å         = 110.976(11)°. 
Volume 1250.8(3) Å3 
Z 2 
Density (calculated) 1.203 Mg/m3 
Absorption coefficient 0.085 mm-1 
F(000) 477 
Crystal size 1.00 x 0.52 x 0.17 mm3 
Theta range for data collection 2.79 to 34.80°. 
Index ranges -18<=h<=18, -18<=k<=17, -19<=l<=18 
Reflections collected 29275 
Independent reflections 10670 [R(int) = 0.0773] 
Completeness to theta = 34.80° 98.4 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10670 / 0 / 312 
Goodness-of-fit on F2 1.745 
Final R indices [I>2sigma(I)] R1 = 0.1519, wR2 = 0.4313 
R indices (all data) R1 = 0.1923, wR2 = 0.4723 
Extinction coefficient 0.21(4) 
Largest diff. peak and hole 3.016 and -0.659 e.Å-3 
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7.6.2. Synthesis of gallium(III) 5,10,15,20-tetrakis(3,5-
dimethoxy-phenyl)-porphyrin chloride ([Ga61]Cl) 
 
61 (0.35 g, 0.41 mmol), GaCl3 (108 mg, 0.62 mmol) and sodium acetate (200mg, 
2.44 mol) were mixed and placed under a nitrogen atmosphere. To this was added 
dry acetic acid (40 ml) and the resulting solution heated to reflux for 24 hr. The 
solution was then concentrated in vacuo and redissolved in toluene (10 ml). This 
solution was placed in a freezer for 14 hr which resulted in crystallization of the 
product. Crystals were collected by filtration to give [Ga61]Cl as purple crystals 
(0.32 g, 81%); 
1
H NMR [CDCl3] δ 9.18 (s, 8H, βH), 7.47 (s, 4H, ArH), 7.31 (s, 4H, 
ArH), 6.91 (t, 4H, J=2.1 Hz, Ar), 3.95 (s, 24H, OMe); 
13
C NMR [CDCl3]  158.84, 
148.87, 143.25, 132.07, 120.23, 113.33, 100.62 (Carom), 55.75 (OMe); MS (MALDI): 
m/z 921 (M-Cl
+
); UV-Vis (DCM): 419 nm, 513 nm, 550 nm, 587 nm, 645 nm. CHN 
not collected. 
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Figure 91: ORTEP representation of the X-ray crystal structure of [Ga61]Cl 
with all non-H atoms labelled. 
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Table 21: Crystal data for the structural refinement of [Ga61]Cl. 
Identification code  sja45_06 
Empirical formula  C52 H46 Cl Ga N4 O8.20 
Formula weight  963.27 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 17.2983(11) Å          = 90°. 
 b = 13.7726(7) Å            = 128.990(4)°. 
 c = 25.3585(17) Å            = 90°. 
Volume 4695.8(5) Å3 
Z 4 
Density (calculated) 1.381 Mg/m3 
Absorption coefficient 0.705 mm-1 
F(000) 2024 
Crystal size 0.24 x 0.22 x 0.18 mm3 
Theta range for data collection 2.74 to 34.95°. 
Index ranges -26<=h<=26, -22<=k<=18, -40<=l<=40 
Reflections collected 57592 
Independent reflections 19072 [R(int) = 0.0697] 
Completeness to theta = 34.95° 92.6 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 19072 / 2 / 618 
Goodness-of-fit on F2 0.857 
Final R indices [I>2sigma(I)] R1 = 0.0536, wR2 = 0.1332 
R indices (all data) R1 = 0.1080, wR2 = 0.1518 
Extinction coefficient 0.00032(19) 
Largest diff. peak and hole 0.786 and -1.844 e.Å-3 
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7.6.3. Synthesis of 5,10,15,20-tetrakis(3,5-dihydroxy-phenyl)-
porphyrin (62) 
 
To 61 (0.76g, 0.88 mmol) in DCM (150 ml) was added BBr3 (1 M solution in 
hexane, 20 ml). The solution was stirred for 20 hr at RT before adding further BBr3 
(1 M solution in hexane, 20 ml). After stirring the solution for a further 72 hours, 
saturated NaHCO3(aq) (200 ml) was added slowly and the DCM layer separated. This 
solution was dried over MgSO4 to give 62 as a purple solid (0.65 g, 84%); 
1
H NMR 
[CDCl3] δ 8.88 (s, 16H, βH and OH), 7.80 (m, 4H, Ar), 6.63 (m, 8H, Ar), −2.63 (s, 
2H, NH); MS (MALDI): m/z 743 (M
+
); HRMS (ES-MS) calculated for C44H30N4O8 
743.2136, found 743.2132; UV-Vis (MeOH): 418 nm, 513 nm, 547 nm, 587 nm, 645 
nm; UV-Vis (H2O): 417 nm, 522 nm, 558 nm, 581 nm, 636 nm. CHN not collected. 
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7.6.4. Synthesis of gallium(III) 5,10,15,20-tetrakis(3,5-
dihydroxy-phenyl)-porphyrin chloride (Ga62Cl) 
 
To [Ga61]Cl (100 mg, 0.1 mmol) dissolved in DCM (80 ml) was added BBr3 (6 ml, 
1 M in hexanes). The resulting green solution was stirred at RT for 72 hr before 
adding saturated NaHCO3(aq) (100 ml). The DCM layer was extracted, dried over 
MgSO4, concentrated in vacuo to give the product as a deep purple solid (0.1g, 
100%); 
1
H NMR δ [CDCl3] 9.1 (s, 8H, βH), 8.93 (br s, 8H, OH), 6.91 (m, 8H, ArH), 
6.50 (m, 4H, ArH); MS (MALDI): m/z 810 (M-Cl
+
); UV-Vis (MeOH): 418 nm, 515 
nm, 546 nm, 588 nm, 646 nm. CHN not collected. 
  
 329 
7.6.5. Synthesis of tetra(pentafluorophenyl) porphyrin (63) 
 
Pentafluorobenzaldehyde (5.32 g, 0.02713 mol) was dissolved in propionic acid and 
the resulting solution heated to reflux. Pyrrole (1.82 g, 0.02713 mol) was then added 
over 5 min. Heating at reflux was continued for 6 hr before cooling and 
concentrating under reduced pressure. The black solid that remained was then 
adsorbed onto Hyflo and transferred to a short silica plug. The chlorin and porphyrin 
bands were then eluted with petroleum ether and hexane (5:8 respectively) leaving 
the polymeric products behind. The chlorin and porphyrin bands were combined and 
concentrated in vacuo to give the crude product (1.67 g). The crude product was then 
dissolved in CHCl3 (100 ml) to which was added zinc acetate (3.76 g, 0.0171 mol) in 
methanol (20 ml) and left to stir for 14 hr. The reaction mixture was concentrated in 
vacuo and purified by column chromatography (DCM/hexane (1:1) raising to DCM 
(100%)). The red fraction was collected and dissolved in concentrated HCl (10 ml) 
and the solution was stirred for an hour. The solution was then diluted with water 
(100 ml) and the organic layer separated. The organic layer was then repeatedly 
washed with water until the aqueous layer was neutral. The organic layer was then 
dried over MgSO4 and concentrated in vacuo to give 63 as a purple solid (0.25g, 
4%); 
1
H NMR [CDCl3] δ 8.92 (s, 8H, βH), −2.93 (s, 2H, NH); 
19
F NMR [CDCl3] δ 
−161.19 (m, 2 F, m-F), −151.09 (t, 1F, J=20.8 Hz, p-F), −136.39 (dd, 2F, J= 6.9, 23.1 
Hz, o-F); MS (MALDI): m/z 975 (M
+
); ε (DMF): 410 nm (345680 mol-1dm3cm-1), 
504 nm nm (22922 mol
-1
dm
3
cm
-1
), 533 nm (1946 mol
-1
dm
3
cm
-1
), 580 nm (6956 mol
-
1
dm
3
cm
-1
), 655 nm (225 mol
-1
dm
3
cm
-1
). CHN not collected. 
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7.6.6. Synthesis of zinc(II) tetra(pentafluorophenyl) porphyrin 
([Zn63]) 
 
Method 1 
Pentafluorobenzaldehyde (5.32 g, 0.02713 mol) was dissolved in propionic acid and 
the resulting solution heated to reflux. Pyrrole (1.82 g, 0.02713 mol) was then added 
over 5 min. Heating at reflux was continued for 6 hr before cooling and 
concentrating under reduced pressure. The black solid that remained was then 
adsorbed onto Hyflo and transferred to a short silica plug. The chlorin and porphyrin 
bands were then eluted with petroleum ether and hexane (5:8 respectively) leaving 
the polymeric products behind. The chlorin and porphyrin bands were combined and 
concentrated in vacuo to give the crude product (1.67 g). The crude product was then 
dissolved in CHCl3 (100 ml) to which was added zinc acetate (3.76 g, 0.0171 mol) in 
methanol (20 ml) and left to stir for 14 hr. The reaction mixture was concentrated in 
vacuo and purified by column chromatography (DCM/hexane (1:1) raising to DCM 
(100%)) to give 34 as a red solid (0.8 g, 11%); 
1
H NMR [CDCl3] δ 8.99 (s, 8H, βH); 
19
F NMR [CDCl3] δ −161.61 (m, 2F, m-F), −151.82 (t, 1F, J=24.2 Hz, p-F), −136.69 
(dd, 2F, J=16.2, 39.0 Hz, o-F); MS (MALDI): m/z 1038 (M
+
); ε (DMF): 419 nm 
(514063 mol
-1
dm
3
cm
-1
), 551 nm nm (24431 mol
-1
dm
3
cm
-1
), 626 nm (3690 mol
-
1
dm
3
cm
-1
). CHN not collected. 
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Method 2 
63 (0.1 g, 0.1 mmol) was dissolved in DCM (10 ml) and heated to reflux. A solution 
of zinc(II) acetate (230 mg, 0.00125 mol) was then added dropwise over 30 min. The 
solution was heated at reflux for a further 4 hr before allowing to cool. Analysis by 
TLC showed complete consumption of the starting material. The solution was then 
concentrated in vacuo and redissolved in DCM (10 ml). The solution was filtered 
and the filtrate collected. Evaporation of the filtrate under reduced pressure gave a 
purple crystalline material (0.0980 g, 92%); Rf=0.7 (1/1 hexane/DCM v/v); 
1
H NMR 
[CDCl3] δ 8.99 (s, 8H, βH); 
19
F NMR [CDCl3] δ −161.61 (m, 2F, m-F), −151.82 (t, 
1F, J=24.2 Hz, p-F), −136.69 (dd, 2F, J=16.2, 39.0 Hz, o-F); MS (MALDI): m/z 
1038 (M
+
); ε (DMF): 419 nm (514063 mol-1dm3cm-1), 551 nm nm (24431 mol-
1
dm
3
cm
-1
), 626 nm (3690 mol
-1
dm
3
cm
-1
). CHN not collected. 
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7.6.7. Synthesis of Gallium tetra-pentafluorophenyl-poprhyrin 
phenoxide or chloride ([Ga63]X, where X=OPh or Cl) 
 
Method 1 (X= Cl) 
63 (0.15 g, 0.15 mmol), sodium acetate (0.08 g, 0.98 mmol) and GaCl3 (0.04 g, 0.21 
mmol) were mixed and placed under a nitrogen atmosphere to which was added dry 
acetic acid (25 ml) and the resulting purple solution then heated to reflux for 12 hr. 
After this time the solution was allowed to cool before removing the solvent in 
vacuo. The product was then purified by silica gel column chromatography (eluting 
with 5% ethyl acetate in hexane). The fractions were combined and concentrated in 
vacuo to give [Ga63]Cl as red needles (10 mg, 6%); 
1
H NMR [CDCl3] δ 8.95 (s, 8H, 
βH); MS (MALDI): m/z 1042 ((M-Cl)+); ε (DMF): 417 nm (595063 mol-1dm3cm-1), 
485 nm nm (3416 mol
-1
dm
3
cm
-1
), 549 nm (26949 mol
-1
dm
3
cm
-1
). CHN not 
collected. 
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Figure 92: ORTEP representation of the X-ray crystal structure [Ga63]NC4H4 
with all non-H atoms labelled. 
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Table 22: Crystal data for the structural refinement of [Ga63]NC4H4. 
Identification code  rem_02 
Empirical formula  C96 H16 F40 Ga4 N10 
Formula weight  2208.63 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 15.349(3) Å            = 90°. 
 b = 25.690(4) Å            = 102.074(15)°. 
 c = 12.609(2) Å              = 90°. 
Volume 4861.9(14) Å3 
Z 2 
Density (calculated) 1.749 Mg/m3 
Absorption coefficient 0.702 mm-1 
F(000) 2548 
Crystal size 0.20 x 0.15 x 0.10 mm3 
Theta range for data collection 2.71 to 34.93°. 
Index ranges -24<=h<=24, -40<=k<=40, -19<=l<=20 
Reflections collected 33475 
Independent reflections 10326 [R(int) = 0.3511] 
Completeness to theta = 34.93° 96.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10326 / 0 / 353 
Goodness-of-fit on F2 0.694 
Final R indices [I>2sigma(I)] R1 = 0.1051, wR2 = 0.2432 
R indices (all data) R1 = 0.3553, wR2 = 0.3249 
Extinction coefficient 0.0037(4) 
Largest diff. peak and hole 1.999 and -0.849 e.Å-3 
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Method 2 (X=OPh) 
63 (20 mg, 0.02 mmol), Ga(acac)3 (10 mg, 0.03 mmol) and phenol (0.75 g) were 
heated to 220
o
C for 30 min before allowing to cool to RT. The crude product was 
then dissolved in benzene and eluted down a short silica column. The red fraction 
was collected and concentrated in vacuo to give [Ga63]OPh as a violet powder (21 
mg, 92%); 
1
H NMR [CDCl3] δ 9.12 (s, 8H, βH), 5.75-5.62 (m, 2H, OPh), 1.81-1.84 
(m, 3H, OPh); MS (MALDI): m/z 1042 ((M-OPh)
+
); ε (DMF): 418 nm (33805 mol-
1
dm
3
cm
-1
), 485 nm nm (178 mol
-1
dm
3
cm
-1
), 550 nm (895 mol
-1
dm
3
cm
-1
). CHN not 
collected. 
 
Figure 93: ORTEP representation of the X-ray crystal structure of [Ga63]OPh 
with all non-H atoms labelled. 
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Table 23: Crystal data for the structural refinement of [Ga63]OPh. 
Identification code  sja21_08 
Empirical formula  C56 H17 F20 Ga2 N4 O2 
Formula weight  1297.18 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.4379(13) Å            = 81.408(13)°. 
 b = 14.743(2) Å              = 78.497(13)°. 
 c = 20.582(3) Å               = 75.383(12)°. 
Volume 2414.5(6) Å3 
Z 2 
Density (calculated) 1.240 Mg/m3 
Absorption coefficient 0.405 mm-1 
F(000) 884 
Crystal size 0.31 x 0.25 x 0.16 mm3 
Theta range for data collection 2.87 to 34.80°. 
Index ranges -13<=h<=13, -23<=k<=23, -33<=l<=29 
Reflections collected 63466 
Independent reflections 20737 [R(int) = 0.1905] 
Completeness to theta = 34.80° 99.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 20737 / 0 / 758 
Goodness-of-fit on F2 0.936 
Final R indices [I>2sigma(I)] R1 = 0.1603, wR2 = 0.4049 
R indices (all data) R1 = 0.3470, wR2 = 0.4577 
Extinction coefficient 0.048(4) 
Largest diff. peak and hole 1.556 and -2.641 e.Å-3 
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7.6.8. Synthesis of nickel(II) tetra(pentafluorophenyl) 
porphyrin [Ni63] 
 
63 (0.08 g, 0.082 mmol) was dissolved in acetic acid (10 ml) to which was added 
nickel(II) acetate.4H2O (0.02 g, 0.082 mmol). The solution was then heated to reflux 
for 24 hr. Analysis by TLC showed complete consumption of the starting material. 
The solution was then concentrated in vacuo to give a purple crystalline material 
(0.08 g, 95%); Rf=0.7 (1/1 hexane/DCM (v/v)); 
1
H NMR [CDCl3] δ 8.72 (s, 8H, 
βH); 19F NMR [CDCl3] δ −161.07 (m, 2F, m-F), −151.19 (t, 1F, J=20.7 Hz, p-F), 
−136.54 (dd, 2F, J= 6.9, 23.1 Hz, o-F); MS (MALDI): m/z 1028 (M+); UV-Vis 
(DCM): 405 nm, 520 nm, 557 nm. CHN not collected. 
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7.6.9. Synthesis of 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-4-{2-
[2-(2-methoxy-ethoxy)-ethoxy]-ethylsulfanyl}-phenyl)-
porphyrin (64) 
 
To 63 (200 mg, 0.21 mmol), 31 (0.37 g, 2.1 mmol) and Na2S (0.16 g, 2.1 mmol) was 
added DMF (5 ml). The reaction mixture was stirred for 3 days after which, the 
reaction was judged complete by TLC (absence of starting material). The reaction 
mixture was then concentrated under reduced pressure before re-dissolving in 50/50 
DCM/hexane (50 ml). This solution was then washed with a saturated brine solution 
from which the organic layer was collected and dried over MgSO4. The purple 
solution was concentrated in vacuo and the oily residue was washed repeatedly with 
hexane under the washings were clear to give the title product as a purple oil (240 
mg, 75%); 
1
H NMR [CDCl3] δ 8.92 (s, 8H, βH), 3.85-3.27 (m, 60H, PEG), −2.97 (s, 
2H, NH); 
19
F NMR [CDCl3] δ −133.64 (s, 2F, o-F), −137.03 (s, 2F, m-F); MS 
(MALDI): m/z= 1615.518 (M
+
); ε (DMF): 401 nm (264000 mol-1dm3cm-1), 505 nm, 
532 nm, 580 nm, 650 nm. CHN not collected. 
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7.6.10. Synthesis of tetraPEGylated 63 with PEG chains of 
an average weight of 550 (65) 
 
63 (20 mg, 0.021 mmol) and 29 (0.13g, 0.21 mmol) were dissolved in DMF (5 ml). 
Na2S (18 mg, 0.21 mmol) was then added and solution stirred at RT for 72 hr. 
Saturated NaHCO3(aq) (10 ml) was then added and the precipitate that formed was 
removed by filtration. The filtrate was then concentrated under reduced pressure and 
the isolated violet oil was then washed repeatedly with hexane until the washings 
were clear. This gave 65 as a purple solid (0.06 g, 100%): 
1
H NMR [CDCl3] δ 8.85 
(s, 8H, βH), 3.73 (t, xH, J=6.32 Hz), 3.68-3.34 (m, xH, PEG chain), −2.13 (br s, 2H, 
NH); UV-Vis (DMF): 417 nm, 505 nm, 535 nm, 580 nm, 634 nm. CHN not 
collected. 
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7.6.11. Synthesis of PEGylated 63 with PEG chains of an 
average weight of 750 (66) 
 
63 (20 mg, 0.021 mmol) and 30 (0.13g, 0.21 mmol) were dissolved in DMF (5 ml). 
Na2S (18 mg, 0.21 mmol) was then added and solution stirred at RT for 72 hr. 
Saturated NaHCO3(aq) (10 ml) was then added and the precipitate that formed was 
removed by filtration. The filtrate was then concentrated under reduced pressure and 
the isolated violet oil was then washed repeatedly with hexane until the washings 
were clear. This gave 66 as a purple solid (110 mg, 87%): 
1
H NMR [CDCl3] δ 8.89 
(s, 8 H, βH), 3.75 (t, J=6.32 Hz, xH, PEG), 3.71-3.45 (m, xH, PEG), 3.41 (t, J=6.32 
Hz, xH, PEG), −2.04 (br s, 2H, NH); UV-Vis (DMF): 411 nm, 505 nm, 532 nm, 581 
nm, 649 nm. CHN not collected. 
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7.6.12. Synthesis of nickel(II) 5,10,15,20-tetrakis(2,3,5,6-
tetrafluoro-4-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylsulfanyl}-
phenyl)-porphyrin ([Ni64]) 
 
To [Ni63] (110 mg, 0.11 mmol), 31 (0.19 g, 1.1 mmol) and Na2S (0.08 g, 1.1 mmol) 
was added DMF (5 ml). The reaction mixture was stirred for 3 days after which, the 
reaction was judged complete by TLC (absence of starting material). The reaction 
mixture was then concentrated under reduced vacuum before re-dissolving in 50/50 
DCM/hexane (50 ml). This solution was then washed with a saturated brine solution 
from which the organic layer was collected and dried over MgSO4. The purple 
solution was concentrated in vacuo and the oily residue was washed repeatedly with 
hexane under the washings were clear to give the title product as a purple oil (110 
mg, 62%); 
1
H NMR [CDCl3] δ 8.74 (s, 8H, βH), 3.87-3.29 (m, 60H, PEG); 
19
F NMR 
[CDCl3] δ −133.49 (s, 2F, o-F), −137.14 (s, 2F, m-F); MS (MALDI): m/z = 1087 
(MH4-(CH2CH2OCH2CH2OCH2CH2OCH3)4
+
); ε (DMF): 405 nm (297280 mol-
1
dm
3
cm
-1
), 523 nm (21652 mol
-1
dm
3
cm
-1
), 557 nm (17115 mol
-1
dm
3
cm
-1
). CHN not 
collected. 
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7.6.13. Synthesis of gallium(III) 5,10,15,20-tetrakis(2,3,5,6-
tetrafluoro-4-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethylsulfanyl}-
phenyl)-porphyrin phenoxide or chloride ([Ga64]X where X= 
OPh or Cl) 
 
X=OPh 
[Ga63]OPh (0.1 g, 0.088 mmol), 31 (0.16 g, 0.88 mmol) and Na2S (0.07 g, 0.88 
mmol) were dissolved in DMF (5 ml) and stirred at RT for 3 days. TLC (silica, 5/95 
MeOH/DCM (v/v)) at this point showed compete consumption of the starting 
material. The solution was then concentrated under reduced pressure and the 
resulting material partitioned between DCM (50 ml) and water (100 ml). The organic 
layer was collected and further washed with brine (100 ml). The organic layer was 
then dried over MgSO4 and filtered. The filtrate was collected and concentrated 
under reduced pressure. The oily residue was then repeatedly washed with hexane 
(~5 x 5 ml) until the washings were clear. The desired compound was isolated as a 
red oil (0.13 g, 83%); 
1
H NMR [CDCl3] 9.09 (s, 8H, βH), 3.09-3.24 (m, 60H, PEG), 
5.11 (s, 2H, OPh), 1.80 (br s, 3H, OPh); 
19
F NMR [CDCl3] δ -133.62 (dq, 2F, 
 343 
J=11.56 and 13.87, o-F), -136.54 (dq, 2F, J=11.56, m-F), MS (MALDI): m/z = 1684 
(M-OPh
+
); ε (DMF): 421 nm (135597 mol-1dm3cm-1), 509 nm (1198 mol-1dm3cm-1), 
551 nm (6964 mol
-1
dm
3
cm
-1
). CHN not collected. 
X=Cl 
64 (150 mg, 0.0924 mmol), sodium acetate (0.04 g, 0.465 mmol) and GaCl3 (0.02 g, 
0.124 mmol) were dissolved in dry acetic acid (15 ml). The resulting purple solution 
was then heated to reflux for 18 hr. The solution was then allowed to cool before 
filtering off any solids and concentrating under reduced pressure. The crude product 
was purified by column chromatography (silica, 5/95 MeOH/ DCM (v/v)). The 
violet/red band was collected and concentrated under reduced pressure to afford a 
violet solid (0.15 g, 94%); Rf=0.35 (5/95 MeOH/ DCM v/v); 
1
H NMR [CDCl3] δ 
9.10 (br s, 8H, βH), 3.81-3.10 (m, 60H, PEG); 19F NMR [CDCl3] δ −133.59 (s, 2F, 
o-F), −137.43 (s, 2F, m-F); MS (MALDI): m/z = 1684 (M-Cl+); ε (DMF): 420 nm 
(287972 mol
-1
dm
3
cm
-1
), 508 nm (4250 mol
-1
dm
3
cm
-1
), 551 nm (12559 mol
-1
dm
3
cm
-
1
). CHN not collected. 
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7.6.14. Synthesis of tetraPEGylated [Ga63]OPh with PEG 
chains of an average weight of 550 ([Ga65]OPh) 
[Ga63]OPh (0.0076 g, 0.00667 mmol), 29 (0.04 g, 0.0667 mmol) and Na2S (0.005 g, 
0.0668 mmol) were dissolved in DMF (6 ml) and stirred at RT for 72 hr. The 
solution was then concentrated under reduced pressure and the resulting material 
partitioned between DCM (50 ml) and water (100 ml). The organic layer was 
collected and further washed with brine (100 ml). The organic layer was then dried 
over MgSO4 and filtered. The filtrate was collected and concentrated under reduced 
pressure. The oily residue was then repeatedly washed with hexane (~5 x 10 ml) 
until the washings were clear. The desired compound was isolated as a purple oil 
(0.0197 g, ~94%); 
1
H NMR [CDCl3] δ 8.88-8.92 (m, 8H, β H), 5.07 (m, 2H, OPh), 
3.76 (t, J=6.26 Hz, xH, PEG), 3.72-3.43 (m, xH, PEG), 3.29 (t, J= 6.26 Hz, xH, 
PEG), 1.73 (m, 3H, OPh); UV-Vis (DMF): 418 nm, 550 nm, 619 nm. CHN not 
collected. 
7.6.15. Synthesis of the tetraPEGylated [Ga63]OPh with 
PEG chains of an average weight of 750 ([Ga66]OPh) 
[Ga63]OPh (0.0076 g, 0.00667 mmol), 30 (0.0541 g, 0.0667 mmol) and Na2S (0.005 
g, 0.0668 mmol) were dissolved in DMF (6 ml) and stirred at RT for 72 hr. The 
solution was then concentrated under reduced pressure and the resulting material 
partitioned between DCM (50 ml) and water (100 ml). The organic layer was 
collected and further washed with brine (100 ml). The organic layer was then dried 
over MgSO4 and filtered. The filtrate was collected and concentrated under reduced 
pressure. The oily residue was then repeatedly washed with hexane (~5 x 10 ml) 
until the washings were clear. The desired compound was isolated as a purple oil 
(0.0257 g, ~93%); 
1
H NMR [CDCl3] δ 8.91-8.94 (m, 8H, β H), 5.09 (m, 2H, OPh), 
3.79 (t, J=6.24 Hz, xH, PEG), 3.74-3.45 (m, xH, PEG), 3.31 (t, J=6.24 Hz, xH, 
PEG), 1.74 (m, 3H, OPh); ; UV-Vis (DMF): 419 nm, 550 nm, 623 nm. CHN not 
collected. 
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7.6.16. Synthesis of tetraPEGylated [Ni63] with PEG 
chains of an average weight of 550 ([Ni65]) 
[Ni63] (40 mg, 0.0388 mmol), 29 (0.24 g, 0.388 mmol) and Na2S (0.03 g, 0.388 
mmol) were dissolved in DMF (6 ml) and stirred at RT for 72 hr. The solution was 
then concentrated under reduced pressure and the resulting material partitioned 
between DCM (50 ml) and water (100 ml). The organic layer was collected and 
further washed with brine (100 ml). The organic layer was then dried over MgSO4 
and filtered. The filtrate was collected and concentrated under reduced pressure. The 
oil formed by this process was then dissolved in MeOH/ water (3 ml) and transferred 
to a Float-A-Lyzer. The Float-A-Lyzer was left in distilled water for a week. The 
solution was then removed from the Float-A-Lyzer and concentrated under reduced 
pressure. The desired compound was isolated as a purple oil (0.1012 g, ~79%); 
1
H 
NMR [CDCl3] δ 8.91 (br s, 8H, βH), 3.81 (t, J=6.26 Hz, xH, PEG), 3.78-3.47 (m, xH 
PEG), 3.35 (t, J= 6.26 Hz, xH, PEG); UV-Vis (DMF): 404 nm, 523 nm, 556 nm. 
CHN not collected. 
7.6.17. Synthesis of tetraPEGylated [Ni63] with PEG 
chains of an average weight of 750 ([Ni66]) 
[Ni63] (40 mg, 0.0388 mmol), 30 (0.32 g, 0.388 mmol) and Na2S (0.03 g, 0.388 
mmol) were dissolved in DMF (6 ml) and stirred at RT for 72 hr. The solution was 
then concentrated under reduced pressure and the resulting material partitioned 
between DCM (50 ml) and water (100 ml). The organic layer was collected and 
further washed with brine (100 ml). The organic layer was then dried over MgSO4 
and filtered. The filtrate was collected and concentrated under reduced pressure. The 
oil formed by this process was then dissolved in MeOH/ water (3 ml) and transferred 
to a Float-A-Lyzer. The Float-A-Lyzer was left in distilled water for a week. The 
solution was then removed from the Float-A-Lyzer and concentrated under reduced 
pressure. The desired compound was isolated as a purple oil (0.1478 g, ~95%); 
1
H 
NMR [CDCl3] δ 8.83 (br s, 8H, βH), 3.79 (t, J=6.31 Hz, xH, PEG), 3.77-3.43 (m, 
xH, PEG), 3.34 (t, J= 6.31 Hz, xH, PEG); UV-Vis (DMF): 403 nm, 522 nm, 556 nm. 
CHN not collected. 
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7.6.18. Synthesis of tetraPEGylated [Zn63] with PEG 
chains of an average weight of 550 ([Zn65]) 
[Zn63] (0.1 g, 0.0963 mmol), 29 (0.59 g, 0.963 mmol) and Na2S (0.08 g, 0.963 
mmol) were dissolved in DMF (6 ml) and stirred at RT for 72 hr. The solution was 
then concentrated under reduced pressure and the resulting material partitioned 
between DCM (50 ml) and water (100 ml). The organic layer was collected and 
further washed with brine (100 ml). The organic layer was then dried over MgSO4 
and filtered. The filtrate was collected and concentrated under reduced pressure. The 
oil formed by this process was then dissolved in MeOH/ water (3 ml) and transferred 
to a Float-A-Lyzer. The Float-A-Lyzer was left in distilled water for a week. The 
solution was then removed from the Float-A-Lyzer and concentrated under reduced 
pressure. The desired compound was isolated as a purple oil (0.18 g, ~58%); 
1
H 
NMR [CDCl3] δ 8.85 (s, 8H, βH), 3.83 (t, J=6.19 Hz, xH, PEG), 3.74-3.49 (m, xH, 
PEG), 3.36 (t, J= 6.19 Hz, xH, PEG); UV-Vis (DMF): 421 nm, 552 nm, 623 nm. 
CHN not collected. 
7.6.19. Synthesis of tetraPEGylated [Zn63] with PEG 
chains of an average molecular weight of 750 ([Zn66]) 
[Zn63] (0.1 g, 0.0963 mmol), 30 (0.78 g, 0.963 mmol) and Na2S (0.08 g, 0.963 
mmol) were dissolved in DMF (6 ml) and stirred at RT for 72 hr. The solution was 
then concentrated under reduced pressure and the resulting material partitioned 
between DCM (50 ml) and water (100 ml). The organic layer was collected and 
further washed with brine (100 ml). The organic layer was then dried over MgSO4 
and filtered. The filtrate was collected and concentrated under reduced pressure. The 
oil formed by this process was then dissolved in MeOH/ water (3 ml) and transferred 
to a Float-A-Lyzer. The Float-A-Lyzer was left in distilled water for a week. The 
solution was then removed from the Float-A-Lyzer and concentrated under reduced 
pressure. The desired compound was isolated as a purple oil (0.28 g, ~72%); 
1
H 
NMR [CDCl3] δ 8.98 (br s, 8 H, β H), 3.88 (t, J=6.27 Hz, xH, PEG), 3.79-3.44 (m, 
xH, PEG), 3.34 (t, J=6.27 Hz, xH, PEG); UV-Vis (DMF): 420 nm, 552 nm, 623 nm. 
CHN not collected. 
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7.6.20. Synthesis of zinc(II)5,10-15-tris-pentafluorophenyl-
20-(2,3,5,6-tetrafluoro-4-{2-[2-(2-methoxy-ethoxy)-ethoxy]-
ethylsulfanyl}-phenyl)-porphyrin ([Zn67]) 
 
[Zn63] (110 mg, 0.106 mmol), 31 (0.19 g, 1.06 mmol) and Na2S (0.08 g, 1.06 mmol) 
were dissolved in DMF and heated to 60°C for three weeks. The solution was then 
allowed to cool to RT and the resulting solution concentrated under reduced 
pressure. The oily residue was partitioned between DCM (50 ml) and water (100 
ml). The organic layer was then dried over MgSO4 and filtered. The filtrate was 
collected and concentrated under reduced pressure. The crude material was purified 
by column chromatography (silica, eluent: DCM initially followed by 10/90 
MeOH/DCM (v/v)). The fractions containing the product were isolated and 
concentrated under reduced pressure to yield the desired compound as a red oil (0.01 
g, 8%); Rf=0.45 (10/90 MeOH/DCM (v/v)); 
1
H NMR [CDCl3] δ 8.86 (br s, 8H, βH), 
3.58-3.24 (m, 15H, PEG); 
19
F NMR [CDCl3] −134.04 to −137.60 (m, 12F, o- and m-
F), −152.23 to −152.28 (m, 3F, p-F); MS (MALDI): m/z= 1197.95 (M+); UV-Vis 
(DMF): 419 nm, 552 nm, 585 nm. CHN not collected. 
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